1	Cumulated	O
2	maximum	O
3	lod	O
4	scores	O
5	between	O
6	FRDA	O
7	and	O
8	D9S5	O
9	and	O
10	between	O
11	FRDA	O
12	and	O
13	D9S15	O
14	are	O
15	above	O
16	36	O
17	and	O
18	61	O
19	,	O
20	respectively	O
21	,	O
22	at	O
23	a	O
24	recombination	O
25	fraction	O
26	of	O
27	0	O
28	,	O
29	indicating	O
30	that	O
31	recombination	O
32	events	O
33	needed	O
34	to	O
35	orient	O
36	the	O
37	search	O
38	of	O
39	the	O
40	gene	O
41	are	O
42	very	O
43	difficult	O
44	to	O
45	identify	O
46	and	O
47	ascertain	O
48	.	O

1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	O
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	I
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O

1	Although	O
2	the	O
3	RAD23	O
4	equivalents	O
5	are	O
6	well	O
7	conserved	O
8	during	O
9	evolution	O
10	,	O
11	the	O
12	mammalian	O
13	genes	O
14	did	O
15	not	O
16	express	O
17	the	O
18	UV	O
19	-	O
20	inducible	O
21	phenotype	O
22	of	O
23	their	O
24	yeast	O
25	counterpart	O
26	.	O

1	Intraperitoneal	O
2	administration	O
3	of	O
4	L	O
5	-	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	L	O
11	-	O
12	5	O
13	-	O
14	HTP	O
15	)	O
16	at	O
17	doses	O
18	of	O
19	25	O
20	to	O
21	100	O
22	mg	O
23	/	O
24	kg	O
25	dramatically	O
26	increase	O
27	defecation	O
28	in	O
29	mice	O
30	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	O
9	level	O
10	boosts	O
11	the	O
12	current	O
13	values	O
14	by	O
15	2	O
16	-	O
17	3	O
18	orders	O
19	of	O
20	magnitude	O
21	;	O
22	contrariwise	O
23	,	O
24	the	O
25	voltage	O
26	values	O
27	rise	O
28	by	O
29	about	O
30	three	O
31	times	O
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O

1	XYL1	O
2	was	O
3	isolated	O
4	as	O
5	a	O
6	highly	O
7	expressed	O
8	fusion	O
9	clone	O
10	from	O
11	a	O
12	'	O
13	lacZ	B
14	translational	O
15	fusion	O
16	library	O
17	.	O

1	Deletions	O
2	were	O
3	examined	O
4	in	O
5	the	O
6	LYS2	O
7	gene	O
8	,	O
9	using	O
10	a	O
11	set	O
12	of	O
13	31	O
14	-	O
15	to	O
16	156	O
17	-	O
18	bp	O
19	inserts	O
20	that	O
21	included	O
22	inserts	O
23	with	O
24	no	O
25	apparent	O
26	potential	O
27	for	O
28	secondary	O
29	structure	O
30	as	O
31	well	O
32	as	O
33	two	O
34	quasipalindromes	O
35	.	O

1	Outflow	O
2	obstruction	O
3	of	O
4	pancreatic	O
5	juice	O
6	,	O
7	i	O
8	.	O
9	e	O
10	.,	O
11	"	O
12	relative	O
13	stenosis	O
14	of	O
15	the	O
16	minor	O
17	papilla	O
18	,"	O
19	was	O
20	considered	O
21	to	O
22	be	O
23	present	O
24	in	O
25	the	O
26	patients	O
27	with	O
28	type	O
29	II	O
30	papilla	O
31	,	O
32	and	O
33	,	O
34	therefore	O
35	,	O
36	the	O
37	patients	O
38	with	O
39	type	O
40	II	O
41	papilla	O
42	might	O
43	suffer	O
44	from	O
45	acute	O
46	pancreatitis	O
47	resulting	O
48	from	O
49	poor	O
50	drainage	O
51	of	O
52	pancreatic	O
53	juice	O
54	and	O
55	excessive	O
56	pressure	O
57	in	O
58	the	O
59	dorsal	O
60	duct	O
61	.	O

1	The	O
2	article	O
3	deals	O
4	with	O
5	the	O
6	diagnosing	O
7	and	O
8	correction	O
9	of	O
10	reversible	O
11	ischemia	O
12	of	O
13	the	O
14	intestine	O
15	.	O

1	Products	O
2	of	O
3	immune	O
4	cells	O
5	such	O
6	as	O
7	transfer	O
8	factor	O
9	and	O
10	lymphokines	O
11	form	O
12	the	O
13	third	O
14	and	O
15	possibly	O
16	most	O
17	important	O
18	group	O
19	of	O
20	immune	O
21	-	O
22	stimulating	O
23	agents	O
24	.	O

1	A	O
2	decanucleotide	O
3	promoter	O
4	sequence	O
5	homologous	O
6	to	O
7	those	O
8	found	O
9	in	O
10	humans	O
11	and	O
12	mice	O
13	was	O
14	located	O
15	in	O
16	the	O
17	5	O
18	'	O
19	untranslated	O
20	region	O
21	of	O
22	one	O
23	horse	B
24	gene	I
25	.	I

1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	B
38	kinase	I
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O

1	Gene	O
2	expression	O
3	occurs	O
4	in	O
5	a	O
6	circadian	O
7	rhythm	O
8	and	O
9	induced	O
10	by	O
11	light	O
12	in	O
13	leaves	O
14	of	O
15	dark	O
16	-	O
17	adapted	O
18	plants	O
19	.	O

1	These	O
2	bacteria	O
3	produce	O
4	and	O
5	export	O
6	proteins	O
7	capable	O
8	of	O
9	specific	O
10	interactions	O
11	with	O
12	key	O
13	mammalian	O
14	cell	O
15	regulatory	O
16	molecules	O
17	in	O
18	order	O
19	to	O
20	derail	O
21	the	O
22	normal	O
23	functions	O
24	of	O
25	the	O
26	cells	O
27	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	if	O
7	the	O
8	measured	O
9	angle	O
10	ANB	O
11	is	O
12	smaller	O
13	than	O
14	the	O
15	calculated	O
16	angle	O
17	,	O
18	the	O
19	skeletal	O
20	relation	O
21	is	O
22	Class	O
23	III	O
24	.	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	a	O
7	Chessmaster	O
8	gradually	O
9	increases	O
10	the	O
11	number	O
12	of	O
13	boards	O
14	he	O
15	can	O
16	reproduce	O
17	with	O
18	higher	O
19	than	O
20	70	O
21	%	O
22	average	O
23	accuracy	O
24	to	O
25	nine	O
26	,	O
27	replacing	O
28	as	O
29	many	O
30	as	O
31	160	O
32	pieces	O
33	correctly	O
34	.	O

1	Metabolic	O
2	labeling	O
3	studies	O
4	in	O
5	S	O
6	.	O
7	cerevisiae	O
8	and	O
9	co	O
10	-	O
11	expression	O
12	of	O
13	nmt72p	O
14	with	O
15	several	O
16	protein	O
17	substrates	O
18	of	O
19	Nmt1p	O
20	in	O
21	Escherichia	O
22	coli	O
23	indicate	O
24	that	O
25	the	O
26	Leu99	O
27	-->	O
28	Pro	O
29	substitution	O
30	causes	O
31	a	O
32	reduction	O
33	in	O
34	the	O
35	acylation	O
36	of	O
37	some	O
38	but	O
39	not	O
40	all	O
41	protein	O
42	substrates	O
43	.	O

1	Mutational	O
2	studies	O
3	provide	O
4	evidence	O
5	to	O
6	this	O
7	end	O
8	and	O
9	indicate	O
10	that	O
11	the	O
12	side	O
13	chains	O
14	of	O
15	subdomain	O
16	4	O
17	.	O
18	2	O
19	make	O
20	specific	O
21	contacts	O
22	with	O
23	the	O
24	nucleotides	O
25	at	O
26	-	O
27	35	O
28	.	O

1	Per	O
2	kg	O
3	FFM	O
4	SMR	O
5	was	O
6	almost	O
7	restored	O
8	to	O
9	baseline	O
10	values	O
11	for	O
12	the	O
13	EX	O
14	group	O
15	,	O
16	whereas	O
17	the	O
18	non	O
19	-	O
20	exercising	O
21	subjects	O
22	still	O
23	showed	O
24	depressed	O
25	values	O
26	(	O
27	EX	O
28	3	O
29	.	O
30	7	O
31	per	O
32	cent	O
33	and	O
34	D	O
35	+	O
36	DE	O
37	15	O
38	.	O
39	8	O
40	per	O
41	cent	O
42	lower	O
43	than	O
44	before	O
45	treatment	O
46	;	O
47	P	O
48	less	O
49	than	O
50	0	O
51	.	O
52	05	O
53	).	O

1	Purple	O
2	photosynthetic	O
3	bacteria	O
4	are	O
5	capable	O
6	of	O
7	generating	O
8	cellular	O
9	energy	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	photosynthesis	O
16	,	O
17	respiration	O
18	,	O
19	and	O
20	H	O
21	(	O
22	2	O
23	)	O
24	oxidation	O
25	.	O

1	We	O
2	examine	O
3	current	O
4	models	O
5	of	O
6	the	O
7	effects	O
8	of	O
9	aging	O
10	on	O
11	mean	O
12	response	O
13	time	O
14	and	O
15	show	O
16	how	O
17	they	O
18	might	O
19	be	O
20	reinterpreted	O
21	.	O

1	METHODS	O
2	:	O
3	A	O
4	total	O
5	of	O
6	15	O
7	pigs	O
8	were	O
9	randomised	O
10	to	O
11	ligation	O
12	of	O
13	left	O
14	marginal	O
15	arteries	O
16	(	O
17	infarction	O
18	group	O
19	,	O
20	n	O
21	=	O
22	5	O
23	),	O
24	to	O
25	TMLR	O
26	of	O
27	the	O
28	left	O
29	lateral	O
30	wall	O
31	using	O
32	a	O
33	holmium	O
34	:	O
35	yttrium	O
36	-	O
37	aluminium	O
38	garnet	O
39	(	O
40	Ho	O
41	:	O
42	YAG	O
43	)	O
44	laser	O
45	(	O
46	laser	O
47	group	O
48	,	O
49	n	O
50	=	O
51	5	O
52	),	O
53	and	O
54	to	O
55	both	O
56	(	O
57	laser	O
58	-	O
59	infarction	O
60	group	O
61	,	O
62	n	O
63	=	O
64	5	O
65	).	O

1	Chrispeels	O
2	[	O
3	1993	O
4	]	O
5	EMBO	O
6	J	O
7	12	O
8	:	O
9	2241	O
10	-	O
11	2247	O
12	).	O

1	Src	B
2	homology	I
3	(	I
4	SH	I
5	)	I
6	domain	I
7	dependent	I
8	protein	I
9	-	I
10	protein	I
11	interactions	O
12	are	O
13	important	O
14	to	O
15	tyrosine	B
16	kinase	I
17	receptor	I
18	signal	I
19	transduction	I
20	.	I

1	Glomerular	O
2	lesions	O
3	in	O
4	renal	O
5	allografts	O
6	.	O

1	Cortical	O
2	dysplasias	O
3	,	O
4	genetics	O
5	,	O
6	and	O
7	epileptogenesis	O
8	.	O

1	Some	O
2	studies	O
3	of	O
4	exercise	O
5	have	O
6	associated	O
7	beta	B
8	-	I
9	endorphin	I
10	release	O
11	with	O
12	increased	O
13	exertion	O
14	levels	O
15	,	O
16	but	O
17	other	O
18	evidence	O
19	suggests	O
20	that	O
21	acidosis	O
22	may	O
23	stimulate	O
24	the	O
25	release	O
26	of	O
27	beta	B
28	-	I
29	endorphin	I
30	.	I

1	The	O
2	objective	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	examine	O
9	the	O
10	influence	O
11	of	O
12	HHCA	O
13	and	O
14	other	O
15	serological	O
16	factors	O
17	upon	O
18	the	O
19	development	O
20	of	O
21	VGS	O
22	.	O

1	A	O
2	single	O
3	amino	O
4	acid	O
5	change	O
6	in	O
7	the	O
8	CPY	O
9	vacuolar	O
10	sorting	O
11	signal	O
12	prevents	O
13	this	O
14	interaction	O
15	.	O

1	Biol	O
2	.	O

1	Band	O
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O

1	Our	O
2	observations	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	HMG	B
9	-	I
10	I	I
11	family	I
12	play	O
13	an	O
14	important	O
15	role	O
16	in	O
17	SRF	B
18	-	I
19	dependent	I
20	transcription	O
21	and	O
22	that	O
23	their	O
24	effect	O
25	is	O
26	mediated	O
27	primarily	O
28	by	O
29	a	O
30	protein	O
31	-	O
32	protein	O
33	interaction	O
34	.	O

1	To	O
2	measure	O
3	the	O
4	enhancer	O
5	activity	O
6	of	O
7	DR60	O
8	,	O
9	a	O
10	reporter	O
11	plasmid	O
12	was	O
13	constructed	O
14	that	O
15	contained	O
16	DR60	O
17	cloned	O
18	upstream	O
19	of	O
20	the	O
21	reporter	O
22	chloramphenicol	B
23	acetyltransferase	I
24	gene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	delayed	O
31	-	O
32	early	O
33	39K	O
34	promoter	O
35	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	cytochromes	O
5	bd	O
6	and	O
7	their	O
8	homologs	O
9	from	O
10	various	O
11	organisms	O
12	demonstrates	O
13	that	O
14	the	O
15	proteins	O
16	can	O
17	be	O
18	classified	O
19	into	O
20	two	O
21	subfamilies	O
22	,	O
23	a	O
24	proteobacterial	O
25	type	O
26	including	O
27	E	O
28	.	O
29	coli	O
30	bd	O
31	and	O
32	a	O
33	more	O
34	widely	O
35	distributed	O
36	type	O
37	including	O
38	the	O
39	B	O
40	.	O
41	stearothermophilus	O
42	enzyme	O
43	,	O
44	suggesting	O
45	that	O
46	the	O
47	latter	O
48	type	O
49	is	O
50	evolutionarily	O
51	older	O
52	.	O

1	Intravenous	O
2	antibiotic	O
3	therapy	O
4	in	O
5	cystic	O
6	fibrosis	O
7	:	O
8	in	O
9	hospital	O
10	or	O
11	at	O
12	home	O
13	?	O

1	Kinetics	O
2	of	O
3	the	O
4	inhibition	O
5	indicated	O
6	that	O
7	this	O
8	polymerase	O
9	domain	O
10	can	O
11	inhibit	O
12	viral	O
13	replication	O
14	only	O
15	during	O
16	the	O
17	preinitiation	O
18	stage	O
19	.	O

1	Sprague	O
2	-	O
3	Dawley	O
4	newborn	O
5	rats	O
6	(	O
7	n	O
8	=	O
9	85	O
10	)	O
11	breathed	O
12	100	O
13	%	O
14	oxygen	O
15	(	O
16	O2	O
17	)	O
18	or	O
19	room	O
20	air	O
21	(	O
22	RA	O
23	)	O
24	during	O
25	the	O
26	first	O
27	8	O
28	days	O
29	of	O
30	life	O
31	,	O
32	and	O
33	then	O
34	RA	O
35	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	DNA	O
6	fragment	O
7	showed	O
8	that	O
9	four	O
10	genes	O
11	are	O
12	present	O
13	encoding	O
14	proteins	O
15	of	O
16	16	O
17	,	O
18	18	O
19	.	O
20	5	O
21	,	O
22	21	O
23	and	O
24	89	O
25	kDal	O
26	.	O

1	The	O
2	resulting	O
3	clone	O
4	pKB11	O
5	,	O
6	which	O
7	has	O
8	a	O
9	1369	O
10	-	O
11	base	O
12	pair	O
13	(	O
14	bp	O
15	)	O
16	cDNA	O
17	insert	O
18	,	O
19	overlapping	O
20	pCAD142	O
21	by	O
22	781	O
23	bp	O
24	,	O
25	was	O
26	identified	O
27	by	O
28	hybridization	O
29	methods	O
30	and	O
31	sequence	O
32	analysis	O
33	and	O
34	found	O
35	to	O
36	contain	O
37	the	O
38	entire	O
39	cDNA	O
40	sequence	O
41	for	O
42	the	O
43	amino	O
44	end	O
45	of	O
46	the	O
47	CAD	O
48	polypeptide	O
49	.	O

1	These	O
2	single	O
3	mutational	O
4	defects	O
5	in	O
6	the	O
7	eRF1	O
8	-	O
9	eRF3	O
10	interaction	O
11	became	O
12	evident	O
13	when	O
14	either	O
15	truncated	O
16	protein	O
17	eRF3C	O
18	or	O
19	C	O
20	-	O
21	terminally	O
22	altered	O
23	eRF1	O
24	proteins	O
25	were	O
26	used	O
27	for	O
28	the	O
29	authentic	O
30	protein	O
31	,	O
32	providing	O
33	further	O
34	support	O
35	for	O
36	the	O
37	presence	O
38	of	O
39	a	O
40	C	O
41	-	O
42	terminal	O
43	interaction	O
44	.	O

1	A	O
2	mutational	O
3	analysis	O
4	has	O
5	resolved	O
6	a	O
7	region	O
8	of	O
9	seven	O
10	amino	O
11	acids	O
12	(	O
13	amino	O
14	acids	O
15	26	O
16	-	O
17	32	O
18	)	O
19	in	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	of	O
25	Bob1	O
26	that	O
27	are	O
28	important	O
29	for	O
30	contacting	O
31	the	O
32	DNA	O
33	binding	O
34	POU	B
35	domain	I
36	of	O
37	Oct	B
38	-	I
39	1	I
40	or	O
41	Oct	B
42	-	I
43	2	I
44	.	I

1	To	O
2	identify	O
3	nuclear	O
4	regulatory	O
5	factors	O
6	,	O
7	we	O
8	have	O
9	located	O
10	and	O
11	functionally	O
12	characterized	O
13	the	O
14	CCR5	B
15	gene	I
16	promoter	I
17	.	I

1	Transformed	O
2	cell	O
3	lines	O
4	expressing	O
5	solely	O
6	E1a	O
7	or	O
8	E1a	O
9	and	O
10	E1b	O
11	gene	O
12	products	O
13	derived	O
14	from	O
15	these	O
16	viruses	O
17	display	O
18	enhanced	O
19	anchorage	O
20	-	O
21	independent	O
22	growth	O
23	at	O
24	37	O
25	degrees	O
26	C	O
27	versus	O
28	32	O
29	degrees	O
30	C	O
31	and	O
32	display	O
33	a	O
34	cytoskeletal	O
35	architecture	O
36	resembling	O
37	untransformed	O
38	fibroblastic	O
39	CREF	O
40	cells	O
41	.	O

1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	B
13	factor	I
14	IX	I
15	to	O
16	factor	O
17	IXa	O
18	by	O
19	factor	O
20	XIa	O
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O

1	In	O
2	patients	O
3	with	O
4	complete	O
5	or	O
6	partial	O
7	remission	O
8	of	O
9	the	O
10	tumor	O
11	,	O
12	the	O
13	neopterine	O
14	excretion	O
15	dropped	O
16	to	O
17	normal	O
18	values	O
19	.	O

1	The	O
2	ultrastructure	O
3	of	O
4	retinal	O
5	vessels	O
6	was	O
7	examined	O
8	in	O
9	three	O
10	eyes	O
11	from	O
12	diabetic	O
13	patients	O
14	and	O
15	two	O
16	eyes	O
17	from	O
18	control	O
19	subjects	O
20	.	O

1	Calcium	O
2	and	O
3	phosphorus	O
4	metabolism	O
5	in	O
6	chronic	O
7	uremia	O
8	.	O

1	Several	O
2	7SL	O
3	RNA	O
4	-	O
5	encoding	O
6	sequences	O
7	and	O
8	various	O
9	intergenic	O
10	spacers	O
11	were	O
12	amplified	O
13	from	O
14	the	O
15	individual	O
16	HindIII	B
17	fragments	I
18	of	O
19	about	O
20	1	O
21	.	O
22	3	O
23	and	O
24	2	O
25	.	O
26	8	O
27	kb	O
28	.	O

1	Comparable	O
2	amounts	O
3	of	O
4	alpha	B
5	5	I
6	beta	I
7	1	I
8	integrin	I
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	B
22	cell	I
23	-	I
24	binding	I
25	fragment	I
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O

1	Allelic	O
2	variation	O
3	in	O
4	HLA	B
5	-	I
6	B	I
7	and	O
8	HLA	B
9	-	I
10	C	I
11	sequences	O
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	B
18	-	I
19	B	I
20	alleles	I
21	.	I

1	High	O
2	dosages	O
3	of	O
4	D	O
5	-	O
6	penicillamine	O
7	in	O
8	pulmonary	O
9	fibroses	B

1	When	O
2	data	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	cumulative	O
8	manner	O
9	,	O
10	the	O
11	response	O
12	to	O
13	intravenous	O
14	adenosine	O
15	3	O
16	mg	O
17	,	O
18	6	O
19	mg	O
20	,	O
21	9	O
22	mg	O
23	and	O
24	12	O
25	mg	O
26	in	O
27	the	O
28	24	O
29	episodes	O
30	of	O
31	PSVT	O
32	were	O
33	5	O
34	episodes	O
35	(	O
36	21	O
37	%),	O
38	16	O
39	episodes	O
40	(	O
41	67	O
42	%),	O
43	20	O
44	episodes	O
45	(	O
46	83	O
47	%)	O
48	and	O
49	20	O
50	episodes	O
51	(	O
52	83	O
53	%)	O
54	respectively	O
55	.	O

1	The	O
2	nucleosomal	O
3	arrays	O
4	detected	O
5	by	O
6	MPE	O
7	X	O
8	Fe	O
9	(	O
10	II	O
11	)	O
12	were	O
13	characterized	O
14	by	O
15	a	O
16	considerable	O
17	loss	O
18	of	O
19	detail	O
20	and	O
21	significantly	O
22	enhanced	O
23	accessibility	O
24	,	O
25	the	O
26	extent	O
27	of	O
28	which	O
29	probably	O
30	reflected	O
31	the	O
32	relative	O
33	transcription	O
34	rate	O
35	of	O
36	each	O
37	gene	O
38	.	O

1	Results	O
2	from	O
3	transient	O
4	assays	O
5	using	O
6	these	O
7	mutants	O
8	showed	O
9	that	O
10	the	O
11	DE1	O
12	received	O
13	signals	O
14	from	O
15	phytochromes	O
16	A	O
17	and	O
18	B	O
19	,	O
20	demonstrating	O
21	that	O
22	this	O
23	element	O
24	is	O
25	indeed	O
26	a	O
27	light	O
28	-	O
29	responsive	O
30	element	O
31	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Rho1p	O
6	regulates	O
7	cytoskeletal	O
8	reorganization	O
9	at	O
10	least	O
11	through	O
12	Bni1p	O
13	and	O
14	Pkc1p	O
15	.	O

1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O

1	Basic	O
2	fibroblast	B
3	growth	I
4	factor	I
5	(	O
6	bFGF	O
7	)	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	induce	O
13	angiogenesis	O
14	in	O
15	various	O
16	animal	O
17	models	O
18	,	O
19	but	O
20	the	O
21	methods	O
22	of	O
23	administration	O
24	used	O
25	experimentally	O
26	are	O
27	not	O
28	clinically	O
29	feasible	O
30	.	O

1	Atherosclerosis	B

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	O
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	B
13	to	O
14	the	O
15	estrogen	B
16	receptor	I
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	O
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	O
28	to	O
29	recruit	O
30	CBP	B
31	and	O
32	p300	B
33	.	I

1	A	O
2	third	O
3	series	O
4	of	O
5	mice	O
6	were	O
7	given	O
8	a	O
9	single	O
10	injection	O
11	of	O
12	5	O
13	-	O
14	OH	O
15	-	O
16	DA	O
17	,	O
18	sacrificed	O
19	,	O
20	and	O
21	prepared	O
22	for	O
23	ultrastructural	O
24	study	O
25	.	O

1	Mutations	O
2	at	O
3	two	O
4	neighboring	O
5	sites	O
6	,	O
7	serine	O
8	242	O
9	and	O
10	threonine	O
11	255	O
12	,	O
13	exacerbated	O
14	the	O
15	effect	O
16	.	O

1	Indium	O
2	-	O
3	111	O
4	leukocyte	O
5	imaging	O
6	in	O
7	patients	O
8	with	O
9	rheumatoid	O
10	arthritis	O
11	.	O

1	One	O
2	of	O
3	these	O
4	small	O
5	inteins	O
6	might	O
7	be	O
8	inactive	O
9	or	O
10	a	O
11	"	O
12	pseudo	O
13	intein	O
14	."	O
15	The	O
16	results	O
17	suggest	O
18	a	O
19	modular	O
20	architecture	O
21	for	O
22	inteins	O
23	,	O
24	clarify	O
25	their	O
26	origin	O
27	and	O
28	relationship	O
29	to	O
30	other	O
31	protein	O
32	families	O
33	,	O
34	and	O
35	extend	O
36	recent	O
37	experimental	O
38	findings	O
39	on	O
40	the	O
41	functional	O
42	roles	O
43	of	O
44	intein	O
45	N	O
46	,	O
47	C	O
48	,	O
49	and	O
50	EN	O
51	motifs	O
52	.	O

1	1	O
2	,	O
3	3	O
4	-	O
5	bis	B
6	(	I
7	2	I
8	-	I
9	chloroethyl	I
10	)-	I
11	1	I
12	-	I
13	nitrosourea	I
14	(	O
15	bcnu	O
16	)	O
17	and	O
18	other	O
19	nitrosoureas	O
20	in	O
21	cancer	O
22	treatment	O
23	:	O
24	a	O
25	review	O
26	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	human	B
7	I	I
8	-	I
9	mfa	I
10	domain	I
11	-	I
12	containing	I
13	protein	I
14	that	O
15	differently	O
16	regulates	O
17	human	B
18	T	I
19	-	I
20	cell	I
21	leukemia	I
22	virus	I
23	type	I
24	I	I
25	and	O
26	HIV	B
27	-	I
28	1	I
29	expression	O
30	.	O

1	A	O
2	sequence	O
3	homology	O
4	analysis	O
5	between	O
6	human	B
7	nm23	I
8	-	I
9	H1	I
10	and	O
11	the	O
12	homolog	O
13	gene	O
14	of	O
15	the	O
16	rat	O
17	(	O
18	NDP	B
19	-	I
20	K	I
21	beta	I
22	)	O
23	shows	O
24	that	O
25	exon	O
26	-	O
27	intron	O
28	boundaries	O
29	are	O
30	well	O
31	conserved	O
32	between	O
33	these	O
34	two	O
35	species	O
36	.	O

1	A	O
2	beta2	O
3	RARE	O
4	reporter	O
5	construct	O
6	in	O
7	which	O
8	the	O
9	methylation	O
10	-	O
11	susceptible	O
12	cytosines	O
13	in	O
14	the	O
15	sense	O
16	strand	O
17	were	O
18	replaced	O
19	by	O
20	thymine	O
21	displayed	O
22	marked	O
23	loss	O
24	of	O
25	activity	O
26	in	O
27	a	O
28	replicated	O
29	chromatin	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	O
16	domain	O
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	a	O
6	nuclear	O
7	gene	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	that	O
12	specifies	O
13	MRP13	O
14	,	O
15	a	O
16	protein	O
17	of	O
18	the	O
19	small	O
20	subunit	O
21	of	O
22	the	O
23	mitochondrial	O
24	ribosome	O
25	.	O

1	Thus	O
2	,	O
3	the	O
4	absence	O
5	of	O
6	residual	O
7	infarct	O
8	-	O
9	zone	O
10	viability	O
11	discriminates	O
12	patients	O
13	who	O
14	develop	O
15	progressive	O
16	left	O
17	ventricular	O
18	dilation	O
19	after	O
20	reperfused	O
21	AMI	O
22	from	O
23	those	O
24	who	O
25	maintain	O
26	normal	O
27	left	O
28	ventricular	O
29	geometry	O
30	.	O

1	Overexpression	O
2	of	O
3	EFG1	O
4	in	O
5	C	O
6	.	O
7	albicans	O
8	leads	O
9	to	O
10	enhanced	O
11	filamentous	O
12	growth	O
13	in	O
14	the	O
15	form	O
16	of	O
17	extended	O
18	pseudohyphae	O
19	in	O
20	liquid	O
21	and	O
22	on	O
23	solid	O
24	media	O
25	.	O

1	The	O
2	therapeutic	O
3	protocole	O
4	used	O
5	at	O
6	the	O
7	Gustave	O
8	Roussy	O
9	Institute	O
10	for	O
11	invasive	O
12	epithelioma	O
13	of	O
14	the	O
15	uterine	O
16	cervix	O
17	rests	O
18	,	O
19	for	O
20	limited	O
21	forms	O
22	(	O
23	T1B	O
24	-	O
25	T2	O
26	proximal	O
27	),	O
28	on	O
29	combined	O
30	radiology	O
31	and	O
32	surgery	O
33	.	O

1	Besides	O
2	,	O
3	it	O
4	was	O
5	considered	O
6	that	O
7	the	O
8	NPF	O
9	was	O
10	a	O
11	useful	O
12	tool	O
13	for	O
14	activation	O
15	of	O
16	velopharyngeal	O
17	activity	O
18	by	O
19	way	O
20	of	O
21	visual	O
22	feed	O
23	-	O
24	back	O
25	control	O
26	.	O

1	CONCLUSION	O
2	:	O
3	During	O
4	chronic	O
5	treatment	O
6	,	O
7	the	O
8	haemodynamic	O
9	response	O
10	to	O
11	oral	O
12	cilazapril	O
13	was	O
14	attenuated	O
15	,	O
16	indicating	O
17	that	O
18	continued	O
19	clinical	O
20	improvement	O
21	in	O
22	patients	O
23	with	O
24	CHF	O
25	on	O
26	CLZ	O
27	is	O
28	independent	O
29	of	O
30	to	O
31	its	O
32	acute	O
33	haemodynamic	O
34	effects	O
35	.	O

1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	O
7	1	O
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	overlapping	O
6	expressed	O
7	sequence	O
8	tag	O
9	clones	O
10	,	O
11	which	O
12	contain	O
13	the	O
14	missing	O
15	4	O
16	.	O
17	4	O
18	-	O
19	kb	O
20	3	O
21	'-	O
22	UTR	O
23	of	O
24	the	O
25	human	B
26	D2	I
27	(	O
28	hD2	O
29	)	O
30	cDNA	O
31	.	O

1	Moreover	O
2	,	O
3	the	O
4	hypoxia	O
5	-	O
6	induced	O
7	expression	O
8	of	O
9	the	O
10	endogenous	O
11	Epo	B
12	gene	I
13	was	O
14	significantly	O
15	inhibited	O
16	in	O
17	Hep3B	O
18	cells	O
19	stably	O
20	transfected	O
21	with	O
22	HNF	B
23	-	I
24	4	I
25	delta	I
26	C	I
27	.	I

1	The	O
2	pel	O
3	gene	O
4	from	O
5	an	O
6	Amycolata	O
7	sp	O
8	.	O
9	encoding	O
10	a	O
11	pectate	B
12	lyase	I
13	(	O
14	EC	O
15	4	O
16	.	O
17	2	O
18	.	O
19	2	O
20	.	O
21	2	O
22	)	O
23	was	O
24	isolated	O
25	by	O
26	activity	O
27	screening	O
28	a	O
29	genomic	O
30	DNA	O
31	library	O
32	in	O
33	Streptomyces	O
34	lividans	O
35	TK24	O
36	.	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	presented	O
6	with	O
7	Transient	O
8	Ischemic	O
9	Attacks	O
10	(	O
11	64	O
12	%)	O
13	or	O
14	Reversible	O
15	Ischemic	O
16	Neurologic	O
17	Deficits	O
18	(	O
19	19	O
20	%).	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	17	O
2	.	O
3	5	O
4	%	O
5	of	O
6	cycles	O
7	).	O

1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	B
8	-	I
9	HT2	I
10	receptor	I
11	antagonism	I
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O

1	The	O
2	rat	O
3	incisor	O
4	is	O
5	an	O
6	excellent	O
7	model	O
8	system	O
9	in	O
10	which	O
11	to	O
12	study	O
13	amelgenesis	O
14	.	O

1	Many	O
2	cytokine	O
3	receptors	O
4	employ	O
5	Janus	B
6	protein	I
7	tyrosine	I
8	kinases	I
9	(	O
10	Jaks	O
11	)	O
12	and	O
13	signal	O
14	transducers	O
15	and	O
16	activators	O
17	of	O
18	transcription	O
19	(	O
20	Stats	O
21	)	O
22	for	O
23	nuclear	O
24	signaling	O
25	.	O

1	On	O
2	the	O
3	diagnosis	O
4	of	O
5	bovine	O
6	leucosis	O
7	and	O
8	its	O
9	control	O
10	in	O
11	southern	O
12	Lower	O
13	Saxony	B

1	Many	O
2	of	O
3	these	O
4	landfill	O
5	operations	O
6	were	O
7	undertaken	O
8	in	O
9	the	O
10	early	O
11	1950s	O
12	and	O
13	1960s	O
14	,	O
15	when	O
16	knowledge	O
17	regarding	O
18	the	O
19	safe	O
20	and	O
21	prolonged	O
22	containment	O
23	of	O
24	the	O
25	waste	O
26	buried	O
27	was	O
28	nonexistent	O
29	or	O
30	minimal	O
31	at	O
32	best	O
33	.	O

1	Deadenylation	O
2	and	O
3	decay	O
4	of	O
5	beta	B
6	-	I
7	globin	I
8	mRNA	I
9	in	O
10	K562	O
11	cells	O
12	is	O
13	extraordinarily	O
14	slow	O
15	compared	O
16	with	O
17	NIH	O
18	3T3	O
19	cells	O
20	,	O
21	suggesting	O
22	that	O
23	the	O
24	increased	O
25	stability	O
26	gained	O
27	by	O
28	beta	B
29	-	I
30	globin	I
31	mRNA	I
32	in	O
33	K562	O
34	cells	O
35	is	O
36	mainly	O
37	controlled	O
38	at	O
39	the	O
40	deadenylation	O
41	step	O
42	.	O

1	A	O
2	polypeptide	O
3	encoded	O
4	by	O
5	the	O
6	NTS	O
7	16	O
8	open	O
9	reading	O
10	frame	O
11	has	O
12	sequence	O
13	similarity	O
14	to	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	several	B
20	receptor	I
21	protein	I
22	kinases	I
23	from	O
24	plants	O
25	including	O
26	the	O
27	S	B
28	-	I
29	receptor	I
30	kinases	I
31	implicated	O
32	in	O
33	the	O
34	rejection	O
35	of	O
36	self	O
37	-	O
38	pollen	O
39	in	O
40	Brassica	O
41	species	O
42	and	O
43	the	O
44	Pto	B
45	gene	I
46	product	I
47	of	O
48	tomato	O
49	which	O
50	confers	O
51	resistance	O
52	to	O
53	a	O
54	bacterial	O
55	pathogen	O
56	.	O

1	Deletion	O
2	analyses	O
3	of	O
4	the	O
5	construct	O
6	revealed	O
7	that	O
8	the	O
9	transcription	O
10	of	O
11	BOXF1	O
12	gene	O
13	is	O
14	regulated	O
15	by	O
16	BOX	O
17	DNA	O
18	,	O
19	preferentially	O
20	in	O
21	undifferentiated	O
22	EC	O
23	cells	O
24	versus	O
25	differentiated	O
26	cells	O
27	.	O

1	In	O
2	the	O
3	ISO	O
4	group	O
5	,	O
6	at	O
7	pre	O
8	-	O
9	DEX	O
10	,	O
11	CBF	O
12	increased	O
13	from	O
14	86	O
15	+/-	O
16	8	O
17	to	O
18	166	O
19	+/-	O
20	19	O
21	mL	O
22	.	O
23	min	O
24	-	O
25	1	O
26	.	O
27	100	O
28	g	O
29	-	O
30	1	O
31	in	O
32	response	O
33	to	O
34	hypercapnia	O
35	(	O
36	PCO2	O
37	approximately	O
38	90	O
39	mmHg	O
40	).(	O
41	ABSTRACT	O
42	TRUNCATED	O
43	AT	O
44	250	O
45	WORDS	O
46	)	O

1	Repeated	O
2	administration	O
3	of	O
4	GRg2	O
5	20	O
6	mg	O
7	/	O
8	kg	O
9	i	O
10	.	O
11	p	O
12	.	O
13	significantly	O
14	improved	O
15	the	O
16	CYP	O
17	-	O
18	induced	O
19	recognitional	O
20	deficits	O
21	by	O
22	increasing	O
23	the	O
24	CYP	O
25	-	O
26	decreased	O
27	rate	O
28	from	O
29	55	O
30	.	O
31	8	O
32	+/-	O
33	9	O
34	.	O
35	6	O
36	to	O
37	80	O
38	.	O
39	8	O
40	+/-	O
41	4	O
42	.	O
43	2	O
44	in	O
45	d	O
46	3	O
47	learning	O
48	acquisition	O
49	(	O
50	F	O
51	(	O
52	1	O
53	,	O
54	14	O
55	)	O
56	=	O
57	5	O
58	.	O
59	6	O
60	,	O
61	p	O
62	<	O
63	0	O
64	.	O
65	05	O
66	),	O
67	from	O
68	53	O
69	.	O
70	4	O
71	+/-	O
72	8	O
73	.	O
74	4	O
75	to	O
76	60	O
77	.	O
78	0	O
79	+/-	O
80	8	O
81	.	O
82	2	O
83	in	O
84	48	O
85	h	O
86	memory	O
87	acquisition	O
88	(	O
89	F	O
90	(	O
91	1	O
92	,	O
93	14	O
94	)	O
95	=	O
96	7	O
97	.	O
98	5	O
99	,	O
100	p	O
101	<	O
102	0	O
103	.	O
104	05	O
105	)	O
106	and	O
107	from	O
108	55	O
109	.	O
110	0	O
111	+/-	O
112	5	O
113	.	O
114	5	O
115	to	O
116	88	O
117	.	O
118	3	O
119	+/-	O
120	2	O
121	.	O
122	5	O
123	in	O
124	24	O
125	h	O
126	memory	O
127	retention	O
128	(	O
129	F	O
130	(	O
131	1	O
132	,	O
133	12	O
134	)	O
135	27	O
136	.	O
137	5	O
138	,	O
139	p	O
140	<	O
141	0	O
142	.	O
143	01	O
144	)	O
145	as	O
146	well	O
147	as	O
148	from	O
149	60	O
150	.	O
151	0	O
152	+/-	O
153	6	O
154	.	O
155	8	O
156	to	O
157	85	O
158	.	O
159	6	O
160	+/-	O
161	6	O
162	.	O
163	9	O
164	in	O
165	48	O
166	h	O
167	memory	O
168	retrieval	O
169	(	O
170	F	O
171	(	O
172	1	O
173	,	O
174	12	O
175	)	O
176	=	O
177	5	O
178	.	O
179	2	O
180	,	O
181	p	O
182	<	O
183	0	O
184	.	O
185	05	O
186	),	O
187	respectively	O
188	.	O

1	Because	O
2	L	B
3	-	I
4	plastin	I
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	B
25	-	I
26	plastin	I
27	gene	I
28	expression	O
29	in	O
30	human	O
31	and	O
32	rodent	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	B
52	L	I
53	-	I
54	plastin	I
55	gene	I
56	promoters	I
57	.	I

1	The	O
2	structural	O
3	gene	O
4	for	O
5	hydrogenase	O
6	encodes	O
7	a	O
8	protein	O
9	product	O
10	of	O
11	molecular	O
12	mass	O
13	45820	O
14	Da	O
15	.	O

1	The	O
2	baroreflex	O
3	latency	O
4	(	O
5	from	O
6	the	O
7	ECG	O
8	R	O
9	-	O
10	wave	O
11	to	O
12	the	O
13	integrated	O
14	MSNA	O
15	burst	O
16	peak	O
17	)	O
18	was	O
19	constant	O
20	at	O
21	approximately	O
22	1	O
23	.	O
24	20	O
25	s	O
26	during	O
27	sleep	O
28	,	O
29	suggesting	O
30	that	O
31	pulse	O
32	-	O
33	synchronicity	O
34	was	O
35	maintained	O
36	.	O

1	Competition	O
2	needs	O
3	to	O
4	be	O
5	better	O
6	studied	O
7	,	O
8	since	O
9	in	O
10	Central	O
11	America	O
12	and	O
13	Caribean	O
14	islands	O
15	this	O
16	kind	O
17	of	O
18	study	O
19	has	O
20	favored	O
21	the	O
22	biological	O
23	control	O
24	of	O
25	planorbid	O
26	species	O
27	.	O

1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	B
7	nuclease	I
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O

1	STP1	O
2	is	O
3	an	O
4	unessential	O
5	yeast	O
6	gene	O
7	involved	O
8	in	O
9	the	O
10	removal	O
11	of	O
12	intervening	O
13	sequences	O
14	from	O
15	some	O
16	,	O
17	but	O
18	not	O
19	all	O
20	,	O
21	families	O
22	of	O
23	intervening	O
24	sequence	O
25	-	O
26	containing	O
27	pre	O
28	-	O
29	tRNAs	O
30	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	activated	I
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	B
16	and	O
17	subsequent	O
18	Erk	B
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	O
27	or	O
28	Stat3	B
29	.	I

1	Marked	O
2	racial	O
3	variation	O
4	in	O
5	birthweight	O
6	percentiles	O
7	by	O
8	gestational	O
9	age	O
10	was	O
11	evident	O
12	.	O

1	In	O
2	one	O
3	,	O
4	exploratory	O
5	behavior	O
6	(	O
7	assessed	O
8	by	O
9	hole	O
10	pokes	O
11	)	O
12	and	O
13	locomotion	O
14	were	O
15	assessed	O
16	during	O
17	a	O
18	10	O
19	-	O
20	min	O
21	test	O
22	session	O
23	.	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	The	O
2	two	O
3	ParA	O
4	proteins	O
5	that	O
6	are	O
7	produced	O
8	as	O
9	a	O
10	result	O
11	of	O
12	independent	O
13	translation	O
14	initiation	O
15	at	O
16	two	O
17	different	O
18	start	O
19	codons	O
20	within	O
21	the	O
22	same	O
23	open	O
24	reading	O
25	frame	O
26	were	O
27	overexpressed	O
28	in	O
29	Escherichia	O
30	coli	O
31	and	O
32	partially	O
33	purified	O
34	.	O

1	2	O
2	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	the	O
6	expression	O
7	of	O
8	LIMK	B
9	-	I
10	1	I
11	mRNA	I
12	predominantly	O
13	in	O
14	the	O
15	brain	O
16	and	O
17	the	O
18	expression	O
19	of	O
20	LIMK	B
21	-	I
22	2	I
23	mRNA	I
24	in	O
25	various	O
26	tissues	O
27	in	O
28	the	O
29	rat	O
30	.	O

1	An	O
2	egg	O
3	protein	O
4	,	O
5	lysozyme	O
6	,	O
7	is	O
8	a	O
9	still	O
10	unlabeled	O
11	additive	O
12	currently	O
13	used	O
14	in	O
15	cheese	O
16	preparation	O
17	.	O

1	We	O
2	detected	O
3	no	O
4	effect	O
5	of	O
6	deleting	O
7	YCL024W	O
8	,	O
9	either	O
10	alone	O
11	or	O
12	in	O
13	combination	O
14	with	O
15	deletion	O
16	of	O
17	GIN4	O
18	.	O

1	The	O
2	C	O
3	terminus	O
4	of	O
5	TRBP	O
6	binds	O
7	to	O
8	CBP	B
9	/	I
10	p300	I
11	and	O
12	DRIP130	O
13	,	O
14	a	O
15	component	O
16	of	O
17	the	O
18	DRIP	O
19	/	O
20	TRAP	B
21	/	I
22	ARC	I
23	complex	I
24	,	O
25	which	O
26	suggests	O
27	that	O
28	TRBP	O
29	may	O
30	activate	O
31	transcription	O
32	by	O
33	means	O
34	of	O
35	such	O
36	interactions	O
37	.	O

1	A	O
2	third	O
3	prominent	O
4	component	O
5	of	O
6	apparent	O
7	molecular	O
8	mass	O
9	16	O
10	kDa	O
11	displayed	O
12	several	O
13	properties	O
14	,	O
15	including	O
16	ability	O
17	to	O
18	bind	O
19	45Ca2	O
20	+,	O
21	that	O
22	are	O
23	characteristic	O
24	of	O
25	the	O
26	regulatory	O
27	(	O
28	B	O
29	)	O
30	subunit	O
31	of	O
32	mammalian	O
33	calcineurin	O
34	and	O
35	was	O
36	recognized	O
37	by	O
38	an	O
39	antiserum	O
40	raised	O
41	against	O
42	bovine	B
43	calcineurin	I
44	.	I

1	Furthermore	O
2	,	O
3	bone	O
4	marrow	O
5	-	O
6	derived	O
7	macrophages	O
8	from	O
9	LAT	B
10	-	I
11	deficient	O
12	mice	O
13	displayed	O
14	reduced	O
15	phagocytic	O
16	efficiency	O
17	in	O
18	comparison	O
19	to	O
20	the	O
21	macrophages	O
22	from	O
23	wild	O
24	-	O
25	type	O
26	mice	O
27	.	O

1	At	O
2	the	O
3	carboxyl	O
4	terminus	O
5	,	O
6	deletion	O
7	as	O
8	far	O
9	as	O
10	residue	O
11	388	O
12	did	O
13	not	O
14	affect	O
15	in	O
16	vitro	O
17	TRF	O
18	.	O
19	C	O
20	assembly	O
21	,	O
22	although	O
23	trans	O
24	-	O
25	activating	O
26	activity	O
27	was	O
28	abolished	O
29	.	O

1	These	O
2	observations	O
3	indicate	O
4	that	O
5	there	O
6	are	O
7	multiple	O
8	mechanisms	O
9	by	O
10	which	O
11	an	O
12	individual	O
13	transcript	O
14	can	O
15	be	O
16	degraded	O
17	following	O
18	deadenylation	O
19	.	O

1	Tele	O
2	-	O
3	Talk	O
4	has	O
5	the	O
6	extra	O
7	capability	O
8	of	O
9	operating	O
10	in	O
11	live	O
12	conference	O
13	situations	O
14	using	O
15	microphone	O
16	input	O
17	.	O

1	Femoral	O
2	strain	O
3	adaptation	O
4	after	O
5	total	O
6	hip	O
7	replacement	O
8	:	O
9	a	O
10	comparison	O
11	of	O
12	cemented	O
13	and	O
14	porous	O
15	ingrowth	O
16	components	O
17	in	O
18	canines	O
19	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	fludarabine	O
6	is	O
7	a	O
8	highly	O
9	useful	O
10	agent	O
11	in	O
12	CLL	O
13	.	O

1	The	O
2	sequence	O
3	up	O
4	to	O
5	-	O
6	267	O
7	bp	O
8	relative	O
9	to	O
10	the	O
11	transcription	O
12	start	O
13	site	O
14	was	O
15	sufficient	O
16	to	O
17	enhance	O
18	reporter	O
19	gene	O
20	expression	O
21	depending	O
22	on	O
23	the	O
24	mesodermal	O
25	differentiation	O
26	of	O
27	P19	O
28	cells	O
29	.	O

1	The	O
2	clinical	O
3	relevance	O
4	of	O
5	these	O
6	findings	O
7	is	O
8	strengthened	O
9	by	O
10	the	O
11	observation	O
12	that	O
13	similar	O
14	results	O
15	were	O
16	obtained	O
17	when	O
18	P	O
19	.	O
20	HCl	O
21	was	O
22	given	O
23	by	O
24	the	O
25	intravenous	O
26	route	O
27	.	O

1	Natl	O
2	.	O

1	An	O
2	IgG	B
3	monoclonal	I
4	gammopathy	O
5	was	O
6	present	O
7	in	O
8	the	O
9	serum	O
10	of	O
11	4	O
12	patients	O
13	and	O
14	Bence	O
15	-	O
16	Joanes	O
17	proteinuria	O
18	was	O
19	found	O
20	in	O
21	1	O
22	patient	O
23	.	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	potential	O
6	for	O
7	prostate	O
8	cancer	O
9	chemoprevention	O
10	using	O
11	nonsteroidal	O
12	anti	B
13	-	I
14	inflammatory	O
15	drugs	O
16	(	O
17	cyclo	B
18	-	I
19	oxygenase	I
20	inhibitors	O
21	;	O
22	NSAIDs	O
23	)	O
24	has	O
25	received	O
26	little	O
27	attention	O
28	.	O

1	The	O
2	transcripts	O
3	were	O
4	equally	O
5	active	O
6	with	O
7	or	O
8	without	O
9	a	O
10	5	O
11	'	O
12	methylated	O
13	capstructure	O
14	as	O
15	expected	O
16	,	O
17	since	O
18	EMCV	O
19	-	O
20	RNA	O
21	is	O
22	one	O
23	of	O
24	the	O
25	mRNAs	O
26	capable	O
27	of	O
28	internal	O
29	initiation	O
30	.	O

1	When	O
2	normalized	O
3	for	O
4	imaging	O
5	time	O
6	,	O
7	all	O
8	parameters	O
9	are	O
10	significantly	O
11	higher	O
12	with	O
13	RASE	O
14	,	O
15	with	O
16	a	O
17	C	O
18	/	O
19	A	O
20	per	O
21	unit	O
22	time	O
23	that	O
24	was	O
25	338	O
26	%	O
27	higher	O
28	.	O

1	A	O
2	high	O
3	efficacy	O
4	of	O
5	the	O
6	combined	O
7	use	O
8	of	O
9	nontoxic	O
10	doses	O
11	of	O
12	two	O
13	pharmaceuticals	O
14	:	O
15	cystamine	O
16	(	O
17	50	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	mexamine	O
24	(	O
25	25	O
26	mg	O
27	/	O
28	kg	O
29	)	O
30	under	O
31	the	O
32	conditions	O
33	of	O
34	short	O
35	-	O
36	term	O
37	exogenous	O
38	hypoxia	O
39	(	O
40	7	O
41	.	O
42	5	O
43	%	O
44	O2	O
45	)	O
46	was	O
47	found	O
48	in	O
49	(	O
50	CBA	O
51	X	O
52	C57Bl	O
53	)	O
54	F1	O
55	mice	O
56	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	unique	O
7	suppository	O
8	formulation	O
9	of	O
10	CZX	O
11	-	O
12	S	O
13	is	O
14	useful	O
15	in	O
16	the	O
17	treatment	O
18	of	O
19	infections	O
20	in	O
21	children	O
22	with	O
23	heavy	O
24	psychophysiologic	O
25	disorders	O
26	and	O
27	in	O
28	children	O
29	who	O
30	cannot	O
31	take	O
32	oral	O
33	drugs	O
34	because	O
35	of	O
36	severe	O
37	vomiting	O
38	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	lengths	O
11	of	O
12	the	O
13	5	O
14	'	O
15	mdr1b	O
16	sequences	O
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	247	O
25	to	O
26	-	O
27	126	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O

1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O

1	The	O
2	remainder	O
3	(	O
4	18	O
5	.	O
6	4	O
7	%)	O
8	was	O
9	with	O
10	IgA	B
11	nephropathy	<s>
12	,	O
13	which	O
14	was	O
15	histologically	O
16	mild	O
17	.	O

1	In	O
2	a	O
3	previous	O
4	study	O
5	(	O
6	Brandl	O
7	,	O
8	C	O
9	.	O

1	Adrenergic	O
2	system	O
3	activation	O
4	,	O
5	indicated	O
6	by	O
7	metanephrine	O
8	/	O
9	epinephrine	O
10	ratio	O
11	,	O
12	increased	O
13	with	O
14	time	O
15	in	O
16	losing	O
17	males	O
18	,	O
19	except	O
20	that	O
21	after	O
22	one	O
23	month	O
24	of	O
25	cohabitation	O
26	,	O
27	turnover	O
28	returned	O
29	to	O
30	levels	O
31	that	O
32	equaled	O
33	those	O
34	of	O
35	control	O
36	animals	O
37	.	O

1	Behavioral	O
2	and	O
3	electrographic	O
4	expression	O
5	of	O
6	natural	O
7	sleep	O
8	and	O
9	wakefulness	O
10	in	O
11	reptiles	B

1	Greater	O
2	attenuation	O
3	of	O
4	the	O
5	N1	O
6	-	O
7	P2	O
8	and	O
9	baseline	O
10	-	O
11	P2	O
12	amplitude	O
13	of	O
14	the	O
15	probe	O
16	EPs	O
17	was	O
18	observed	O
19	when	O
20	the	O
21	probe	O
22	stimulus	O
23	was	O
24	presented	O
25	to	O
26	the	O
27	right	O
28	ear	O
29	and	O
30	the	O
31	verbal	O
32	material	O
33	presented	O
34	to	O
35	the	O
36	left	O
37	ear	O
38	than	O
39	when	O
40	the	O
41	opposite	O
42	stimulation	O
43	arrangement	O
44	was	O
45	used	O
46	.	O

1	Schlegel	O
2	,	O
3	J	O
4	.	O

1	A	O
2	highly	O
3	significant	O
4	correlation	O
5	was	O
6	found	O
7	between	O
8	the	O
9	presence	O
10	of	O
11	fibrinolytic	O
12	degradation	O
13	products	O
14	(	O
15	FDP	O
16	)	O
17	and	O
18	the	O
19	incidence	O
20	of	O
21	nephropathy	O
22	and	O
23	renal	O
24	insufficiency	O
25	,	O
26	as	O
27	well	O
28	as	O
29	between	O
30	the	O
31	presence	O
32	of	O
33	fibrin	B
34	monomers	I
35	(	O
36	Godal	O
37	'	O
38	s	O
39	ethanol	O
40	-	O
41	gelification	O
42	test	O
43	)	O
44	and	O
45	the	O
46	evolutive	O
47	signs	O
48	of	O
49	the	O
50	primary	O
51	disease	O
52	(	O
53	fever	O
54	,	O
55	accelerated	O
56	ESR	O
57	).	O

1	To	O
2	our	O
3	knowledge	O
4	,	O
5	type	O
6	IV	O
7	renal	O
8	tubular	O
9	acidosis	O
10	has	O
11	not	O
12	been	O
13	reported	O
14	previously	O
15	in	O
16	association	O
17	with	O
18	Alport	O
19	'	O
20	s	O
21	syndrome	O
22	in	O
23	an	O
24	adult	O
25	patient	O
26	.	O

1	Both	O
2	quantitative	O
3	and	O
4	qualitative	O
5	analysis	O
6	of	O
7	individual	O
8	cytoarchitectonic	O
9	peculiarities	O
10	of	O
11	Meynart	O
12	'	O
13	s	O
14	nucleus	O
15	as	O
16	well	O
17	as	O
18	of	O
19	external	O
20	part	O
21	of	O
22	dorsomedial	O
23	nucleus	O
24	of	O
25	thalamus	O
26	was	O
27	performed	O
28	in	O
29	mentally	O
30	normal	O
31	individuals	O
32	.	O

1	RESULTS	O
2	:	O
3	Nodular	O
4	opacities	O
5	,	O
6	mainly	O
7	centrilobular	O
8	in	O
9	distribution	O
10	,	O
11	were	O
12	the	O
13	most	O
14	common	O
15	finding	O
16	,	O
17	seen	O
18	in	O
19	21	O
20	(	O
21	72	O
22	%)	O
23	and	O
24	15	O
25	(	O
26	65	O
27	%)	O
28	of	O
29	patients	O
30	with	O
31	MTB	O
32	and	O
33	NTMB	O
34	,	O
35	respectively	O
36	.	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	O
20	Na3	B

1	Moreover	O
2	,	O
3	the	O
4	Rho	B
5	family	I
6	protein	I
7	Cdc42	I
8	,	O
9	a	O
10	conserved	O
11	morphogenetic	B
12	G	I
13	protein	I
14	,	O
15	is	O
16	also	O
17	a	O
18	potent	O
19	regulator	O
20	of	O
21	filamentous	O
22	growth	O
23	and	O
24	FG	B
25	(	I
26	TyA	I
27	)::	O
28	lacZ	B
29	expression	O
30	in	O
31	S	O
32	.	O
33	cerevisiae	O
34	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	have	O
5	already	O
6	had	O
7	an	O
8	enormous	O
9	impact	O
10	on	O
11	transfusion	O
12	practice	O
13	by	O
14	eliminating	O
15	or	O
16	reducing	O
17	the	O
18	need	O
19	for	O
20	red	O
21	blood	O
22	cell	O
23	transfusions	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	anemic	O
29	states	O
30	characterized	O
31	by	O
32	an	O
33	absolute	O
34	or	O
35	relative	O
36	decrease	O
37	in	O
38	erythropoietin	B
39	.	I

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	O
8	protein	O
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	O
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O

1	Four	O
2	transcription	O
3	initiation	O
4	sites	O
5	have	O
6	been	O
7	identified	O
8	by	O
9	full	B
10	-	I
11	length	I
12	RNA	I
13	ligase	I
14	-	I
15	mediated	O
16	rapid	O
17	amplification	O
18	of	O
19	cDNA	O
20	ends	O
21	(	O
22	RLM	O
23	-	O
24	RACE	O
25	)	O
26	between	O
27	-	O
28	61	O
29	and	O
30	-	O
31	32	O
32	bp	O
33	from	O
34	the	O
35	translation	O
36	initiation	O
37	codon	O
38	.	O
39	Reverse	O
40	transcription	O
41	-	O
42	PCR	O
43	analysis	O
44	revealed	O
45	that	O
46	PFK	B
47	-	I
48	A	I
49	,	O
50	PFK	B
51	-	I
52	B	I
53	and	O
54	PFK	B
55	-	I
56	C	I
57	genes	I
58	were	O
59	expressed	O
60	,	O
61	in	O
62	all	O
63	mouse	O
64	tissues	O
65	tested	O
66	,	O
67	at	O
68	varying	O
69	levels	O
70	.	O

1	To	O
2	determine	O
3	the	O
4	function	O
5	of	O
6	VZV	O
7	gK	O
8	in	O
9	virus	O
10	growth	O
11	,	O
12	a	O
13	series	O
14	of	O
15	gK	B
16	deletion	I
17	mutants	I
18	were	O
19	constructed	O
20	with	O
21	VZV	O
22	cosmid	O
23	DNA	O
24	derived	O
25	from	O
26	the	O
27	Oka	O
28	strain	O
29	.	O

1	Relaxation	O
2	of	O
3	catch	O
4	in	O
5	a	O
6	molluscan	O
7	smooth	O
8	muscle	O
9	.	O

1	When	O
2	blood	O
3	samples	O
4	of	O
5	patients	O
6	with	O
7	hyperbilirubinemia	O
8	were	O
9	analyzed	O
10	,	O
11	direct	O
12	measurement	O
13	of	O
14	ZPP	O
15	by	O
16	this	O
17	fluorimeter	O
18	yielded	O
19	significantly	O
20	higher	O
21	levels	O
22	than	O
23	did	O
24	an	O
25	alternate	O
26	extraction	O
27	method	O
28	.	O

1	Unitary	O
2	-	O
3	group	O
4	approach	O
5	to	O
6	spin	O
7	-	O
8	dependent	O
9	operators	O
10	.	O

1	But	O
2	the	O
3	application	O
4	solutions	O
5	of	O
6	instrument	O
7	disinfectants	O
8	should	O
9	not	O
10	be	O
11	used	O
12	longer	O
13	than	O
14	one	O
15	day	O
16	.	O

1	Standard	O
2	curve	O
3	correlation	O
4	coefficients	O
5	of	O
6	0	O
7	.	O
8	995	O
9	or	O
10	greater	O
11	were	O
12	obtained	O
13	during	O
14	validation	O
15	experiments	O
16	and	O
17	analysis	O
18	of	O
19	study	O
20	samples	O
21	.	O

1	Using	O
2	various	O
3	techniques	O
4	,	O
5	we	O
6	have	O
7	undertaken	O
8	a	O
9	systematic	O
10	analysis	O
11	of	O
12	the	O
13	natural	O
14	TATA	O
15	-	O
16	less	O
17	human	B
18	DNA	I
19	polymerase	I
20	beta	I
21	(	I
22	beta	I
23	-	I
24	pol	I
25	)	I
26	gene	I
27	promoter	I
28	.	I

1	Mycotoxins	O
2	in	O
3	feeds	O
4	and	O
5	foods	O
6	.	O

1	The	O
2	remaining	O
3	80	O
4	patients	O
5	underwent	O
6	recordings	O
7	of	O
8	ECG	O
9	,	O
10	beat	O
11	-	O
12	to	O
13	-	O
14	beat	O
15	arterial	O
16	oxygen	O
17	saturation	O
18	(	O
19	SaO2	O
20	),	O
21	and	O
22	respiration	O
23	during	O
24	both	O
25	spontaneous	O
26	and	O
27	controlled	O
28	breathing	O
29	.	O

1	Venkatesan	O
2	,	O
3	and	O
4	D	O
5	.	O

1	The	O
2	metabolic	O
3	clearance	O
4	rate	O
5	of	O
6	progesterone	O
7	was	O
8	295	O
9	+/-	O
10	49	O
11	(	O
12	S	O
13	.	O
14	E	O
15	.)	O
16	1	O
17	/	O
18	day	O
19	.	O

1	However	O
2	,	O
3	in	O
4	those	O
5	studies	O
6	due	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	thiol	O
12	agents	O
13	in	O
14	the	O
15	PKC	B
16	preparations	O
17	,	O
18	the	O
19	sensitive	O
20	reaction	O
21	of	O
22	BPO	O
23	with	O
24	redox	O
25	-	O
26	active	O
27	cysteine	O
28	residues	O
29	in	O
30	PKC	B
31	was	O
32	not	O
33	observed	O
34	.	O

1	If	O
2	we	O
3	apply	O
4	the	O
5	finding	O
6	of	O
7	non	O
8	-	O
9	visualization	O
10	of	O
11	the	O
12	GB	O
13	at	O
14	4	O
15	h	O
16	post	O
17	injection	O
18	as	O
19	the	O
20	criterion	O
21	for	O
22	the	O
23	diagnosis	O
24	of	O
25	AC	O
26	,	O
27	the	O
28	diagnostic	O
29	accuracy	O
30	was	O
31	only	O
32	40	O
33	.	O
34	7	O
35	%	O
36	(	O
37	11	O
38	/	O
39	27	O
40	).	O

1	The	O
2	response	O
3	chain	O
4	in	O
5	each	O
6	component	O
7	was	O
8	maintained	O
9	by	O
10	food	O
11	presentation	O
12	under	O
13	a	O
14	fixed	O
15	-	O
16	ratio	O
17	schedule	O
18	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	bradycardic	O
7	agents	O
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O

1	The	O
2	transcription	O
3	factor	O
4	E2F	B
5	plays	O
6	an	O
7	important	O
8	role	O
9	in	O
10	G	O
11	(	O
12	1	O
13	)	O
14	to	O
15	S	O
16	phase	O
17	transition	O
18	in	O
19	the	O
20	higher	O
21	eukaryotic	O
22	cell	O
23	cycle	O
24	.	O

1	The	O
2	3	O
3	.	O
4	3	O
5	-	O
6	fold	O
7	higher	O
8	expression	O
9	in	O
10	the	O
11	fetal	O
12	heart	O
13	than	O
14	in	O
15	the	O
16	adult	O
17	heart	O
18	suggests	O
19	that	O
20	HFHZ	O
21	mRNA	O
22	is	O
23	downregulated	O
24	in	O
25	the	O
26	process	O
27	of	O
28	development	O
29	.	O

1	Stress	B
2	-	I
3	inducible	I
4	protein	I
5	kinases	I
6	capable	O
7	of	O
8	activating	O
9	c	B
10	-	I
11	jun	I
12	expression	O
13	include	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	/	I
20	c	I
21	-	I
22	Jun	I
23	N	I
24	-	I
25	terminal	I
26	protein	I
27	kinase	I
28	(	O
29	SAPK	B
30	/	O
31	JNK	B
32	)	O
33	and	O
34	p38	B
35	members	O
36	of	O
37	the	O
38	mitogen	B
39	-	I
40	activated	I
41	protein	I
42	kinase	I
43	(	I
44	MAPK	I
45	)	I
46	superfamily	I
47	of	O
48	signaling	O
49	molecules	O
50	.	O

1	In	O
2	vivo	O
3	,	O
4	selective	O
5	activation	O
6	of	O
7	SAPKs	O
8	stimulates	O
9	formation	O
10	of	O
11	the	O
12	ternary	O
13	complex	O
14	containing	O
15	Elk	B
16	-	I
17	1	I
18	,	O
19	serum	O
20	response	O
21	factor	O
22	and	O
23	the	O
24	serum	O
25	response	O
26	element	O
27	,	O
28	and	O
29	enhances	O
30	Elk	B
31	-	I
32	1	I
33	-	I
34	dependent	I
35	transcription	I
36	.	I

1	Predictors	O
2	of	O
3	success	O
4	in	O
5	pharmacy	O
6	school	O
7	:	O
8	PCAT	O
9	vs	O
10	.	O
11	other	O
12	admission	O
13	criteria	O
14	.	O

1	We	O
2	discuss	O
3	these	O
4	results	O
5	with	O
6	respect	O
7	to	O
8	the	O
9	transcriptional	O
10	induction	O
11	of	O
12	the	O
13	HNF	B
14	-	I
15	3	I
16	alpha	I
17	gene	I
18	in	O
19	respiratory	O
20	epithelium	O
21	during	O
22	embryogenesis	O
23	.	O

1	The	O
2	patients	O
3	in	O
4	one	O
5	group	O
6	had	O
7	intrauterine	O
8	catheters	O
9	inserted	O
10	and	O
11	oxytocin	B
12	was	O
13	titrated	O
14	to	O
15	achieve	O
16	the	O
17	75th	O
18	percentile	O
19	of	O
20	uterine	O
21	activity	O
22	observed	O
23	in	O
24	spontaneous	O
25	normal	O
26	labour	O
27	according	O
28	to	O
29	parity	O
30	.	O

1	Strategic	O
2	change	O
3	in	O
4	the	O
5	NHS	O
6	.	O

1	A	O
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	porin	O
16	gene	O
17	(	O
18	named	O
19	porCa	O
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O

1	Ischemic	O
2	stroke	O
3	due	O
4	to	O
5	protein	O
6	C	O
7	deficiency	O
8	.	O

1	Four	O
2	forms	O
3	of	O
4	salmonellosis	O
5	were	O
6	recognised	O
7	in	O
8	feedlots	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	septicaemic	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	subacute	O
21	and	O
22	chronic	O
23	enteric	O
24	.	O

1	Fatal	O
2	encephalitis	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O

1	Neither	O
2	ethanol	O
3	regimen	O
4	impaired	O
5	spontaneous	O
6	alternation	O
7	,	O
8	but	O
9	the	O
10	4	O
11	g	O
12	ethanol	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	x	O
18	day	O
19	-	O
20	1	O
21	regimen	O
22	increased	O
23	the	O
24	percent	O
25	completed	O
26	trials	O
27	.	O

1	The	O
2	amino	O
3	acid	O
4	changes	O
5	D206A	O
6	and	O
7	D208A	O
8	abolish	O
9	singly	O
10	or	O
11	in	O
12	combination	O
13	the	O
14	exonuclease	O
15	activity	O
16	in	O
17	vivo	O
18	.	O

1	The	O
2	same	O
3	ligands	O
4	also	O
5	exhibit	O
6	a	O
7	similar	O
8	inhibitory	O
9	effect	O
10	on	O
11	PDGF	B
12	-	I
13	BB	I
14	-	I
15	dependent	I
16	[	O
17	3H	O
18	]	O
19	thymidine	O
20	incorporation	O
21	in	O
22	PAE	O
23	cells	O
24	expressing	O
25	the	O
26	PDGF	B
27	beta	I
28	-	I
29	receptors	I
30	.	I

1	In	O
2	the	O
3	absence	O
4	of	O
5	Mg2	O
6	+,	O
7	a	O
8	hydrophobic	O
9	exonuclease	O
10	site	O
11	dominates	O
12	over	O
13	the	O
14	polymerase	O
15	site	O
16	for	O
17	possession	O
18	of	O
19	the	O
20	primer	O
21	terminus	O
22	.	O

1	Structural	O
2	basis	O
3	for	O
4	activation	O
5	of	O
6	human	B
7	lymphocyte	I
8	kinase	I
9	Lck	I
10	upon	O
11	tyrosine	O
12	phosphorylation	O
13	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	signaling	O
6	triggered	O
7	by	O
8	surface	O
9	Ig	B
10	engagement	<s>
11	in	O
12	B	O
13	lymphocytes	O
14	,	O
15	CD38	O
16	ligation	O
17	did	O
18	not	O
19	appear	O
20	to	O
21	induce	O
22	tyrosine	O
23	phosphorylation	O
24	of	O
25	the	O
26	src	B
27	-	I
28	like	I
29	protein	I
30	tyrosine	I
31	kinases	I
32	lyn	O
33	,	O
34	fyn	O
35	,	O
36	and	O
37	btk	O
38	,	O
39	or	O
40	of	O
41	vav	O
42	-	O
43	and	O
44	ras	B
45	-	I
46	GTPase	I
47	-	I
48	activating	I
49	protein	I
50	,	O
51	nor	O
52	did	O
53	it	O
54	induce	O
55	detectable	O
56	changes	O
57	in	O
58	cytosolic	O
59	CA2	O
60	+	O
61	concentrations	O
62	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	I
9	-	I
10	1	I
11	)	O
12	preferentially	O
13	infects	O
14	CD4	B
15	+	I
16	T	O
17	lymphocytes	O
18	and	O
19	may	O
20	exist	O
21	as	O
22	a	O
23	latent	O
24	provirus	O
25	within	O
26	these	O
27	cells	O
28	for	O
29	extended	O
30	periods	O
31	.	O

1	In	O
2	a	O
3	recent	O
4	measles	O
5	epidemic	O
6	in	O
7	El	O
8	Paso	O
9	,	O
10	TX	O
11	,	O
12	120	O
13	,	O
14	000	O
15	records	O
16	were	O
17	screened	O
18	using	O
19	these	O
20	criteria	O
21	,	O
22	and	O
23	as	O
24	a	O
25	result	O
26	13	O
27	,	O
28	000	O
29	students	O
30	were	O
31	vaccinated	O
32	.	O

1	As	O
2	a	O
3	sequence	O
4	-	O
5	specific	O
6	DNA	O
7	binding	O
8	transcription	O
9	factor	O
10	,	O
11	p53	B
12	specifically	O
13	binds	O
14	to	O
15	a	O
16	20	O
17	-	O
18	bp	O
19	consensus	O
20	motif	O
21	5	O
22	'-	O
23	PuPuPuC	O
24	(	O
25	A	O
26	/	O
27	T	O
28	)	O
29	(	O
30	T	O
31	/	O
32	A	O
33	)	O
34	GPyPyPyPuPuPuC	O
35	(	O
36	A	O
37	/	O
38	T	B
39	)(	I
40	T	I
41	/	I
42	A	I
43	)	I
44	GPyPyPy	I
45	-	I
46	3	I
47	'.	I

1	Cooperative	O
2	roles	O
3	of	O
4	Bozozok	O
5	/	O
6	Dharma	O
7	and	O
8	Nodal	B
9	-	I
10	related	I
11	proteins	I
12	in	O
13	the	O
14	formation	O
15	of	O
16	the	O
17	dorsal	O
18	organizer	O
19	in	O
20	zebrafish	O
21	.	O

1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O

1	Altogether	O
2	these	O
3	results	O
4	indicate	O
5	that	O
6	the	O
7	Syn	O
8	5	O
9	locus	O
10	segregates	O
11	from	O
12	the	O
13	gene	O
14	specifying	O
15	gH	O
16	,	O
17	to	O
18	a	O
19	region	O
20	encompassing	O
21	portions	O
22	of	O
23	the	O
24	TK	B
25	and	O
26	UL	O
27	24	O
28	genes	O
29	,	O
30	and	O
31	that	O
32	the	O
33	syn	O
34	mutation	O
35	does	O
36	not	O
37	affect	O
38	the	O
39	expression	O
40	or	O
41	activity	O
42	of	O
43	TK	B
44	.	I

1	This	O
2	effect	O
3	required	O
4	(	O
5	i	O
6	)	O
7	IR	O
8	activation	O
9	since	O
10	it	O
11	was	O
12	abrogated	O
13	by	O
14	IR	O
15	mutation	O
16	at	O
17	tyrosines	O
18	1162	O
19	and	O
20	1163	O
21	and	O
22	(	O
23	ii	O
24	)	O
25	NF	B
26	-	I
27	kappaB	I
28	activation	O
29	since	O
30	it	O
31	was	O
32	abolished	O
33	by	O
34	overexpression	O
35	of	O
36	dominant	O
37	-	O
38	negative	O
39	IkappaB	B
40	-	I
41	alpha	I
42	(	O
43	A32	O
44	/	O
45	36	O
46	)	O
47	and	O
48	mimicked	O
49	by	O
50	overexpression	O
51	of	O
52	the	O
53	NF	B
54	-	I
55	kappaB	I
56	c	I
57	-	I
58	Rel	I
59	subunit	I
60	.	I

1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O

1	Paralemmin	O
2	is	O
3	also	O
4	phosphorylated	O
5	,	O
6	and	O
7	its	O
8	mRNA	O
9	is	O
10	differentially	O
11	spliced	O
12	in	O
13	a	O
14	tissue	O
15	-	O
16	specific	O
17	and	O
18	developmentally	O
19	regulated	O
20	manner	O
21	.	O

1	Therefore	O
2	,	O
3	in	O
4	conjunction	O
5	with	O
6	a	O
7	positive	O
8	pregnancy	O
9	test	O
10	and	O
11	the	O
12	patient	O
13	'	O
14	s	O
15	clinical	O
16	history	O
17	,	O
18	a	O
19	severely	O
20	depressed	O
21	or	O
22	absent	O
23	serum	O
24	PAPP	O
25	-	O
26	A	O
27	level	O
28	may	O
29	aid	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	extrauterine	O
35	pregnancy	O
36	.	O

1	Transfection	O
2	studies	O
3	also	O
4	showed	O
5	that	O
6	3	O
7	'-	O
8	deletion	O
9	of	O
10	sequences	O
11	downstream	O
12	of	O
13	the	O
14	transcriptional	O
15	start	O
16	site	O
17	(+	O
18	1	O
19	/+	O
20	47	O
21	)	O
22	markedly	O
23	reduced	O
24	OSM	O
25	-	O
26	fold	O
27	induction	O
28	.	O

1	The	O
2	responsiveness	O
3	of	O
4	visual	O
5	cortex	O
6	(	O
7	VC	O
8	)	O
9	and	O
10	superior	O
11	colliculus	O
12	(	O
13	SC	O
14	)	O
15	was	O
16	simultaneously	O
17	compared	O
18	following	O
19	conditioning	O
20	"	O
21	ON	O
22	"	O
23	or	O
24	"	O
25	OFF	O
26	"	O
27	stimulation	O
28	,	O
29	in	O
30	the	O
31	rabbit	O
32	.	O

1	These	O
2	thyroid	O
3	hormone	O
4	changes	O
5	may	O
6	be	O
7	mediated	O
8	in	O
9	part	O
10	by	O
11	cytokines	O
12	or	O
13	other	O
14	inflammatory	O
15	mediators	O
16	,	O
17	acting	O
18	at	O
19	the	O
20	level	O
21	of	O
22	the	O
23	hypothalamus	O
24	and	O
25	pituitary	O
26	gland	O
27	,	O
28	the	O
29	thyroid	O
30	gland	O
31	,	O
32	and	O
33	the	O
34	hepatic	O
35	deiodinase	O
36	system	O
37	.	O

1	Looming	O
2	detectors	O
3	in	O
4	the	O
5	human	O
6	visual	O
7	pathway	O
8	.	O

1	This	O
2	enzyme	O
3	is	O
4	designated	O
5	(	O
6	1	O
7	-->	B
8	4	I
9	)-	I
10	beta	I
11	-	I
12	xylan	I
13	endohydrolase	I
14	isoenzyme	I
15	X	I
16	-	I
17	I	I
18	.	I

1	Using	O
2	a	O
3	natural	O
4	dominant	O
5	negative	O
6	for	O
7	AP	B
8	-	I
9	1	I
10	transcriptional	O
11	activity	O
12	in	O
13	ROS	O
14	17	O
15	/	O
16	2	O
17	.	O
18	8	O
19	cells	O
20	,	O
21	we	O
22	then	O
23	showed	O
24	that	O
25	AP	B
26	-	I
27	1	I
28	transcription	I
29	factors	I
30	mediated	O
31	TGF	B
32	-	I
33	beta1	I
34	-	I
35	and	O
36	BMP	B
37	-	I
38	2	I
39	-	I
40	regulated	O
41	expression	O
42	of	O
43	the	O
44	(	O
45	alpha1	B
46	)	I
47	collagen	I
48	I	I
49	gene	I
50	as	O
51	well	O
52	as	O
53	TGF	B
54	-	I
55	beta1	I
56	-	I
57	regulated	O
58	expression	O
59	of	O
60	the	O
61	parathyroid	B
62	hormone	I
63	(	I
64	PTH	I
65	)/	I
66	PTH	I
67	-	I
68	related	I
69	peptide	I
70	(	I
71	PTHrP	I
72	)	I
73	receptor	I
74	.	I

1	Re	O
2	-	O
3	examination	O
4	of	O
5	the	O
6	ED01	O
7	study	O
8	.	O

1	From	O
2	day	O
3	10	O
4	,	O
5	a	O
6	significant	O
7	increase	O
8	in	O
9	platelet	O
10	count	O
11	was	O
12	observed	O
13	in	O
14	eight	O
15	of	O
16	the	O
17	ten	O
18	patients	O
19	treated	O
20	with	O
21	heparin	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	),	O
29	with	O
30	return	O
31	to	O
32	the	O
33	initial	O
34	value	O
35	after	O
36	heparin	O
37	cessation	O
38	in	O
39	six	O
40	of	O
41	the	O
42	responders	O
43	.	O

1	To	O
2	understand	O
3	whether	O
4	Shc	B
5	localization	O
6	in	O
7	membrane	O
8	rafts	O
9	is	O
10	sufficient	O
11	to	O
12	regulate	O
13	Shc	B
14	function	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	Shc	B
20	chimera	<s>
21	containing	O
22	the	O
23	Ras	B
24	membrane	O
25	localization	O
26	motif	O
27	at	O
28	the	O
29	C	O
30	-	O
31	terminus	O
32	.	O

1	Type	O
2	I	O
3	position	O
4	-	O
5	vestibular	O
6	-	O
7	pause	O
8	(	O
9	PVP	O
10	I	O
11	)	O
12	and	O
13	vestibular	O
14	-	O
15	only	O
16	(	O
17	V	O
18	I	O
19	)	O
20	neurons	O
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	smaller	O
27	number	O
28	of	O
29	other	O
30	type	O
31	I	O
32	and	O
33	type	O
34	II	O
35	eye	O
36	-	O
37	plus	O
38	-	O
39	vestibular	O
40	neurons	O
41	were	O
42	studied	O
43	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	release	O
6	of	O
7	interleukin	B
8	-	I
9	1	I
10	beta	I
11	(	I
12	IL	I
13	-	I
14	1	I
15	)	I
16	and	I
17	tumour	I
18	necrosis	I
19	factor	I
20	-	I
21	alpha	I
22	(	I
23	TNF	I
24	)	O
25	by	O
26	unstimulated	O
27	monocytes	O
28	and	O
29	monocytes	O
30	stimulated	O
31	with	O
32	lipopolysaccharide	O
33	(	O
34	LPS	O
35	)	O
36	isolated	O
37	from	O
38	the	O
39	peripheral	O
40	blood	O
41	of	O
42	two	O
43	patients	O
44	with	O
45	acute	O
46	poststreptococcal	O
47	glomerulonephritis	O
48	(	O
49	AGN	O
50	)	O
51	and	O
52	16	O
53	healthy	O
54	controls	O
55	.	O

1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	O
11	sequences	O
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	Low	O
2	NA	O
3	and	O
4	A	O
5	may	O
6	participate	O
7	in	O
8	lowering	O
9	the	O
10	plasma	B
11	renin	I
12	activity	O
13	which	O
14	in	O
15	PA	O
16	in	O
17	suppressed	O
18	,	O
19	sometimes	O
20	disproportionately	O
21	to	O
22	the	O
23	actual	O
24	body	O
25	sodium	O
26	content	O
27	.	O

1	Several	O
2	genes	O
3	or	O
4	transcriptional	O
5	units	O
6	were	O
7	identified	O
8	,	O
9	including	O
10	the	O
11	3	O
12	'	O
13	end	O
14	of	O
15	ribosomal	B
16	s6	I
17	kinase	I
18	(	O
19	Rsk3	O
20	);	O
21	two	O
22	apparently	O
23	intronless	O
24	and	O
25	ORF	O
26	-	O
27	less	O
28	genes	O
29	;	O
30	and	O
31	Gpr31	O
32	,	O
33	an	O
34	intronless	O
35	,	O
36	putative	O
37	G	B
38	-	I
39	protein	I
40	coupled	I
41	receptor	I
42	.	I

1	These	O
2	sequences	O
3	were	O
4	then	O
5	used	O
6	to	O
7	clone	O
8	the	O
9	full	O
10	-	O
11	length	O
12	genes	O
13	from	O
14	a	O
15	yeast	O
16	genomic	O
17	library	O
18	.	O

1	Study	O
2	of	O
3	the	O
4	physico	O
5	-	O
6	chemical	O
7	state	O
8	of	O
9	plutonium	O
10	-	O
11	239	O
12	in	O
13	a	O
14	citrate	O
15	solution	O
16	-	O
17	blood	O
18	system	O

1	Influence	O
2	of	O
3	diet	O
4	on	O
5	urinary	O
6	VMA	O
7	excretion	O
8	.	O

1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	O
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	I
18	CD3	I
19	monoclonal	I
20	antibodies	I
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	B
26	and	O
27	MEK	B
28	enzymatic	O
29	activity	O
30	.	O

1	When	O
2	expressed	O
3	in	O
4	and	O
5	purified	O
6	from	O
7	Escherichia	O
8	coli	O
9	,	O
10	both	O
11	full	O
12	-	O
13	length	O
14	Fpr3	O
15	and	O
16	its	O
17	isolated	O
18	COOH	O
19	-	O
20	terminal	O
21	domain	O
22	exhibit	O
23	readily	O
24	detectable	O
25	PPIase	O
26	activity	O
27	.	O

1	These	O
2	differences	O
3	involve	O
4	specific	O
5	hydrogen	O
6	-	O
7	bonding	O
8	interactions	O
9	between	O
10	the	O
11	protein	O
12	and	O
13	DNA	O
14	,	O
15	including	O
16	guanine	O
17	N7	O
18	sites	O
19	in	O
20	the	O
21	major	O
22	groove	O
23	of	O
24	DNA	O
25	,	O
26	and	O
27	alterations	O
28	in	O
29	DNA	O
30	phosphodiester	O
31	conformation	O
32	induced	O
33	by	O
34	protein	O
35	binding	O
36	.	O

1	The	O
2	extended	O
3	rat	O
4	SP	B
5	-	I
6	A	I
7	isoforms	I
8	were	O
9	enriched	O
10	in	O
11	the	O
12	more	O
13	fully	O
14	glycosylated	O
15	and	O
16	multimeric	O
17	SP	O
18	-	O
19	A	O
20	species	O
21	separated	O
22	on	O
23	SDS	O
24	-	O
25	PAGE	O
26	gels	O
27	.	O

1	The	O
2	method	O
3	involves	O
4	preliminary	O
5	isolation	O
6	of	O
7	oxiracetam	O
8	and	O
9	internal	O
10	standard	O
11	from	O
12	plasma	O
13	by	O
14	solid	O
15	-	O
16	phase	O
17	extraction	O
18	prior	O
19	to	O
20	the	O
21	formation	O
22	of	O
23	their	O
24	n	O
25	-	O
26	propyl	O
27	carbamate	O
28	derivatives	O
29	.	O

1	Videonystagmoscopy	O
2	has	O
3	been	O
4	used	O
5	to	O
6	subjectively	O
7	observe	O
8	the	O
9	responses	O
10	of	O
11	the	O
12	vestibular	O
13	system	O
14	in	O
15	a	O
16	population	O
17	of	O
18	patients	O
19	with	O
20	vestibular	O
21	deficits	O
22	.	O

1	The	O
2	vigilance	O
3	task	O
4	and	O
5	the	O
6	measurement	O
7	of	O
8	attentional	O
9	deficits	O
10	.	O

1	C	I
2	/	I
3	EBP	I
4	beta	I
5	V	I
6	>	O
7	A	O
8	selectively	O
9	binds	O
10	only	O
11	the	O
12	subset	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	sites	I
18	that	O
19	are	O
20	also	O
21	DBP	O
22	sites	O
23	,	O
24	both	O
25	as	O
26	oligonucleotides	O
27	and	O
28	within	O
29	the	O
30	natural	O
31	contexts	O
32	of	O
33	the	O
34	albumin	B
35	and	I
36	cholesterol	I
37	hydroxylase	I
38	promoters	I
39	.	I

1	Genomic	O
2	DNA	O
3	hybridization	O
4	suggests	O
5	that	O
6	SpSHR2	O
7	is	O
8	a	O
9	single	O
10	-	O
11	copy	O
12	gene	O
13	in	O
14	the	O
15	S	O
16	.	O
17	purpuratus	O
18	genome	O
19	.	O

1	Kodak	O
2	XV	B
3	-	I
4	2	I
5	film	I
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	The	O
2	future	O
3	of	O
4	research	O
5	with	O
6	interferon	B
7	may	O
8	be	O
9	divided	O
10	into	O
11	three	O
12	areas	O
13	:	O
14	Efforts	O
15	must	O
16	be	O
17	made	O
18	to	O
19	determine	O
20	how	O
21	best	O
22	to	O
23	translate	O
24	the	O
25	in	O
26	vitro	O
27	synergy	O
28	into	O
29	clinically	O
30	meaningful	O
31	terms	O
32	;	O
33	in	O
34	order	O
35	to	O
36	exploit	O
37	the	O
38	fullest	O
39	potential	O
40	of	O
41	IFN	B
42	,	O
43	research	O
44	is	O
45	moving	O
46	toward	O
47	using	O
48	this	O
49	agent	O
50	earlier	O
51	in	O
52	disease	O
53	either	O
54	as	O
55	an	O
56	adjuvant	O
57	after	O
58	tumor	O
59	debulking	O
60	or	O
61	after	O
62	initial	O
63	diagnosis	O
64	;	O
65	the	O
66	medical	O
67	community	O
68	must	O
69	rethink	O
70	the	O
71	natural	O
72	history	O
73	of	O
74	some	O
75	diseases	O
76	,	O
77	because	O
78	the	O
79	fullest	O
80	potential	O
81	of	O
82	the	O
83	biologic	O
84	agents	O
85	will	O
86	most	O
87	likely	O
88	manifest	O
89	itself	O
90	when	O
91	these	O
92	agents	O
93	are	O
94	used	O
95	together	O
96	.	O

1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	(	I
8	snRNP	I
9	)	O
10	to	O
11	the	O
12	pre	O
13	-	O
14	mRNA	O
15	is	O
16	an	O
17	early	O
18	and	O
19	important	O
20	step	O
21	in	O
22	spliceosome	O
23	assembly	O
24	.	O

1	Effect	O
2	of	O
3	proteolytic	O
4	enzymes	O
5	and	O
6	polypeptides	O
7	on	O
8	the	O
9	antacid	O
10	activity	O
11	of	O
12	almagate	O
13	and	O
14	other	O
15	antacids	O
16	.	O

1	In	O
2	untransformed	O
3	cells	O
4	,	O
5	three	O
6	major	O
7	proteins	O
8	coprecipitated	O
9	with	O
10	CRKL	B
11	,	O
12	identified	O
13	as	O
14	C3G	O
15	,	O
16	SOS	O
17	and	O
18	c	B
19	-	I
20	ABL	I
21	.	I

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	revealed	O
6	that	O
7	two	O
8	clusters	O
9	of	O
10	basic	O
11	amino	O
12	acids	O
13	within	O
14	a	O
15	conserved	O
16	basic	O
17	region	O
18	and	O
19	two	O
20	amphipathic	O
21	helices	O
22	within	O
23	the	O
24	adjacent	O
25	HLH	O
26	domain	O
27	are	O
28	essential	O
29	for	O
30	sequence	O
31	-	O
32	specific	O
33	DNA	O
34	binding	O
35	and	O
36	hetero	O
37	-	O
38	oligomerization	O
39	,	O
40	respectively	O
41	.	O

1	Substantial	O
2	amounts	O
3	of	O
4	liposomal	O
5	ampicillin	O
6	were	O
7	recovered	O
8	from	O
9	isolated	O
10	Kupffer	O
11	cells	O
12	,	O
13	the	O
14	target	O
15	cells	O
16	of	O
17	L	O
18	.	O
19	monocytogenes	O
20	after	O
21	intravenous	O
22	inoculation	O
23	.	O

1	Finally	O
2	,	O
3	a	O
4	role	O
5	for	O
6	NF	B
7	-	I
8	kappaB	I
9	in	O
10	preventing	O
11	apoptosis	O
12	induced	O
13	by	O
14	ER	O
15	calcium	O
16	release	O
17	was	O
18	demonstrated	O
19	by	O
20	data	O
21	showing	O
22	that	O
23	sAPPalpha	O
24	prevents	O
25	thapsigargin	O
26	-	O
27	induced	O
28	apoptosis	O
29	,	O
30	an	O
31	effect	O
32	blocked	O
33	by	O
34	kappaB	B
35	decoy	O
36	DNA	O
37	.	O

1	Handgrip	O
2	dynamometry	O
3	was	O
4	also	O
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	O
11	patients	O
12	.	O

1	The	O
2	side	O
3	-	O
4	to	O
5	-	O
6	side	O
7	difference	O
8	was	O
9	statistically	O
10	significant	O
11	at	O
12	EXT	O
13	30	O
14	degrees	O
15	/	O
16	s	O
17	and	O
18	60	O
19	degrees	O
20	/	O
21	s	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	activity	O
5	was	O
6	increased	O
7	up	O
8	to	O
9	15	O
10	times	O
11	above	O
12	the	O
13	upper	O
14	normal	O
15	limit	O
16	in	O
17	children	O
18	,	O
19	who	O
20	received	O
21	aminopyrine	O
22	for	O
23	two	O
24	weeks	O
25	or	O
26	longer	O
27	.	O

1	Effect	O
2	of	O
3	the	O
4	methods	O
5	of	O
6	cutaneous	O
7	administration	O
8	of	O
9	methyl	O
10	isobutyl	O
11	ketone	O
12	on	O
13	its	O
14	toxicity	O

1	A	O
2	5	O
3	'	O
4	RNA	O
5	stem	O
6	-	O
7	loop	O
8	participates	O
9	in	O
10	the	O
11	transcription	O
12	attenuation	O
13	mechanism	O
14	that	O
15	controls	O
16	expression	O
17	of	O
18	the	O
19	Bacillus	B
20	subtilis	I
21	trpEDCFBA	I
22	operon	I
23	.	I

1	Amino	O
2	acid	O
3	sequence	O
4	comparisons	O
5	of	O
6	the	O
7	E74A	O
8	protein	O
9	reveal	O
10	a	O
11	highly	O
12	conserved	O
13	C	O
14	-	O
15	terminal	O
16	region	O
17	that	O
18	is	O
19	rich	O
20	in	O
21	basic	O
22	amino	O
23	acid	O
24	residues	O
25	and	O
26	which	O
27	has	O
28	been	O
29	proposed	O
30	to	O
31	possess	O
32	sequence	O
33	-	O
34	specific	O
35	DNA	O
36	binding	O
37	activity	O
38	.	O

1	Twenty	O
2	-	O
3	two	O
4	consecutive	O
5	patients	O
6	with	O
7	ischaemic	O
8	ulcers	O
9	had	O
10	tcPO2	O
11	measured	O
12	and	O
13	the	O
14	ankle	O
15	/	O
16	brachial	O
17	(	O
18	ABI	O
19	)	O
20	and	O
21	toe	O
22	/	O
23	brachial	O
24	(	O
25	TBI	O
26	)	O
27	indices	O
28	calculated	O
29	.	O

1	Naloxone	O
2	(	O
3	2	O
4	mg	O
5	/	O
6	kg	O
7	bolus	O
8	+	O
9	2	O
10	mg	O
11	X	O
12	kg	O
13	-	O
14	1	O
15	X	O
16	h	O
17	-	O
18	1	O
19	)	O
20	was	O
21	given	O
22	with	O
23	one	O
24	of	O
25	the	O
26	two	O
27	doses	O
28	of	O
29	the	O
30	lipopolysaccharide	O
31	.	O

1	Hypothermia	O
2	After	O
3	Cardiac	O
4	Arrest	O
5	(	O
6	HACA	O
7	)	O
8	Study	O
9	Group	O
10	.	O

1	DATA	O
2	SYNTHESIS	O
3	:	O
4	Intracoronary	O
5	ultrasound	O
6	has	O
7	been	O
8	shown	O
9	to	O
10	improve	O
11	upon	O
12	demonstrated	O
13	weaknesses	O
14	of	O
15	coronary	O
16	angiography	O
17	.	O

1	Distribution	O
2	and	O
3	correlations	O
4	of	O
5	serum	O
6	uric	O
7	-	O
8	acid	O
9	in	O
10	two	O
11	French	O
12	adult	O
13	populations	O
14	:	O
15	13	O
16	,	O
17	885	O
18	men	O
19	and	O
20	6	O
21	,	O
22	861	O
23	women	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	Sip1	O
2	was	O
3	initially	O
4	identified	O
5	by	O
6	virtue	O
7	of	O
8	its	O
9	interaction	O
10	with	O
11	SC35	O
12	,	O
13	a	O
14	splicing	O
15	factor	O
16	of	O
17	the	O
18	SR	B
19	family	I
20	.	I

1	The	O
2	fragments	O
3	of	O
4	each	O
5	region	O
6	were	O
7	amplified	O
8	by	O
9	polymerase	O
10	chain	O
11	reaction	O
12	and	O
13	analyzed	O
14	by	O
15	gel	O
16	electrophoresis	O
17	to	O
18	detect	O
19	single	O
20	-	O
21	strand	O
22	conformation	O
23	polymorphism	O
24	.	O

1	Mean	O
2	intake	O
3	of	O
4	vitamin	O
5	A	O
6	amounted	O
7	to	O
8	1	O
9	.	O
10	1	O
11	and	O
12	0	O
13	.	O
14	9	O
15	mg	O
16	RE	O
17	/	O
18	day	O
19	for	O
20	men	O
21	and	O
22	women	O
23	,	O
24	respectively	O
25	;	O
26	the	O
27	contributions	O
28	of	O
29	meat	O
30	,	O
31	fats	O
32	and	O
33	oils	O
34	,	O
35	vegetables	O
36	and	O
37	dairy	O
38	products	O
39	to	O
40	total	O
41	intake	O
42	were	O
43	35	O
44	%,	O
45	24	O
46	%,	O
47	16	O
48	%,	O
49	and	O
50	16	O
51	%,	O
52	respectively	O
53	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	requirements	O
6	of	O
7	the	O
8	CH	B
9	gene	I
10	switch	O
11	by	O
12	characterizing	O
13	two	O
14	rearranged	B
15	gamma	I
16	2b	I
17	genes	I
18	from	O
19	a	O
20	gamma	B
21	2b	I
22	producing	O
23	mouse	O
24	myeloma	O
25	(	O
26	MPC	O
27	-	O
28	11	O
29	).	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	fodrin	O
6	proteolysis	O
7	in	O
8	vivo	O
9	may	O
10	reflect	O
11	the	O
12	activity	O
13	of	O
14	multiple	O
15	ICE	B
16	/	I
17	Ced	I
18	-	I
19	3	I
20	proteases	I
21	whose	O
22	partial	O
23	sensitivity	O
24	to	O
25	DEVD	O
26	-	O
27	CHO	O
28	reflects	O
29	a	O
30	limited	O
31	contribution	O
32	from	O
33	CPP32	O
34	,	O
35	or	O
36	an	O
37	ICE	B
38	/	I
39	Ced	I
40	-	I
41	3	I
42	protease	I
43	less	O
44	sensitive	O
45	than	O
46	CPP32	O
47	to	O
48	DEVD	O
49	-	O
50	CHO	O
51	inhibition	O
52	.	O

1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPAR	O
8	)	O
9	modulate	O
10	transcription	O
11	by	O
12	binding	O
13	to	O
14	specific	O
15	peroxisome	B
16	proliferator	I
17	-	I
18	response	O
19	elements	O
20	(	O
21	PPRE	O
22	)	O
23	through	O
24	heterodimerization	O
25	with	O
26	the	O
27	9	O
28	-	O
29	cis	O
30	retinoic	B
31	acid	I
32	receptor	I
33	(	O
34	RXR	B
35	).	O

1	The	O
2	iron	O
3	dependence	O
4	of	O
5	transcription	O
6	and	O
7	expression	O
8	of	O
9	cvaA	O
10	,	O
11	which	O
12	encodes	O
13	a	O
14	transporter	O
15	accessory	O
16	protein	O
17	,	O
18	and	O
19	cvi	O
20	,	O
21	encoding	O
22	the	O
23	colicin	O
24	V	O
25	immunity	O
26	protein	O
27	,	O
28	was	O
29	assessed	O
30	under	O
31	conditions	O
32	of	O
33	iron	O
34	excess	O
35	or	O
36	depletion	O
37	.	O

1	Total	O
2	VO2	O
3	was	O
4	decreased	O
5	in	O
6	both	O
7	groups	O
8	during	O
9	severe	O
10	hypoxia	O
11	but	O
12	limb	O
13	VO2	O
14	was	O
15	maintained	O
16	in	O
17	the	O
18	beta	O
19	-	O
20	block	O
21	group	O
22	.	O
23	beta	O
24	-	O
25	Block	O
26	prevented	O
27	the	O
28	fall	O
29	in	O
30	total	O
31	and	O
32	limb	O
33	peripheral	O
34	resistance	O
35	seen	O
36	in	O
37	severe	O
38	hypoxia	O
39	but	O
40	did	O
41	not	O
42	alter	O
43	the	O
44	consistently	O
45	more	O
46	efficient	O
47	utilization	O
48	of	O
49	total	O
50	O2	O
51	delivery	O
52	shown	O
53	by	O
54	the	O
55	limb	O
56	in	O
57	comparison	O
58	to	O
59	the	O
60	whole	O
61	body	O
62	by	O
63	higher	O
64	O2	O
65	extraction	O
66	ratios	O
67	and	O
68	lower	O
69	venous	O
70	O2	O
71	pressure	O
72	.	O
73	beta	B
74	-	I
75	Vasodilator	I
76	receptors	I
77	evidently	I
78	played	I
79	an	O
80	active	O
81	part	O
82	in	O
83	the	O
84	vasodilatation	O
85	seen	O
86	during	O
87	severe	O
88	hypoxia	O
89	.	O

1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O

1	Metastasis	O
2	of	O
3	colon	O
4	carcinoma	O
5	to	O
6	the	O
7	lip	O
8	.	O

1	In	O
2	human	O
3	brain	O
4	,	O
5	contactin	O
6	was	O
7	first	O
8	identified	O
9	by	O
10	amino	O
11	terminal	O
12	and	O
13	peptide	O
14	sequencing	O
15	of	O
16	the	O
17	lentil	B
18	-	I
19	lectin	I
20	-	I
21	binding	I
22	glycoprotein	I
23	Gp135	O
24	.	O

1	The	O
2	ns2	O
3	gene	O
4	comprises	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	(	O
10	ORF	O
11	)	O
12	encoding	O
13	a	O
14	putative	O
15	nonstructural	O
16	(	O
17	ns	O
18	)	O
19	protein	O
20	of	O
21	279	O
22	amino	O
23	acids	O
24	with	O
25	a	O
26	predicted	O
27	molecular	O
28	mass	O
29	of	O
30	32	O
31	-	O
32	kDa	O
33	.	O

1	The	O
2	evaluation	O
3	of	O
4	amniotic	O
5	fluid	O
6	delta	O
7	OD450	O
8	is	O
9	considered	O
10	to	O
11	be	O
12	the	O
13	cornerstone	O
14	of	O
15	clinical	O
16	management	O
17	.	O

1	The	O
2	catenins	O
3	bind	O
4	to	O
5	APC	B
6	and	I
7	E	I
8	-	I
9	cadherin	I
10	in	O
11	a	O
12	similar	O
13	fashion	O
14	,	O
15	but	O
16	APC	B
17	and	I
18	E	I
19	-	I
20	cadherin	I
21	do	O
22	not	O
23	associate	O
24	with	O
25	each	O
26	other	O
27	either	O
28	in	O
29	the	O
30	presence	O
31	or	O
32	absence	O
33	of	O
34	catenins	O
35	.	O

1	During	O
2	latency	O
3	,	O
4	more	O
5	than	O
6	1	O
7	%	O
8	of	O
9	neurons	O
10	in	O
11	ganglia	O
12	that	O
13	innervate	O
14	the	O
15	footpad	O
16	expressed	O
17	beta	B
18	-	I
19	galactosidase	I
20	,	O
21	with	O
22	the	O
23	number	O
24	of	O
25	positive	O
26	cells	O
27	remaining	O
28	constant	O
29	for	O
30	at	O
31	least	O
32	5	O
33	months	O
34	.	O

1	Thus	O
2	,	O
3	blocks	O
4	in	O
5	the	O
6	RARalpha	O
7	-	O
8	specific	O
9	pathway	O
10	of	O
11	retinoid	O
12	-	O
13	induced	O
14	differentiation	O
15	may	O
16	be	O
17	bypassed	O
18	during	O
19	retinoid	O
20	induction	O
21	of	O
22	FR	B
23	-	I
24	beta	I
25	expression	O
26	.	O

1	Adrenergic	O
2	nerve	O
3	function	O
4	,	O
5	noradrenaline	O
6	level	O
7	and	O
8	noradrenaline	O
9	uptake	O
10	in	O
11	cat	O
12	nictitating	O
13	membrane	O
14	after	O
15	reserpine	O
16	treatment	O
17	.	O

1	Unlike	O
2	wild	B
3	-	I
4	type	I
5	p53	I
6	,	O
7	the	O
8	delta	O
9	proAE	O
10	mutant	O
11	cDNA	O
12	can	O
13	be	O
14	stably	O
15	expressed	O
16	in	O
17	tumor	O
18	derived	O
19	cell	O
20	lines	O
21	with	O
22	few	O
23	immediate	O
24	detrimental	O
25	effects	O
26	.	O

1	Fast	O
2	goal	O
3	-	O
4	directed	O
5	voluntary	O
6	movements	O
7	of	O
8	the	O
9	human	O
10	upper	O
11	extremity	O
12	are	O
13	known	O
14	to	O
15	be	O
16	associated	O
17	with	O
18	three	O
19	distinct	O
20	bursts	O
21	of	O
22	EMG	O
23	activity	O
24	in	O
25	antagonistic	O
26	muscles	O
27	.	O

1	Isolation	O
2	of	O
3	T	O
4	.	O
5	gambiense	O
6	strains	O
7	in	O
8	Zaire	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O

1	Telomeres	O
2	prevent	O
3	end	O
4	-	O
5	to	O
6	-	O
7	end	O
8	fusions	O
9	and	O
10	exonucleolytic	O
11	degradation	O
12	,	O
13	enable	O
14	the	O
15	end	O
16	of	O
17	the	O
18	linear	O
19	DNA	O
20	molecule	O
21	to	O
22	replicate	O
23	,	O
24	and	O
25	function	O
26	in	O
27	cell	O
28	division	O
29	.	O

1	The	O
2	somatoform	O
3	conundrum	O
4	:	O
5	a	O
6	question	O
7	of	O
8	nosological	O
9	valves	O
10	.	O

1	Thyroid	O
2	disease	O
3	and	O
4	pregnancy	O
5	.	O

1	Increasing	O
2	the	O
3	cut	O
4	-	O
5	off	O
6	point	O
7	to	O
8	3	O
9	positive	O
10	responses	O
11	decreased	O
12	the	O
13	sensitivity	O
14	to	O
15	81	O
16	%	O
17	and	O
18	increased	O
19	the	O
20	specificity	O
21	to	O
22	94	O
23	%.	O

1	It	O
2	is	O
3	largely	O
4	predicted	O
5	by	O
6	lupus	O
7	anticoagulant	O
8	(	O
9	estimated	O
10	by	O
11	activated	O
12	partial	O
13	thromboplastin	B
14	time	O
15	)	O
16	and	O
17	/	O
18	or	O
19	antibody	O
20	to	O
21	cardiolipin	O
22	.	O

1	Mechanism	O
2	of	O
3	the	O
4	t	O
5	(	O
6	14	O
7	;	O
8	18	O
9	)	O
10	chromosomal	O
11	translocation	O
12	:	O
13	structural	O
14	analysis	O
15	of	O
16	both	O
17	derivative	O
18	14	O
19	and	O
20	18	O
21	reciprocal	O
22	partners	O
23	.	O

1	Here	O
2	we	O
3	examine	O
4	the	O
5	potential	O
6	for	O
7	VP16	B
8	protein	I
9	-	I
10	protein	I
11	interactions	O
12	specific	O
13	to	O
14	virus	O
15	-	O
16	infected	O
17	cells	O
18	and	O
19	show	O
20	that	O
21	VP16	B
22	copurifies	O
23	in	O
24	a	O
25	highly	O
26	enriched	O
27	fraction	O
28	with	O
29	a	O
30	single	O
31	major	O
32	polypeptide	O
33	which	O
34	we	O
35	identify	O
36	as	O
37	the	O
38	virus	O
39	-	O
40	encoded	O
41	structural	O
42	protein	O
43	VP22	O
44	.	O

1	Disruption	O
2	mutations	O
3	have	O
4	been	O
5	constructed	O
6	in	O
7	the	O
8	SLK1	O
9	gene	O
10	.	O
11	slk1	O
12	null	O
13	mutants	O
14	cannot	O
15	grow	O
16	at	O
17	37	O
18	degrees	O
19	C	O
20	,	O
21	but	O
22	many	O
23	cells	O
24	can	O
25	grow	O
26	at	O
27	30	O
28	,	O
29	24	O
30	,	O
31	and	O
32	17	O
33	degrees	O
34	C	O
35	.	O

1	Microwave	O
2	hyperthermia	O
3	-	O
4	induced	O
5	blood	O
6	-	O
7	brain	O
8	barrier	O
9	alterations	O
10	.	O

1	An	O
2	in	O
3	vitro	O
4	binding	O
5	site	O
6	selection	O
7	procedure	O
8	was	O
9	used	O
10	to	O
11	determine	O
12	DNA	O
13	sequences	O
14	preferentially	O
15	bound	O
16	by	O
17	wild	O
18	-	O
19	type	O
20	HLF	O
21	and	O
22	chimeric	O
23	E2A	O
24	-	O
25	HLF	O
26	proteins	O
27	isolated	O
28	from	O
29	various	O
30	t	O
31	(	O
32	17	O
33	;	O
34	19	O
35	)-	O
36	bearing	O
37	leukemias	O
38	.	O

1	If	O
2	no	O
3	alloantibodies	O
4	are	O
5	detected	O
6	,	O
7	further	O
8	analysis	O
9	to	O
10	define	O
11	a	O
12	role	O
13	of	O
14	drug	O
15	-	O
16	related	O
17	or	O
18	autoantibodies	O
19	is	O
20	required	O
21	.	O

1	Polycythemia	O
2	-	O
3	1973	O
4	.	O

1	In	O
2	12	O
3	cases	O
4	(	O
5	3	O
6	.	O
7	1	O
8	%),	O
9	a	O
10	change	O
11	in	O
12	stage	O
13	resulted	O
14	.	O

1	The	O
2	encoded	O
3	polypeptide	O
4	is	O
5	similar	O
6	in	O
7	sequence	O
8	to	O
9	the	O
10	ABA	B
11	-	I
12	1	I
13	allergen	O
14	of	O
15	Ascaris	O
16	,	O
17	the	O
18	gp15	O
19	/	O
20	400	O
21	'	O
22	ladder	O
23	'	O
24	protein	O
25	of	O
26	Brugia	O
27	malayi	O
28	,	O
29	Brugia	O
30	pahangi	O
31	and	O
32	Wuchereria	O
33	bancrofti	O
34	,	O
35	and	O
36	a	O
37	15	O
38	-	O
39	kDa	O
40	antigen	O
41	of	O
42	Dirofilaria	O
43	immitis	O
44	.	O

1	Similar	O
2	to	O
3	Hp140	O
4	,	O
5	isolated	O
6	Hp55	O
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O

1	Further	O
2	studies	O
3	demonstrated	O
4	that	O
5	the	O
6	PPARalpha	B
7	ligand	O
8	8	O
9	(	O
10	S	O
11	)-	O
12	hydroxyeicosatetraenoic	O
13	acid	O
14	strongly	O
15	promotes	O
16	the	O
17	interaction	O
18	of	O
19	PPARalpha	B
20	with	O
21	the	O
22	co	B
23	-	I
24	activator	I
25	RIP	I
26	-	I
27	140	O
28	but	O
29	decreases	O
30	the	O
31	interaction	O
32	of	O
33	PPARalpha	B
34	with	O
35	the	O
36	co	O
37	-	O
38	repressor	O
39	SMRT	B
40	.	I

1	We	O
2	also	O
3	present	O
4	evidence	O
5	that	O
6	human	O
7	HYAL1	O
8	is	O
9	identical	O
10	to	O
11	an	O
12	uncharacterized	O
13	gene	O
14	positionally	O
15	cloned	O
16	by	O
17	others	O
18	from	O
19	chromosome	O
20	3p21	O
21	.	O
22	3	O
23	that	O
24	is	O
25	homozygously	O
26	deleted	O
27	in	O
28	several	O
29	small	O
30	-	O
31	cell	O
32	lung	O
33	carcinoma	O
34	cell	O
35	lines	O
36	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	characterization	O
6	is	O
7	given	O
8	of	O
9	clinical	O
10	and	O
11	biochemical	O
12	features	O
13	of	O
14	VH	B
15	B	I
16	course	O
17	against	O
18	the	O
19	background	O
20	of	O
21	narcomania	O
22	.	O

1	Immunolocalization	O
2	of	O
3	Sop1p	O
4	revealed	O
5	a	O
6	cytoplasmic	O
7	distribution	O
8	and	O
9	cell	O
10	fractionation	O
11	studies	O
12	showed	O
13	that	O
14	a	O
15	significant	O
16	fraction	O
17	of	O
18	Sop1p	O
19	was	O
20	recovered	O
21	in	O
22	a	O
23	sedimentable	O
24	fraction	O
25	of	O
26	the	O
27	cytosolic	O
28	material	O
29	.	O

1	The	O
2	reduced	O
3	rate	O
4	of	O
5	F	O
6	absorption	O
7	and	O
8	slower	O
9	rise	O
10	in	O
11	plasma	O
12	F	O
13	concentration	O
14	accompanying	O
15	delayed	O
16	gastric	O
17	emptying	O
18	indicate	O
19	that	O
20	passage	O
21	of	O
22	F	O
23	into	O
24	the	O
25	small	O
26	intestine	O
27	is	O
28	the	O
29	major	O
30	factor	O
31	in	O
32	rapid	O
33	F	O
34	absorption	O
35	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	specific	O
7	human	B
8	alpha	I
9	1	I
10	,	I
11	2	I
12	-	I
13	mannosidase	I
14	that	O
15	trims	O
16	Man9GlcNAc2	O
17	to	O
18	Man8GlcNAc2	O
19	isomer	O
20	B	O
21	during	O
22	N	O
23	-	O
24	glycan	O
25	biosynthesis	O
26	.	O

1	Mutations	O
2	in	O
3	UPF1	O
4	lead	O
5	to	O
6	the	O
7	selective	O
8	stabilization	O
9	of	O
10	mRNAs	O
11	containing	O
12	early	O
13	nonsense	O
14	mutations	O
15	without	O
16	affecting	O
17	the	O
18	decay	O
19	rates	O
20	of	O
21	most	O
22	other	O
23	mRNAs	O
24	.	O

1	Chaperones	O
2	/	O
3	HSPs	O
4	thus	O
5	play	O
6	important	O
7	roles	O
8	within	O
9	cell	O
10	cycle	O
11	processes	O
12	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	rabbits	O
6	were	O
7	used	O
8	to	O
9	evaluate	O
10	the	O
11	sutured	O
12	wound	O
13	reaction	O
14	with	O
15	Dexon	O
16	or	O
17	nylon	O
18	in	O
19	the	O
20	conjunctival	O
21	flap	O
22	1	O
23	,	O
24	4	O
25	,	O
26	7	O
27	,	O
28	14	O
29	and	O
30	28	O
31	days	O
32	after	O
33	trabeculectomy	O
34	surgery	O
35	with	O
36	or	O
37	without	O
38	the	O
39	use	O
40	of	O
41	mitomycin	O
42	-	O
43	C	O
44	.	O

1	From	O
2	an	O
3	RNK	B
4	-	I
5	16	I
6	lambda	I
7	-	I
8	gt11	O
9	library	O
10	,	O
11	we	O
12	have	O
13	isolated	O
14	and	O
15	sequenced	O
16	a	O
17	novel	O
18	cDNA	O
19	rat	B
20	NK	I
21	cell	I
22	protease	I
23	1	I
24	(	I
25	RNKP	I
26	-	I
27	1	I
28	)	O
29	that	O
30	has	O
31	characteristics	O
32	unique	O
33	to	O
34	serine	O
35	proteases	O
36	.	O

1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	Kimura	O
7	,	O
8	Y	O
9	.,	O
10	Kurzydlowski	O
11	,	O
12	K	O
13	.,	O
14	Tada	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	MacLennan	O
20	,	O
21	D	O
22	.	O

1	A	O
2	novel	O
3	,	O
4	testis	B
5	-	I
6	specific	I
7	mRNA	I
8	transcript	I
9	encoding	O
10	an	O
11	NH2	O
12	-	O
13	terminal	O
14	truncated	O
15	nitric	B
16	-	I
17	oxide	I
18	synthase	I
19	.	O
20	mRNA	O
21	diversity	O
22	represents	O
23	a	O
24	major	O
25	theme	O
26	of	O
27	neuronal	O
28	nitric	B
29	-	I
30	oxide	I
31	synthase	I
32	(	O
33	nNOS	O
34	)	O
35	gene	O
36	expression	O
37	in	O
38	somatic	O
39	cells	O
40	/	O
41	tissues	O
42	.	O

1	Cytokine	O
2	-	O
3	induced	O
4	NF	B
5	-	I
6	kappa	I
7	B	I
8	DNA	I
9	binding	I
10	activity	O
11	,	O
12	RelA	O
13	nuclear	O
14	translocation	O
15	,	O
16	I	B
17	kappa	I
18	B	I
19	alpha	I
20	degradation	I
21	,	I
22	I	I
23	kappa	I
24	B	I
25	serine	I
26	32	O
27	phosphorylation	O
28	,	O
29	and	O
30	I	B
31	kappa	I
32	B	I
33	kinase	I
34	(	O
35	IKK	O
36	)	O
37	activity	O
38	were	O
39	blocked	O
40	by	O
41	curcumin	O
42	treatment	O
43	.	O

1	DNA	O
2	sequence	O
3	and	O
4	evolution	O
5	of	O
6	the	O
7	CPS	O
8	domain	O
9	of	O
10	the	O
11	Syrian	B
12	hamster	I
13	multifunctional	I
14	protein	I
15	CAD	I
16	.	I

1	The	O
2	short	O
3	-	O
4	term	O
5	synthesis	O
6	and	O
7	infant	O
8	-	O
9	regulated	O
10	removal	O
11	of	O
12	milk	O
13	in	O
14	lactating	O
15	women	O
16	.	O

1	Several	O
2	agents	O
3	have	O
4	been	O
5	tried	O
6	for	O
7	treatment	O
8	,	O
9	often	O
10	limited	O
11	by	O
12	toxic	O
13	side	O
14	effects	O
15	.	O

1	Effect	O
2	of	O
3	Azadirachta	O
4	indica	O
5	hydroalcoholic	O
6	leaf	O
7	extract	O
8	on	O
9	the	O
10	cardiovascular	O
11	system	O
12	.	O

1	Entry	O
2	of	O
3	yeast	O
4	cells	O
5	into	O
6	the	O
7	mitotic	O
8	cell	O
9	cycle	O
10	(	O
11	Start	O
12	)	O
13	involves	O
14	a	O
15	form	O
16	of	O
17	the	O
18	CDC28	B
19	kinase	I
20	that	O
21	associates	O
22	with	O
23	G1	B
24	-	I
25	specific	I
26	cyclins	I
27	encoded	O
28	by	O
29	CLN1	O
30	and	O
31	CLN2	O
32	(	O
33	ref	O
34	.	O

1	The	O
2	Scm	B
3	and	O
4	ph	O
5	proteins	O
6	share	O
7	a	O
8	homology	O
9	domain	O
10	with	O
11	38	O
12	%	O
13	identity	O
14	over	O
15	a	O
16	length	O
17	of	O
18	65	O
19	amino	O
20	acids	O
21	,	O
22	termed	O
23	the	O
24	SPM	O
25	domain	O
26	,	O
27	that	O
28	is	O
29	located	O
30	at	O
31	their	O
32	respective	O
33	C	O
34	termini	O
35	.	O

1	Analysis	O
2	of	O
3	proteins	O
4	synthesized	O
5	by	O
6	plasmids	O
7	containing	O
8	deleted	O
9	forms	O
10	of	O
11	the	O
12	trfA	O
13	region	O
14	indicates	O
15	that	O
16	the	O
17	A2	O
18	protein	O
19	is	O
20	the	O
21	essential	O
22	trfA	O
23	-	O
24	encoded	O
25	replication	O
26	protein	O
27	of	O
28	plasmid	O
29	RK2	O
30	.	O

1	For	O
2	Al	O
3	,	O
4	the	O
5	exposure	O
6	to	O
7	1	O
8	.	O
9	36	O
10	mg	O
11	/	O
12	m3	O
13	during	O
14	the	O
15	shift	O
16	corresponded	O
17	to	O
18	a	O
19	urinary	O
20	concentration	O
21	at	O
22	the	O
23	end	O
24	of	O
25	the	O
26	shift	O
27	of	O
28	200	O
29	microgram	O
30	/	O
31	g	O
32	creatinine	O
33	.	O

1	Western	O
2	blot	O
3	analysis	O
4	showed	O
5	a	O
6	rapid	O
7	corresponding	O
8	increase	O
9	in	O
10	p21WAF1	O
11	/	O
12	CIP1	B
13	protein	I
14	,	O
15	whereas	O
16	protein	O
17	levels	O
18	of	O
19	another	O
20	member	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	I
28	family	I
29	,	O
30	p27kip1	O
31	,	O
32	were	O
33	unchanged	O
34	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	TEF	B
20	-	I
21	1	I
22	isoforms	I
23	,	O
24	TEF	B
25	-	I
26	1beta	I
27	and	O
28	TEF	B
29	-	I
30	1gamma	O
31	.	O

1	The	O
2	present	O
3	findings	O
4	revealed	O
5	that	O
6	the	O
7	rib	B
8	-	I
9	2	I
10	protein	I
11	was	O
12	a	O
13	unique	O
14	alpha1	B
15	,	I
16	4	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	involved	O
22	in	O
23	the	O
24	biosynthetic	O
25	initiation	O
26	and	O
27	elongation	O
28	of	O
29	heparan	O
30	sulfate	O
31	.	O

1	The	O
2	malate	B
3	synthase	I
4	gene	I
5	,	O
6	MLS1	O
7	,	O
8	of	O
9	the	O
10	yeast	O
11	Saccharomyces	O
12	cerevisiae	O
13	is	O
14	transcriptionally	O
15	regulated	O
16	by	O
17	the	O
18	carbon	O
19	source	O
20	in	O
21	the	O
22	growth	O
23	medium	O
24	.	O

1	Sensitivity	O
2	and	O
3	specificity	O
4	was	O
5	established	O
6	for	O
7	the	O
8	Pharmacia	O
9	CAP	O
10	System	O
11	and	O
12	the	O
13	DPC	O
14	AlaSTAT	O
15	System	O
16	by	O
17	comparison	O
18	with	O
19	results	O
20	of	O
21	the	O
22	skin	O
23	prick	O
24	test	O
25	.	O

1	What	O
2	to	O
3	look	O
4	for	O
5	during	O
6	a	O
7	compliance	O
8	review	O
9	:	O
10	10	O
11	common	O
12	mistakes	O
13	made	O
14	by	O
15	SNFs	O
16	.	O

1	SETTING	O
2	:	O
3	University	O
4	hospital	O
5	-	O
6	based	O
7	,	O
8	tertiary	O
9	care	O
10	infertility	O
11	center	O
12	.	O

1	Activation	O
2	of	O
3	c	B
4	-	I
5	fos	I
6	gene	I
7	expression	O
8	by	O
9	a	O
10	kinase	O
11	-	O
12	deficient	O
13	epidermal	B
14	growth	I
15	factor	I
16	receptor	I
17	.	I

1	Partial	O
2	N	O
3	-	O
4	terminal	O
5	amino	O
6	acid	O
7	sequence	O
8	analysis	O
9	showed	O
10	that	O
11	the	O
12	43K	O
13	and	O
14	42K	O
15	T	O
16	antigens	O
17	contain	O
18	methionine	O
19	at	O
20	residues	O
21	1	O
22	and	O
23	5	O
24	,	O
25	as	O
26	predicted	O
27	from	O
28	the	O
29	DNA	O
30	sequence	O
31	,	O
32	whereas	O
33	no	O
34	methionine	O
35	was	O
36	released	O
37	from	O
38	the	O
39	39K	B
40	T	I
41	antigen	I
42	during	O
43	the	O
44	first	O
45	six	O
46	cycles	O
47	of	O
48	Edman	O
49	degradation	O
50	.	O

1	135	O
2	students	O
3	had	O
4	a	O
5	count	O
6	of	O
7	less	O
8	than	O
9	50	O
10	eggs	O
11	/	O
12	10	O
13	ml	O
14	.	O
15	urine	O
16	and	O
17	56	O
18	had	O
19	more	O
20	than	O
21	50	O
22	eggs	O
23	/	O
24	10ml	O
25	.	O

1	Serum	O
2	ascorbic	O
3	acid	O
4	had	O
5	an	O
6	inverse	O
7	and	O
8	the	O
9	strongest	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	triglyceride	O
27	,	O
28	gamma	B
29	-	I
30	GTP	I
31	and	O
32	obesity	O
33	.	O

1	The	O
2	SH2	B
3	domain	I
4	-	I
5	containing	I
6	inositol	I
7	5	I
8	'-	I
9	phosphatase	I
10	(	I
11	SHIP	I
12	)	O
13	recruits	O
14	the	O
15	p85	B
16	subunit	I
17	of	I
18	phosphoinositide	I
19	3	I
20	-	I
21	kinase	I
22	during	O
23	FcgammaRIIb1	O
24	-	O
25	mediated	O
26	inhibition	O
27	of	O
28	B	O
29	cell	O
30	receptor	O
31	signaling	O
32	.	O

1	The	O
2	new	O
3	algorithm	O
4	,	O
5	called	O
6	RBI	B
7	-	I
8	MAP	I
9	,	O
10	is	O
11	based	O
12	on	O
13	the	O
14	rescaled	O
15	block	O
16	iterative	O
17	EM	O
18	(	O
19	RBI	O
20	-	O
21	EM	O
22	)	O
23	algorithm	O
24	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	negative	O
6	Smad2	O
7	significantly	O
8	reduces	O
9	the	O
10	level	O
11	of	O
12	luciferase	B
13	reporter	I
14	activity	O
15	induced	O
16	by	O
17	nodal	O
18	treatment	O
19	.	O

1	Four	O
2	patients	O
3	(	O
4	group	O
5	1	O
6	)	O
7	had	O
8	type	O
9	I	O
10	basement	O
11	membrane	O
12	nephropathy	O
13	,	O
14	characterized	O
15	by	O
16	marked	O
17	thickening	O
18	and	O
19	lamellation	O
20	of	O
21	the	O
22	basement	O
23	membrane	O
24	in	O
25	a	O
26	pattern	O
27	resembling	O
28	that	O
29	of	O
30	Alport	O
31	'	O
32	s	O
33	syndrome	O
34	.	O

1	Oligonucleotide	O
2	-	O
3	directed	O
4	mutagenesis	O
5	was	O
6	used	O
7	to	O
8	create	O
9	an	O
10	NdeI	O
11	restriction	O
12	site	O
13	at	O
14	the	O
15	natural	O
16	ATG	O
17	of	O
18	the	O
19	yeast	O
20	R	O
21	.	O

1	The	O
2	mechanism	O
3	involves	O
4	Gbetagamma	B
5	subunit	I
6	-	I
7	mediated	O
8	increases	O
9	in	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	Shc	B
15	adapter	I
16	protein	I
17	,	O
18	Shc	B
19	*	I
20	Grb2	I
21	complex	I
22	formation	O
23	,	O
24	and	O
25	recruitment	O
26	of	O
27	Ras	B
28	guanine	I
29	nucleotide	I
30	exchange	I
31	factor	I
32	activity	O
33	.	O

1	Moreover	O
2	,	O
3	we	O
4	found	O
5	that	O
6	cyclin	B
7	E	I
8	,	O
9	in	O
10	contrast	O
11	to	O
12	cyclin	B
13	D1	I
14	,	O
15	was	O
16	required	O
17	for	O
18	the	O
19	G1	O
20	/	O
21	S	O
22	transition	O
23	even	O
24	in	O
25	cells	O
26	lacking	O
27	retinoblastoma	B
28	protein	I
29	function	O
30	.	O

1	While	O
2	no	O
3	obvious	O
4	transmembrane	O
5	regions	O
6	were	O
7	identified	O
8	,	O
9	several	O
10	short	O
11	hydrophobic	O
12	amino	O
13	acid	O
14	stretches	O
15	were	O
16	found	O
17	to	O
18	be	O
19	localized	O
20	in	O
21	and	O
22	around	O
23	the	O
24	Pro	O
25	II	O
26	region	O
27	,	O
28	and	O
29	these	O
30	may	O
31	be	O
32	responsible	O
33	for	O
34	attachment	O
35	of	O
36	precursors	O
37	to	O
38	membranes	O
39	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	human	O
9	goosecoid	O
10	gene	O
11	(	O
12	GSC	O
13	)	O
14	from	O
15	a	O
16	genomic	O
17	library	O
18	and	O
19	the	O
20	sequence	O
21	of	O
22	its	O
23	encoded	O
24	protein	O
25	.	O

1	The	O
2	DNA	O
3	sequences	O
4	upstream	O
5	of	O
6	these	O
7	termini	O
8	exhibit	O
9	homology	O
10	to	O
11	plant	O
12	mitochondrial	O
13	-	O
14	processing	O
15	sites	O
16	,	O
17	therefore	O
18	the	O
19	proximal	O
20	5	O
21	'	O
22	ends	O
23	are	O
24	most	O
25	probably	O
26	generated	O
27	by	O
28	RNA	O
29	processing	O
30	.	O

1	Simple	O
2	models	O
3	of	O
4	bimolecular	O
5	interaction	O
6	did	O
7	not	O
8	fully	O
9	account	O
10	for	O
11	the	O
12	kinetic	O
13	profiles	O
14	obtained	O
15	with	O
16	the	O
17	parental	O
18	antibodies	O
19	and	O
20	the	O
21	hybrids	O
22	,	O
23	and	O
24	this	O
25	complexity	O
26	suggested	O
27	the	O
28	existence	O
29	of	O
30	a	O
31	conformational	O
32	heterogeneity	O
33	in	O
34	these	O
35	molecules	O
36	.	O

1	The	O
2	nucleotide	O
3	(	O
4	nt	O
5	)	O
6	sequences	O
7	of	O
8	the	O
9	exons	O
10	,	O
11	exon	O
12	/	O
13	intron	O
14	boundaries	O
15	and	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	untranslated	O
22	regions	O
23	were	O
24	determined	O
25	.	O

1	Low	O
2	MAO	B
3	subjects	O
4	showed	O
5	a	O
6	pattern	O
7	of	O
8	higher	O
9	scores	O
10	in	O
11	KSP	O
12	Impulsiveness	O
13	,	O
14	EPQ	O
15	Neuroticism	O
16	,	O
17	and	O
18	KSP	O
19	Somatic	O
20	Anxiety	O
21	and	O
22	Irritability	O
23	and	O
24	lower	O
25	scores	O
26	in	O
27	KSP	O
28	Socialization	O
29	,	O
30	in	O
31	line	O
32	with	O
33	personality	O
34	profiles	O
35	found	O
36	in	O
37	alcoholics	O
38	,	O
39	psychopaths	O
40	,	O
41	and	O
42	suicide	O
43	attempters	O
44	who	O
45	also	O
46	tend	O
47	to	O
48	have	O
49	low	O
50	platelet	B
51	MAO	I
52	activity	O
53	.	O

1	Differential	O
2	sensitivity	O
3	of	O
4	the	O
5	MMPI	O
6	-	O
7	2	O
8	depression	O
9	scales	O
10	and	O
11	subscales	O
12	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	the	O
12	response	O
13	rates	O
14	and	O
15	toxicity	O
16	of	O
17	two	O
18	regimens	O
19	containing	O
20	granulocyte	B
21	-	I
22	macrophage	I
23	-	I
24	colony	I
25	stimulating	I
26	factor	I
27	(	I
28	GM	I
29	-	I
30	CSF	I
31	)	O
32	in	O
33	combination	O
34	with	O
35	interleukin	B
36	-	I
37	2	I
38	(	I
39	IL	I
40	-	I
41	2	I
42	)	O
43	in	O
44	the	O
45	treatment	O
46	of	O
47	patients	O
48	with	O
49	metastatic	O
50	renal	O
51	cell	O
52	carcinoma	O
53	.	O

1	Anti	B
2	-	I
3	B	I
4	.	O
5	burgdorferi	O
6	,	O
7	anti	B
8	-	I
9	B	I
10	.	O
11	turicatae	O
12	and	O
13	anti	B
14	-	I
15	B	I
16	.	O
17	parkeri	O
18	antibodies	O
19	,	O
20	tested	O
21	by	O
22	the	O
23	indirect	O
24	immunofluorescent	O
25	assay	O
26	(	O
27	IFA	O
28	),	O
29	were	O
30	detected	O
31	in	O
32	10	O
33	.	O
34	8	O
35	,	O
36	16	O
37	.	O
38	1	O
39	and	O
40	8	O
41	.	O
42	2	O
43	%	O
44	of	O
45	the	O
46	serum	O
47	samples	O
48	tested	O
49	,	O
50	and	O
51	confirmed	O
52	by	O
53	IFA	O
54	-	O
55	ABS	O
56	in	O
57	1	O
58	.	O
59	3	O
60	,	O
61	1	O
62	.	O
63	3	O
64	and	O
65	1	O
66	.	O
67	0	O
68	%,	O
69	respectively	O
70	.	O

1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O

1	(	O
2	5	O
3	)	O
4	An	O
5	increase	O
6	in	O
7	leukocyte	O
8	-	O
9	counts	O
10	occurred	O
11	on	O
12	the	O
13	administration	O
14	of	O
15	serum	O
16	obtained	O
17	from	O
18	rabbit	O
19	during	O
20	phase	O
21	-	O
22	2	O
23	.	O

1	GCR1	O
2	gene	O
3	function	O
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	level	O
10	glycolytic	O
11	gene	O
12	expression	O
13	in	O
14	Saccharomyces	O
15	cerevisiae	O
16	.	O

1	Vertebrate	O
2	synapsins	O
3	constitute	O
4	a	O
5	family	O
6	of	O
7	synaptic	O
8	proteins	O
9	that	O
10	participate	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	neurotransmitter	O
16	release	O
17	.	O

1	A	O
2	mouse	B
3	brain	I
4	beta	I
5	-	I
6	spectrin	I
7	of	O
8	cDNA	O
9	was	O
10	identified	O
11	within	O
12	a	O
13	lambda	O
14	Gt11	O
15	expression	O
16	library	O
17	using	O
18	an	O
19	antibody	O
20	which	O
21	specifically	O
22	binds	O
23	with	O
24	the	O
25	235	B
26	kDa	I
27	spectrin	I
28	beta	I
29	-	I
30	subunit	I
31	.	I

1	Apoptosis	O
2	of	O
3	small	O
4	cells	O
5	is	O
6	still	O
7	observed	O
8	after	O
9	co	O
10	-	O
11	transfection	O
12	of	O
13	JBD	O
14	and	O
15	LMP1	B
16	but	O
17	in	O
18	addition	O
19	a	O
20	few	O
21	apoptotic	O
22	HD	O
23	-	O
24	MyZ	O
25	cells	O
26	with	O
27	large	O
28	fused	O
29	nuclear	O
30	masses	O
31	are	O
32	identified	O
33	suggesting	O
34	that	O
35	specific	O
36	inhibition	O
37	of	O
38	JNK	B
39	leads	O
40	also	O
41	to	O
42	apoptosis	O
43	of	O
44	LMP1	B
45	induced	O
46	RS	O
47	cells	O
48	.	O

1	These	O
2	sites	O
3	are	O
4	also	O
5	potential	O
6	keratan	O
7	sulfate	O
8	attachment	O
9	sites	O
10	.	O

1	Splicing	O
2	of	O
3	the	O
4	K	O
5	-	O
6	SAM	O
7	alternative	O
8	exon	O
9	of	O
10	the	O
11	fibroblast	B
12	growth	I
13	factor	I
14	receptor	I
15	2	I
16	gene	I
17	is	O
18	heavily	O
19	dependent	O
20	on	O
21	the	O
22	U	O
23	-	O
24	rich	O
25	sequence	O
26	IAS1	O
27	lying	O
28	immediately	O
29	downstream	O
30	from	O
31	its	O
32	5	O
33	'	O
34	splice	O
35	site	O
36	.	O

1	Insertional	O
2	inactivation	O
3	of	O
4	sms	O
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	Two	O
2	of	O
3	these	O
4	resulted	O
5	in	O
6	increased	O
7	levels	O
8	of	O
9	the	O
10	alpha	O
11	subunit	O
12	,	O
13	and	O
14	one	O
15	caused	O
16	a	O
17	substitution	O
18	of	O
19	glycine	O
20	for	O
21	the	O
22	aspartic	O
23	acid	O
24	residue	O
25	at	O
26	position	O
27	171	O
28	,	O
29	in	O
30	the	O
31	N	O
32	-	O
33	terminal	O
34	domain	O
35	.	O

1	Several	O
2	PTPases	O
3	were	O
4	expressed	O
5	abundantly	O
6	in	O
7	the	O
8	5	O
9	-	O
10	FU	O
11	-	O
12	treated	O
13	bone	O
14	marrow	O
15	stem	O
16	cells	O
17	.	O

1	Cross	O
2	-	O
3	reaction	O
4	between	O
5	a	O
6	monoclonal	O
7	antibody	O
8	and	O
9	two	O
10	alpha	B
11	beta	I
12	T	I
13	cell	I
14	receptors	I
15	.	I

1	Persistence	O
2	of	O
3	toxaphene	O
4	in	O
5	treated	O
6	lakes	O
7	.	O

1	Enhancer	O
2	and	O
3	promoter	O
4	elements	O
5	directing	O
6	activation	O
7	and	O
8	glucocorticoid	O
9	repression	O
10	of	O
11	the	O
12	alpha	B
13	1	I
14	-	I
15	fetoprotein	I
16	gene	I
17	in	O
18	hepatocytes	O
19	.	O

1	The	O
2	frequency	O
3	of	O
4	previous	O
5	transfusion	O
6	in	O
7	chronic	O
8	hepatitis	O
9	,	O
10	cirrhosis	O
11	and	O
12	hepatocellular	O
13	carcinoma	O
14	of	O
15	type	O
16	NANB	O
17	was	O
18	42	O
19	.	O
20	8	O
21	,	O
22	37	O
23	.	O
24	1	O
25	and	O
26	15	O
27	.	O
28	1	O
29	%,	O
30	respectively	O
31	,	O
32	whereas	O
33	the	O
34	incidence	O
35	of	O
36	early	O
37	posttransfusion	O
38	hepatitis	O
39	was	O
40	8	O
41	.	O
42	5	O
43	,	O
44	8	O
45	.	O
46	6	O
47	and	O
48	7	O
49	.	O
50	5	O
51	%,	O
52	respectively	O
53	.	O
54	in	O
55	chronic	O
56	liver	O
57	diseases	O
58	with	O
59	a	O
60	history	O
61	of	O
62	jaundice	O
63	and	O
64	/	O
65	or	O
66	hepatitis	O
67	,	O
68	previous	O
69	transfusions	O
70	are	O
71	more	O
72	frequently	O
73	associated	O
74	with	O
75	type	O
76	NANB	O
77	than	O
78	with	O
79	type	O
80	B	O
81	disease	O
82	.	O

1	The	O
2	mean	O
3	power	O
4	(	O
5	in	O
6	mu	O
7	W	O
8	)	O
9	required	O
10	to	O
11	produce	O
12	the	O
13	observed	O
14	flow	O
15	rate	O
16	was	O
17	estimated	O
18	at	O
19	each	O
20	outflow	O
21	pressure	O
22	as	O
23	the	O
24	product	O
25	of	O
26	the	O
27	flow	O
28	rate	O
29	and	O
30	the	O
31	pressure	O
32	across	O
33	the	O
34	lymphatic	O
35	vessel	O
36	.	O

1	The	O
2	alternative	O
3	sigma	B
4	factor	I
5	sigmaB	O
6	in	O
7	Staphylococcus	O
8	aureus	O
9	:	O
10	regulation	O
11	of	O
12	the	O
13	sigB	O
14	operon	O
15	in	O
16	response	O
17	to	O
18	growth	O
19	phase	O
20	and	O
21	heat	B
22	shock	I

1	Determination	O
2	of	O
3	aortic	O
4	distensibility	O
5	and	O
6	its	O
7	variations	O
8	in	O
9	arterial	O
10	hypertension	O
11	.	O

1	A	O
2	critical	O
3	heart	O
4	rate	O
5	and	O
6	/	O
7	or	O
8	appropriate	O
9	sympathetic	O
10	state	O
11	was	O
12	found	O
13	to	O
14	provoke	O
15	all	O
16	instances	O
17	of	O
18	reentrant	O
19	or	O
20	automatic	O
21	atrial	O
22	tachycardia	O
23	and	O
24	atypical	O
25	junctional	O
26	tachycardia	O
27	.	O

1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	258	O
10	dentally	O
11	aware	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	supragingival	O
33	calculus	O
34	,	O
35	taking	O
36	into	O
37	account	O
38	possible	O
39	confounding	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	gender	O
46	,	O
47	oral	O
48	hygiene	O
49	and	O
50	gingival	O
51	inflammation	O
52	.	O

1	Genetic	O
2	studies	O
3	in	O
4	Drosophila	O
5	have	O
6	led	O
7	to	O
8	the	O
9	identification	O
10	of	O
11	several	O
12	components	O
13	of	O
14	the	O
15	Notch	B
16	pathway	O
17	.	O

1	CONCLUSION	O
2	:	O
3	Patients	O
4	wit	O
5	clinically	O
6	palpable	O
7	neck	O
8	disease	O
9	(	O
10	N1	O
11	-	O
12	3	O
13	),	O
14	histological	O
15	evidence	O
16	of	O
17	metastatic	O
18	nodal	O
19	disease	O
20	,	O
21	extracapsular	O
22	spread	O
23	,	O
24	and	O
25	three	O
26	or	O
27	more	O
28	positive	O
29	lymph	O
30	nodes	O
31	are	O
32	at	O
33	greater	O
34	risk	O
35	of	O
36	developing	O
37	failure	O
38	at	O
39	distant	O
40	sites	O
41	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	(	O
7	EMSA	O
8	),	O
9	this	O
10	GLUT4	B
11	repressor	I
12	element	I
13	(	O
14	G4RE	O
15	)	O
16	generated	O
17	specific	O
18	bands	O
19	with	O
20	nuclear	O
21	extracts	O
22	from	O
23	preadipocytes	O
24	,	O
25	but	O
26	not	O
27	from	O
28	adipocytes	O
29	.	O

1	This	O
2	dynamic	O
3	response	O
4	strongly	O
5	suggests	O
6	that	O
7	the	O
8	p53	B
9	and	O
10	Rb	B
11	tumor	I
12	suppressor	I
13	pathways	O
14	are	O
15	intact	O
16	in	O
17	HeLa	O
18	cells	O
19	and	O
20	that	O
21	repression	O
22	of	O
23	HPV	B
24	E6	I
25	and	O
26	E7	B
27	mobilizes	O
28	these	O
29	pathways	O
30	in	O
31	an	O
32	orderly	O
33	fashion	O
34	to	O
35	deliver	O
36	growth	O
37	inhibitory	O
38	signals	O
39	to	O
40	the	O
41	cells	O
42	.	O

1	A	O
2	newly	O
3	developed	O
4	broad	O
5	-	O
6	spectrum	O
7	fluoroquinolone	O
8	,	O
9	levofloxacin	O
10	(	O
11	LVFX	O
12	,	O
13	DR	O
14	-	O
15	3355	O
16	),	O
17	was	O
18	evaluated	O
19	in	O
20	vitro	O
21	and	O
22	in	O
23	vivo	O
24	in	O
25	comparison	O
26	with	O
27	ciprofloxacin	O
28	(	O
29	CPFX	O
30	),	O
31	ofloxacin	O
32	(	O
33	OFLX	O
34	)	O
35	and	O
36	norfloxacin	O
37	(	O
38	NFLX	O
39	).	O

1	The	O
2	survival	O
3	rate	O
4	at	O
5	forty	O
6	months	O
7	in	O
8	15	O
9	patients	O
10	with	O
11	N2	O
12	disease	O
13	who	O
14	underwent	O
15	R2b	O
16	operation	O
17	was	O
18	51	O
19	%.	O

1	One	O
2	possible	O
3	solution	O
4	is	O
5	a	O
6	thin	O
7	radial	O
8	forearm	O
9	free	O
10	flap	O
11	.	O

1	Pharmacological	O
2	action	O
3	of	O
4	eptazocine	O
5	(	O
6	l	O
7	-	O
8	1	O
9	,	O
10	4	O
11	-	O
12	dimethyl	B
13	-	I
14	10	I
15	-	I
16	hydroxy	I
17	-	I
18	2	I
19	,	O
20	3	O
21	,	O
22	4	O
23	,	O
24	5	O
25	,	O
26	6	O
27	,	O
28	7	O
29	-	O
30	hexahydro	O
31	-	O
32	1	O
33	,	O
34	6	O
35	-	O
36	methano	B
37	-	I
38	1H	I
39	-	I
40	4	I
41	-	I
42	benz	O
43	azonine	O
44	).	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	hGCN5	O
9	is	O
10	also	O
11	an	O
12	HAT	O
13	and	O
14	has	O
15	the	O
16	same	O
17	substrate	O
18	specificity	O
19	as	O
20	yGCN5	O
21	.	O

1	PMEK1	O
2	displays	O
3	96	O
4	and	O
5	80	O
6	%	O
7	identity	O
8	respectively	O
9	with	O
10	the	O
11	tobacco	O
12	NTF3	O
13	and	O
14	Arabidopsis	O
15	ATMPK1	B
16	kinases	I
17	,	O
18	and	O
19	only	O
20	50	O
21	%	O
22	to	O
23	the	O
24	more	O
25	distantly	O
26	related	O
27	plant	O
28	MAP	B
29	kinase	I
30	MsERK1	O
31	from	O
32	alfalfa	O
33	.	O

1	Gastric	O
2	CO2	O
3	/	O
4	HCO3	O
5	was	O
6	determined	O
7	in	O
8	absence	O
9	of	O
10	simultaneous	O
11	inhibition	O
12	of	O
13	acid	O
14	secretion	O
15	by	O
16	intra	O
17	-	O
18	and	O
19	extragastric	O
20	pCO2	O
21	/	O
22	pH	O
23	measurements	O
24	in	O
25	23	O
26	persons	O
27	and	O
28	calculated	O
29	using	O
30	the	O
31	equation	O
32	of	O
33	Henderson	O
34	-	O
35	Hasselbalch	O
36	.	O
37	pCO2	O
38	was	O
39	measured	O
40	with	O
41	use	O
42	of	O
43	a	O
44	new	O
45	electrode	O
46	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	study	O
5	demonstrates	O
6	that	O
7	transvaginal	O
8	ultrasonography	O
9	has	O
10	an	O
11	efficiency	O
12	of	O
13	88	O
14	%	O
15	in	O
16	differentiating	O
17	endometriomas	O
18	from	O
19	other	O
20	ovarian	O
21	masses	O
22	with	O
23	a	O
24	specificity	O
25	of	O
26	90	O
27	%.	O

1	We	O
2	conclude	O
3	that	O
4	this	O
5	new	O
6	measurement	O
7	technique	O
8	provides	O
9	an	O
10	easy	O
11	and	O
12	accurate	O
13	P0	O
14	.	O
15	1	O
16	measurement	O
17	using	O
18	standard	O
19	respiratory	O
20	equipment	O
21	when	O
22	tested	O
23	in	O
24	a	O
25	lung	O
26	model	O
27	.	O

1	Deletion	O
2	of	O
3	the	O
4	POR2	O
5	gene	O
6	alone	O
7	had	O
8	no	O
9	detectable	O
10	phenotype	O
11	,	O
12	while	O
13	yeasts	O
14	with	O
15	deletions	O
16	of	O
17	both	O
18	the	O
19	POR1	O
20	and	O
21	POR2	O
22	genes	O
23	were	O
24	viable	O
25	and	O
26	able	O
27	to	O
28	grow	O
29	on	O
30	glycerol	O
31	at	O
32	30	O
33	degrees	O
34	C	O
35	,	O
36	albeit	O
37	more	O
38	slowly	O
39	than	O
40	delta	O
41	por1	O
42	single	O
43	mutants	O
44	.	O

1	Large	O
2	strain	O
3	differences	O
4	were	O
5	found	O
6	for	O
7	all	O
8	variables	O
9	recorded	O
10	,	O
11	i	O
12	.	O
13	e	O
14	.,	O
15	the	O
16	proportion	O
17	of	O
18	attacking	O
19	males	O
20	,	O
21	the	O
22	time	O
23	spent	O
24	in	O
25	the	O
26	brightly	O
27	lit	O
28	box	O
29	,	O
30	and	O
31	the	O
32	number	O
33	of	O
34	transitions	O
35	between	O
36	the	O
37	lit	O
38	and	O
39	the	O
40	dark	O
41	boxes	O
42	.	O

1	To	O
2	determine	O
3	the	O
4	relationship	O
5	of	O
6	these	O
7	viruses	O
8	,	O
9	the	O
10	complete	O
11	DNA	O
12	sequence	O
13	of	O
14	KV	O
15	consisting	O
16	of	O
17	4754	O
18	bp	O
19	was	O
20	determined	O
21	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	comparative	O
6	efficacy	O
7	of	O
8	diflucortolone	O
9	valerate	O
10	0	O
11	.	O
12	3	O
13	%	O
14	ointment	O
15	and	O
16	clobetasol	O
17	propionate	O
18	0	O
19	.	O
20	05	O
21	%	O
22	ointment	O
23	.	O

1	Disability	O
2	insurance	O
3	under	O
4	social	O
5	security	O
6	.	O

1	Effect	O
2	of	O
3	castration	O
4	on	O
5	pituitary	O
6	and	O
7	serum	O
8	LH	B
9	and	O
10	FSH	B
11	in	O
12	testosterone	O
13	-	O
14	sterilized	O
15	rats	O
16	.	O

1	The	O
2	isolation	O
3	of	O
4	this	O
5	gene	O
6	was	O
7	based	O
8	on	O
9	the	O
10	identification	O
11	of	O
12	the	O
13	Y	O
14	-	O
15	231	O
16	cosmid	O
17	that	O
18	contains	O
19	CpG	O
20	rich	O
21	sequences	O
22	(	O
23	HTF	O
24	islands	O
25	)	O
26	in	O
27	its	O
28	human	O
29	insert	O
30	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	CDC25B	O
5	may	O
6	therefore	O
7	contribute	O
8	to	O
9	the	O
10	control	O
11	of	O
12	cell	O
13	proliferation	O
14	.	O

1	Piroxicam	O
2	produced	O
3	a	O
4	lower	O
5	incidence	O
6	of	O
7	gastric	O
8	ulcers	O
9	than	O
10	equivalent	O
11	doses	O
12	of	O
13	indomethacin	O
14	.	O

1	Our	O
2	results	O
3	favor	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	Drosophila	O
9	EGF	B
10	receptor	I
11	DER	I
12	/	O
13	Egfr	O
14	expressed	O
15	by	O
16	the	O
17	EMA	O
18	cells	O
19	functions	O
20	as	O
21	a	O
22	receptor	O
23	for	O
24	Vein	O
25	.	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	assess	O
5	the	O
6	ability	O
7	of	O
8	pretreatment	O
9	and	O
10	post	O
11	-	O
12	treatment	O
13	prostate	B
14	-	I
15	specific	I
16	antigen	I
17	(	I
18	PSA	I
19	)	O
20	measurements	O
21	,	O
22	clinical	O
23	tumor	O
24	stage	O
25	,	O
26	tumor	O
27	grade	O
28	,	O
29	Gleason	O
30	sum	O
31	,	O
32	race	O
33	,	O
34	age	O
35	,	O
36	and	O
37	radiation	O
38	dose	O
39	to	O
40	predict	O
41	the	O
42	recurrence	O
43	of	O
44	prostate	O
45	cancer	O
46	following	O
47	external	O
48	beam	O
49	radiation	O
50	therapy	O
51	(	O
52	XRT	O
53	)	O
54	since	O
55	the	O
56	introduction	O
57	of	O
58	PSA	B
59	as	O
60	a	O
61	tumor	O
62	marker	O
63	at	O
64	one	O
65	tertiary	O
66	care	O
67	center	O
68	.	O

1	SEA	O
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	opiate	O
6	receptors	O
7	bordering	O
8	the	O
9	fourth	O
10	cerebral	O
11	ventricle	O
12	mediate	O
13	the	O
14	cardiovascular	O
15	and	O
16	hypnotic	O
17	action	O
18	of	O
19	fentanyl	O
20	.	O

1	Our	O
2	findings	O
3	demonstrate	O
4	a	O
5	dose	O
6	-	O
7	dependent	O
8	blockade	O
9	of	O
10	the	O
11	mechanical	O
12	sensitivity	O
13	caused	O
14	by	O
15	a	O
16	mild	O
17	thermal	O
18	injury	O
19	by	O
20	both	O
21	GBP	O
22	and	O
23	IBG	O
24	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	mechanism	O
7	of	O
8	activation	O
9	of	O
10	HIF	B
11	-	I
12	1alpha	I
13	is	O
14	a	O
15	multi	O
16	-	O
17	step	O
18	process	O
19	which	O
20	includes	O
21	hypoxia	O
22	-	O
23	dependent	O
24	nuclear	O
25	import	O
26	and	O
27	activation	O
28	(	O
29	derepression	O
30	)	O
31	of	O
32	the	O
33	transactivation	O
34	domain	O
35	,	O
36	resulting	O
37	in	O
38	recruitment	O
39	of	O
40	the	O
41	CREB	B
42	-	I
43	binding	I
44	protein	I
45	(	I
46	CBP	I
47	)/	I
48	p300	I
49	coactivator	I
50	.	I

1	Pentachlorophenol	O
2	accelerates	O
3	the	O
4	onset	O
5	of	O
6	HCB	O
7	porphyria	O
8	,	O
9	in	O
10	other	O
11	words	O
12	it	O
13	increases	O
14	the	O
15	total	O
16	urinary	O
17	porphyrin	O
18	excretion	O
19	and	O
20	causes	O
21	an	O
22	earlier	O
23	disturbance	O
24	of	O
25	the	O
26	porphyrin	O
27	pattern	O
28	.	O

1	In	O
2	these	O
3	cells	O
4	,	O
5	E2	O
6	proteins	O
7	had	O
8	little	O
9	or	O
10	no	O
11	stimulatory	O
12	effect	O
13	on	O
14	the	O
15	transcriptional	O
16	activity	O
17	of	O
18	the	O
19	HPV	B
20	-	I
21	11	I
22	enhancer	I
23	-	I
24	SV40	I
25	promoter	I
26	.	I

1	By	O
2	using	O
3	interleukin	B
4	-	I
5	3	I
6	-	I
7	dependent	I
8	cells	O
9	that	O
10	ectopically	O
11	express	O
12	the	O
13	three	O
14	ErbB	B
15	proteins	I
16	or	O
17	their	O
18	combinations	O
19	,	O
20	we	O
21	found	O
22	that	O
23	ErbB	B
24	-	I
25	3	I
26	is	O
27	devoid	O
28	of	O
29	any	O
30	biological	O
31	activity	O
32	but	O
33	both	O
34	ErbB	B
35	-	I
36	1	I
37	and	O
38	ErbB	B
39	-	I
40	2	I
41	can	O
42	reconstitute	O
43	its	O
44	extremely	O
45	potent	O
46	mitogenic	O
47	activity	O
48	.	O

1	This	O
2	observation	O
3	calls	O
4	for	O
5	careful	O
6	monitoring	O
7	of	O
8	calcium	O
9	and	O
10	alkaline	B
11	phosphatase	I
12	values	O
13	and	O
14	possible	O
15	adjustments	O
16	of	O
17	vitamin	O
18	D	O
19	intake	O
20	when	O
21	fortifiers	O
22	are	O
23	used	O
24	for	O
25	extended	O
26	periods	O
27	.	O

1	Like	O
2	the	O
3	p190	B
4	-	I
5	B	I
6	exon	O
7	,	O
8	the	O
9	first	O
10	exon	O
11	of	O
12	p190	B
13	-	I
14	A	I
15	is	O
16	extremely	O
17	large	O
18	(	O
19	3	O
20	.	O
21	7	O
22	kb	O
23	in	O
24	length	O
25	),	O
26	encoding	O
27	both	O
28	the	O
29	GTPase	B
30	and	O
31	middle	O
32	domains	O
33	(	O
34	residues	O
35	1	O
36	-	O
37	1228	O
38	),	O
39	but	O
40	not	O
41	the	O
42	remaining	O
43	GAP	B
44	domain	I
45	,	O
46	suggesting	O
47	a	O
48	high	O
49	conservation	O
50	of	O
51	genomic	O
52	structure	O
53	between	O
54	two	O
55	p190	B
56	genes	I
57	.	I

1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	for	O
7	a	O
8	model	O
9	in	O
10	which	O
11	mRNA	O
12	sequences	O
13	up	O
14	to	O
15	around	O
16	100	O
17	nucleotides	O
18	downstream	O
19	from	O
20	the	O
21	start	O
22	codon	O
23	of	O
24	21K	O
25	fold	O
26	back	O
27	and	O
28	base	O
29	-	O
30	pair	O
31	to	O
32	the	O
33	21K	O
34	translation	O
35	initiation	O
36	region	O
37	,	O
38	thereby	O
39	decreasing	O
40	the	O
41	translation	O
42	initiation	O
43	frequency	O
44	.	O

1	TCR	B
2	alpha	I
3	(	O
4	TCRA	O
5	)	O
6	expression	O
7	was	O
8	examined	O
9	in	O
10	RNA	O
11	samples	O
12	from	O
13	PBMC	O
14	and	O
15	isolated	O
16	populations	O
17	of	O
18	CD4	B
19	+,	I
20	CD8	I
21	+,	I
22	and	O
23	DN	O
24	T	O
25	cells	O
26	from	O
27	15	O
28	healthy	O
29	individuals	O
30	.	O

1	Value	O
2	of	O
3	Normotest	O
4	and	O
5	antithrombin	B
6	3	I
7	in	O
8	the	O
9	assessment	O
10	of	O
11	liver	O
12	function	O
13	.	O

1	The	O
2	gene	O
3	pairs	O
4	psbB	B
5	-	I
6	psbT	O
7	and	O
8	psbH	O
9	-	O
10	psbN	O
11	are	O
12	cotranscribed	O
13	from	O
14	opposite	O
15	strands	O
16	.	O

1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	B
9	actin	I
10	crosslinking	I
11	factor	I
12	(	O
13	MACF	O
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	O
22	associated	O
23	proteins	O
24	.	O

1	Taken	O
2	together	O
3	,	O
4	the	O
5	results	O
6	suggest	O
7	that	O
8	chlorphentermine	O
9	may	O
10	be	O
11	capable	O
12	of	O
13	producing	O
14	dual	O
15	stimulus	O
16	effects	O
17	in	O
18	animals	O
19	.	O

1	The	O
2	structural	O
3	study	O
4	of	O
5	peptides	O
6	belonging	O
7	to	O
8	the	O
9	terminal	O
10	domains	O
11	of	O
12	histone	B
13	H1	I
14	can	O
15	be	O
16	considered	O
17	as	O
18	a	O
19	step	O
20	toward	O
21	the	O
22	understanding	O
23	of	O
24	the	O
25	function	O
26	of	O
27	H1	O
28	in	O
29	chromatin	O
30	.	O

1	In	O
2	human	O
3	proliferative	O
4	cells	O
5	,	O
6	the	O
7	NADP	O
8	-	O
9	dependent	O
10	ME	O
11	activity	O
12	is	O
13	poorly	O
14	expressed	O
15	and	O
16	barely	O
17	inducible	O
18	by	O
19	thyroid	O
20	hormones	O
21	.	O

1	Using	O
2	PRL	B
3	-	I
4	R	I
5	tagged	O
6	both	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	or	O
13	C	O
14	-	O
15	terminal	O
16	regions	O
17	of	O
18	the	O
19	mature	O
20	receptor	O
21	excludes	O
22	the	O
23	possibility	O
24	of	O
25	a	O
26	cleaved	O
27	fragment	O
28	which	O
29	could	O
30	have	O
31	been	O
32	subsequently	O
33	imported	O
34	into	O
35	the	O
36	nucleus	O
37	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	NZ	O
6	-	O
7	107	O
8	may	O
9	be	O
10	a	O
11	useful	O
12	drug	O
13	for	O
14	the	O
15	treatment	O
16	of	O
17	bronchial	O
18	asthma	O
19	by	O
20	reducing	O
21	late	O
22	-	O
23	phase	O
24	airway	O
25	responses	O
26	and	O
27	airway	O
28	hyperreactivity	O
29	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	alpha	I
5	,	O
6	the	O
7	cytokine	O
8	that	O
9	participates	O
10	in	O
11	the	O
12	autocrine	O
13	growth	O
14	control	O
15	of	O
16	hairy	O
17	cell	O
18	leukemia	O
19	has	O
20	strong	O
21	bone	O
22	resorptive	O
23	properties	O
24	.	O

1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O

1	The	O
2	DNA	O
3	sequence	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	1520	O
9	amino	O
10	acids	O
11	with	O
12	sequence	O
13	homology	O
14	to	O
15	the	O
16	human	O
17	c	B
18	-	I
19	abl	I
20	proto	I
21	-	I
22	oncogene	I
23	product	I
24	,	O
25	beginning	O
26	at	O
27	the	O
28	amino	O
29	terminus	O
30	and	O
31	extending	O
32	656	O
33	amino	O
34	acids	O
35	through	O
36	the	O
37	region	O
38	essential	O
39	for	O
40	tyrosine	B
41	kinase	I
42	activity	O
43	.	O

1	(	O
2	ii	O
3	)	O
4	ICP27	O
5	binds	O
6	preferentially	O
7	to	O
8	less	O
9	modified	O
10	forms	O
11	of	O
12	ICP4	B
13	,	O
14	a	O
15	protein	O
16	that	O
17	is	O
18	extensively	O
19	modified	O
20	posttranslationally	O
21	.	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	O
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	O
30	alpha	O
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O

1	With	O
2	a	O
3	sample	O
4	of	O
5	mothers	O
6	of	O
7	healthy	O
8	infants	O
9	,	O
10	all	O
11	three	O
12	subscales	O
13	of	O
14	the	O
15	revised	O
16	instrument	O
17	,	O
18	WPL	O
19	-	O
20	R	O
21	,	O
22	had	O
23	acceptable	O
24	levels	O
25	of	O
26	internal	O
27	consistency	O
28	at	O
29	7	O
30	,	O
31	30	O
32	,	O
33	and	O
34	90	O
35	days	O
36	postpartum	O
37	,	O
38	and	O
39	stability	O
40	across	O
41	administrations	O
42	.	O

1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	O
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	O
29	expression	O
30	.	O

1	The	O
2	physical	O
3	linkage	O
4	of	O
5	the	O
6	FHR2	O
7	and	O
8	the	O
9	factor	O
10	H	O
11	genes	O
12	provides	O
13	additional	O
14	evidence	O
15	for	O
16	a	O
17	close	O
18	relatedness	O
19	of	O
20	complement	B
21	factor	I
22	H	I
23	and	O
24	the	O
25	factor	O
26	H	B
27	-	I
28	related	I
29	proteins	I
30	.	I

1	Dangers	O
2	in	O
3	use	O
4	of	O
5	live	O
6	-	O
7	virus	O
8	vaccines	O
9	.	O

1	Using	O
2	a	O
3	MOS	O
4	-	O
5	Hypersil	O
6	reversed	O
7	-	O
8	phase	O
9	column	O
10	with	O
11	a	O
12	phosphate	O
13	buffer	O
14	--	O
15	acetonitrile	O
16	mobile	O
17	phase	O
18	,	O
19	baseline	O
20	separation	O
21	of	O
22	antipyrine	O
23	,	O
24	its	O
25	metabolites	O
26	3	O
27	-	O
28	hydroxymethylantipyrine	O
29	,	O
30	norantipyrine	O
31	and	O
32	4	O
33	-	O
34	hydroxyantipyrine	O
35	,	O
36	and	O
37	the	O
38	internal	O
39	standard	O
40	,	O
41	phenacetin	O
42	,	O
43	was	O
44	achieved	O
45	within	O
46	6	O
47	min	O
48	.	O

1	We	O
2	report	O
3	the	O
4	construction	O
5	of	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	7	O
11	-	O
12	Mb	O
13	sequence	O
14	-	O
15	ready	O
16	YAC	O
17	/	O
18	BAC	O
19	clone	O
20	contig	O
21	of	O
22	8p22	O
23	-	O
24	p23	O
25	.	O

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	These	O
2	studies	O
3	support	O
4	the	O
5	view	O
6	that	O
7	HMG	B
8	I	I
9	(	O
10	Y	O
11	)	O
12	is	O
13	an	O
14	important	O
15	cofactor	O
16	for	O
17	HLA	B
18	-	I
19	DRA	I
20	gene	I
21	activation	O
22	by	O
23	Oct	B
24	-	I
25	2A	I
26	and	O
27	provide	O
28	insights	O
29	into	O
30	its	O
31	mechanism	O
32	of	O
33	action	O
34	.	O

1	The	O
2	complete	O
3	gene	O
4	organization	O
5	was	O
6	obtained	O
7	by	O
8	combining	O
9	the	O
10	results	O
11	of	O
12	the	O
13	sequence	O
14	of	O
15	these	O
16	clones	O
17	and	O
18	those	O
19	of	O
20	the	O
21	characterization	O
22	of	O
23	polymerase	O
24	chain	O
25	reaction	O
26	-	O
27	amplified	O
28	genomic	O
29	segments	O
30	.	O

1	Mapping	O
2	of	O
3	RNA	O
4	-	O
5	temperature	O
6	-	O
7	sensitive	O
8	mutants	O
9	of	O
10	Sindbis	O
11	virus	O
12	:	O
13	complementation	O
14	group	O
15	F	O
16	mutants	O
17	have	O
18	lesions	O
19	in	O
20	nsP4	O
21	.	O

1	No	O
2	difference	O
3	in	O
4	telomere	O
5	length	O
6	was	O
7	seen	O
8	in	O
9	mutants	O
10	affected	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	Cdc2	B
16	,	O
17	whereas	O
18	some	O
19	of	O
20	the	O
21	DNA	O
22	repair	O
23	mutants	O
24	examined	O
25	had	O
26	slightly	O
27	longer	O
28	telomeres	O
29	than	O
30	did	O
31	the	O
32	wild	O
33	type	O
34	.	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	Recombinant	O
2	BRI1	O
3	-	O
4	KD	O
5	autophosphorylated	O
6	on	O
7	serine	O
8	(	O
9	Ser	O
10	)	O
11	and	O
12	threonine	O
13	(	O
14	Thr	O
15	)	O
16	residues	O
17	with	O
18	p	O
19	-	O
20	Ser	O
21	predominating	O
22	.	O

1	Our	O
2	studies	O
3	also	O
4	excluded	O
5	the	O
6	possibility	O
7	that	O
8	the	O
9	phosphorylation	O
10	of	O
11	Ser	O
12	-	O
13	2	O
14	,	O
15	Ser	O
16	-	O
17	123	O
18	,	O
19	or	O
20	Ser	O
21	-	O
22	210	O
23	,	O
24	had	O
25	roles	O
26	in	O
27	the	O
28	trans	O
29	-	O
30	suppression	O
31	activity	O
32	of	O
33	the	O
34	large	O
35	HDAg	O
36	,	O
37	in	O
38	the	O
39	assembly	O
40	of	O
41	empty	B
42	virus	I
43	-	I
44	like	I
45	HDAg	O
46	particle	O
47	,	O
48	and	O
49	in	O
50	the	O
51	nuclear	O
52	transport	O
53	of	O
54	HDAgs	O
55	.	O

1	There	O
2	was	O
3	also	O
4	a	O
5	highly	O
6	significant	O
7	correlation	O
8	between	O
9	total	O
10	selenium	O
11	intake	O
12	and	O
13	liver	O
14	selenium	O
15	concentration	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	99	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	01	O
28	)	O
29	after	O
30	1	O
31	mo	O
32	of	O
33	treatment	O
34	,	O
35	but	O
36	this	O
37	time	O
38	liver	O
39	selenium	O
40	did	O
41	not	O
42	change	O
43	with	O
44	time	O
45	,	O
46	and	O
47	the	O
48	correlation	O
49	remained	O
50	highly	O
51	significant	O
52	throughout	O
53	the	O
54	investigation	O
55	.	O

1	Genomic	O
2	and	O
3	functional	O
4	characterization	O
5	of	O
6	the	O
7	oas	B
8	gene	I
9	family	I
10	encoding	I
11	O	I
12	-	I
13	acetylserine	O
14	(	O
15	thiol	O
16	)	O
17	lyases	O
18	,	O
19	enzymes	O
20	catalyzing	O
21	the	O
22	final	O
23	step	O
24	in	O
25	cysteine	O
26	biosynthesis	O
27	in	O
28	Arabidopsis	O
29	thaliana	O
30	.	O

1	Statistics	O
2	for	O
3	nurse	O
4	managers	O
5	--	O
6	3	O
7	.	O

1	A	O
2	total	O
3	of	O
4	1060	O
5	clones	O
6	were	O
7	randomly	O
8	selected	O
9	for	O
10	sequencing	O
11	of	O
12	one	O
13	end	O
14	.	O

1	A	O
2	reversed	O
3	-	O
4	phase	O
5	high	O
6	-	O
7	performance	O
8	liquid	O
9	chromatographic	O
10	(	O
11	HPLC	O
12	)	O
13	method	O
14	for	O
15	the	O
16	determination	O
17	of	O
18	cocaine	O
19	metabolites	O
20	produced	O
21	in	O
22	vitro	O
23	by	O
24	serum	O
25	and	O
26	liver	O
27	esterases	O
28	is	O
29	described	O
30	.	O

1	The	O
2	muscles	O
3	from	O
4	the	O
5	ischemic	O
6	group	O
7	had	O
8	significantly	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	.	O
15	05	O
16	)	O
17	values	O
18	for	O
19	capillary	O
20	density	O
21	and	O
22	capillary	O
23	to	O
24	fiber	O
25	ratio	O
26	and	O
27	significantly	O
28	higher	O
29	intercapillary	O
30	distance	O
31	than	O
32	those	O
33	from	O
34	the	O
35	normal	O
36	group	O
37	.	O

1	The	O
2	Aie1	O
3	locus	O
4	was	O
5	mapped	O
6	to	O
7	mouse	O
8	chromosome	O
9	7A2	B
10	-	I
11	A3	I
12	by	O
13	fluorescent	O
14	in	O
15	situ	O
16	hybridization	O
17	.	O

1	Phylogenetic	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	ToLCV	O
7	isolates	O
8	from	O
9	Bangalore	O
10	constitute	O
11	a	O
12	group	O
13	of	O
14	viruses	O
15	separated	O
16	from	O
17	those	O
18	of	O
19	Northern	O
20	India	O
21	.	O

1	The	O
2	cellular	O
3	rate	O
4	of	O
5	anticoagulant	O
6	heparan	O
7	sulfate	O
8	proteoglycan	O
9	(	O
10	HSPGact	O
11	)	O
12	generation	O
13	is	O
14	determined	O
15	by	O
16	the	O
17	level	O
18	of	O
19	a	O
20	kinetically	O
21	limiting	O
22	microsomal	O
23	activity	O
24	,	O
25	HSact	O
26	conversion	O
27	activity	O
28	,	O
29	which	O
30	is	O
31	predominantly	O
32	composed	O
33	of	O
34	the	O
35	long	O
36	sought	O
37	heparan	O
38	sulfate	O
39	D	O
40	-	O
41	glucosaminyl	B
42	3	I
43	-	I
44	O	I
45	-	I
46	sulfotransferase	O
47	(	O
48	3	O
49	-	O
50	OST	O
51	)	O
52	(	O
53	Shworak	O
54	,	O
55	N	O
56	.	O

1	In	O
2	contrast	O
3	,	O
4	injection	O
5	of	O
6	a	O
7	plasmid	O
8	encoding	O
9	simian	B
10	virus	I
11	40	I
12	small	I
13	t	I
14	antigen	I
15	,	O
16	which	O
17	interacts	O
18	with	O
19	PP2A	B
20	to	O
21	inhibit	O
22	its	O
23	activity	O
24	towards	O
25	several	O
26	phosphoprotein	O
27	substrates	O
28	,	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	the	O
34	phosphorylation	O
35	state	O
36	of	O
37	CREB	B
38	in	O
39	stimulated	O
40	or	O
41	unstimulated	O
42	NIH	O
43	3T3	O
44	cells	O
45	.	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	O
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	We	O
2	conclude	O
3	that	O
4	for	O
5	mono	O
6	-	O
7	intronic	O
8	precursors	O
9	in	O
10	which	O
11	there	O
12	is	O
13	only	O
14	one	O
15	choice	O
16	of	O
17	splice	O
18	sites	O
19	,	O
20	most	O
21	of	O
22	the	O
23	exon	O
24	sequences	O
25	are	O
26	not	O
27	mechanistically	O
28	involved	O
29	in	O
30	the	O
31	splicing	O
32	process	O
33	.	O

1	These	O
2	women	O
3	should	O
4	not	O
5	be	O
6	given	O
7	the	O
8	current	O
9	estrogen	O
10	PPI	O
11	,	O
12	which	O
13	was	O
14	designed	O
15	to	O
16	warn	O
17	women	O
18	of	O
19	the	O
20	risks	O
21	of	O
22	long	O
23	-	O
24	term	O
25	estrogen	O
26	use	O
27	;	O
28	a	O
29	PPI	O
30	should	O
31	be	O
32	written	O
33	specifically	O
34	for	O
35	patients	O
36	receiving	O
37	short	O
38	courses	O
39	.	O

1	Therefore	O
2	,	O
3	homozygous	O
4	co	O
5	-	O
6	deletions	O
7	of	O
8	CDKN2A	O
9	and	O
10	CDKN2B	O
11	rather	O
12	than	O
13	mutations	O
14	targeting	O
15	individual	O
16	transcripts	O
17	are	O
18	frequently	O
19	selected	O
20	for	O
21	in	O
22	these	O
23	tumors	O
24	.	O

1	Comparison	O
2	was	O
3	made	O
4	with	O
5	other	O
6	neuroradiological	O
7	imaging	O
8	modalities	O
9	including	O
10	CT	O
11	,	O
12	myelography	O
13	,	O
14	CT	O
15	ventriculography	O
16	,	O
17	and	O
18	CT	O
19	myelocisternography	O
20	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	O
13	ARS1	O
14	DNA	O
15	-	O
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	O
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	Analysis	O
2	of	O
3	the	O
4	rate	O
5	constants	O
6	indicated	O
7	that	O
8	the	O
9	isomerization	O
10	rate	O
11	k12	O
12	was	O
13	approximately	O
14	equal	O
15	to	O
16	the	O
17	apparent	O
18	degradation	O
19	rate	O
20	of	O
21	the	O
22	delta	O
23	3	O
24	ester	O
25	kdeg	O
26	,	O
27	and	O
28	slower	O
29	than	O
30	the	O
31	hydrolysis	O
32	rate	O
33	of	O
34	the	O
35	delta	O
36	2	O
37	ester	O
38	k24	O
39	.	O

1	The	O
2	available	O
3	data	O
4	suggest	O
5	that	O
6	the	O
7	NF	B
8	kappa	I
9	B2	I
10	nucleoprotein	I
11	complex	I
12	may	O
13	cooperate	O
14	with	O
15	DNA	O
16	-	O
17	bound	O
18	STAT6	O
19	to	O
20	achieve	O
21	IL	B
22	-	I
23	4	I
24	-	I
25	dependent	I
26	activation	O
27	of	O
28	the	O
29	human	B
30	IgE	I
31	germline	I
32	gene	I
33	.	I

1	The	O
2	American	O
3	Burkitt	O
4	Lymphoma	O
5	Registry	O
6	:	O
7	a	O
8	progress	O
9	report	O
10	.	O

1	Although	O
2	YopH	O
3	is	O
4	a	O
5	highly	O
6	active	O
7	PTP	B
8	,	O
9	it	O
10	preferentially	O
11	targets	O
12	a	O
13	subset	O
14	of	O
15	tyrosine	O
16	-	O
17	phosphorylated	O
18	proteins	O
19	in	O
20	host	O
21	cells	O
22	,	O
23	including	O
24	p130Cas	O
25	.	O

1	Hprp3p	O
2	is	O
3	a	O
4	77	O
5	kDa	O
6	protein	O
7	,	O
8	which	O
9	is	O
10	homologous	O
11	to	O
12	the	O
13	Saccharomyces	O
14	cerevisiae	O
15	splicing	O
16	factor	O
17	Prp3p	O
18	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	protein	O
7	product	O
8	of	O
9	the	O
10	ref	B
11	-	I
12	1	I
13	gene	I
14	stimulates	O
15	the	O
16	DNA	O
17	binding	O
18	activity	O
19	of	O
20	Fos	B
21	-	I
22	Jun	I
23	heterodimers	I
24	,	I
25	Jun	I
26	-	I
27	Jun	I
28	homodimers	I
29	and	O
30	Hela	O
31	cell	O
32	AP	B
33	-	I
34	1	I
35	proteins	I
36	as	O
37	well	O
38	as	O
39	that	O
40	of	O
41	several	O
42	other	O
43	transcription	O
44	factors	O
45	including	O
46	NF	B
47	-	I
48	kappa	I
49	B	I
50	,	I
51	Myb	I
52	and	O
53	members	O
54	of	O
55	the	O
56	ATF	B
57	/	I
58	CREB	I
59	family	I
60	.	I

1	Induction	O
2	of	O
3	B	O
4	cell	O
5	apoptosis	O
6	by	O
7	co	O
8	-	O
9	cross	O
10	-	O
11	linking	O
12	CD23	B
13	and	O
14	sIg	O
15	involves	O
16	aberrant	O
17	regulation	O
18	of	O
19	c	B
20	-	I
21	myc	I
22	and	O
23	is	O
24	inhibited	O
25	by	O
26	bcl	B
27	-	I
28	2	I
29	.	I

1	Serum	B
2	alkaline	I
3	phosphatase	I
4	activity	O
5	,	O
6	bone	O
7	mass	O
8	measurements	O
9	,	O
10	dual	O
11	energy	O
12	x	O
13	-	O
14	ray	O
15	absortiometric	O
16	analysis	O
17	of	O
18	mineral	O
19	density	O
20	,	O
21	and	O
22	mechanical	O
23	testing	O
24	values	O
25	in	O
26	vertebrae	O
27	and	O
28	femora	O
29	of	O
30	the	O
31	-	O
32	D	O
33	Sal	O
34	animals	O
35	did	O
36	not	O
37	significantly	O
38	differ	O
39	from	O
40	those	O
41	in	O
42	+	O
43	D	O
44	Sal	O
45	animals	O
46	.	O

1	The	O
2	concentrations	O
3	of	O
4	vitamin	O
5	A	O
6	precursors	O
7	and	O
8	vitamin	O
9	E	O
10	in	O
11	the	O
12	hay	O
13	were	O
14	below	O
15	currently	O
16	recommended	O
17	dietary	O
18	levels	O
19	for	O
20	llamas	O
21	,	O
22	and	O
23	alfalfa	O
24	hay	O
25	appears	O
26	to	O
27	provide	O
28	an	O
29	unreliable	O
30	source	O
31	of	O
32	vitamins	O
33	A	O
34	and	O
35	E	O
36	in	O
37	this	O
38	species	O
39	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	ketamine	O
6	-	O
7	treated	O
8	rats	O
9	had	O
10	more	O
11	neurons	O
12	and	O
13	glial	O
14	cells	O
15	surrounding	O
16	the	O
17	ventricles	O
18	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	O
6	deaminase	O
7	variants	O
8	,	O
9	termed	O
10	M	O
11	(	O
12	muscle	O
13	),	O
14	L	O
15	(	O
16	liver	O
17	),	O
18	E1	O
19	,	O
20	and	O
21	E2	O
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O

1	Similarly	O
2	,	O
3	PCDFs	O
4	/	O
5	PCDDs	O
6	ratio	O
7	in	O
8	ESP	O
9	ash	O
10	was	O
11	lower	O
12	than	O
13	that	O
14	in	O
15	boiler	O
16	ash	O
17	.	O

1	We	O
2	also	O
3	isolated	O
4	two	O
5	alternatively	O
6	spliced	O
7	forms	O
8	of	O
9	human	O
10	CD6	O
11	cDNA	O
12	lacking	O
13	sequences	O
14	encoding	O
15	membrane	O
16	-	O
17	proximal	O
18	regions	O
19	of	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	which	O
24	maintain	O
25	the	O
26	same	O
27	reading	O
28	frame	O
29	as	O
30	CD6	O
31	-	O
32	PB1	O
33	.	O

1	Factor	I
2	VIII	I
3	procoagulant	O
4	activity	O
5	,	O
6	antigen	O
7	concentration	O
8	and	O
9	von	B
10	Willebrand	I
11	activity	O
12	as	O
13	ristocetin	O
14	cofactor	O
15	were	O
16	determined	O
17	several	O
18	times	O
19	in	O
20	10	O
21	patients	O
22	with	O
23	DIC	O
24	.	O

1	Thus	O
2	,	O
3	transcriptional	O
4	regulation	O
5	,	O
6	splicing	O
7	,	O
8	kinase	O
9	interaction	O
10	sites	O
11	,	O
12	and	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	the	O
17	LMP2A	B
18	homologs	I
19	have	O
20	been	O
21	conserved	O
22	despite	O
23	significant	O
24	sequences	O
25	heterogeneity	O
26	in	O
27	the	O
28	preterminal	O
29	repeat	O
30	regions	O
31	of	O
32	these	O
33	human	O
34	and	O
35	nonhuman	O
36	primate	O
37	EBVs	O
38	.	O

1	Changes	O
2	following	O
3	periodontal	O
4	surgery	O
5	.	O

1	The	O
2	artery	O
3	cuff	O
4	was	O
5	slightly	O
6	superior	O
7	to	O
8	the	O
9	fat	O
10	wrap	O
11	,	O
12	particularly	O
13	in	O
14	having	O
15	fewer	O
16	adhesions	O
17	and	O
18	a	O
19	better	O
20	histological	O
21	picture	O
22	.	O

1	The	O
2	MCAD	B
3	nuclear	I
4	receptor	I
5	response	I
6	element	I
7	1	I
8	(	I
9	NRRE	I
10	-	I
11	1	I
12	)	O
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	ERR	O
18	alpha	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O

1	Phenotypic	O
2	changes	O
3	induced	O
4	by	O
5	wild	O
6	type	O
7	and	O
8	variant	O
9	c	B
10	-	I
11	src	I
12	genes	I
13	carrying	I
14	C	I
15	-	I
16	terminal	O
17	sequence	O
18	alterations	O
19	.	O

1	Regions	O
2	of	O
3	the	O
4	translated	O
5	open	O
6	reading	O
7	frames	O
8	of	O
9	cobA	O
10	and	O
11	the	O
12	third	O
13	intron	O
14	of	O
15	the	O
16	cob	B
17	gene	I
18	in	O
19	yeast	O
20	show	O
21	high	O
22	amino	O
23	acid	O
24	homology	O
25	.	O

1	The	O
2	multiple	O
3	factors	O
4	affecting	O
5	plasma	B
6	renin	I
7	activity	O
8	in	O
9	essential	O
10	hypertension	O
11	.	O

1	Furthermore	O
2	,	O
3	microinjection	O
4	of	O
5	dominant	O
6	negative	O
7	forms	O
8	of	O
9	Rac	B
10	and	O
11	Cdc42	B
12	or	O
13	of	O
14	the	O
15	Rho	B
16	inhibitor	I
17	C3	I
18	transferase	I
19	blocked	O
20	serum	O
21	-	O
22	induced	O
23	DNA	O
24	synthesis	O
25	.	O

1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	B
15	myoglobin	I
16	gene	I
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	O
38	site	O
39	)	O
40	linked	O
41	to	O
42	a	O
43	firefly	B
44	luciferase	I
45	gene	I
46	.	I

1	Anesthesia	O
2	with	O
3	M	O
4	/	O
5	K	O
6	was	O
7	reversed	O
8	after	O
9	41	O
10	.	O
11	6	O
12	min	O
13	of	O
14	immobilization	O
15	with	O
16	atipamezole	O
17	.	O

1	Samples	O
2	obtained	O
3	from	O
4	normal	O
5	volunteers	O
6	and	O
7	from	O
8	the	O
9	great	O
10	majority	O
11	of	O
12	the	O
13	patients	O
14	,	O
15	excluding	O
16	those	O
17	with	O
18	asthma	O
19	,	O
20	had	O
21	no	O
22	effect	O
23	on	O
24	ciliary	O
25	beating	O
26	.	O

1	Such	O
2	a	O
3	mechanism	O
4	may	O
5	allow	O
6	acceleration	O
7	of	O
8	degenerative	O
9	joint	O
10	conditions	O
11	,	O
12	and	O
13	may	O
14	account	O
15	for	O
16	the	O
17	increased	O
18	prevalence	O
19	of	O
20	such	O
21	conditions	O
22	seen	O
23	with	O
24	HMS	O
25	subjects	O
26	.	O

1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	increment	O
9	to	O
10	32	O
11	Gpt	O
12	/	O
13	l	O
14	(	O
15	CCI	O
16	11	O
17	).	O

1	He	O
2	was	O
3	administered	O
4	recombinant	O
5	IFN	B
6	alpha	I
7	-	I
8	2b	I
9	under	O
10	the	O
11	diagnosis	O
12	of	O
13	chronic	O
14	hepatitis	O
15	C	O
16	.	O

1	The	O
2	results	O
3	revealed	O
4	a	O
5	hierarchy	O
6	of	O
7	ligand	O
8	affinities	O
9	that	O
10	mirrored	O
11	their	O
12	adhesive	O
13	activity	O
14	(	O
15	rsVCAM	O
16	-	O
17	1	O
18	>	O
19	fibronectin	B
20	variants	I
21	containing	O
22	CS1	O
23	>>	O
24	other	O
25	fibronectin	B
26	variants	I
27	).	O

1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	O
28	.	O

1	A	O
2	review	O
3	of	O
4	studies	O
5	published	O
6	between	O
7	1983	O
8	and	O
9	1995	O
10	shows	O
11	that	O
12	there	O
13	are	O
14	some	O
15	common	O
16	factors	O
17	as	O
18	regards	O
19	the	O
20	psychological	O
21	distress	O
22	and	O
23	social	O
24	and	O
25	functional	O
26	limitations	O
27	this	O
28	group	O
29	of	O
30	patients	O
31	has	O
32	to	O
33	deal	O
34	with	O
35	.	O

1	Nuclear	B
2	factor	I
3	III	I
4	(	O
5	NFIII	O
6	)	O
7	is	O
8	a	O
9	protein	O
10	from	O
11	HeLa	O
12	cells	O
13	that	O
14	stimulates	O
15	the	O
16	initiation	O
17	of	O
18	adenovirus	B
19	type	I
20	2	I
21	(	O
22	Ad2	O
23	)	O
24	DNA	O
25	replication	O
26	by	O
27	binding	O
28	to	O
29	a	O
30	specific	O
31	nucleotide	O
32	sequence	O
33	in	O
34	the	O
35	origin	O
36	,	O
37	adjacent	O
38	to	O
39	the	O
40	nuclear	B
41	factor	I
42	I	I
43	recognition	I
44	site	I
45	.	I

1	The	O
2	decrease	O
3	of	O
4	TNF	B
5	receptors	I
6	by	O
7	IL	B
8	-	I
9	4	I
10	was	O
11	accompanied	O
12	by	O
13	down	O
14	-	O
15	regulation	O
16	of	O
17	TNF	B
18	-	I
19	induced	O
20	activities	O
21	,	O
22	including	O
23	cytotoxicity	O
24	,	O
25	caspase	B
26	-	I
27	3	I
28	activation	O
29	,	O
30	NF	B
31	-	I
32	kappaB	I
33	and	O
34	AP	B
35	-	I
36	1	I
37	activation	O
38	,	O
39	and	O
40	c	B
41	-	I
42	Jun	I
43	N	I
44	-	I
45	terminal	I
46	kinase	I
47	induction	O
48	.	O

1	The	O
2	tip	O
3	of	O
4	the	O
5	button	O
6	caused	O
7	a	O
8	perforation	O
9	of	O
10	the	O
11	posterior	O
12	stomach	O
13	wall	O
14	,	O
15	leading	O
16	to	O
17	death	O
18	.	O

1	The	O
2	sample	O
3	includes	O
4	all	O
5	the	O
6	HIV	O
7	-	O
8	infected	O
9	-	O
10	patients	O
11	continuously	O
12	referred	O
13	to	O
14	the	O
15	Outpatient	O
16	Service	O
17	of	O
18	the	O
19	Infectious	O
20	Diseases	O
21	dept	O
22	.	O
23	of	O
24	Bologna	O
25	'	O
26	s	O
27	"	O
28	Ospedale	O
29	Maggiore	O
30	"	O
31	General	O
32	Hospital	O
33	during	O
34	some	O
35	five	O
36	days	O
37	(	O
38	19	O
39	-	O
40	23rd	O
41	,	O
42	July	O
43	1993	O
44	).	O

1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O

1	Km	O
2	values	O
3	for	O
4	ammonium	O
5	,	O
6	2	O
7	-	O
8	oxoglutarate	O
9	,	O
10	NADH	O
11	,	O
12	glutamate	O
13	and	O
14	NAD	O
15	+	O
16	were	O
17	6	O
18	.	O
19	5	O
20	,	O
21	3	O
22	.	O
23	5	O
24	,	O
25	0	O
26	.	O
27	06	O
28	,	O
29	37	O
30	.	O
31	1	O
32	and	O
33	0	O
34	.	O
35	046	O
36	mM	O
37	,	O
38	respectively	O
39	.	O

1	Escherichia	O
2	coli	O
3	BL21	O
4	(	O
5	DE3	O
6	)	O
7	plysS	O
8	,	O
9	harbouring	O
10	a	O
11	recombinant	O
12	plasmid	O
13	containing	O
14	the	O
15	catalase	B
16	-	I
17	peroxidase	I
18	gene	I
19	,	O
20	produced	O
21	a	O
22	large	O
23	amount	O
24	of	O
25	proteins	O
26	that	O
27	co	O
28	-	O
29	migrated	O
30	on	O
31	SDS	O
32	/	O
33	PAGE	O
34	with	O
35	the	O
36	native	O
37	enzyme	O
38	.	O

1	Nineteen	O
2	patients	O
3	with	O
4	non	O
5	-	O
6	visualized	O
7	gallbladder	O
8	with	O
9	OCG	O
10	subsequently	O
11	had	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	PyG	O
17	cholescintigraphy	O
18	performed	O
19	.	O

1	ZEBRA	O
2	and	O
3	cellular	O
4	AP	B
5	-	I
6	1	I
7	bZip	I
8	activators	I
9	,	O
10	such	O
11	as	O
12	c	B
13	-	I
14	Fos	I
15	,	O
16	have	O
17	homologous	O
18	DNA	O
19	-	O
20	binding	O
21	domains	O
22	,	O
23	and	O
24	their	O
25	DNA	O
26	-	O
27	binding	O
28	specificities	O
29	overlap	O
30	.	O

1	The	O
2	role	O
3	of	O
4	daunorubicin	O
5	in	O
6	induction	O
7	therapy	O
8	for	O
9	adult	O
10	acute	O
11	myeloid	O
12	leukemia	O

1	When	O
2	the	O
3	high	O
4	affinity	O
5	hnRNP	B
6	A1	I
7	binding	I
8	site	I
9	was	O
10	inserted	O
11	into	O
12	the	O
13	beta	B
14	-	I
15	globin	I
16	reporter	I
17	,	O
18	Rev	B
19	was	O
20	able	O
21	to	O
22	increase	O
23	the	O
24	cytoplasmic	O
25	levels	O
26	of	O
27	unspliced	O
28	mRNAs	O
29	to	O
30	14	O
31	%.	O

1	We	O
2	conclude	O
3	that	O
4	grade	O
5	III	O
6	BGCT	O
7	can	O
8	be	O
9	treated	O
10	by	O
11	modified	O
12	intralesional	O
13	excision	O
14	provided	O
15	the	O
16	articular	O
17	surfaces	O
18	and	O
19	part	O
20	of	O
21	the	O
22	metaphysis	O
23	are	O
24	intact	O
25	.	O

1	The	O
2	pre	O
3	-	O
4	and	O
5	postoperative	O
6	haemoglobin	O
7	concentrations	O
8	in	O
9	the	O
10	autologous	O
11	group	O
12	were	O
13	lower	O
14	by	O
15	15	O
16	and	O
17	10	O
18	g	O
19	/	O
20	L	O
21	,	O
22	respectively	O
23	,	O
24	after	O
25	primary	O
26	THR	O
27	and	O
28	by	O
29	10	O
30	g	O
31	/	O
32	L	O
33	in	O
34	both	O
35	instances	O
36	after	O
37	revision	O
38	THR	O
39	.	O

1	The	O
2	rationale	O
3	for	O
4	continuous	O
5	dopaminergic	O
6	stimulation	O
7	in	O
8	patients	O
9	with	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	.	O

1	The	O
2	conditions	O
3	for	O
4	obtaining	O
5	titanium	O
6	dioxide	O
7	from	O
8	the	O
9	substrates	O
10	titanium	O
11	tetrachloride	O
12	and	O
13	oxygen	O
14	and	O
15	applying	O
16	this	O
17	to	O
18	a	O
19	surgical	O
20	stainless	O
21	steel	O
22	of	O
23	the	O
24	type	O
25	316L	O
26	by	O
27	the	O
28	plasma	O
29	assisted	O
30	chemical	O
31	vapour	O
32	deposition	O
33	method	O
34	have	O
35	been	O
36	determined	O
37	.	O

1	Vasopressin	O
2	(	O
3	AVP	B
4	),	O
5	the	O
6	antidiuretic	O
7	hormone	O
8	,	O
9	is	O
10	a	O
11	cyclic	O
12	nonapeptide	O
13	that	O
14	acts	O
15	through	O
16	binding	O
17	to	O
18	G	B
19	protein	I
20	-	I
21	coupled	I
22	specific	I
23	membrane	I
24	receptors	I
25	pharmacologically	O
26	divided	O
27	into	O
28	three	O
29	subtypes	O
30	(	O
31	V1a	O
32	,	O
33	V1b	O
34	,	O
35	and	O
36	V2	O
37	)	O
38	linked	O
39	to	O
40	distinct	O
41	second	O
42	messengers	O
43	.	O

1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	O
6	-	O
7	specific	O
8	and	O
9	MAP2	O
10	-	O
11	specific	O
12	mRNAs	O
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	O
24	-	O
25	specific	O
26	mRNA	O
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	B
38	growth	I
39	factor	I
40	.	I

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	I
9	-	I
10	1	I
11	)	I
12	Rev	I
13	protein	I
14	is	O
15	a	O
16	positive	O
17	posttranscriptional	O
18	regulator	O
19	of	O
20	viral	O
21	structural	O
22	gene	O
23	expression	O
24	and	O
25	essential	O
26	for	O
27	virus	O
28	replication	O
29	.	O

1	A	O
2	small	O
3	amount	O
4	of	O
5	HSP81	B
6	-	I
7	1	I
8	mRNA	I
9	was	O
10	detected	O
11	only	O
12	in	O
13	roots	O
14	.	O

1	Perceptions	O
2	of	O
3	illness	O
4	intrusiveness	O
5	were	O
6	significantly	O
7	higher	O
8	when	O
9	both	O
10	muscle	O
11	cramp	O
12	and	O
13	headache	O
14	symptoms	O
15	occurred	O
16	during	O
17	one	O
18	or	O
19	more	O
20	assessment	O
21	intervals	O
22	as	O
23	compared	O
24	to	O
25	when	O
26	muscle	O
27	cramps	O
28	or	O
29	headaches	O
30	,	O
31	only	O
32	,	O
33	occurred	O
34	.	O

1	The	O
2	assessment	O
3	using	O
4	7	O
5	H	O
6	9	O
7	liquid	O
8	medium	O
9	by	O
10	the	O
11	former	O
12	author	O
13	demonstrated	O
14	the	O
15	potent	O
16	activities	O
17	of	O
18	both	O
19	CS	O
20	-	O
21	940	O
22	*	O
23	and	O
24	sparfloxacin	O
25	(	O
26	SPFX	O
27	),	O
28	followed	O
29	by	O
30	AM	O
31	-	O
32	1155	O
33	*,	O
34	ciprofloxacin	O
35	(	O
36	CPFX	O
37	),	O
38	levofloxacin	O
39	(	O
40	LVFX	O
41	),	O
42	OPC	O
43	-	O
44	17116	O
45	*,	O
46	NM	O
47	-	O
48	394	O
49	*	O
50	in	O
51	sequence	O
52	.	O

1	The	O
2	response	O
3	properties	O
4	of	O
5	cat	O
6	horizontal	O
7	canal	O
8	afferents	O
9	(	O
10	N	O
11	=	O
12	81	O
13	)	O
14	were	O
15	characterized	O
16	by	O
17	three	O
18	parameters	O
19	:	O
20	their	O
21	long	O
22	time	O
23	constants	O
24	(	O
25	tau	O
26	),	O
27	low	O
28	frequency	O
29	gain	O
30	constants	O
31	(	O
32	G1	O
33	),	O
34	and	O
35	middle	O
36	frequency	O
37	gain	O
38	constants	O
39	(	O
40	Gm	O
41	).	O

1	The	O
2	alpha	B
3	4	I
4	gene	I
5	5	O
6	'	O
7	flanking	O
8	region	O
9	acted	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O

1	Data	O
2	from	O
3	the	O
4	V	O
5	-	O
6	HeFT	O
7	II	O
8	show	O
9	that	O
10	at	O
11	2	O
12	-	O
13	year	O
14	follow	O
15	-	O
16	up	O
17	,	O
18	a	O
19	progressive	O
20	rise	O
21	of	O
22	plasma	O
23	norepinephrine	O
24	was	O
25	observed	O
26	in	O
27	both	O
28	treatment	O
29	arms	O
30	,	O
31	suggesting	O
32	that	O
33	disease	O
34	progresses	O
35	despite	O
36	treatment	O
37	with	O
38	either	O
39	an	O
40	angiotensin	B
41	-	I
42	converting	I
43	enzyme	I
44	inhibitor	O
45	,	O
46	enalapril	O
47	,	O
48	or	O
49	vasodilator	O
50	therapy	O
51	with	O
52	hydralazine	O
53	/	O
54	isosorbide	O
55	dinitrate	O
56	.	O

1	This	O
2	reveals	O
3	a	O
4	new	O
5	test	O
6	for	O
7	short	O
8	saphenous	O
9	incompetence	O
10	and	O
11	shows	O
12	that	O
13	14	O
14	per	O
15	cent	O
16	of	O
17	varices	O
18	stem	O
19	from	O
20	a	O
21	saphenopopliteal	O
22	reflux	O
23	.	O

1	Two	O
2	scintigraphic	O
3	methods	O
4	,	O
5	resting	O
6	dipyridamole	O
7	and	O
8	exercise	O
9	thallium	O
10	-	O
11	201	O
12	myocardial	O
13	perfusion	O
14	imaging	O
15	,	O
16	to	O
17	detect	O
18	and	O
19	localize	O
20	coronary	O
21	artery	O
22	stenosis	O
23	were	O
24	compared	O
25	in	O
26	32	O
27	patients	O
28	suffering	O
29	from	O
30	coronary	O
31	artery	O
32	disease	O
33	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	meta	O
5	-	O
6	analysis	O
7	of	O
8	67	O
9	controlled	O
10	trials	O
11	was	O
12	performed	O
13	to	O
14	quantify	O
15	the	O
16	cholesterol	O
17	-	O
18	lowering	O
19	effect	O
20	of	O
21	major	O
22	dietary	O
23	fibers	O
24	.	O

1	To	O
2	determine	O
3	whether	O
4	interaction	O
5	of	O
6	arsenite	O
7	with	O
8	the	O
9	hormone	O
10	-	O
11	binding	O
12	domain	O
13	results	O
14	in	O
15	receptor	O
16	activation	O
17	,	O
18	COS	O
19	-	O
20	1	O
21	cells	O
22	were	O
23	transiently	O
24	cotransfected	O
25	with	O
26	the	O
27	chimeric	B
28	receptors	I
29	GAL	I
30	-	I
31	ER	I
32	,	O
33	which	O
34	contains	O
35	the	O
36	hormone	O
37	-	O
38	binding	O
39	domain	O
40	of	O
41	ERalpha	O
42	and	O
43	the	O
44	DNA	O
45	-	O
46	binding	O
47	domain	O
48	of	O
49	the	O
50	transcription	O
51	factor	O
52	GAL4	B
53	,	O
54	and	O
55	a	O
56	GAL4	B
57	-	I
58	responsive	I
59	CAT	I
60	reporter	I
61	gene	I
62	.	I

1	The	O
2	latter	O
3	was	O
4	determined	O
5	as	O
6	follows	O
7	:	O
8	Type	O
9	I	O
10	-	O
11	solid	O
12	tumor	O
13	tissue	O
14	without	O
15	significant	O
16	peripheral	O
17	isolated	O
18	tumor	O
19	cells	O
20	;	O
21	Type	O
22	II	O
23	-	O
24	solid	O
25	tumor	O
26	tissue	O
27	associated	O
28	with	O
29	peripheral	O
30	isolated	O
31	tumor	O
32	cells	O
33	;	O
34	Type	O
35	III	O
36	-	O
37	isolated	O
38	tumor	O
39	cells	O
40	only	O
41	.	O

1	Late	O
2	complications	O
3	of	O
4	catheterisation	O
5	for	O
6	intravenous	O
7	nutrition	O
8	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	findings	O
5	indicate	O
6	a	O
7	physical	O
8	barrier	O
9	of	O
10	oesophageal	O
11	surfactant	O
12	which	O
13	could	O
14	offer	O
15	some	O
16	degree	O
17	of	O
18	protection	O
19	against	O
20	gastro	O
21	-	O
22	oesophageal	O
23	reflux	O
24	but	O
25	one	O
26	which	O
27	is	O
28	particularly	O
29	prone	O
30	to	O
31	attack	O
32	by	O
33	bile	O
34	.	O

1	We	O
2	conclude	O
3	that	O
4	solidification	O
5	could	O
6	occur	O
7	in	O
8	all	O
9	feeds	O
10	containing	O
11	casein	B
12	and	O
13	that	O
14	alternative	O
15	feeds	O
16	should	O
17	be	O
18	considered	O
19	in	O
20	patients	O
21	with	O
22	increased	O
23	gastric	O
24	acidity	O
25	.	O

1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	B
9	and	O
10	PPARgamma	B
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O

1	Following	O
2	2	O
3	.	O
4	5	O
5	Gy	O
6	,	O
7	HbO2	O
8	changes	O
9	were	O
10	minimal	O
11	.	O

1	Cord	O
2	swelling	O
3	was	O
4	observed	O
5	in	O
6	2	O
7	patients	O
8	who	O
9	developed	O
10	complete	O
11	lesions	O
12	.	O

1	Presentation	O
2	of	O
3	a	O
4	horse	B
5	cytochrome	I
6	c	I
7	peptide	I
8	by	O
9	multiple	O
10	H	B
11	-	I
12	2b	I
13	class	I
14	I	I
15	major	I
16	histocompatibility	I
17	complex	I
18	(	I
19	MHC	I
20	)	O
21	molecules	O
22	to	O
23	C57BL	O
24	/	O
25	6	O
26	-	O
27	and	O
28	bm1	O
29	-	O
30	derived	O
31	cytotoxic	O
32	T	O
33	lymphocytes	O
34	:	O
35	presence	O
36	of	O
37	a	O
38	single	O
39	MHC	B
40	anchor	I
41	residue	O
42	may	O
43	confer	O
44	efficient	O
45	peptide	O
46	-	O
47	specific	O
48	CTL	O
49	recognition	O
50	.	O

1	Detection	O
2	of	O
3	airborne	O
4	Mycobacterium	O
5	tuberculosis	O
6	by	O
7	air	O
8	filtration	O
9	and	O
10	polymerase	O
11	chain	O
12	reaction	O
13	.	O

1	CT	O
2	abnormalities	O
3	noted	O
4	in	O
5	term	O
6	babies	O
7	included	O
8	hemorrhage	O
9	(	O
10	subarachnoid	O
11	5	O
12	.	O
13	8	O
14	%,	O
15	intracerebral	O
16	11	O
17	.	O
18	6	O
19	%),	O
20	hypodensity	O
21	(	O
22	mild	O
23	23	O
24	.	O
25	2	O
26	%,	O
27	moderate	O
28	11	O
29	.	O
30	6	O
31	%	O
32	severe	O
33	5	O
34	.	O
35	8	O
36	%);	O
37	hypodensity	O
38	with	O
39	hemorrhage	O
40	5	O
41	.	O
42	8	O
43	%	O
44	and	O
45	cerebral	O
46	atrophy	O
47	5	O
48	.	O
49	8	O
50	%.	O

1	Hyperthyroidism	B

1	Multivariate	O
2	predictors	O
3	were	O
4	concentric	O
5	remodeling	O
6	(	O
7	P	O
8	<	O
9	0	O
10	.	O
11	0001	O
12	;	O
13	odds	O
14	ratio	O
15	,	O
16	13	O
17	.	O
18	5	O
19	),	O
20	left	O
21	ventricular	O
22	ejection	O
23	fraction	O
24	>	O
25	2	O
26	SD	O
27	above	O
28	normal	O
29	(	O
30	P	O
31	<	O
32	0	O
33	.	O
34	0001	O
35	),	O
36	and	O
37	single	O
38	-	O
39	vessel	O
40	left	O
41	circumflex	O
42	disease	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	0007	O
49	;	O
50	odds	O
51	ratio	O
52	,	O
53	7	O
54	.	O
55	6	O
56	).	O

1	Cutaneous	O
2	necrosis	O
3	associated	O
4	with	O
5	protein	O
6	S	O
7	deficiency	O
8	.	O

1	Some	O
2	of	O
3	them	O
4	produce	O
5	gigantic	O
6	sperm	O
7	several	O
8	times	O
9	the	O
10	total	O
11	male	O
12	body	O
13	length	O
14	.	O

1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	O
12	)	O
13	substitutions	O
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	O
20	GP64	O
21	EFP	O
22	.	O

1	This	O
2	finding	O
3	is	O
4	consistent	O
5	with	O
6	the	O
7	notion	O
8	that	O
9	the	O
10	dsRNA	B
11	binding	I
12	domains	I
13	may	O
14	be	O
15	composed	O
16	of	O
17	two	O
18	separate	O
19	functional	O
20	subdomains	O
21	.	O

1	Patients	O
2	receiving	O
3	VPA	O
4	showed	O
5	differences	O
6	in	O
7	attention	O
8	,	O
9	visuomotor	O
10	performance	O
11	,	O
12	verbal	O
13	span	O
14	and	O
15	sensory	O
16	discrimination	O
17	tasks	O
18	at	O
19	T1	O
20	,	O
21	in	O
22	visuomotor	O
23	performance	O
24	at	O
25	T2	O
26	and	O
27	in	O
28	spatial	O
29	span	O
30	at	O
31	T3	O
32	,	O
33	whereas	O
34	no	O
35	differences	O
36	were	O
37	detected	O
38	at	O
39	T4	O
40	.	O

1	There	O
2	was	O
3	a	O
4	positive	O
5	correlation	O
6	between	O
7	pyridinium	O
8	cross	O
9	-	O
10	link	O
11	excretion	O
12	and	O
13	thyroid	O
14	hormone	O
15	concentrations	O
16	.	O

1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPARs	O
8	)	O
9	and	O
10	retinoid	B
11	X	I
12	receptors	I
13	(	O
14	RXRs	O
15	)	O
16	are	O
17	nuclear	B
18	hormone	I
19	receptors	I
20	that	O
21	are	O
22	activated	O
23	by	O
24	fatty	O
25	acids	O
26	and	O
27	9	O
28	-	O
29	cis	O
30	-	O
31	retinoic	O
32	acid	O
33	,	O
34	respectively	O
35	.	O

1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O

1	The	O
2	experimental	O
3	end	O
4	points	O
5	were	O
6	the	O
7	time	O
8	required	O
9	for	O
10	treated	O
11	tumors	O
12	to	O
13	reach	O
14	3	O
15	times	O
16	their	O
17	treatment	O
18	size	O
19	,	O
20	the	O
21	survival	O
22	of	O
23	stem	O
24	cells	O
25	in	O
26	the	O
27	duodenal	O
28	crypts	O
29	,	O
30	and	O
31	the	O
32	breathing	O
33	rate	O
34	measured	O
35	early	O
36	(	O
37	19	O
38	-	O
39	23	O
40	weeks	O
41	)	O
42	and	O
43	late	O
44	(	O
45	41	O
46	-	O
47	46	O
48	weeks	O
49	)	O
50	after	O
51	treatment	O
52	.	O

1	To	O
2	isolate	O
3	this	O
4	gene	O
5	,	O
6	a	O
7	P	O
8	-	O
9	1	O
10	artificial	O
11	chromosome	O
12	(	O
13	PAC	O
14	)	O
15	library	O
16	was	O
17	screened	O
18	with	O
19	a	O
20	full	O
21	length	O
22	UGT2B7	O
23	probe	O
24	and	O
25	a	O
26	clone	O
27	of	O
28	approximately	O
29	100	O
30	kb	O
31	in	O
32	length	O
33	was	O
34	isolated	O
35	.	O

1	Routine	O
2	blood	O
3	examination	O
4	showed	O
5	leukocytosis	O
6	,	O
7	thrombocytopenia	O
8	,	O
9	positive	O
10	CRP	B
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O

1	The	O
2	3	O
3	'	O
4	fragment	O
5	was	O
6	shown	O
7	to	O
8	accumulate	O
9	as	O
10	full	B
11	-	I
12	length	I
13	mRNA	I
14	disappeared	I
15	in	O
16	actinomycin	O
17	D	O
18	-	O
19	treated	O
20	cells	O
21	,	O
22	indicating	O
23	a	O
24	precursor	O
25	-	O
26	product	O
27	relationship	O
28	.	O

1	Endogenous	O
2	RMP	O
3	was	O
4	immunologically	O
5	detected	O
6	interacting	O
7	with	O
8	assembled	O
9	RPB5	O
10	in	O
11	RNA	B
12	polymerase	I
13	in	O
14	mammalian	O
15	cells	O
16	.	O

1	Effects	O
2	of	O
3	moderate	O
4	hypercapnia	O
5	on	O
6	hypothermia	O
7	induced	O
8	by	O
9	cold	O
10	He	O
11	-	O
12	O2	O
13	in	O
14	rats	O
15	.	O

1	Thus	O
2	,	O
3	in	O
4	stress	O
5	-	O
6	induced	O
7	arrhythmic	O
8	disease	O
9	as	O
10	well	O
11	as	O
12	in	O
13	ischemic	O
14	heart	O
15	disease	O
16	,	O
17	the	O
18	main	O
19	pathogenetic	O
20	links	O
21	are	O
22	outside	O
23	the	O
24	heart	O
25	,	O
26	but	O
27	they	O
28	differ	O
29	from	O
30	those	O
31	observed	O
32	in	O
33	ischemia	O
34	.	O

1	The	O
2	plasmid	O
3	shuffle	O
4	technique	O
5	was	O
6	used	O
7	to	O
8	replace	O
9	the	O
10	wild	B
11	-	I
12	type	I
13	gene	I
14	with	O
15	the	O
16	mutant	O
17	form	O
18	,	O
19	resulting	O
20	in	O
21	failure	O
22	of	O
23	the	O
24	yeast	O
25	cells	O
26	to	O
27	grow	O
28	.	O

1	A	O
2	thermal	O
3	Kubo	B
4	-	I
5	Martin	I
6	-	I
7	Schwinger	O
8	condition	O
9	arises	O
10	due	O
11	to	O
12	the	O
13	coupling	O
14	of	O
15	a	O
16	computer	O
17	to	O
18	a	O
19	strong	O
20	periodic	O
21	source	O
22	,	O
23	namely	O
24	,	O
25	the	O
26	daily	O
27	and	O
28	weekly	O
29	usage	O
30	patterns	O
31	of	O
32	the	O
33	system	O
34	.	O

1	The	O
2	method	O
3	also	O
4	eliminates	O
5	tagging	O
6	of	O
7	venous	O
8	spins	O
9	and	O
10	concern	O
11	about	O
12	asymmetric	O
13	magnetization	O
14	transfer	O
15	effects	O
16	.	O

1	Strengthening	O
2	the	O
3	biological	O
4	weapons	O
5	convention	O
6	and	O
7	implications	O
8	on	O
9	the	O
10	pharmaceutical	O
11	and	O
12	biotechnology	O
13	industry	O
14	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	I	I
8	induces	I
9	bcl	I
10	-	I
11	2	I
12	promoter	I
13	through	O
14	the	O
15	transcription	B
16	factor	I
17	cAMP	I
18	-	I
19	response	I
20	element	I
21	-	I
22	binding	I
23	protein	I
24	.	I

1	Efficacy	O
2	was	O
3	determined	O
4	by	O
5	responses	O
6	to	O
7	question	O
8	3	O
9	(	O
10	ability	O
11	to	O
12	achieve	O
13	an	O
14	erection	O
15	)	O
16	and	O
17	question	O
18	4	O
19	(	O
20	ability	O
21	to	O
22	maintain	O
23	an	O
24	erection	O
25	)	O
26	of	O
27	the	O
28	15	O
29	-	O
30	item	O
31	International	O
32	Index	O
33	of	O
34	Erectile	O
35	Function	O
36	(	O
37	IIEF	O
38	).	O

1	We	O
2	show	O
3	that	O
4	a	O
5	protein	O
6	,	O
7	UBC9	O
8	,	O
9	interacts	O
10	specifically	O
11	with	O
12	TEL	O
13	in	O
14	vitro	O
15	and	O
16	in	O
17	vivo	O
18	.	O

1	Mg	O
2	-	O
3	chelatase	O
4	of	O
5	tobacco	O
6	:	O
7	identification	O
8	of	O
9	a	O
10	Chl	O
11	D	O
12	cDNA	O
13	sequence	O
14	encoding	O
15	a	O
16	third	O
17	subunit	O
18	,	O
19	analysis	O
20	of	O
21	the	O
22	interaction	O
23	of	O
24	the	O
25	three	O
26	subunits	O
27	with	O
28	the	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	system	O
34	,	O
35	and	O
36	reconstitution	O
37	of	O
38	the	O
39	enzyme	O
40	activity	O
41	by	O
42	co	O
43	-	O
44	expression	O
45	of	O
46	recombinant	O
47	CHL	O
48	D	O
49	,	O
50	CHL	O
51	H	O
52	and	O
53	CHL	O
54	I	O
55	.	O

1	Hu	B
2	-	I
3	Met	I
4	-	I
5	1	I
6	mRNA	I
7	expression	O
8	in	O
9	a	O
10	small	O
11	number	O
12	of	O
13	human	O
14	T	O
15	cell	O
16	tumor	O
17	lines	O
18	did	O
19	not	O
20	correlate	O
21	with	O
22	any	O
23	particular	O
24	phenotype	O
25	or	O
26	stage	O
27	of	O
28	development	O
29	.	O

1	In	O
2	sixteen	O
3	patients	O
4	with	O
5	moderate	O
6	essential	O
7	hypertension	O
8	the	O
9	effects	O
10	of	O
11	10	O
12	-	O
13	day	O
14	nifedipine	O
15	treatment	O
16	on	O
17	serum	O
18	uric	O
19	acid	O
20	and	O
21	renal	O
22	excretion	O
23	of	O
24	uric	O
25	acid	O
26	were	O
27	evaluated	O
28	.	O

1	The	O
2	two	O
3	-	O
4	hybrid	O
5	assay	O
6	was	O
7	then	O
8	performed	O
9	using	O
10	full	O
11	-	O
12	length	O
13	genes	O
14	of	O
15	CI	O
16	,	O
17	HC	B
18	-	I
19	Pro	O
20	,	O
21	P1	O
22	,	O
23	P3	O
24	,	O
25	and	O
26	CP	O
27	,	O
28	but	O
29	no	O
30	heterologous	O
31	interactions	O
32	were	O
33	detected	O
34	.	O

1	During	O
2	insulin	B
3	infusion	O
4	,	O
5	a	O
6	20	O
7	%	O
8	dextrose	O
9	solution	O
10	was	O
11	infused	O
12	by	O
13	a	O
14	Biostator	O
15	in	O
16	order	O
17	to	O
18	maintain	O
19	the	O
20	patient	O
21	'	O
22	s	O
23	glycemia	O
24	at	O
25	90	O
26	mg	O
27	/	O
28	dl	O
29	.	O

1	No	O
2	symptoms	O
3	other	O
4	than	O
5	hot	O
6	flush	O
7	showed	O
8	such	O
9	significant	O
10	correlation	O
11	with	O
12	plasma	O
13	epinephrine	O
14	or	O
15	norepinephrine	O
16	levels	O
17	.	O

1	Each	O
2	patient	O
3	had	O
4	measurable	O
5	LH	B
6	and	O
7	FSH	B
8	levels	O
9	,	O
10	with	O
11	pulsed	O
12	nocturnal	O
13	secretion	O
14	,	O
15	and	O
16	pubertal	O
17	LH	B
18	and	O
19	FSH	B
20	responses	O
21	to	O
22	LRH	O
23	.	O

1	We	O
2	report	O
3	an	O
4	example	O
5	of	O
6	an	O
7	MDV	O
8	-	O
9	transformed	O
10	T	O
11	-	O
12	lymphoblastoid	O
13	cell	O
14	line	O
15	(	O
16	T9	O
17	)	O
18	expressing	O
19	high	O
20	levels	O
21	of	O
22	a	O
23	truncated	O
24	C	O
25	-	O
26	MYB	O
27	protein	O
28	as	O
29	a	O
30	result	O
31	of	O
32	RAV	O
33	integration	O
34	within	O
35	one	O
36	c	B
37	-	I
38	myb	I
39	allele	I
40	.	I

1	Sequence	O
2	divergence	O
3	is	O
4	observed	O
5	in	O
6	untranslated	O
7	regions	O
8	which	O
9	allows	O
10	the	O
11	definition	O
12	of	O
13	gene	O
14	-	O
15	specific	O
16	probes	O
17	.	O

1	Chemical	O
2	histologic	O
3	and	O
4	immunologic	O
5	responses	O
6	in	O
7	rats	O
8	to	O
9	CC1	O
10	-	O
11	4	O
12	by	O
13	different	O
14	routes	O
15	of	O
16	administration	O
17	.	O

1	The	O
2	structural	O
3	gene	O
4	for	O
5	copper	O
6	-	O
7	and	O
8	topa	B
9	quinone	I
10	-	I
11	containing	I
12	monoamine	I
13	oxidase	I
14	(	O
15	maoA	O
16	)	O
17	and	O
18	an	O
19	unknown	O
20	amine	B
21	oxidase	I
22	gene	I
23	have	O
24	been	O
25	located	O
26	at	O
27	30	O
28	.	O
29	9	O
30	min	O
31	on	O
32	the	O
33	Escherichia	O
34	coli	O
35	chromosome	O
36	.	O

1	Also	O
2	,	O
3	component	O
4	I	O
5	significantly	O
6	correlated	O
7	with	O
8	fasting	O
9	insulin	B
10	and	O
11	VO2	O
12	max	O
13	for	O
14	both	O
15	sexes	O
16	and	O
17	with	O
18	basal	O
19	metabolism	O
20	and	O
21	HDL	B
22	-	I
23	cholesterol	I
24	for	O
25	females	O
26	and	O
27	males	O
28	,	O
29	respectively	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	5	O
5	'	O
6	deletions	O
7	removing	O
8	all	O
9	but	O
10	34	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	transcription	O
16	start	O
17	point	O
18	retained	O
19	greater	O
20	than	O
21	90	O
22	%	O
23	promoter	O
24	activity	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	-	O
30	35	O
31	hexamer	O
32	was	O
33	not	O
34	essential	O
35	for	O
36	promoter	O
37	activity	O
38	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	The	O
2	PDE4A	B
3	-	I
4	subfamily	I
5	-	I
6	specific	I
7	linker	I
8	region	O
9	LR1	O
10	,	O
11	which	O
12	joins	O
13	UCR1	O
14	and	O
15	UCR2	O
16	,	O
17	is	O
18	encoded	O
19	by	O
20	two	O
21	exons	O
22	,	O
23	whereas	O
24	LR2	O
25	,	O
26	which	O
27	joins	O
28	UCR2	O
29	to	O
30	the	O
31	catalytic	O
32	unit	O
33	,	O
34	is	O
35	encoded	O
36	by	O
37	a	O
38	single	O
39	exon	O
40	.	O

1	Short	O
2	-	O
3	course	O
4	amphotericin	O
5	B	O
6	therapy	O
7	for	O
8	candidemia	O
9	in	O
10	pediatric	O
11	patients	O
12	.	O

1	In	O
2	synchronized	O
3	HeLa	O
4	cells	O
5	,	O
6	expression	O
7	of	O
8	luciferase	B
9	activity	O
10	was	O
11	induced	O
12	at	O
13	the	O
14	beginning	O
15	of	O
16	DNA	O
17	synthesis	O
18	and	O
19	was	O
20	dependent	O
21	on	O
22	the	O
23	presence	O
24	of	O
25	an	O
26	E2F	B
27	-	I
28	binding	I
29	site	I
30	in	O
31	the	O
32	H2A	O
33	.	O
34	1	O
35	promoter	O
36	.	O

1	Cutis	O
2	aplasia	O
3	.	O

1	Purified	O
2	spleen	O
3	GAP	B
4	accelerated	O
5	hydrolysis	O
6	of	O
7	GTP	O
8	bound	O
9	to	O
10	recombinant	O
11	ARF1	O
12	,	O
13	ARF3	O
14	,	O
15	ARF5	O
16	,	O
17	and	O
18	ARF6	O
19	;	O
20	no	O
21	effect	O
22	of	O
23	NH2	O
24	-	O
25	terminal	O
26	myristoylation	O
27	was	O
28	observed	O
29	.	O

1	Platelet	O
2	aggregation	O
3	and	O
4	metabolic	O
5	control	O
6	are	O
7	not	O
8	affected	O
9	by	O
10	calcium	O
11	antagonist	O
12	treatment	O
13	in	O
14	type	O
15	II	O
16	diabetes	O
17	mellitus	O
18	.	O

1	No	O
2	case	O
3	of	O
4	SMF	O
5	demonstrated	O
6	expansive	O
7	tumorous	O
8	growth	O
9	.	O

1	Further	O
2	support	O
3	for	O
4	a	O
5	direct	O
6	interaction	O
7	of	O
8	Tub4p	O
9	,	O
10	Spc98p	O
11	and	O
12	Spc97p	O
13	comes	O
14	from	O
15	the	O
16	toxicity	O
17	of	O
18	strong	O
19	SPC97	O
20	overexpression	O
21	which	O
22	is	O
23	suppressed	O
24	by	O
25	co	O
26	-	O
27	overexpression	O
28	of	O
29	TUB4	O
30	or	O
31	SPC98	O
32	.	O

1	In	O
2	that	O
3	case	O
4	,	O
5	the	O
6	ratio	O
7	of	O
8	brush	O
9	abrasion	O
10	was	O
11	0	O
12	.	O
13	268	O
14	,	O
15	compressive	O
16	and	O
17	transverse	O
18	strength	O
19	,	O
20	124	O
21	.	O
22	3	O
23	and	O
24	86	O
25	.	O
26	3	O
27	MPa	O
28	respectively	O
29	,	O
30	hardness	O
31	,	O
32	43	O
33	.	O
34	2	O
35	Hk	O
36	,	O
37	water	O
38	absorption	O
39	14	O
40	.	O
41	2	O
42	micrograms	O
43	/	O
44	mm3	O
45	and	O
46	thermal	O
47	expansion	O
48	coefficient	O
49	,	O
50	47	O
51	.	O
52	4	O
53	x	O
54	10	O
55	(-	O
56	6	O
57	)/	O
58	degrees	O
59	C	O
60	.	O

1	Liver	O
2	TG	O
3	and	O
4	serum	O
5	NEFA	O
6	concentrations	O
7	were	O
8	positively	O
9	correlated	O
10	.	O

1	Therefore	O
2	,	O
3	ICSBP	O
4	may	O
5	be	O
6	involved	O
7	in	O
8	maintaining	O
9	submaximal	O
10	transcriptional	O
11	activity	O
12	of	O
13	IFN	B
14	-	I
15	inducible	I
16	genes	I
17	in	O
18	hematopoietic	O
19	cells	O
20	.	O

1	Expression	O
2	of	O
3	the	O
4	second	O
5	gene	O
6	(	O
7	XT3	O
8	)	O
9	was	O
10	found	O
11	to	O
12	be	O
13	conserved	O
14	in	O
15	human	O
16	kidney	O
17	,	O
18	and	O
19	partial	O
20	sequence	O
21	was	O
22	obtained	O
23	from	O
24	a	O
25	human	O
26	cDNA	O
27	library	O
28	.	O

1	Holliday	O
2	junction	O
3	resolvase	O
4	in	O
5	Schizosaccharomyces	O
6	pombe	O
7	has	O
8	identical	O
9	endonuclease	O
10	activity	O
11	to	O
12	the	O
13	CCE1	O
14	homologue	O
15	YDC2	O
16	.	O

1	Interestingly	O
2	,	O
3	highly	O
4	charged	O
5	residues	O
6	were	O
7	abundantly	O
8	possessed	O
9	in	O
10	the	O
11	carboxy	O
12	-	O
13	terminal	O
14	part	O
15	of	O
16	the	O
17	MDV2	O
18	UL10	O
19	protein	O
20	.	O

1	We	O
2	conclude	O
3	from	O
4	these	O
5	studies	O
6	that	O
7	CKII	O
8	may	O
9	act	O
10	as	O
11	a	O
12	positive	O
13	regulator	O
14	of	O
15	myogenesis	O
16	by	O
17	preventing	O
18	E	B
19	protein	I
20	homodimers	I
21	from	O
22	binding	O
23	to	O
24	muscle	O
25	gene	O
26	regulatory	O
27	elements	O
28	.	O

1	The	O
2	SSB	B
3	-	I
4	poly	O
5	(	O
6	dT	O
7	)	O
8	affinity	O
9	is	O
10	too	O
11	high	O
12	to	O
13	measure	O
14	in	O
15	buffers	O
16	containing	O
17	even	O
18	5	O
19	M	O
20	NaCl	O
21	;	O
22	however	O
23	,	O
24	in	O
25	1	O
26	.	O
27	8	O
28	-	O
29	2	O
30	.	O
31	5	O
32	M	O
33	NaBr	O
34	,	O
35	we	O
36	measure	O
37	alpha	O
38	log	O
39	Kobsd	O
40	/	O
41	alpha	O
42	log	O
43	[	O
44	NaBr	O
45	]	O
46	=	O
47	-	O
48	5	O
49	.	O
50	7	O
51	+/-	O
52	0	O
53	.	O
54	7	O
55	,	O
56	with	O
57	a	O
58	lower	O
59	value	O
60	of	O
61	omega	O
62	T	O
63	/	O
64	O	O
65	=	O
66	130	O
67	+/-	O
68	70	O
69	.	O

1	In	O
2	diethyl	O
3	ether	O
4	solution	O
5	the	O
6	main	O
7	peak	O
8	is	O
9	that	O
10	of	O
11	2	O
12	-	O
13	benzylidenamio	B
14	-	I
15	1	I
16	-	I
17	phenylpropane	O
18	,	O
19	which	O
20	has	O
21	a	O
22	retention	O
23	time	O
24	of	O
25	23	O
26	,	O
27	2	O
28	minutes	O
29	under	O
30	the	O
31	condition	O
32	delineated	O
33	.	O

1	IA	O
2	-	O
3	CT	O
4	with	O
5	cisplatin	O
6	50	O
7	mg	O
8	and	O
9	doxorubicin	O
10	30	O
11	mg	O
12	was	O
13	administered	O
14	by	O
15	one	O
16	shot	O
17	method	O
18	in	O
19	bilateral	O
20	internal	O
21	iliac	O
22	arteries	O
23	.	O

1	It	O
2	has	O
3	been	O
4	proposed	O
5	that	O
6	the	O
7	parCBA	O
8	operon	O
9	encodes	O
10	a	O
11	plasmid	O
12	partitioning	O
13	system	O
14	(	O
15	M	O
16	.	O

1	Administration	O
2	of	O
3	RIFA	O
4	at	O
5	200	O
6	mg	O
7	/	O
8	kg	O
9	/	O
10	day	O
11	in	O
12	combination	O
13	with	O
14	ATO	O
15	at	O
16	100	O
17	mg	O
18	/	O
19	kg	O
20	/	O
21	day	O
22	resulted	O
23	in	O
24	a	O
25	marked	O
26	prolongation	O
27	of	O
28	survival	O
29	compared	O
30	with	O
31	that	O
32	for	O
33	mice	O
34	that	O
35	received	O
36	ATO	O
37	or	O
38	RIFA	O
39	alone	O
40	.	O

1	OBJECTIVE	O
2	:	O
3	The	O
4	purpose	O
5	of	O
6	this	O
7	article	O
8	is	O
9	to	O
10	review	O
11	balance	O
12	instruments	O
13	developed	O
14	within	O
15	the	O
16	past	O
17	10	O
18	years	O
19	that	O
20	can	O
21	be	O
22	used	O
23	in	O
24	the	O
25	clinic	O
26	or	O
27	home	O
28	environment	O
29	.	O

1	I	O
2	report	O
3	here	O
4	that	O
5	induction	O
6	of	O
7	HSP82	O
8	is	O
9	regulated	O
10	by	O
11	the	O
12	early	O
13	meiotic	O
14	IME1	B
15	-	I
16	IME2	I
17	transcriptional	O
18	cascade	O
19	.	O

1	Correlation	O
2	coefficients	O
3	between	O
4	the	O
5	reference	O
6	methods	O
7	and	O
8	NIT	O
9	were	O
10	>	O
11	or	O
12	=	O
13	0	O
14	.	O
15	95	O
16	for	O
17	water	O
18	,	O
19	fat	O
20	,	O
21	crude	O
22	protein	O
23	and	O
24	connective	B
25	-	I
26	tissue	I
27	-	I
28	protein	I
29	frei	I
30	meat	I
31	protein	I
32	,	O
33	and	O
34	>	O
35	or	O
36	=	O
37	0	O
38	.	O
39	86	O
40	for	O
41	connective	B
42	-	I
43	tissue	I
44	-	I
45	protein	I
46	.	I

1	This	O
2	site	O
3	acts	O
4	as	O
5	a	O
6	negative	O
7	element	O
8	when	O
9	transferred	O
10	to	O
11	the	O
12	thymidine	B
13	kinase	I
14	promoter	I
15	,	O
16	but	O
17	does	O
18	not	O
19	confer	O
20	inducibility	O
21	.	O

1	To	O
2	avoid	O
3	complications	O
4	,	O
5	accurate	O
6	quantitative	O
7	analysis	O
8	of	O
9	NO	O
10	and	O
11	NO2	O
12	is	O
13	necessary	O
14	during	O
15	this	O
16	therapy	O
17	.	O

1	The	O
2	juxtamembrane	O
3	region	O
4	of	O
5	the	O
6	insulin	B
7	receptor	I
8	(	I
9	IR	I
10	)	I
11	beta	I
12	-	I
13	subunit	I
14	contains	O
15	an	O
16	unphosphorylated	O
17	tyrosyl	O
18	residue	O
19	(	O
20	Tyr960	O
21	)	O
22	that	O
23	is	O
24	essential	O
25	for	O
26	insulin	B
27	-	I
28	stimulated	O
29	tyrosyl	O
30	phosphorylation	O
31	of	O
32	some	O
33	endogenous	O
34	substrates	O
35	and	O
36	certain	O
37	biological	O
38	responses	O
39	(	O
40	White	O
41	,	O
42	M	O
43	.	O
44	F	O
45	.,	O
46	Livingston	O
47	,	O
48	J	O
49	.	O
50	N	O
51	.,	O
52	Backer	O
53	,	O
54	J	O
55	.	O
56	M	O
57	.,	O
58	Lauris	O
59	,	O
60	V	O
61	.,	O
62	Dull	O
63	,	O
64	T	O
65	.	O
66	J	O
67	.,	O
68	Ullrich	O
69	,	O
70	A	O
71	.,	O
72	and	O
73	Kahn	O
74	,	O
75	C	O
76	.	O
77	R	O
78	.	O

1	The	O
2	structural	O
3	analysis	O
4	also	O
5	demonstrated	O
6	that	O
7	the	O
8	heterogeneity	O
9	of	O
10	the	O
11	HDC	O
12	mRNA	O
13	is	O
14	caused	O
15	by	O
16	an	O
17	insertion	O
18	of	O
19	the	O
20	seventh	O
21	intron	O
22	sequence	O
23	and	O
24	alternative	O
25	use	O
26	of	O
27	the	O
28	splicing	O
29	acceptor	O
30	site	O
31	at	O
32	the	O
33	12th	O
34	exon	O
35	.	O

1	Evaluation	O
2	of	O
3	thyroid	O
4	function	O
5	.	O

1	The	O
2	standard	O
3	method	O
4	for	O
5	calculating	O
6	the	O
7	composite	O
8	score	O
9	on	O
10	the	O
11	S	O
12	-	O
13	B	O
14	IV	O
15	excludes	O
16	subtests	O
17	with	O
18	a	O
19	raw	O
20	score	O
21	of	O
22	0	O
23	,	O
24	which	O
25	overestimates	O
26	cognitive	O
27	functioning	O
28	in	O
29	young	O
30	biologically	O
31	high	O
32	risk	O
33	children	O
34	.	O

1	Low	O
2	-	O
3	grade	O
4	gastric	O
5	MALT	O
6	lymphoma	O
7	and	O
8	helicobacter	O
9	heilmannii	O
10	(	O
11	Gastrospirillum	O
12	hominis	B

1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	that	O
7	exposure	O
8	of	O
9	DT40	O
10	lymphoma	O
11	B	O
12	cells	O
13	to	O
14	low	O
15	energy	O
16	electromagnetic	O
17	field	O
18	(	O
19	EMF	O
20	)	O
21	results	O
22	in	O
23	a	O
24	tyrosine	B
25	kinase	I
26	-	I
27	dependent	I
28	activation	O
29	of	O
30	phospholipase	B
31	Cgamma2	I
32	(	I
33	PLC	I
34	-	I
35	gamma2	O
36	)	O
37	leading	O
38	to	O
39	increased	O
40	inositol	O
41	phospholipid	O
42	turnover	O
43	.	O

1	Improvement	O
2	of	O
3	nursing	O
4	instruction	O
5	to	O
6	be	O
7	given	O
8	at	O
9	the	O
10	time	O
11	of	O
12	discharge	O
13	from	O
14	the	O
15	ward	O
16	for	O
17	premature	O
18	infants	O

1	Overexpression	O
2	of	O
3	MDR1	B
4	has	O
5	been	O
6	demonstrated	O
7	in	O
8	many	O
9	cancers	O
10	,	O
11	both	O
12	in	O
13	patient	O
14	tumors	O
15	and	O
16	in	O
17	cell	O
18	lines	O
19	selected	O
20	with	O
21	a	O
22	variety	O
23	of	O
24	chemotherapeutic	O
25	agents	O
26	.	O

1	CONCLUSION	O
2	:	O
3	In	O
4	our	O
5	animal	O
6	model	O
7	,	O
8	blood	O
9	-	O
10	brain	O
11	barrier	O
12	disruption	O
13	was	O
14	a	O
15	reproducible	O
16	,	O
17	integral	O
18	finding	O
19	of	O
20	single	O
21	-	O
22	fraction	O
23	,	O
24	high	O
25	-	O
26	dose	O
27	irradiation	O
28	injury	O
29	.	O

1	Such	O
2	mutations	O
3	are	O
4	thought	O
5	to	O
6	exert	O
7	their	O
8	dominant	O
9	phenotype	O
10	by	O
11	sequestration	O
12	of	O
13	the	O
14	guanine	B
15	nucleotide	I
16	exchange	I
17	factor	I
18	(	O
19	GNEF	O
20	).	O

1	The	O
2	experiment	O
3	included	O
4	6	O
5	male	O
6	and	O
7	4	O
8	female	O
9	healthy	O
10	subjects	O
11	who	O
12	,	O
13	during	O
14	a	O
15	24	O
16	-	O
17	hour	O
18	stay	O
19	in	O
20	the	O
21	respiration	O
22	chambers	O
23	,	O
24	performed	O
25	,	O
26	in	O
27	the	O
28	morning	O
29	and	O
30	afternoon	O
31	,	O
32	15	O
33	min	O
34	cycling	O
35	with	O
36	the	O
37	total	O
38	work	O
39	of	O
40	6	O
41	,	O
42	750	O
43	kg	O
44	m	O
45	.	O

1	The	O
2	control	O
3	group	O
4	revealed	O
5	significantly	O
6	higher	O
7	levels	O
8	of	O
9	coagulation	B
10	factors	I
11	II	I
12	,	O
13	V	O
14	and	O
15	VIII	O
16	,	O
17	compared	O
18	to	O
19	the	O
20	index	O
21	group	O
22	.	O

1	The	O
2	PDGFR	B
3	mutants	I
4	that	O
5	failed	O
6	to	O
7	associate	O
8	with	O
9	PLC	B
10	gamma	I
11	were	O
12	not	O
13	able	O
14	to	O
15	mediate	O
16	the	O
17	PDGF	B
18	-	I
19	dependent	I
20	production	O
21	of	O
22	inositol	O
23	phosphates	O
24	.	O

1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	O
6	protein	O
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O

1	IFN	B
2	alpha	I
3	and	O
4	IFN	B
5	gamma	I
6	inducibility	O
7	is	O
8	mediated	O
9	by	O
10	a	O
11	single	O
12	element	O
13	:	O
14	a	O
15	high	O
16	affinity	O
17	,	O
18	nearly	O
19	palindromic	O
20	version	O
21	of	O
22	the	O
23	IFN	B
24	gamma	I
25	activation	O
26	site	O
27	(	O
28	GAS	O
29	).	O

1	The	O
2	zta	O
3	transactivator	O
4	involved	O
5	in	O
6	induction	O
7	of	O
8	lytic	O
9	cycle	O
10	gene	O
11	expression	O
12	in	O
13	Epstein	B
14	-	I
15	Barr	I
16	virus	I
17	-	I
18	infected	O
19	lymphocytes	O
20	binds	O
21	to	O
22	both	O
23	AP	B
24	-	I
25	1	I
26	and	O
27	ZRE	O
28	sites	O
29	in	O
30	target	O
31	promoter	O
32	and	O
33	enhancer	O
34	regions	O
35	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	O
8	is	O
9	a	O
10	distant	O
11	homolog	O
12	of	O
13	alphavirus	O
14	nonstructural	O
15	protein	O
16	nsP1	O
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O

1	Given	O
2	its	O
3	relative	O
4	longevity	O
5	on	O
6	the	O
7	Web	O
8	,	O
9	TIE	O
10	researchers	O
11	have	O
12	been	O
13	in	O
14	a	O
15	unique	O
16	position	O
17	to	O
18	observe	O
19	trends	O
20	in	O
21	telemedicine	O
22	.	O

1	Erythrocyte	O
2	protoporphyrin	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	remainder	O
41	of	O
42	the	O
43	study	O
44	.	O

1	Factors	O
2	that	O
3	showed	O
4	significant	O
5	correlation	O
6	to	O
7	elevated	O
8	CIC	O
9	'	O
10	s	O
11	in	O
12	the	O
13	highly	O
14	elevated	O
15	portion	O
16	of	O
17	our	O
18	CIC	O
19	population	O
20	were	O
21	poor	O
22	NIH	O
23	score	O
24	,	O
25	increased	O
26	patient	O
27	age	O
28	,	O
29	low	O
30	peak	O
31	expiratory	O
32	flow	O
33	rate	O
34	,	O
35	and	O
36	elevated	O
37	total	O
38	serum	O
39	IgG	B
40	.	I

1	The	O
2	methylation	O
3	of	O
4	nuclear	O
5	and	O
6	chloroplast	O
7	DNAs	O
8	has	O
9	been	O
10	examined	O
11	in	O
12	relation	O
13	to	O
14	the	O
15	known	O
16	differential	O
17	expression	O
18	of	O
19	C4	O
20	photosynthesis	O
21	genes	O
22	in	O
23	the	O
24	bundle	O
25	sheath	O
26	and	O
27	mesophyll	O
28	cells	O
29	of	O
30	etiolated	O
31	,	O
32	greening	O
33	,	O
34	and	O
35	fully	O
36	green	O
37	maize	O
38	leaves	O
39	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	the	O
6	same	O
7	males	O
8	,	O
9	breeding	O
10	in	O
11	different	O
12	years	O
13	on	O
14	the	O
15	same	O
16	territories	O
17	,	O
18	had	O
19	significantly	O
20	larger	O
21	harems	O
22	in	O
23	the	O
24	years	O
25	they	O
26	had	O
27	familiar	O
28	neighbors	O
29	.	O

1	These	O
2	genetic	O
3	alterations	O
4	do	O
5	not	O
6	affect	O
7	synthesis	O
8	of	O
9	the	O
10	major	O
11	c	B
12	-	I
13	myc	I
14	protein	I
15	,	O
16	p64	O
17	,	O
18	which	O
19	is	O
20	initiated	O
21	from	O
22	the	O
23	first	O
24	AUG	O
25	codon	O
26	in	O
27	exon	O
28	2	O
29	.	O

1	These	O
2	studies	O
3	identify	O
4	several	O
5	of	O
6	the	O
7	signal	O
8	-	O
9	transduction	O
10	events	O
11	involved	O
12	in	O
13	the	O
14	apoptosis	O
15	of	O
16	malignant	O
17	B	O
18	cells	O
19	that	O
20	transpire	O
21	following	O
22	ligation	O
23	of	O
24	CD20	O
25	by	O
26	anti	B
27	-	I
28	CD20	I
29	antibodies	I
30	in	O
31	the	O
32	presence	O
33	of	O
34	Fc	B
35	-	I
36	receptor	I
37	-	I
38	expressing	O
39	cells	O
40	or	O
41	secondary	O
42	goat	O
43	anti	O
44	-(	O
45	mouse	O
46	Ig	B
47	)	I
48	antibodies	I
49	and	O
50	which	O
51	may	O
52	contribute	O
53	to	O
54	the	O
55	tumor	O
56	regressions	O
57	observed	O
58	in	O
59	mouse	O
60	models	O
61	and	O
62	clinical	O
63	trials	O
64	.	O

1	Bone	O
2	marrow	O
3	transplantation	O
4	-	O
5	1979	O
6	.	O

1	The	O
2	association	O
3	of	O
4	clopamide	O
5	and	O
6	hydergine	O
7	(	O
8	Brinedine	O
9	)	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	the	O
15	vasculo	O
16	-	O
17	renal	O
18	syndromes	O
19	of	O
20	pregnancy	O

1	Animals	O
2	that	O
3	received	O
4	DSP	O
5	-	O
6	4	O
7	were	O
8	significantly	O
9	retarded	O
10	in	O
11	motor	O
12	recovery	O
13	compared	O
14	with	O
15	the	O
16	saline	O
17	group	O
18	.	O

1	The	O
2	Tax	B
3	/	O
4	IKKgamma	O
5	interaction	O
6	serves	O
7	to	O
8	recruit	O
9	Tax	B
10	to	O
11	the	O
12	IKK	O
13	catalytic	O
14	subunits	O
15	,	O
16	IKKalpha	O
17	and	O
18	IKKbeta	O
19	,	O
20	and	O
21	this	O
22	recruitment	O
23	appears	O
24	to	O
25	be	O
26	an	O
27	essential	O
28	mechanism	O
29	by	O
30	which	O
31	Tax	B
32	stimulates	O
33	the	O
34	activity	O
35	of	O
36	IKK	O
37	.	O

1	Guiding	O
2	patients	O
3	in	O
4	the	O
5	decision	O
6	should	O
7	involve	O
8	a	O
9	multidisciplinary	O
10	team	O
11	composed	O
12	of	O
13	a	O
14	surgical	O
15	oncologist	O
16	,	O
17	geneticist	O
18	,	O
19	pathologist	O
20	,	O
21	psychotherapist	O
22	and	O
23	plastic	O
24	surgeon	O
25	.	O

1	From	O
2	this	O
3	library	O
4	,	O
5	LEU2	O
6	and	O
7	HIS3	B
8	cDNAs	I
9	were	O
10	recovered	O
11	at	O
12	a	O
13	frequency	O
14	of	O
15	about	O
16	1	O
17	in	O
18	10	O
19	(	O
20	4	O
21	)	O
22	and	O
23	in	O
24	12	O
25	out	O
26	of	O
27	13	O
28	cases	O
29	these	O
30	were	O
31	expressed	O
32	in	O
33	a	O
34	galactose	O
35	-	O
36	dependent	O
37	manner	O
38	.	O

1	The	O
2	inhibitory	O
3	response	O
4	to	O
5	taps	O
6	is	O
7	essentially	O
8	a	O
9	protective	O
10	reflex	O
11	which	O
12	probably	O
13	serves	O
14	to	O
15	reduce	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	jaw	O
21	-	O
22	closing	O
23	muscles	O
24	when	O
25	one	O
26	bites	O
27	unexpectedly	O
28	on	O
29	hard	O
30	objects	O
31	.	O

1	Measurement	O
2	of	O
3	SaO2	O
4	at	O
5	moderate	O
6	altitude	O
7	can	O
8	be	O
9	helpful	O
10	in	O
11	the	O
12	care	O
13	of	O
14	both	O
15	healthy	O
16	and	O
17	ill	O
18	newborns	O
19	or	O
20	infants	O
21	.	O

1	Retrograde	O
2	filling	O
3	consists	O
4	in	O
5	sealing	O
6	endodontics	O
7	system	O
8	directly	O
9	at	O
10	the	O
11	apical	O
12	zone	O
13	after	O
14	surgical	O
15	approach	O
16	.	O

1	Effect	O
2	of	O
3	succimer	O
4	on	O
5	the	O
6	intensity	O
7	of	O
8	tricarboxylic	B
9	acid	I
10	dehydrogenase	I
11	reactions	O
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	B
20	chloride	I

1	This	O
2	effect	O
3	was	O
4	abolished	O
5	once	O
6	the	O
7	EM	O
8	motif	O
9	in	O
10	the	O
11	promoter	O
12	-	O
13	reporter	O
14	construct	O
15	was	O
16	mutated	O
17	,	O
18	thus	O
19	suggesting	O
20	that	O
21	the	O
22	synergistic	O
23	transactivation	O
24	function	O
25	of	O
26	the	O
27	TEF	B
28	-	I
29	1	I
30	-	I
31	Max	I
32	heterotypic	O
33	complex	O
34	is	O
35	mediated	O
36	through	O
37	binding	O
38	of	O
39	the	O
40	complex	O
41	to	O
42	the	O
43	EM	O
44	motif	O
45	.	O

1	Anesthesia	O
2	was	O
3	maintained	O
4	with	O
5	isoflurane	O
6	(	O
7	ISO	O
8	)/	O
9	N2O	O
10	/	O
11	O2	O
12	inhalation	O
13	.	O

1	Modeling	O
2	also	O
3	revealed	O
4	a	O
5	very	O
6	hydrophobic	O
7	surface	O
8	due	O
9	to	O
10	the	O
11	absence	O
12	of	O
13	H12	O
14	,	O
15	exposing	O
16	residues	O
17	from	O
18	H3	O
19	,	O
20	loop	O
21	3	O
22	-	O
23	4	O
24	,	O
25	H4	O
26	,	O
27	and	O
28	H11	O
29	.	O

1	The	O
2	influence	O
3	of	O
4	adrenergic	O
5	nerves	O
6	of	O
7	the	O
8	response	O
9	of	O
10	blood	O
11	vessels	O
12	in	O
13	the	O
14	rabbit	O
15	ear	O
16	to	O
17	2	O
18	--	O
19	phenylalanine	B
20	-	I
21	8	I
22	-	I
23	lysine	I
24	vasopressin	I
25	(	O
26	Octapressin	O
27	).	O

1	We	O
2	analyzed	O
3	data	O
4	from	O
5	56	O
6	patients	O
7	with	O
8	Systemic	O
9	Lupus	O
10	Erythematosus	O
11	(	O
12	SLE	O
13	)	O
14	in	O
15	whom	O
16	renal	O
17	biopsies	O
18	were	O
19	done	O
20	systematically	O
21	.	O

1	All	O
2	62	O
3	isolates	O
4	were	O
5	resistant	O
6	to	O
7	lincomycin	O
8	,	O
9	colistin	O
10	,	O
11	nystatin	O
12	,	O
13	amphotericin	O
14	B	O
15	,	O
16	trimethoprim	O
17	lactate	O
18	,	O
19	polymyxin	O
20	B	O
21	,	O
22	and	O
23	anisomycin	O
24	.	O

1	To	O
2	gain	O
3	further	O
4	insight	O
5	into	O
6	the	O
7	pathogenesis	O
8	of	O
9	the	O
10	adult	O
11	respiratory	O
12	distress	O
13	syndrome	O
14	(	O
15	ARDS	O
16	),	O
17	the	O
18	authors	O
19	studied	O
20	possible	O
21	relationships	O
22	among	O
23	the	O
24	activation	O
25	status	O
26	of	O
27	circulating	O
28	polymorphonuclear	O
29	neutrophils	O
30	(	O
31	PMN	O
32	),	O
33	cytokine	O
34	levels	O
35	,	O
36	and	O
37	the	O
38	severity	O
39	of	O
40	lung	O
41	injury	O
42	in	O
43	31	O
44	patients	O
45	:	O
46	15	O
47	with	O
48	ARDS	O
49	,	O
50	9	O
51	with	O
52	severe	O
53	pneumonia	O
54	uncomplicated	O
55	by	O
56	ARDS	O
57	,	O
58	and	O
59	7	O
60	mechanically	O
61	ventilated	O
62	patients	O
63	with	O
64	neither	O
65	ARDS	O
66	nor	O
67	pneumonia	O
68	.	O

1	Using	O
2	Scheffe	O
3	'	O
4	s	O
5	procedure	O
6	as	O
7	an	O
8	illustration	O
9	,	O
10	comparisons	O
11	are	O
12	made	O
13	to	O
14	usual	O
15	sample	O
16	size	O
17	methods	O
18	that	O
19	incorrectly	O
20	ignore	O
21	the	O
22	stochastic	O
23	nature	O
24	of	O
25	S2p	O
26	.	O

1	Mechanism	O
2	of	O
3	activation	O
4	of	O
5	the	O
6	vav	O
7	protooncogene	O
8	.	O
9	vav	O
10	is	O
11	a	O
12	human	B
13	locus	I
14	that	O
15	appears	O
16	to	O
17	be	O
18	specifically	O
19	expressed	O
20	in	O
21	cells	O
22	of	O
23	hematopoietic	O
24	origin	O
25	regardless	O
26	of	O
27	their	O
28	differentiation	O
29	lineage	O
30	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	these	O
7	clones	O
8	encode	O
9	two	O
10	distinct	O
11	forms	O
12	of	O
13	translocase	O
14	.	O

1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	mDAP	O
7	-	O
8	3	O
9	/	O
10	EGFP	O
11	fusion	O
12	protein	O
13	,	O
14	cell	O
15	fractionation	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	mDAP	O
22	-	O
23	3	O
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O

1	A	O
2	distinct	O
3	staining	O
4	pattern	O
5	for	O
6	the	O
7	N	O
8	-	O
9	utrophin	O
10	was	O
11	not	O
12	detectable	O
13	,	O
14	although	O
15	it	O
16	was	O
17	expected	O
18	to	O
19	localise	O
20	at	O
21	the	O
22	actin	B
23	stress	O
24	fibers	O
25	.	O

1	The	O
2	galactose	O
3	transporter	O
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	O
15	transporters	O
16	which	O
17	includes	O
18	the	O
19	human	O
20	HepG2	O
21	-	O
22	erythrocyte	O
23	and	O
24	fetal	O
25	muscle	O
26	glucose	O
27	transporters	O
28	,	O
29	the	O
30	rat	O
31	brain	O
32	and	O
33	liver	O
34	glucose	O
35	transporters	O
36	,	O
37	the	O
38	Escherichia	O
39	coli	O
40	xylose	O
41	and	O
42	arabinose	O
43	permeases	O
44	,	O
45	and	O
46	the	O
47	S	O
48	.	O
49	cerevisiae	O
50	glucose	O
51	,	O
52	maltose	O
53	,	O
54	and	O
55	galactose	O
56	transporters	O
57	.	O

1	Analysis	O
2	of	O
3	intragenic	O
4	revertants	O
5	shows	O
6	that	O
7	this	O
8	function	O
9	depends	O
10	on	O
11	the	O
12	amino	O
13	acid	O
14	preceding	O
15	the	O
16	first	O
17	cysteine	O
18	residue	O
19	of	O
20	the	O
21	DNA	O
22	-	O
23	binding	O
24	domain	O
25	of	O
26	Hap1p	O
27	.	O

1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	B
25	-	I
26	type	I
27	constructs	I
28	.	I

1	Changes	O
2	in	O
3	stimulation	O
4	levels	O
5	over	O
6	time	O
7	in	O
8	nucleus	O
9	22	O
10	cochlear	O
11	implant	O
12	users	O
13	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	to	O
6	characterize	O
7	the	O
8	gene	O
9	for	O
10	protein	O
11	Z	O
12	,	O
13	its	O
14	organization	O
15	and	O
16	structure	O
17	were	O
18	determined	O
19	by	O
20	a	O
21	combination	O
22	of	O
23	PCR	O
24	amplification	O
25	of	O
26	leukocyte	O
27	DNA	O
28	and	O
29	isolation	O
30	of	O
31	phage	O
32	clones	O
33	from	O
34	a	O
35	human	O
36	genomic	O
37	library	O
38	.	O

1	Residues	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O

1	During	O
2	the	O
3	observation	O
4	period	O
5	of	O
6	0	O
7	.	O
8	4	O
9	-	O
10	30	O
11	weeks	O
12	,	O
13	cardiac	O
14	white	O
15	spots	O
16	on	O
17	the	O
18	right	O
19	ventricle	O
20	of	O
21	BALB	O
22	/	O
23	c	B
24	mice	O
25	were	O
26	first	O
27	detected	O
28	at	O
29	three	O
30	weeks	O
31	(	O
32	6	O
33	of	O
34	20	O
35	mice	O
36	;	O
37	30	O
38	%),	O
39	and	O
40	the	O
41	maximal	O
42	incidence	O
43	of	O
44	cardiac	O
45	white	O
46	spots	O
47	was	O
48	obtained	O
49	at	O
50	nine	O
51	weeks	O
52	(	O
53	39	O
54	of	O
55	44	O
56	mice	O
57	;	O
58	88	O
59	%).	O

1	A	O
2	--	O
3	A	O
4	natural	O
5	hydrostatic	O
6	phenomenon	O
7	,	O
8	at	O
9	the	O
10	level	O
11	of	O
12	the	O
13	ends	O
14	of	O
15	the	O
16	plantar	O
17	arcs	O
18	,	O
19	diffuses	O
20	body	O
21	weight	O
22	,	O
23	as	O
24	PAIN	O
25	plays	O
26	the	O
27	role	O
28	of	O
29	outsentry	O
30	(	O
31	fig	O
32	.--	O
33	1	O
34	)	O
35	(	O
36	5	O
37	);	O
38	B	O
39	--	O
40	Plantar	O
41	perforating	O
42	ulceration	O
43	(	O
44	PPU	O
45	)	O
46	is	O
47	caused	O
48	by	O
49	a	O
50	combination	O
51	of	O
52	INSENSITIVITY	O
53	and	O
54	TRAUMATIS	O
55	(	O
56	1	O
57	);	O
58	C	O
59	--	O
60	The	O
61	patient	O
62	reposing	O
63	,	O
64	as	O
65	body	O
66	weight	O
67	(	O
68	traumatism	O
69	)	O
70	effects	O
71	disappear	O
72	,	O
73	cicatrization	O
74	process	O
75	can	O
76	be	O
77	easily	O
78	observed	O
79	;	O
80	D	O
81	--	O
82	PNEUMATIC	O
83	INSOLE	O
84	,	O
85	being	O
86	elastic	O
87	,	O
88	diffuses	O
89	localized	O
90	compression	O
91	at	O
92	the	O
93	ends	O
94	of	O
95	the	O
96	plantar	O
97	arcs	O
98	,	O
99	reduces	O
100	attrition	O
101	,	O
102	makes	O
103	easier	O
104	blood	O
105	circulation	O
106	,	O
107	as	O
108	well	O
109	as	O
110	cure	O
111	and	O
112	prophylaxis	O
113	of	O
114	PPU	O
115	(	O
116	fig	O
117	.--	O
118	6	O
119	)	O
120	(	O
121	3	O
122	).	O

1	W	O
2	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	the	O
6	mechanism	O
7	of	O
8	action	O
9	,	O
10	two	O
11	groups	O
12	of	O
13	inodilators	O
14	are	O
15	distinguished	O
16	,	O
17	the	O
18	phosphodiesterase	O
19	inhibitors	O
20	and	O
21	the	O
22	dopaminergic	O
23	agents	O
24	.	O

1	The	O
2	glomerular	O
3	filtration	O
4	rate	O
5	and	O
6	effective	O
7	renal	O
8	plasma	O
9	flow	O
10	were	O
11	determined	O
12	by	O
13	a	O
14	standard	O
15	clearance	O
16	method	O
17	,	O
18	employing	O
19	continuous	O
20	infusion	O
21	of	O
22	inulin	O
23	and	O
24	para	O
25	-	O
26	aminohippuric	O
27	acid	O
28	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	CSFHU	O
6	can	O
7	increase	O
8	neutrophil	O
9	counts	O
10	by	O
11	increasing	O
12	the	O
13	number	O
14	and	O
15	maturity	O
16	of	O
17	the	O
18	marrow	O
19	neutrophil	O
20	precursors	O
21	in	O
22	some	O
23	types	O
24	of	O
25	childhood	O
26	chronic	O
27	neutropenia	O
28	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	the	O
5	importance	O
6	of	O
7	phosphate	O
8	and	O
9	calcium	O
10	in	O
11	influencing	O
12	the	O
13	secretion	O
14	of	O
15	PTH	O
16	and	O
17	CT	O
18	in	O
19	uremia	O
20	.	O

1	Although	O
2	olfactory	O
3	associative	O
4	conditioning	O
5	in	O
6	newborn	O
7	rats	O
8	produces	O
9	marked	O
10	structural	O
11	and	O
12	functional	O
13	changes	O
14	in	O
15	the	O
16	olfactory	O
17	bulb	O
18	,	O
19	recent	O
20	evidence	O
21	suggests	O
22	that	O
23	extrabulbar	O
24	circuits	O
25	must	O
26	be	O
27	involved	O
28	in	O
29	storing	O
30	these	O
31	early	O
32	memories	O
33	.	O

1	A	O
2	protein	O
3	lacking	O
4	the	O
5	SH2	B
6	and	I
7	RING	I
8	finger	I
9	domains	I
10	has	O
11	no	O
12	activity	O
13	,	O
14	but	O
15	a	O
16	chimeric	O
17	protein	O
18	with	O
19	the	O
20	SH2	B
21	and	I
22	RING	I
23	finger	I
24	domains	I
25	of	O
26	SLI	O
27	-	O
28	1	O
29	replaced	O
30	by	O
31	the	O
32	equivalent	O
33	domains	O
34	of	O
35	c	B
36	-	I
37	Cbl	I
38	has	O
39	activity	O
40	.	O

1	Neither	O
2	the	O
3	reaction	O
4	of	O
5	monosaccharides	O
6	nor	O
7	the	O
8	disaccharides	O
9	with	O
10	beta	O
11	-	O
12	alanine	O
13	resulted	O
14	in	O
15	the	O
16	formation	O
17	of	O
18	maltol	O
19	.	O

1	Modulation	O
2	of	O
3	25	O
4	-	O
5	hydroxyvitamin	B
6	D3	I
7	-	I
8	24	I
9	-	I
10	hydroxylase	I
11	by	O
12	aminophylline	O
13	:	O
14	a	O
15	cytochrome	B
16	P	I
17	-	I
18	450	I
19	monooxygenase	I
20	system	O
21	.	O

1	EGV	O
2	had	O
3	no	O
4	detectable	O
5	effect	O
6	on	O
7	PP	O
8	secretion	O
9	under	O
10	basal	O
11	or	O
12	stimulated	O
13	conditions	O
14	.	O

1	Epidemiological	O
2	data	O
3	are	O
4	quite	O
5	controversial	O
6	but	O
7	sudden	O
8	death	O
9	occurring	O
10	during	O
11	sporting	O
12	activity	O
13	is	O
14	probably	O
15	not	O
16	a	O
17	rare	O
18	occurrence	O
19	.	O

1	This	O
2	spindle	O
3	defect	O
4	of	O
5	pds1	O
6	mutants	O
7	results	O
8	from	O
9	a	O
10	temperature	O
11	-	O
12	sensitive	O
13	step	O
14	that	O
15	occurs	O
16	around	O
17	the	O
18	G1	O
19	/	O
20	S	O
21	boundary	O
22	about	O
23	the	O
24	time	O
25	of	O
26	spindle	O
27	assembly	O
28	.	O

1	Six	O
2	healthy	O
3	male	O
4	subjects	O
5	received	O
6	single	O
7	oral	O
8	doses	O
9	of	O
10	regular	O
11	release	O
12	(	O
13	RR	O
14	)	O
15	quinidine	O
16	sulfate	O
17	,	O
18	sustained	O
19	release	O
20	(	O
21	SR	B
22	)	O
23	quinidine	O
24	bisulfate	O
25	and	O
26	the	O
27	same	O
28	dose	O
29	of	O
30	the	O
31	SR	B
32	product	I
33	with	O
34	food	O
35	(	O
36	SR	B
37	-	I
38	F	O
39	).	O

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	CSF	I
2	adenosine	I
3	deaminase	I
4	activity	O
5	(	O
6	ADA	O
7	)	O
8	was	O
9	measured	O
10	at	O
11	the	O
12	same	O
13	time	O
14	.	O

1	Since	O
2	the	O
3	integrated	O
4	13h00	O
5	-	O
6	16h00	O
7	plasma	O
8	cortisol	O
9	estimation	O
10	is	O
11	cheaper	O
12	and	O
13	simpler	O
14	than	O
15	the	O
16	mean	O
17	13h00	O
18	-	O
19	16h00	O
20	plasma	O
21	cortisol	O
22	estimation	O
23	,	O
24	we	O
25	recommend	O
26	it	O
27	as	O
28	an	O
29	adjunct	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	Cushing	O
35	'	O
36	s	O
37	syndrome	O
38	.	O

1	Testing	O
2	for	O
3	serum	O
4	IgM	B
5	binding	I
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O

1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O

1	However	O
2	,	O
3	expression	O
4	of	O
5	sigma	B
6	3	I
7	from	I
8	S4	I
9	(	I
10	3	I
11	'	I
12	UTR	I
13	/	I
14	S1	I
15	),	O
16	which	O
17	included	O
18	the	O
19	PKR	B
20	activator	I
21	sequence	O
22	from	O
23	S1	O
24	within	O
25	the	O
26	3	O
27	'-	O
28	UTR	O
29	of	O
30	S4	O
31	,	O
32	was	O
33	comparable	O
34	to	O
35	that	O
36	from	O
37	wild	B
38	-	I
39	type	I
40	S4	I
41	.	I

1	Badcock	O
2	and	O
3	Westheimer	O
4	(	O
5	Spatial	O
6	Vision	O
7	1	O
8	(	O
9	1	O
10	),	O
11	3	O
12	-	O
13	11	O
14	,	O
15	1985	O
16	)	O
17	showed	O
18	that	O
19	a	O
20	thin	O
21	vertical	O
22	line	O
23	induces	O
24	nearby	O
25	zones	O
26	of	O
27	attraction	O
28	and	O
29	repulsion	O
30	;	O
31	this	O
32	study	O
33	extends	O
34	those	O
35	results	O
36	by	O
37	more	O
38	closely	O
39	examining	O
40	the	O
41	horizontal	O
42	and	O
43	vertical	O
44	extents	O
45	of	O
46	the	O
47	repulsion	O
48	zone	O
49	and	O
50	by	O
51	using	O
52	an	O
53	illusory	O
54	contour	O
55	to	O
56	induce	O
57	repulsion	O
58	.	O

1	Peptide	O
2	sequences	O
3	of	O
4	the	O
5	zinc	B
6	finger	I
7	protein	I
8	Ttk	O
9	and	O
10	the	O
11	transcription	O
12	factor	O
13	Adf	O
14	-	O
15	1	O
16	were	O
17	obtained	O
18	.	O

1	The	O
2	integrity	O
3	of	O
4	the	O
5	cDNA	O
6	sequence	O
7	was	O
8	confirmed	O
9	by	O
10	analysis	O
11	of	O
12	several	O
13	overlapping	O
14	genomic	O
15	clones	O
16	that	O
17	span	O
18	the	O
19	GAR1	B
20	gene	I
21	.	I

1	CONCLUSIONS	O
2	:	O
3	Use	O
4	of	O
5	the	O
6	first	O
7	method	O
8	was	O
9	associated	O
10	with	O
11	a	O
12	reduction	O
13	in	O
14	the	O
15	time	O
16	patients	O
17	remained	O
18	in	O
19	the	O
20	ICU	O
21	before	O
22	transfer	O
23	to	O
24	another	O
25	unit	O
26	and	O
27	savings	O
28	in	O
29	nursing	O
30	time	O
31	,	O
32	but	O
33	the	O
34	two	O
35	methods	O
36	did	O
37	not	O
38	differ	O
39	according	O
40	to	O
41	clinical	O
42	outcomes	O
43	.	O

1	As	O
2	stands	O
3	shifted	O
4	in	O
5	dominance	O
6	from	O
7	pine	O
8	to	O
9	fir	O
10	with	O
11	age	O
12	,	O
13	subalpine	O
14	fir	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	forest	O
25	productivity	O
26	until	O
27	stands	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O

1	Replication	O
2	of	O
3	bovine	B
4	papillomavirus	I
5	-	I
6	1	I
7	(	I
8	BPV	I
9	-	I
10	1	I
11	)	O
12	DNA	O
13	requires	O
14	two	O
15	viral	O
16	gene	O
17	products	O
18	,	O
19	the	O
20	E1	B
21	protein	I
22	and	O
23	the	O
24	full	B
25	-	I
26	length	I
27	E2	I
28	protein	I
29	.	I

1	Arm	O
2	function	O
3	tests	O
4	.	O

1	Smoking	O
2	was	O
3	regarded	O
4	as	O
5	the	O
6	major	O
7	contribution	O
8	to	O
9	pulmonary	O
10	dysfunction	O
11	.	O

1	The	O
2	9	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	characteristic	O
8	of	O
9	CML	O
10	results	O
11	in	O
12	a	O
13	fused	O
14	bcr	B
15	/	I
16	abl	I
17	gene	I
18	and	O
19	an	O
20	abnormal	O
21	fusion	O
22	protein	O
23	,	O
24	p210bcr	B
25	/	I
26	abl	I
27	.	I

1	The	O
2	transcription	O
3	factor	O
4	Sp1	B
5	bound	O
6	to	O
7	eight	O
8	sites	O
9	,	O
10	as	O
11	demonstrated	O
12	by	O
13	footprinting	O
14	assays	O
15	and	O
16	gel	O
17	shift	O
18	analysis	O
19	with	O
20	purified	O
21	Sp1	B
22	.	I

1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	simple	O
7	respiration	O
8	-	O
9	control	O
10	device	O
11	has	O
12	been	O
13	developed	O
14	that	O
15	enables	O
16	the	O
17	patient	O
18	to	O
19	monitor	O
20	breath	O
21	-	O
22	holding	O
23	during	O
24	successive	O
25	scans	O
26	.	O

1	Addition	O
2	of	O
3	soluble	O
4	recombinant	O
5	human	O
6	SLF	O
7	to	O
8	SI4	O
9	-	O
10	h220	O
11	cultures	O
12	enhanced	O
13	reduction	O
14	of	O
15	cell	O
16	-	O
17	surface	O
18	c	B
19	-	I
20	kit	I
21	expression	O
22	and	O
23	its	O
24	protein	O
25	degradation	O
26	.	O

1	Separation	O
2	of	O
3	ninhydrin	O
4	-	O
5	positive	O
6	compounds	O
7	in	O
8	urine	O
9	by	O
10	the	O
11	combined	O
12	methods	O
13	of	O
14	medium	O
15	-	O
16	tension	O
17	intophoresis	O
18	and	O
19	partition	O
20	chromatography	O

1	The	O
2	ability	O
3	of	O
4	sodium	O
5	phenobarbital	O
6	(	O
7	60	O
8	mg	O
9	/	O
10	kg	O
11	)	O
12	and	O
13	sodium	O
14	barbital	O
15	(	O
16	80	O
17	mg	O
18	/	O
19	kg	O
20	)	O
21	to	O
22	produce	O
23	a	O
24	taste	O
25	aversion	O
26	in	O
27	23	O
28	hr	O
29	fluid	O
30	deprived	O
31	rats	O
32	was	O
33	examined	O
34	using	O
35	a	O
36	discrimination	O
37	or	O
38	two	O
39	bottle	O
40	taste	O
41	aversion	O
42	task	O
43	(	O
44	0	O
45	.	O
46	125	O
47	%	O
48	sodium	O
49	saccharin	O
50	solution	O
51	or	O
52	water	O
53	).	O

1	The	O
2	parameters	O
3	of	O
4	nonspecific	O
5	humoral	O
6	immunity	O
7	--	O
8	serum	B
9	immunoglobulins	I
10	and	O
11	immune	O
12	complexes	O
13	--	O
14	were	O
15	evaluated	O
16	in	O
17	irradiated	O
18	group	O
19	of	O
20	patients	O
21	with	O
22	uterine	O
23	cervix	O
24	carcinoma	O
25	(	O
26	Stages	O
27	IIB	O
28	and	O
29	IIIB	O
30	),	O
31	during	O
32	one	O
33	year	O
34	follow	O
35	up	O
36	.	O

1	The	O
2	expression	O
3	of	O
4	ERV3	O
5	env	B
6	mRNA	I
7	was	O
8	found	O
9	to	O
10	be	O
11	differentiation	O
12	-	O
13	associated	O
14	,	O
15	with	O
16	high	O
17	expression	O
18	detected	O
19	in	O
20	the	O
21	late	O
22	stages	O
23	of	O
24	monocytic	O
25	development	O
26	.	O

1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	I
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O

1	Eukaryotic	O
2	translation	O
3	initiation	O
4	factor	O
5	4GI	O
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	Of	O
2	115	O
3	hepatitis	O
4	B	O
5	patients	O
6	seen	O
7	at	O
8	12	O
9	months	O
10	,	O
11	6	O
12	%	O
13	had	O
14	chronic	O
15	hepatitis	O
16	Bs	O
17	antigenaemia	O
18	,	O
19	60	O
20	%	O
21	had	O
22	developed	O
23	anti	B
24	-	I
25	HBs	I
26	antibodies	I
27	,	O
28	and	O
29	7	O
30	.	O
31	3	O
32	%	O
33	still	O
34	had	O
35	abnormal	O
36	liver	O
37	function	O
38	.	O

1	Microstructure	O
2	and	O
3	conductivity	O
4	of	O
5	hierarchical	O
6	laminate	O
7	composites	O
8	.	O

1	The	O
2	control	O
3	group	O
4	included	O
5	8	O
6	afterbirth	O
7	samples	O
8	from	O
9	physiological	O
10	full	O
11	-	O
12	term	O
13	pregnancies	O
14	.	O

1	Oral	O
2	candidiasis	B

1	A	O
2	long	O
3	follow	O
4	-	O
5	up	O
6	study	O
7	revealed	O
8	that	O
9	convalescent	O
10	stage	O
11	children	O
12	still	O
13	have	O
14	the	O
15	potency	O
16	to	O
17	have	O
18	an	O
19	immediate	O
20	type	O
21	hypersensitivity	O
22	reaction	O
23	on	O
24	exposure	O
25	to	O
26	mite	B
27	antigen	I
28	,	O
29	with	O
30	a	O
31	high	O
32	titer	O
33	of	O
34	mite	O
35	specific	O
36	IgE	B
37	in	O
38	their	O
39	sera	O
40	,	O
41	but	O
42	they	O
43	are	O
44	free	O
45	from	O
46	asthmatic	O
47	attacks	O
48	because	O
49	of	O
50	the	O
51	reduction	O
52	in	O
53	the	O
54	amount	O
55	of	O
56	mite	B
57	antigen	I
58	in	O
59	the	O
60	body	O
61	,	O
62	as	O
63	shown	O
64	by	O
65	the	O
66	reduction	O
67	in	O
68	the	O
69	amount	O
70	of	O
71	mite	O
72	specific	O
73	IgG	B
74	.	I

1	Capsular	O
2	antigens	O
3	of	O
4	Staphylococcus	B
5	aureus	I

1	European	O
2	Community	O
3	Huntington	O
4	'	O
5	s	O
6	Disease	O
7	Collaborative	O
8	Study	O
9	Group	O
10	.	O

1	A	O
2	more	O
3	complete	O
4	analysis	O
5	of	O
6	dose	O
7	response	O
8	,	O
9	time	O
10	and	O
11	mode	O
12	of	O
13	Ga	O
14	administration	O
15	(	O
16	preinjury	O
17	or	O
18	postinjury	O
19	),	O
20	and	O
21	availability	O
22	of	O
23	Ga	O
24	across	O
25	the	O
26	blood	O
27	-	O
28	brain	O
29	barrier	O
30	is	O
31	needed	O
32	to	O
33	further	O
34	evaluate	O
35	the	O
36	efficacy	O
37	of	O
38	this	O
39	compound	O
40	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	O
11	knuckle	O
12	9G8	O
13	variant	O
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	O
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	O
30	and	O
31	SRp20	O
32	are	O
33	similar	O
34	.	O

1	In	O
2	transformed	O
3	E	O
4	.	O
5	coli	O
6	,	O
7	constitutive	O
8	CAT	B
9	expression	O
10	is	O
11	maintained	O
12	when	O
13	as	O
14	little	O
15	as	O
16	0	O
17	.	O
18	3	O
19	kilobase	O
20	of	O
21	DNA	O
22	from	O
23	the	O
24	3	O
25	'	O
26	end	O
27	of	O
28	the	O
29	1	O
30	.	O
31	6	O
32	-	O
33	kilobase	O
34	segment	O
35	is	O
36	inserted	O
37	in	O
38	the	O
39	correct	O
40	orientation	O
41	in	O
42	front	O
43	of	O
44	the	O
45	CAT	B
46	gene	I
47	.	I

1	One	O
2	hundred	O
3	fifty	O
4	patients	O
5	were	O
6	reviewed	O
7	at	O
8	1	O
9	year	O
10	after	O
11	arthroplasty	O
12	.	O

1	Felodipine	O
2	did	O
3	not	O
4	alter	O
5	the	O
6	baseline	O
7	FEV1	O
8	,	O
9	but	O
10	showed	O
11	a	O
12	small	O
13	significant	O
14	inhibitory	O
15	effect	O
16	upon	O
17	histamine	O
18	and	O
19	AMP	O
20	induced	O
21	bronchoconstriction	O
22	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	:	O
5	1	O
6	)	O
7	a	O
8	kinase	O
9	catalytic	O
10	domain	O
11	most	O
12	characteristic	O
13	of	O
14	serine	B
15	/	I
16	threonine	I
17	kinases	I
18	but	O
19	hybrid	O
20	between	O
21	members	O
22	of	O
23	the	O
24	family	O
25	of	O
26	microtubule	B
27	-	I
28	associated	I
29	protein	I
30	kinase	I
31	kinase	I
32	kinases	I
33	and	O
34	the	O
35	fibroblast	B
36	growth	I
37	factor	I
38	receptor	I
39	family	I
40	;	O
41	2	O
42	)	O
43	two	O
44	putative	O
45	alpha	B
46	-	I
47	helical	I
48	leucine	I
49	zipper	I
50	motifs	O
51	separated	O
52	by	O
53	a	O
54	25	O
55	-	O
56	amino	O
57	acid	O
58	charged	O
59	intermediate	O
60	segment	O
61	but	O
62	lacking	O
63	an	O
64	NH2	O
65	-	O
66	terminal	O
67	basic	O
68	domain	O
69	;	O
70	and	O
71	3	O
72	)	O
73	COOH	O
74	-	O
75	terminal	O
76	and	O
77	NH2	O
78	-	O
79	terminal	O
80	proline	O
81	-	O
82	rich	O
83	domains	O
84	suggestive	O
85	of	O
86	src	B
87	homology	I
88	3	I
89	(	I
90	SH3	I
91	)	I
92	domain	I
93	binding	I
94	regions	O
95	.	O

1	Coronary	O
2	flow	O
3	was	O
4	reduced	O
5	by	O
6	10	O
7	%	O
8	in	O
9	the	O
10	phosphocreatine	O
11	and	O
12	by	O
13	18	O
14	%	O
15	in	O
16	the	O
17	control	O
18	group	O
19	.	O

1	Standardized	O
2	gastric	O
3	wall	O
4	specimens	O
5	from	O
6	the	O
7	area	O
8	of	O
9	grossly	O
10	healed	O
11	ulcers	O
12	were	O
13	obtained	O
14	,	O
15	processed	O
16	,	O
17	and	O
18	evaluated	O
19	by	O
20	light	O
21	microscopy	O
22	and	O
23	by	O
24	transmission	O
25	electron	O
26	microscopy	O
27	.	O

1	Furthermore	O
2	,	O
3	a	O
4	mutant	O
5	receptor	O
6	(	O
7	Y977F	O
8	/	O
9	Y989F	O
10	[	O
11	PLC	B
12	gamma	I
13	-	I
14	binding	I
15	sites	I
16	])	I
17	could	O
18	fully	O
19	activate	O
20	Ras	B
21	,	O
22	and	O
23	the	O
24	direct	O
25	activation	O
26	of	O
27	protein	B
28	kinase	I
29	C	I
30	and	O
31	calcium	O
32	mobilization	O
33	had	O
34	almost	O
35	no	O
36	effect	O
37	on	O
38	the	O
39	GDP	O
40	/	O
41	GTP	O
42	state	O
43	of	O
44	Ras	B
45	in	O
46	this	O
47	cell	O
48	line	O
49	.	O

1	Transcription	O
2	factor	O
3	recognition	O
4	surface	O
5	on	O
6	the	O
7	RNA	B
8	polymerase	I
9	alpha	I
10	subunit	I
11	is	O
12	involved	O
13	in	O
14	contact	O
15	with	O
16	the	O
17	DNA	O
18	enhancer	O
19	element	O
20	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	cyclic	O
6	variations	O
7	in	O
8	heme	O
9	turnover	O
10	are	O
11	related	O
12	to	O
13	changes	O
14	in	O
15	erythrocyte	O
16	characteristics	O
17	during	O
18	the	O
19	progesterone	O
20	phase	O
21	.	O

1	A	O
2	survey	O
3	is	O
4	given	O
5	of	O
6	the	O
7	pharmacological	O
8	backgrounds	O
9	that	O
10	are	O
11	relevant	O
12	for	O
13	the	O
14	drug	O
15	treatment	O
16	of	O
17	essential	O
18	hypertension	O
19	in	O
20	the	O
21	elderly	O
22	.	O

1	Correlation	O
2	between	O
3	intraocular	O
4	involvement	O
5	and	O
6	systemic	O
7	outcome	O
8	was	O
9	poor	O
10	.	O

1	The	O
2	pulmonary	O
3	toxic	O
4	events	O
5	induced	O
6	by	O
7	acute	O
8	nitrogen	O
9	dioxide	O
10	(	O
11	NO	O
12	)	O
13	2	O
14	exposure	O
15	were	O
16	studied	O
17	in	O
18	the	O
19	rat	O
20	to	O
21	develop	O
22	an	O
23	inhalation	O
24	model	O
25	to	O
26	investigate	O
27	therapeutic	O
28	measures	O
29	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	region	O
6	revealed	O
7	three	O
8	eight	O
9	-	O
10	bp	O
11	repetitive	O
12	elements	O
13	,	O
14	the	O
15	deletion	O
16	of	O
17	which	O
18	restored	O
19	wild	O
20	-	O
21	type	O
22	levels	O
23	of	O
24	luciferase	B
25	activity	O
26	to	O
27	the	O
28	-	O
29	916	O
30	-	O
31	bp	O
32	reporter	O
33	plasmid	O
34	.	O

1	The	O
2	tryptase	O
3	locus	O
4	also	O
5	contains	O
6	at	O
7	least	O
8	four	O
9	tryptase	B
10	-	I
11	like	I
12	pseudogenes	O
13	,	O
14	including	O
15	mastin	O
16	,	O
17	a	O
18	gene	O
19	expressed	O
20	in	O
21	dogs	O
22	but	O
23	not	O
24	in	O
25	humans	O
26	.	O

1	Acute	O
2	pancreatitis	O
3	is	O
4	a	O
5	rather	O
6	common	O
7	abdominal	O
8	disorder	O
9	.	O

1	Involvement	O
2	of	O
3	AP1	B
4	and	O
5	PEA3	B
6	binding	I
7	sites	I
8	in	O
9	the	O
10	regulation	O
11	of	O
12	murine	O
13	tissue	O
14	inhibitor	O
15	of	O
16	metalloproteinases	B
17	-	I
18	1	I
19	(	I
20	TIMP	I
21	-	I
22	1	I
23	)	O
24	transcription	O
25	.	O

1	Pharmacodynamic	O
2	studies	O
3	on	O
4	the	O
5	cardiovascular	O
6	system	O
7	of	O
8	spontaneously	O
9	hypertensive	O
10	rats	O
11	.	O

1	Regressing	O
2	microaneurysms	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	polyarteritis	O
12	nodosa	O
13	.	O

1	This	O
2	is	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	proposing	O
8	that	O
9	SSV	O
10	was	O
11	generated	O
12	by	O
13	recombination	O
14	between	O
15	proviral	O
16	DNA	O
17	of	O
18	a	O
19	simian	B
20	sarcoma	I
21	associated	I
22	virus	I
23	and	I
24	proto	I
25	-	I
26	sis	I
27	and	O
28	that	O
29	introns	O
30	were	O
31	spliced	O
32	out	O
33	subsequently	O
34	from	O
35	a	O
36	fused	O
37	viral	B
38	-	I
39	sis	I
40	messenger	I
41	RNA	I
42	.	I

1	Activation	O
2	mediated	O
3	by	O
4	Cat8p	O
5	was	O
6	no	O
7	longer	O
8	detectable	O
9	in	O
10	a	O
11	cat1	O
12	mutant	O
13	.	O

1	Differential	O
2	expression	O
3	and	O
4	regulation	O
5	by	O
6	20	O
7	-	O
8	hydroxyecdysone	O
9	of	O
10	mosquito	O
11	ultraspiracle	O
12	isoforms	O
13	.	O

1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	I
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O

1	During	O
2	exercise	O
3	K	O
4	+	O
5	is	O
6	released	O
7	from	O
8	contracting	O
9	muscle	O
10	and	O
11	plasma	O
12	K	O
13	+	O
14	concentration	O
15	rises	O
16	.	O

1	A	O
2	note	O
3	on	O
4	some	O
5	consequences	O
6	of	O
7	UV	O
8	vision	O
9	in	O
10	birds	O
11	.	O

1	Plasma	O
2	was	O
3	tested	O
4	before	O
5	and	O
6	after	O
7	(	O
8	14	O
9	+/-	O
10	7	O
11	.	O
12	5	O
13	[	O
14	SD	O
15	]	O
16	days	O
17	)	O
18	surgery	O
19	for	O
20	IgG	B
21	antibodies	I
22	to	O
23	the	O
24	complex	O
25	of	O
26	heparin	O
27	/	O
28	platelet	B
29	factor	I
30	4	I
31	,	O
32	using	O
33	a	O
34	standardized	O
35	,	O
36	validated	O
37	enzyme	O
38	-	O
39	linked	O
40	immunosorbent	O
41	assay	O
42	(	O
43	ELISA	O
44	).	O

1	This	O
2	study	O
3	demonstrated	O
4	that	O
5	the	O
6	PFA	O
7	-	O
8	100	O
9	analyzer	O
10	can	O
11	accurately	O
12	assess	O
13	vWF	B
14	-	I
15	dependent	I
16	platelet	I
17	function	O
18	and	O
19	detect	O
20	other	O
21	platelet	O
22	defects	O
23	under	O
24	high	O
25	shear	O
26	stress	O
27	in	O
28	complex	O
29	patient	O
30	populations	O
31	.	O

1	All	O
2	stimulations	O
3	were	O
4	down	O
5	-	O
6	regulated	O
7	with	O
8	GnRH	B
9	-	I
10	a	O
11	commenced	O
12	on	O
13	day	O
14	21	O
15	in	O
16	a	O
17	long	O
18	protocol	O
19	before	O
20	gonadotropin	O
21	stimulation	O
22	.	O

1	Calves	O
2	fed	O
3	MCT	O
4	-	O
5	milk	O
6	had	O
7	significantly	O
8	lower	O
9	blood	O
10	cholesterol	O
11	than	O
12	calves	O
13	fed	O
14	T	O
15	-	O
16	or	O
17	SBO	O
18	-	O
19	milk	O
20	.	O

1	Pseudosubstrate	O
2	(	O
3	19	O
4	-	O
5	36	O
6	),	O
7	derived	O
8	from	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	of	O
14	Ca	B
15	-	I
16	dependent	I
17	PKC	I
18	isotypes	O
19	,	O
20	inhibited	O
21	beta	B
22	-	I
23	PKC	I
24	but	O
25	not	O
26	nPKC	O
27	activity	O
28	using	O
29	either	O
30	Histone	O
31	IIIS	O
32	or	O
33	peptide	O
34	(	O
35	19	O
36	-	O
37	31	O
38	)	O
39	as	O
40	substrate	O
41	.	O

1	Schwab	O
2	and	O
3	England	O
4	ADL	O
5	scores	O
6	in	O
7	the	O
8	"	O
9	off	O
10	"	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	"	O
21	on	O
22	"	O
23	state	O
24	the	O
25	scores	O
26	declined	O
27	by	O
28	2	O
29	%.	O

1	Plasma	B
2	renin	I
3	concentration	O
4	is	O
5	significantly	O
6	higher	O
7	in	O
8	the	O
9	subcapsular	O
10	venous	O
11	outflow	O
12	,	O
13	which	O
14	drains	O
15	the	O
16	superficial	O
17	cortex	O
18	,	O
19	than	O
20	in	O
21	the	O
22	deep	O
23	venous	O
24	outflow	O
25	,	O
26	which	O
27	drains	O
28	the	O
29	inner	O
30	half	O
31	of	O
32	the	O
33	cortex	O
34	and	O
35	medulla	O
36	of	O
37	the	O
38	cat	O
39	kidney	O
40	.	O

1	A	O
2	reduced	O
3	matrix	O
4	distribution	O
5	and	O
6	enhanced	O
7	cell	O
8	density	O
9	were	O
10	observed	O
11	as	O
12	the	O
13	biofilm	O
14	aged	O
15	.	O

1	As	O
2	an	O
3	extension	O
4	of	O
5	our	O
6	structural	O
7	characterization	O
8	of	O
9	the	O
10	exon	O
11	-	O
12	intron	O
13	organization	O
14	of	O
15	the	O
16	mouse	O
17	Pkr	O
18	gene	O
19	,	O
20	we	O
21	now	O
22	have	O
23	isolated	O
24	and	O
25	characterized	O
26	the	O
27	mouse	O
28	Pkr	O
29	promoter	O
30	region	O
31	required	O
32	for	O
33	IFN	B
34	-	I
35	inducible	I
36	transcription	I
37	.	I

1	Four	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	showed	O
7	clinical	O
8	improvement	O
9	according	O
10	to	O
11	Ritchie	O
12	-	O
13	Index	O
14	,	O
15	pain	O
16	score	O
17	,	O
18	ESR	O
19	and	O
20	CRP	B
21	.	I

1	Tctex	B
2	-	I
3	1	I
4	binding	I
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	B
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	B
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	O
35	tyrosine	O
36	-	O
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	O
42	)	O
43	of	O
44	lymphocyte	B
45	Ag	I
46	receptors	I
47	.	I

1	This	O
2	two	O
3	-	O
4	helix	O
5	motif	O
6	is	O
7	thought	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	specific	O
13	DNA	O
14	sequence	O
15	recognition	O
16	by	O
17	CAP	O
18	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	sequences	O
5	revealed	O
6	that	O
7	the	O
8	two	O
9	mRNA	O
10	species	O
11	arise	O
12	as	O
13	a	O
14	result	O
15	of	O
16	alternate	O
17	use	O
18	of	O
19	poly	O
20	(	O
21	A	O
22	)-	O
23	addition	O
24	sites	O
25	.	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	I
10	kappaB	I
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	B
26	-	I
27	1	I
28	.	I

1	Under	O
2	halothane	O
3	anesthesia	O
4	,	O
5	the	O
6	flow	O
7	pneumocardiogram	O
8	(	O
9	PnCG	O
10	)	O
11	and	O
12	its	O
13	time	O
14	derivative	O
15	(	O
16	acceleration	O
17	pneumocardiogram	O
18	or	O
19	dPn	O
20	/	O
21	dt	O
22	)	O
23	were	O
24	transduced	O
25	during	O
26	apnea	O
27	by	O
28	a	O
29	small	O
30	high	O
31	-	O
32	gain	O
33	pneumotachograph	O
34	.	O

1	Transfer	O
2	also	O
3	correlated	O
4	inversely	O
5	with	O
6	gastric	O
7	juice	O
8	pH	O
9	(	O
10	r	O
11	=	O
12	-	O
13	0	O
14	.	O
15	619	O
16	,	O
17	P	O
18	<	O
19	0	O
20	.	O
21	02	O
22	).	O

1	Both	O
2	proprioceptive	O
3	and	O
4	electroreceptive	O
5	units	O
6	showed	O
7	a	O
8	progression	O
9	of	O
10	receptive	O
11	fields	O
12	from	O
13	anterior	O
14	to	O
15	posterior	O
16	body	O
17	in	O
18	the	O
19	rostral	O
20	to	O
21	caudal	O
22	direction	O
23	along	O
24	the	O
25	length	O
26	of	O
27	DGR	O
28	.	O

1	RESULTS	O
2	:	O
3	The	O
4	age	O
5	distribution	O
6	was	O
7	28	O
8	to	O
9	83	O
10	years	O
11	old	O
12	(	O
13	mean	O
14	was	O
15	54	O
16	.	O
17	1	O
18	years	O
19	).	O

1	The	O
2	specificity	O
3	of	O
4	action	O
5	of	O
6	C	B
7	/	I
8	EBP	I
9	family	I
10	members	O
11	may	O
12	be	O
13	derived	O
14	from	O
15	the	O
16	characteristics	O
17	of	O
18	each	O
19	factor	O
20	,	O
21	including	O
22	the	O
23	expression	O
24	profiles	O
25	,	O
26	the	O
27	DNA	O
28	binding	O
29	affinities	O
30	,	O
31	the	O
32	cofactors	O
33	,	O
34	and	O
35	so	O
36	on	O
37	,	O
38	in	O
39	addition	O
40	to	O
41	the	O
42	DNA	O
43	binding	O
44	specificities	O
45	.	O

1	Examination	O
2	of	O
3	neurohumoral	O
4	factors	O
5	revealed	O
6	a	O
7	hyperactive	O
8	sympathetic	O
9	nervous	O
10	system	O
11	and	O
12	an	O
13	increase	O
14	in	O
15	plasma	B
16	renin	I
17	activity	O
18	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	-	O
6	negative	O
7	ras	B
8	gene	I
9	also	O
10	blocks	O
11	TIS10	O
12	/	O
13	PGS2	O
14	induction	O
15	by	O
16	v	B
17	-	I
18	src	I
19	.	I

1	The	O
2	csbA	O
3	fusion	O
4	was	O
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O

1	Expression	O
2	of	O
3	a	O
4	novel	O
5	murine	O
6	phospholipase	B
7	D	I
8	homolog	I
9	coincides	O
10	with	O
11	late	O
12	neuronal	O
13	development	O
14	in	O
15	the	O
16	forebrain	O
17	.	O

1	The	O
2	STAT	B
3	-	I
4	1	I
5	signaling	O
6	pathway	O
7	provides	O
8	at	O
9	least	O
10	one	O
11	mechanism	O
12	for	O
13	activation	O
14	of	O
15	the	O
16	CAEV	O
17	LTR	O
18	by	O
19	IFN	B
20	-	I
21	gamma	I
22	in	O
23	monocytes	O
24	.	O

1	JNK	B
2	and	O
3	p38	B
4	are	O
5	constitutively	O
6	present	O
7	in	O
8	the	O
9	nucleus	O
10	,	O
11	and	O
12	DNA	O
13	-	O
14	bound	O
15	c	B
16	-	I
17	JUN	O
18	and	O
19	ATF	B
20	-	I
21	2	I
22	are	O
23	stably	O
24	contacted	O
25	by	O
26	JNK	B
27	and	O
28	p38	B
29	,	O
30	respectively	O
31	.	O

1	S1	B
2	nuclease	I
3	analysis	O
4	of	O
5	RNA	O
6	prepared	O
7	after	O
8	transfection	O
9	of	O
10	these	O
11	HIV	O
12	constructs	O
13	into	O
14	HeLa	O
15	cells	O
16	infected	O
17	with	O
18	wild	O
19	-	O
20	type	O
21	adenovirus	O
22	indicated	O
23	that	O
24	the	O
25	enhancer	O
26	,	O
27	SP1	B
28	,	O
29	TATA	O
30	,	O
31	and	O
32	a	O
33	portion	O
34	of	O
35	the	O
36	transactivation	O
37	-	O
38	responsive	O
39	element	O
40	were	O
41	each	O
42	required	O
43	for	O
44	complete	O
45	E1A	B
46	/	I
47	E1B	I
48	-	I
49	mediated	O
50	activation	O
51	of	O
52	the	O
53	HIV	B
54	LTR	I
55	.	I

1	High	O
2	ADR1	B
3	gene	I
4	dosage	O
5	increased	O
6	the	O
7	transcription	O
8	of	O
9	genes	O
10	encoding	O
11	peroxisomal	O
12	proteins	O
13	as	O
14	compared	O
15	to	O
16	one	O
17	copy	O
18	of	O
19	the	O
20	ADR1	B
21	gene	I
22	.	I

1	On	O
2	the	O
3	basis	O
4	of	O
5	serological	O
6	studies	O
7	,	O
8	the	O
9	highly	O
10	conserved	O
11	A	O
12	domain	O
13	of	O
14	HspA	O
15	was	O
16	found	O
17	to	O
18	be	O
19	the	O
20	immunodominant	O
21	domain	O
22	.	O

1	The	O
2	role	O
3	of	O
4	ascorbic	O
5	acid	O
6	in	O
7	the	O
8	prevention	O
9	of	O
10	bladder	O
11	tumor	O
12	formation	O
13	.	O

1	The	O
2	ultrastructural	O
3	findings	O
4	,	O
5	as	O
6	well	O
7	as	O
8	the	O
9	urinary	O
10	C	O
11	-	O
12	peptide	O
13	excretion	O
14	,	O
15	confirmed	O
16	that	O
17	the	O
18	glycemic	O
19	effects	O
20	should	O
21	not	O
22	be	O
23	thought	O
24	to	O
25	be	O
26	due	O
27	to	O
28	a	O
29	direct	O
30	action	O
31	of	O
32	the	O
33	drugs	O
34	used	O
35	on	O
36	the	O
37	endocrine	O
38	pancreas	O
39	.	O

1	B	I
2	cell	I
3	antigen	I
4	receptor	I
5	(	O
6	BCR	B
7	)-	I
8	mediated	O
9	formation	O
10	of	O
11	a	O
12	SHP	B
13	-	I
14	2	I
15	-	I
16	pp120	O
17	complex	O
18	and	O
19	its	O
20	inhibition	O
21	by	O
22	Fc	B
23	gamma	I
24	RIIB1	I
25	-	I
26	BCR	I
27	coligation	O
28	.	O

1	Deformities	O
2	of	O
3	the	O
4	tip	O
5	of	O
6	the	O
7	olecranon	O
8	and	O
9	of	O
10	the	O
11	coronoid	O
12	process	O
13	are	O
14	also	O
15	described	O
16	(	O
17	De	O
18	Palma	O
19	1956	O
20	,	O
21	Jordan	O
22	1958	O
23	,	O
24	Ahlberg	O
25	1965	O
26	,	O
27	Weseloh	O
28	1973	O
29	).	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	we	O
6	used	O
7	a	O
8	series	O
9	of	O
10	plasmid	O
11	constructs	O
12	encoding	O
13	different	O
14	forms	O
15	of	O
16	the	O
17	envelope	B
18	glycoprotein	I
19	E	I
20	of	O
21	the	O
22	flavivirus	O
23	tick	O
24	-	O
25	borne	O
26	encephalitis	O
27	virus	O
28	.	O

1	Fructokinase	O
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	O
28	mRNA	O
29	levels	O
30	.	O

1	E2	O
2	treatments	O
3	elevated	O
4	hen	O
5	plasma	O
6	TG	O
7	7	O
8	.	O
9	2X	O
10	,	O
11	PL	O
12	5	O
13	.	O
14	1X	O
15	,	O
16	and	O
17	C	O
18	7	O
19	.	O
20	2X	O
21	;	O
22	and	O
23	pullet	O
24	plasma	O
25	TG	O
26	6	O
27	.	O
28	8X	O
29	,	O
30	PL	O
31	3	O
32	.	O
33	7X	O
34	,	O
35	and	O
36	C	O
37	2	O
38	.	O
39	5X	O
40	.	O

1	Consistent	O
2	with	O
3	this	O
4	prediction	O
5	,	O
6	transfections	O
7	into	O
8	the	O
9	hematopoietic	O
10	cell	O
11	line	O
12	Jurkat	O
13	showed	O
14	a	O
15	9	O
16	.	O
17	0	O
18	-	O
19	and	O
20	2	O
21	.	O
22	5	O
23	-	O
24	fold	O
25	activation	O
26	of	O
27	the	O
28	mim	B
29	-	I
30	1	I
31	promoter	I
32	by	O
33	the	O
34	p32	O
35	and	O
36	p30	B
37	isoforms	I
38	,	O
39	respectively	O
40	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	an	O
6	analysis	O
7	of	O
8	the	O
9	dynamics	O
10	in	O
11	the	O
12	closing	O
13	phase	O
14	of	O
15	the	O
16	occluder	O
17	of	O
18	a	O
19	mechanical	O
20	monoleaflet	O
21	heart	O
22	valve	O
23	prosthesis	O
24	is	O
25	presented	O
26	.	O

1	One	O
2	of	O
3	its	O
4	unique	O
5	features	O
6	appears	O
7	to	O
8	be	O
9	the	O
10	unusually	O
11	short	O
12	5	O
13	'-	O
14	untranslated	O
15	regions	O
16	(	O
17	UTR	O
18	)	O
19	(	O
20	1	O
21	-	O
22	6	O
23	nucleotides	O
24	(	O
25	nts	O
26	))	O
27	and	O
28	the	O
29	apparent	O
30	absence	O
31	of	O
32	5	O
33	'-	O
34	cap	O
35	structures	O
36	from	O
37	its	O
38	mRNAs	O
39	.	O

1	Five	O
2	healthy	O
3	male	O
4	subjects	O
5	inspired	O
6	air	O
7	for	O
8	20	O
9	min	O
10	and	O
11	then	O
12	5	O
13	%	O
14	CO2	O
15	/	O
16	95	O
17	%	O
18	O2	O
19	for	O
20	30	O
21	min	O
22	,	O
23	of	O
24	which	O
25	the	O
26	first	O
27	10	O
28	min	O
29	was	O
30	used	O
31	to	O
32	achieve	O
33	a	O
34	steady	O
35	-	O
36	state	O
37	end	O
38	-	O
39	tidal	O
40	CO2	O
41	measurement	O
42	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	Spatiotemporal	O
2	expression	O
3	of	O
4	the	O
5	PAX3	B
6	gene	I
7	is	O
8	tightly	O
9	regulated	O
10	during	O
11	development	O
12	.	O

1	Eucaryotic	O
2	transcription	O
3	factors	O
4	that	O
5	stimulate	O
6	RNA	B
7	polymerase	I
8	II	I
9	by	O
10	increasing	O
11	the	O
12	efficiency	O
13	of	O
14	elongation	O
15	of	O
16	specifically	O
17	or	O
18	randomly	O
19	initiated	O
20	RNA	O
21	chains	O
22	have	O
23	been	O
24	isolated	O
25	and	O
26	characterized	O
27	.	O

1	Invited	O
2	editorial	O
3	on	O
4	"	O
5	Acute	O
6	and	O
7	chronic	O
8	effects	O
9	of	O
10	exercise	O
11	on	O
12	leptin	B
13	levels	O
14	in	O
15	humans	O
16	".	B

1	Short	O
2	therapy	O
3	with	O
4	omeprazole	O
5	20	O
6	mg	O
7	/	O
8	b	O
9	.	O
10	i	O
11	.	O
12	d	O
13	.,	O
14	clarithromycin	O
15	500	O
16	mg	O
17	/	O
18	b	O
19	.	O
20	i	O
21	.	O
22	d	O
23	.,	O
24	and	O
25	CBS	O
26	120	O
27	mg	O
28	/	O
29	q	O
30	.	O
31	i	O
32	.	O
33	d	O
34	.	O
35	is	O
36	a	O
37	safe	O
38	,	O
39	well	O
40	tolerated	O
41	combination	O
42	that	O
43	achieves	O
44	a	O
45	80	O
46	.	O
47	6	O
48	%	O
49	eradication	O
50	rate	O
51	of	O
52	H	O
53	.	O
54	pylori	O
55	and	O
56	duodenal	O
57	ulcer	O
58	healing	O
59	rates	O
60	as	O
61	good	O
62	as	O
63	those	O
64	achieved	O
65	by	O
66	omeprazole	O
67	20	O
68	mg	O
69	/	O
70	d	O
71	when	O
72	given	O
73	for	O
74	4	O
75	wk	O
76	.	O

1	Myocardial	O
2	interstitial	O
3	edema	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	DC	O
15	shocks	O
16	.	O

1	Because	O
2	of	O
3	the	O
4	probable	O
5	causal	O
6	relationship	O
7	between	O
8	constitutive	O
9	p210	O
10	(	O
11	bcr	B
12	/	I
13	abl	I
14	)	I
15	protein	I
16	tyrosine	I
17	kinase	I
18	activity	O
19	and	O
20	manifestations	O
21	of	O
22	chronic	O
23	-	O
24	phase	O
25	chronic	O
26	myelogenous	O
27	leukemia	O
28	(	O
29	CML	O
30	;	O
31	myeloid	O
32	expansion	O
33	),	O
34	a	O
35	key	O
36	goal	O
37	is	O
38	to	O
39	identify	O
40	relevant	O
41	p210	O
42	substrates	O
43	in	O
44	primary	O
45	chronic	O
46	-	O
47	phase	O
48	CML	O
49	hematopoietic	O
50	progenitor	O
51	cells	O
52	.	O

1	Isolation	O
2	of	O
3	Proteus	B
4	vulgaris	I
5	MC	I
6	-	I
7	63	O
8	from	O
9	carcinoma	O
10	63	O
11	and	O
12	its	O
13	antitumor	O
14	effect	O
15	on	O
16	Crocker	O
17	sarcoma	O
18	180	O
19	and	O
20	Ehrlich	O
21	carcinoma	O
22	.	O

1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O

1	3	O
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O

1	One	O
2	air	O
3	embolism	O
4	occurred	O
5	;	O
6	this	O
7	was	O
8	the	O
9	only	O
10	filter	O
11	-	O
12	or	O
13	retrieval	O
14	-	O
15	related	O
16	complication	O
17	.	O

1	Furthermore	O
2	,	O
3	cpxA	O
4	*	O
5	mutations	O
6	suppress	O
7	the	O
8	toxicity	O
9	conferred	O
10	by	O
11	the	O
12	LamB	O
13	-	O
14	LacZ	O
15	hybrid	O
16	protein	O
17	,	O
18	which	O
19	exerts	O
20	its	O
21	effects	O
22	in	O
23	the	O
24	cytoplasm	O
25	,	O
26	sequestered	O
27	from	O
28	DegP	O
29	.	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	We	O
2	demonstrate	O
3	that	O
4	the	O
5	protein	O
6	is	O
7	a	O
8	murine	O
9	homologue	O
10	of	O
11	SAF	O
12	-	O
13	A	O
14	which	O
15	has	O
16	been	O
17	shown	O
18	to	O
19	bind	O
20	selectively	O
21	to	O
22	MARs	O
23	and	O
24	is	O
25	responsible	O
26	for	O
27	the	O
28	satMa	O
29	-	O
30	binding	O
31	activity	O
32	in	O
33	the	O
34	chromatographic	O
35	fractions	O
36	.	O

1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	O
15	RXR	B
16	)	I
17	gene	I
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	O
28	RXRgamma2	O
29	isoform	O
30	was	O
31	characterized	O
32	.	O

1	This	O
2	compound	O
3	is	O
4	the	O
5	main	O
6	bioactive	O
7	metabolite	O
8	of	O
9	trimebutine	O
10	II	O
11	(	O
12	Debridat	O
13	,	O
14	CAS	O
15	39133	O
16	-	O
17	31	O
18	-	O
19	8	O
20	),	O
21	an	O
22	antispasmodic	O
23	widely	O
24	used	O
25	for	O
26	intestinal	O
27	diseases	O
28	since	O
29	1969	O
30	.	O

1	Finally	O
2	,	O
3	the	O
4	pathophysiological	O
5	aspects	O
6	of	O
7	urinary	O
8	acidification	O
9	are	O
10	discussed	O
11	,	O
12	focusing	O
13	on	O
14	renal	O
15	tubular	O
16	acidosis	O
17	models	O
18	(	O
19	induced	O
20	by	O
21	maleate	O
22	and	O
23	amphotericin	O
24	B	O
25	treatment	O
26	)	O
27	and	O
28	their	O
29	cellular	O
30	mechanisms	O
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	role	O
37	of	O
38	adrenal	O
39	steroids	O
40	in	O
41	urinary	O
42	acidification	O
43	.	O

1	Five	O
2	patients	O
3	developed	O
4	metastatic	O
5	spread	O
6	,	O
7	and	O
8	all	O
9	of	O
10	them	O
11	died	O
12	of	O
13	tumor	O
14	.	O

1	Environmental	O
2	factors	O
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	cohorts	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	recall	O
17	).	O

1	The	O
2	association	O
3	of	O
4	p255	O
5	with	O
6	splicing	O
7	complexes	O
8	is	O
9	suggested	O
10	by	O
11	the	O
12	finding	O
13	that	O
14	mAb	O
15	CC3	O
16	can	O
17	inhibit	O
18	in	O
19	vitro	O
20	splicing	O
21	and	O
22	immunoprecipitate	B
23	pre	I
24	-	I
25	messenger	I
26	RNA	I
27	and	O
28	splicing	O
29	products	O
30	.	O

1	I	O
2	.	O

1	Despite	O
2	the	O
3	presence	O
4	of	O
5	one	O
6	additional	O
7	ribonucleotide	B
8	reductase	I
9	,	O
10	the	O
11	nrdAB	O
12	-	O
13	encoded	O
14	enzyme	O
15	is	O
16	essential	O
17	to	O
18	the	O
19	aerobic	O
20	growth	O
21	of	O
22	the	O
23	cell	O
24	because	O
25	nrdAB	O
26	-	O
27	defective	O
28	mutants	O
29	of	O
30	both	O
31	species	O
32	are	O
33	not	O
34	viable	O
35	in	O
36	the	O
37	presence	O
38	of	O
39	oxygen	O
40	.	O

1	IFN	B
2	-	I
3	stimulated	I
4	gene	I
5	factor	I
6	-	I
7	3	I
8	and	O
9	STAT1	B
10	homodimers	I
11	formed	O
12	and	O
13	bound	O
14	an	O
15	IFN	B
16	-	I
17	stimulated	O
18	response	O
19	element	O
20	(	O
21	ISRE	O
22	)	O
23	and	O
24	gamma	B
25	-	I
26	activated	I
27	sequence	O
28	(	O
29	GAS	O
30	)	O
31	element	O
32	,	O
33	respectively	O
34	.	O

1	Autotransplantation	O
2	of	O
3	a	O
4	vein	O
5	segment	O
6	with	O
7	valve	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	deep	O
13	vein	O
14	valvular	O
15	insufficiency	O
16	of	O
17	the	O
18	lower	O
19	extremity	B

1	In	O
2	the	O
3	commercially	O
4	available	O
5	intravenous	O
6	formulation	O
7	of	O
8	Cyclosporin	O
9	A	O
10	(	O
11	Sandimmun	O
12	),	O
13	polyoxyethylated	O
14	castor	O
15	oil	O
16	(	O
17	Cremophor	O
18	EL	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	solubilizing	O
25	agent	O
26	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	identified	O
8	as	O
9	CACGTGACCCG	O
10	,	O
11	is	O
12	located	O
13	34	O
14	bp	O
15	upstream	O
16	from	O
17	the	O
18	transcription	O
19	initiation	O
20	site	O
21	,	O
22	and	O
23	contains	O
24	the	O
25	core	O
26	sequence	O
27	of	O
28	the	O
29	upstream	O
30	promoter	O
31	sequence	O
32	of	O
33	Ad2MLP	O
34	.	O

1	Vitamin	O
2	D3	O
3	and	O
4	calcium	O
5	absorption	O
6	in	O
7	the	O
8	chick	O
9	.	O

1	To	O
2	evaluate	O
3	the	O
4	effect	O
5	of	O
6	altitude	O
7	on	O
8	adolescent	O
9	growth	O
10	and	O
11	development	O
12	,	O
13	three	O
14	groups	O
15	of	O
16	healthy	O
17	,	O
18	well	O
19	-	O
20	nourished	O
21	youth	O
22	of	O
23	similar	O
24	socioeconomic	O
25	status	O
26	and	O
27	ethnic	O
28	grouping	O
29	who	O
30	resided	O
31	at	O
32	sea	O
33	level	O
34	(	O
35	n	O
36	=	O
37	1262	O
38	subjects	O
39	),	O
40	mid	O
41	-	O
42	altitude	O
43	(	O
44	n	O
45	=	O
46	1743	O
47	subjects	O
48	),	O
49	and	O
50	high	O
51	altitude	O
52	(	O
53	n	O
54	=	O
55	1137	O
56	subjects	O
57	)	O
58	were	O
59	studied	O
60	.	O

1	Structure	O
2	of	O
3	the	O
4	gene	O
5	encoding	O
6	the	O
7	human	O
8	cyclin	B
9	-	I
10	dependent	I
11	kinase	I
12	inhibitor	O
13	p18	O
14	and	O
15	mutational	O
16	analysis	O
17	in	O
18	breast	O
19	cancer	O
20	.	O

1	Three	O
2	experiments	O
3	contrasted	O
4	the	O
5	effects	O
6	of	O
7	6	O
8	-	O
9	hydroxydopamine	O
10	-	O
11	induced	O
12	lesions	O
13	of	O
14	the	O
15	ventral	O
16	noradrenergic	O
17	and	O
18	dorsal	O
19	noradrenergic	O
20	projections	O
21	,	O
22	predominantly	O
23	to	O
24	hypothalamus	O
25	and	O
26	cortex	O
27	,	O
28	respectively	O
29	,	O
30	upon	O
31	body	O
32	weight	O
33	changes	O
34	and	O
35	food	O
36	-	O
37	related	O
38	behaviour	O
39	in	O
40	the	O
41	rat	O
42	.	O

1	The	O
2	behavior	O
3	of	O
4	different	O
5	types	O
6	of	O
7	polytetrafluoroethylene	O
8	(	O
9	PTFE	O
10	)	O
11	prostheses	O
12	in	O
13	the	O
14	reparative	O
15	scarring	O
16	process	O
17	of	O
18	abdominal	O
19	wall	O
20	defects	O
21	.	O

1	This	O
2	structure	O
3	of	O
4	cucumisin	O
5	suggests	O
6	that	O
7	it	O
8	is	O
9	probably	O
10	synthesized	O
11	as	O
12	an	O
13	inactive	O
14	precursor	O
15	.	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	Cdk2	B
7	-	I
8	phosphorylated	O
9	MARCKS	O
10	was	O
11	digested	O
12	with	O
13	lysyl	O
14	endoprotease	O
15	and	O
16	analysed	O
17	by	O
18	electrospray	O
19	MS	O
20	.	O

1	The	O
2	tissue	O
3	-	O
4	specific	O
5	expression	O
6	of	O
7	DP	B
8	family	I
9	members	O
10	suggests	O
11	that	O
12	the	O
13	combination	O
14	of	O
15	DP	B
16	/	I
17	E2F	I
18	heterodimers	I
19	that	O
20	constitute	O
21	DRTF1	O
22	/	O
23	E2F	B
24	is	O
25	influenced	O
26	by	O
27	the	O
28	phenotype	O
29	of	O
30	the	O
31	cell	O
32	.	O

1	During	O
2	1985	O
3	,	O
4	1990	O
5	,	O
6	and	O
7	1995	O
8	,	O
9	respectively	O
10	,	O
11	11	O
12	.	O
13	7	O
14	,	O
15	11	O
16	.	O
17	3	O
18	,	O
19	and	O
20	11	O
21	.	O
22	4	O
23	infants	O
24	per	O
25	100	O
26	,	O
27	000	O
28	live	O
29	births	O
30	had	O
31	a	O
32	diagnosis	O
33	of	O
34	HSV	O
35	(	O
36	P	O
37	=.	O
38	98	O
39	).	O

1	A	O
2	rather	O
3	similar	O
4	pattern	O
5	of	O
6	results	O
7	was	O
8	obtained	O
9	with	O
10	respect	O
11	to	O
12	LMP2B	O
13	mRNA	O
14	expression	O
15	,	O
16	such	O
17	transcripts	O
18	being	O
19	detectable	O
20	only	O
21	in	O
22	a	O
23	subset	O
24	of	O
25	tumors	O
26	,	O
27	and	O
28	then	O
29	at	O
30	apparently	O
31	low	O
32	levels	O
33	.	O

1	Transient	O
2	expression	O
3	of	O
4	human	O
5	and	O
6	chicken	B
7	progesterone	I
8	receptors	I
9	does	O
10	not	O
11	support	O
12	alternative	O
13	translational	O
14	initiation	O
15	from	O
16	a	O
17	single	O
18	mRNA	O
19	as	O
20	the	O
21	mechanism	O
22	generating	O
23	two	O
24	receptor	O
25	isoforms	O
26	.	O

1	From	O
2	August	O
3	1989	O
4	to	O
5	October	O
6	1990	O
7	,	O
8	83	O
9	pregnant	O
10	Chinese	O
11	women	O
12	were	O
13	the	O
14	subjects	O
15	for	O
16	measuring	O
17	the	O
18	levels	O
19	of	O
20	plasma	O
21	functional	O
22	antithrombin	B
23	III	I
24	(	O
25	AT	O
26	III	O
27	)	O
28	activity	O
29	.	O

1	A	O
2	consensus	O
3	binding	O
4	site	O
5	for	O
6	the	O
7	transcription	B
8	factor	I
9	SP1	I
10	was	O
11	identified	O
12	in	O
13	intron	O
14	As	O
15	downstream	O
16	of	O
17	the	O
18	proenkephalin	O
19	germ	O
20	cell	O
21	cap	O
22	site	O
23	region	O
24	.	O

1	While	O
2	interactions	O
3	of	O
4	WT	O
5	and	O
6	variant	O
7	TGF	B
8	-	I
9	alpha	I
10	with	O
11	the	O
12	ErbBs	O
13	all	O
14	result	O
15	in	O
16	ErbB2	B
17	activation	O
18	,	O
19	they	O
20	produce	O
21	different	O
22	biological	O
23	consequences	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	various	O
29	TGF	B
30	-	I
31	alpha	I
32	precursors	I
33	differentially	O
34	modulate	O
35	ErbB	B
36	signaling	O
37	.	O

1	The	O
2	mutation	O
3	within	O
4	the	O
5	asgB480	O
6	allele	O
7	was	O
8	identified	O
9	as	O
10	an	O
11	A	O
12	-	O
13	to	O
14	-	O
15	G	O
16	transition	O
17	that	O
18	results	O
19	in	O
20	a	O
21	threonine	O
22	-	O
23	to	O
24	-	O
25	alanine	O
26	substitution	O
27	in	O
28	the	O
29	predicted	O
30	protein	O
31	product	O
32	.	O

1	Expression	O
2	of	O
3	thiamin	O
4	biosynthetic	O
5	genes	O
6	(	O
7	thiCOGE	O
8	)	O
9	and	O
10	production	O
11	of	O
12	symbiotic	B
13	terminal	I
14	oxidase	I
15	cbb3	O
16	in	O
17	Rhizobium	O
18	etli	O
19	.	O

1	In	O
2	transient	O
3	analysis	O
4	using	O
5	particle	O
6	bombardment	O
7	of	O
8	tobacco	O
9	leaf	O
10	sections	O
11	,	O
12	a	O
13	tetramer	O
14	of	O
15	the	O
16	distB	O
17	ABRE	O
18	(	O
19	abscisic	O
20	acid	O
21	-	O
22	responsive	O
23	element	O
24	)	O
25	mediated	O
26	transactivation	O
27	by	O
28	ABI3	O
29	and	O
30	ABI3	O
31	-	O
32	dependent	O
33	response	O
34	to	O
35	ABA	O
36	,	O
37	whereas	O
38	a	O
39	tetramer	O
40	of	O
41	the	O
42	composite	O
43	RY	O
44	/	O
45	G	O
46	complex	O
47	,	O
48	containing	O
49	RY	O
50	repeats	O
51	and	O
52	a	O
53	G	B
54	-	I
55	box	I
56	,	O
57	mediated	O
58	only	O
59	ABA	O
60	-	O
61	independent	O
62	transactivation	O
63	by	O
64	ABI3	O
65	.	O

1	Deletion	O
2	from	O
3	either	O
4	the	O
5	N	O
6	-	O
7	or	O
8	C	O
9	-	O
10	terminal	O
11	ends	O
12	of	O
13	repA	B
14	(	O
15	28	O
16	and	O
17	69	O
18	codons	O
19	,	O
20	respectively	O
21	,	O
22	out	O
23	of	O
24	the	O
25	286	O
26	-	O
27	codon	O
28	open	O
29	reading	O
30	frame	O
31	)	O
32	affected	O
33	the	O
34	initiator	O
35	but	O
36	not	O
37	the	O
38	inhibitory	O
39	activity	O
40	.	O

1	The	O
2	across	O
3	-	O
4	fiber	O
5	pattern	O
6	of	O
7	the	O
8	responses	O
9	to	O
10	hypotonic	O
11	NaCl	O
12	solutions	O
13	correlated	O
14	strongly	O
15	to	O
16	that	O
17	elicited	O
18	by	O
19	distilled	O
20	H2O	O
21	.(	O
22	ABSTRACT	O
23	TRUNCATED	O
24	AT	O
25	400	O
26	WORDS	O
27	)	O

1	The	O
2	gene	O
3	organization	O
4	of	O
5	CRSV	B
6	RNA	I
7	-	I
8	1	I
9	is	O
10	similar	O
11	to	O
12	those	O
13	of	O
14	red	O
15	clover	O
16	necrotic	O
17	mosaic	O
18	(	O
19	RCNMV	O
20	)	O
21	and	O
22	sweet	O
23	clover	O
24	necrotic	O
25	mosaic	O
26	(	O
27	SCNMV	O
28	)	O
29	dianthoviruses	O
30	with	O
31	the	O
32	exception	O
33	that	O
34	CRSV	B
35	RNA	I
36	-	I
37	1	I
38	contains	O
39	the	O
40	additional	O
41	3	O
42	'-	O
43	terminal	O
44	ORF	O
45	.	O

1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	B

1	Indeed	O
2	,	O
3	ERM	O
4	and	O
5	c	B
6	-	I
7	Jun	I
8	synergistically	I
9	activated	I
10	the	O
11	EBS	O
12	-	O
13	CRE	O
14	without	O
15	making	O
16	an	O
17	apparent	O
18	ternary	O
19	complex	O
20	.	O

1	Trial	O
2	treatment	O
3	of	O
4	schizophrenia	O
5	with	O
6	des	B
7	-	I
8	Tyr	I
9	-	I
10	gamma	I
11	-	I
12	endorphin	I

1	Cryoglobulinemia	O
2	in	O
3	Raynaud	O
4	'	O
5	s	O
6	syndrome	O

1	The	O
2	monoclonal	B
3	immunoglobulin	I
4	products	O
5	of	O
6	plasma	O
7	cell	O
8	neoplasm	O
9	can	O
10	give	O
11	rise	O
12	to	O
13	a	O
14	variety	O
15	of	O
16	manifestations	O
17	including	O
18	hyperviscosity	O
19	,	O
20	amyloidosis	O
21	,	O
22	cryoglobulinemia	O
23	,	O
24	neuropathy	O
25	,	O
26	and	O
27	renal	O
28	failure	O
29	.	O

1	Regional	O
2	CBF	O
3	was	O
4	determined	O
5	by	O
6	clearance	O
7	of	O
8	xenon	O
9	133	O
10	in	O
11	67	O
12	patients	O
13	undergoing	O
14	coronary	O
15	bypass	O
16	grafting	O
17	procedures	O
18	.	O

1	Small	B
2	Maf	I
3	proteins	I
4	interact	O
5	with	O
6	the	O
7	human	B
8	transcription	I
9	factor	I
10	TCF11	I
11	/	I
12	Nrf1	I
13	/	I
14	LCR	I
15	-	I
16	F1	I
17	.	I

1	This	O
2	multimodality	O
3	treatment	O
4	for	O
5	locally	O
6	advanced	O
7	gynecologic	O
8	tumors	O
9	appears	O
10	feasible	O
11	with	O
12	modification	O
13	,	O
14	and	O
15	continued	O
16	work	O
17	exploring	O
18	this	O
19	approach	O
20	is	O
21	encouraged	O
22	.	O

1	The	O
2	patient	O
3	was	O
4	treated	O
5	with	O
6	benzathine	O
7	penicillin	O
8	,	O
9	2	O
10	,	O
11	400	O
12	,	O
13	000	O
14	U	O
15	weekly	O
16	for	O
17	three	O
18	weeks	O
19	.	O

1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	O
19	chalcone	B
20	synthase	I
21	promoter	I
22	.	I

1	Because	O
2	decreases	O
3	in	O
4	the	O
5	disfluency	O
6	rates	O
7	of	O
8	stutterers	O
9	were	O
10	observed	O
11	during	O
12	the	O
13	presentation	O
14	of	O
15	all	O
16	three	O
17	stimulus	O
18	words	O
19	,	O
20	the	O
21	data	O
22	failed	O
23	to	O
24	support	O
25	the	O
26	operant	O
27	model	O
28	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	B
14	PCI	I
15	gene	I
16	required	O
17	for	O
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	B
34	PCI	I
35	mRNA	I
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	In	O
2	the	O
3	present	O
4	experiments	O
5	,	O
6	we	O
7	investigate	O
8	the	O
9	role	O
10	played	O
11	by	O
12	the	O
13	temporal	O
14	pattern	O
15	of	O
16	neural	O
17	activity	O
18	during	O
19	the	O
20	ontogeny	O
21	of	O
22	frequency	O
23	tuning	O
24	in	O
25	the	O
26	mouse	O
27	central	O
28	auditory	O
29	system	O
30	.	O

1	Our	O
2	study	O
3	cohorts	O
4	consisted	O
5	of	O
6	15	O
7	patients	O
8	who	O
9	received	O
10	SC	O
11	rIL	O
12	-	O
13	2	O
14	at	O
15	doses	O
16	of	O
17	4	O
18	.	O
19	8	O
20	-	O
21	14	O
22	.	O
23	4	O
24	million	O
25	IU	O
26	/	O
27	m2	O
28	/	O
29	day	O
30	on	O
31	5	O
32	days	O
33	per	O
34	week	O
35	for	O
36	a	O
37	total	O
38	of	O
39	8	O
40	weeks	O
41	,	O
42	20	O
43	patients	O
44	who	O
45	received	O
46	rIFN	B
47	-	I
48	alpha	I
49	2b	I
50	at	O
51	3	O
52	.	O
53	0	O
54	-	O
55	6	O
56	.	O
57	0	O
58	million	O
59	U	O
60	/	O
61	m2	O
62	/	O
63	day	O
64	thrice	O
65	weekly	O
66	for	O
67	a	O
68	total	O
69	of	O
70	6	O
71	weeks	O
72	,	O
73	and	O
74	72	O
75	patients	O
76	who	O
77	were	O
78	given	O
79	SC	O
80	rIFN	B
81	-	I
82	alpha	I
83	2b	I
84	at	O
85	6	O
86	.	O
87	0	O
88	million	O
89	U	O
90	/	O
91	m2	O
92	/	O
93	day	O
94	thrice	O
95	weekly	O
96	plus	O
97	SC	O
98	rIL	O
99	-	O
100	2	O
101	at	O
102	14	O
103	.	O
104	4	O
105	-	O
106	18	O
107	.	O
108	0	O
109	million	O
110	IU	O
111	/	O
112	m2	O
113	/	O
114	day	O
115	on	O
116	days	O
117	1	O
118	and	O
119	2	O
120	,	O
121	followed	O
122	by	O
123	4	O
124	.	O
125	8	O
126	million	O
127	IU	O
128	/	O
129	m2	O
130	/	O
131	day	O
132	,	O
133	5	O
134	days	O
135	per	O
136	week	O
137	for	O
138	6	O
139	consecutive	O
140	weeks	O
141	.	O

1	The	O
2	equilibrium	O
3	dissociation	O
4	binding	O
5	constant	O
6	for	O
7	the	O
8	interaction	O
9	of	O
10	TnrA	O
11	with	O
12	the	O
13	nrgAB	O
14	promoter	O
15	fragment	O
16	was	O
17	7	O
18	.	O
19	7	O
20	nM	O
21	under	O
22	the	O
23	conditions	O
24	used	O
25	here	O
26	.	O

1	Another	O
2	full	O
3	ORF	O
4	was	O
5	found	O
6	on	O
7	the	O
8	opposite	O
9	strand	O
10	downstream	O
11	from	O
12	the	O
13	nspC	B
14	gene	I
15	.	I

1	The	O
2	effects	O
3	produced	O
4	by	O
5	oral	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	/	O
11	kg	O
12	p	O
13	-	O
14	xylene	O
15	or	O
16	toluene	O
17	lasted	O
18	at	O
19	least	O
20	8	O
21	hr	O
22	,	O
23	while	O
24	the	O
25	effect	O
26	of	O
27	inhaled	O
28	p	O
29	-	O
30	xylene	O
31	dissipated	O
32	within	O
33	75	O
34	min	O
35	of	O
36	removal	O
37	from	O
38	the	O
39	exposure	O
40	.	O

1	Pacing	O
2	the	O
3	Roux	O
4	limb	O
5	abolished	O
6	the	O
7	ectopic	O
8	pacemakers	O
9	,	O
10	restored	O
11	the	O
12	slow	O
13	emptying	O
14	of	O
15	liquids	O
16	to	O
17	the	O
18	more	O
19	rapid	O
20	rate	O
21	found	O
22	in	O
23	the	O
24	Billroth	O
25	dogs	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	:	O
31	paced	O
32	Roux	O
33	,	O
34	72	O
35	+/-	O
36	15	O
37	minutes	O
38	;	O
39	Billroth	O
40	,	O
41	43	O
42	+/-	O
43	9	O
44	minutes	O
45	;	O
46	p	O
47	greater	O
48	than	O
49	0	O
50	.	O
51	05	O
52	)	O
53	and	O
54	did	O
55	not	O
56	change	O
57	emptying	O
58	of	O
59	solids	O
60	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	pregnant	O
6	group	O
7	,	O
8	serum	O
9	PP14	O
10	concentrations	O
11	were	O
12	markedly	O
13	increased	O
14	after	O
15	ET	O
16	,	O
17	and	O
18	a	O
19	significant	O
20	difference	O
21	between	O
22	the	O
23	pregnant	O
24	group	O
25	and	O
26	the	O
27	nonpregnant	O
28	group	O
29	was	O
30	observed	O
31	8	O
32	days	O
33	following	O
34	ET	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	01	O
41	).	O

1	After	O
2	gamma	O
3	-	O
4	irradiation	O
5	,	O
6	the	O
7	majority	O
8	of	O
9	F9	O
10	cells	O
11	undergo	O
12	apoptosis	O
13	implying	O
14	that	O
15	wt	B
16	-	I
17	p53	I
18	likely	I
19	triggers	I
20	pro	I
21	-	I
22	apoptotic	I
23	gene	I
24	expression	O
25	in	O
26	DNA	O
27	damaged	O
28	cells	O
29	.	O

1	A	O
2	secondary	O
3	spread	O
4	of	O
5	an	O
6	imported	O
7	methicillin	O
8	-	O
9	resistant	O
10	Staphylococcus	O
11	aureus	O
12	strain	O
13	(	O
14	MRSA	O
15	)	O
16	to	O
17	two	O
18	other	O
19	patients	O
20	occurred	O
21	within	O
22	a	O
23	Danish	O
24	surgical	O
25	ward	O
26	in	O
27	spite	O
28	of	O
29	isolation	O
30	of	O
31	a	O
32	multitraumatized	O
33	index	O
34	-	O
35	patient	O
36	immediately	O
37	after	O
38	arrival	O
39	from	O
40	a	O
41	hospital	O
42	in	O
43	the	O
44	Mediterranean	O
45	area	O
46	.	O

1	Inhibition	O
2	of	O
3	RNA2	O
4	translation	O
5	was	O
6	selective	O
7	,	O
8	with	O
9	no	O
10	effect	O
11	on	O
12	general	O
13	cellular	O
14	translation	O
15	or	O
16	translation	O
17	of	O
18	BMV	O
19	RNA1	B
20	-	I
21	encoded	I
22	replication	I
23	factor	I
24	1a	I
25	,	O
26	and	O
27	was	O
28	independent	O
29	of	O
30	p20	O
31	,	O
32	a	O
33	cellular	O
34	antagonist	O
35	of	O
36	DED1	O
37	function	O
38	in	O
39	translation	O
40	.	O

1	TPTA	O
2	produced	O
3	brain	O
4	congestion	O
5	,	O
6	and	O
7	hepatic	O
8	and	O
9	pulmonary	O
10	petechial	O
11	and	O
12	generalized	O
13	hemorrhages	O
14	.	O

1	As	O
2	well	O
3	,	O
4	further	O
5	deletion	O
6	of	O
7	the	O
8	promoter	O
9	region	O
10	to	O
11	nucleotide	O
12	-	O
13	110	O
14	,	O
15	which	O
16	contains	O
17	only	O
18	one	O
19	SF	B
20	-	I
21	1	I
22	binding	I
23	site	I
24	,	O
25	still	O
26	retained	O
27	the	O
28	ability	O
29	to	O
30	respond	O
31	to	O
32	exogenous	O
33	SF	B
34	-	I
35	1	I
36	.	I

1	Such	O
2	multisensory	O
3	interactions	O
4	can	O
5	be	O
6	significant	O
7	for	O
8	behavior	O
9	.	O

1	A	O
2	model	O
3	with	O
4	age	O
5	and	O
6	weight	O
7	described	O
8	the	O
9	best	O
10	fit	O
11	for	O
12	TBBMD	O
13	,	O
14	whereas	O
15	age	O
16	,	O
17	weight	O
18	,	O
19	and	O
20	height	O
21	described	O
22	the	O
23	best	O
24	fit	O
25	for	O
26	total	O
27	body	O
28	TBBMC	O
29	.	O

1	(	O
2	1997	O
3	)	O
4	Science	O
5	275	O
6	,	O
7	1927	O
8	-	O
9	1930	O
10	).	O

1	4	O
2	.	O

1	A	O
2	736	O
3	-	O
4	bp	O
5	sequence	O
6	of	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	adjacent	O
13	to	O
14	the	O
15	cap	O
16	site	O
17	of	O
18	the	O
19	human	B
20	AFP	I
21	gene	I
22	shows	O
23	a	O
24	61	O
25	%	O
26	similarity	O
27	with	O
28	the	O
29	corresponding	O
30	region	O
31	of	O
32	the	O
33	mouse	O
34	AFP	B
35	gene	I
36	.	I

1	Comparison	O
2	with	O
3	the	O
4	bHLH	B
5	/	I
6	PAS	I
7	family	I
8	genes	I
9	revealed	O
10	that	O
11	the	O
12	intron	O
13	/	O
14	exon	O
15	splice	O
16	pattern	O
17	of	O
18	mBMAL1	O
19	most	O
20	closely	O
21	matches	O
22	that	O
23	of	O
24	the	O
25	mAhr	O
26	,	O
27	which	O
28	suggests	O
29	that	O
30	BMAL1	O
31	and	O
32	Ahr	O
33	belong	O
34	to	O
35	the	O
36	same	O
37	subclass	O
38	and	O
39	may	O
40	be	O
41	derived	O
42	from	O
43	a	O
44	common	O
45	primordial	B
46	gene	I
47	.	I

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	V	O
2	.	O

1	Comparison	O
2	of	O
3	patients	O
4	receiving	O
5	phenytoin	O
6	and	O
7	those	O
8	who	O
9	were	O
10	not	O
11	showed	O
12	significantly	O
13	lower	O
14	serum	O
15	folate	O
16	in	O
17	the	O
18	sub	O
19	-	O
20	group	O
21	receiving	O
22	phenytoin	O
23	,	O
24	but	O
25	there	O
26	was	O
27	no	O
28	significant	O
29	difference	O
30	between	O
31	the	O
32	sub	O
33	-	O
34	groups	O
35	with	O
36	respect	O
37	to	O
38	vitamin	O
39	B12	O
40	or	O
41	behaviour	O
42	problem	O
43	rating	O
44	.	O

1	The	O
2	sequence	O
3	similarity	O
4	has	O
5	suggested	O
6	that	O
7	SCG10	O
8	and	O
9	stathmin	O
10	have	O
11	been	O
12	derived	O
13	from	O
14	structurally	O
15	and	O
16	evolutionarily	O
17	related	O
18	genes	O
19	.	O

1	Computer	O
2	analysis	O
3	included	O
4	digital	O
5	averaging	O
6	,	O
7	followed	O
8	by	O
9	digital	O
10	filtering	O
11	in	O
12	different	O
13	frequency	O
14	bands	O
15	in	O
16	order	O
17	to	O
18	determine	O
19	the	O
20	frequency	O
21	range	O
22	corresponding	O
23	to	O
24	notches	O
25	and	O
26	slurs	O
27	.	O

1	5	O
2	micrograms	O
3	/	O
4	l	O
5	was	O
6	detected	O
7	in	O
8	urine	O
9	from	O
10	some	O
11	non	O
12	-	O
13	occupationally	O
14	exposed	O
15	persons	O
16	.	O

1	One	O
2	antibody	O
3	,	O
4	mAb1C2	O
5	,	O
6	and	O
7	a	O
8	synthetic	O
9	peptide	O
10	comprising	O
11	its	O
12	epitope	O
13	selectively	O
14	inhibited	O
15	in	O
16	vitro	O
17	transcription	O
18	from	O
19	TATA	O
20	-	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	from	O
26	TATA	O
27	-	O
28	less	O
29	promoters	O
30	,	O
31	irrespective	O
32	of	O
33	whether	O
34	they	O
35	were	O
36	transcribed	O
37	by	O
38	Pol	B
39	II	I
40	or	O
41	Pol	B
42	III	I
43	.	I

1	The	O
2	QT	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O

1	A	O
2	decrease	O
3	of	O
4	the	O
5	lysozyme	O
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	O
12	of	O
13	the	O
14	bacterial	O
15	meningitis	O
16	.	O

1	Both	O
2	HERV	B
3	-	I
4	K	I
5	type	I
6	1	I
7	and	O
8	2	O
9	clones	O
10	were	O
11	isolated	O
12	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	-	I
5	beta1	I
6	(	O
7	TGF	B
8	-	I
9	beta1	I
10	)	O
11	can	O
12	act	O
13	as	O
14	a	O
15	tumor	O
16	suppressor	O
17	or	O
18	a	O
19	tumor	O
20	promoter	O
21	depending	O
22	on	O
23	the	O
24	characteristics	O
25	of	O
26	the	O
27	malignant	O
28	cell	O
29	.	O

1	The	O
2	study	O
3	of	O
4	calcium	O
5	metabolism	O
6	in	O
7	ten	O
8	thalassaemic	O
9	children	O
10	comperatively	O
11	with	O
12	controls	O
13	after	O
14	oral	O
15	administration	O
16	of	O
17	47Ca	O
18	has	O
19	shown	O
20	diminished	O
21	intestinal	O
22	absorption	O
23	.	O

1	Clinical	O
2	accuracy	O
3	of	O
4	updated	O
5	version	O
6	of	O
7	the	O
8	Phadebas	O
9	RAST	O
10	test	O
11	.	O

1	In	O
2	contrast	O
3	,	O
4	gel	O
5	mobility	O
6	shift	O
7	experiments	O
8	have	O
9	failed	O
10	to	O
11	reveal	O
12	that	O
13	HAP2	O
14	or	O
15	HAP3	O
16	binds	O
17	to	O
18	domain	O
19	1	O
20	or	O
21	that	O
22	hap3	O
23	mutations	O
24	affect	O
25	the	O
26	complexes	O
27	bound	O
28	to	O
29	it	O
30	.	O

1	Microscopic	O
2	anatomy	O
3	and	O
4	cell	O
5	population	O
6	dynamics	O
7	.	O

1	PAO	O
2	blocks	O
3	turnover	O
4	of	O
5	the	O
6	phosphoryl	O
7	group	O
8	of	O
9	pp15	O
10	,	O
11	causing	O
12	its	O
13	accumulation	O
14	,	O
15	and	O
16	thereby	O
17	appears	O
18	to	O
19	interrupt	O
20	signal	O
21	transmission	O
22	from	O
23	the	O
24	receptor	O
25	to	O
26	the	O
27	glucose	O
28	-	O
29	transport	O
30	system	O
31	.	O

1	An	O
2	8	O
3	-	O
4	h	O
5	exposure	O
6	to	O
7	10	O
8	mg	O
9	DMEA	O
10	/	O
11	m3	O
12	corresponds	O
13	to	O
14	a	O
15	postexposure	O
16	plasma	O
17	concentration	O
18	and	O
19	2	O
20	-	O
21	h	O
22	postexposure	O
23	urinary	O
24	excretion	O
25	of	O
26	4	O
27	.	O
28	9	O
29	mumol	O
30	/	O
31	l	O
32	and	O
33	75	O
34	mmol	O
35	/	O
36	mol	O
37	creatinine	O
38	,	O
39	respectively	O
40	.	O

1	A	O
2	mutation	O
3	linked	O
4	to	O
5	the	O
6	SOC1	O
7	gene	O
8	,	O
9	previously	O
10	defined	O
11	by	O
12	recessive	O
13	mutations	O
14	that	O
15	suppress	O
16	cbp1	B
17	ts	I
18	alleles	I
19	and	O
20	stabilize	O
21	many	O
22	mitochondrial	O
23	mRNAs	O
24	,	O
25	was	O
26	also	O
27	isolated	O
28	.	O

1	Western	O
2	blot	O
3	analyses	O
4	detect	O
5	anti	B
6	-	I
7	E	I
8	-	I
9	specific	O
10	immunoreactivity	O
11	in	O
12	affinity	O
13	-	O
14	purified	O
15	extracts	O
16	derived	O
17	from	O
18	the	O
19	bacterial	O
20	expression	O
21	of	O
22	a	O
23	truncated	O
24	AMPD3	O
25	cDNA	O
26	.	O

1	Particles	O
2	resembling	O
3	microbodies	O
4	in	O
5	normal	O
6	and	O
7	neoplastic	O
8	perianal	O
9	glands	O
10	of	O
11	dogs	O
12	.	O

1	Oncogenic	O
2	activation	O
3	of	O
4	the	O
5	tyrosine	B
6	kinase	I
7	domain	I
8	of	O
9	the	O
10	human	O
11	trk	B
12	proto	I
13	-	I
14	oncogene	I
15	by	O
16	fusion	O
17	to	O
18	a	O
19	cell	O
20	adhesion	O
21	molecule	O
22	.	O

1	Dose	O
2	of	O
3	20	O
4	ig	O
5	were	O
6	administered	O
7	within	O
8	a	O
9	scheme	O
10	from	O
11	0	O
12	.	O
13	1	O
14	to	O
15	6	O
16	months	O
17	in	O
18	order	O
19	to	O
20	study	O
21	its	O
22	immunogenicity	O
23	,	O
24	which	O
25	was	O
26	evaluated	O
27	at	O
28	2	O
29	,	O
30	7	O
31	,	O
32	and	O
33	12	O
34	months	O
35	after	O
36	the	O
37	first	O
38	dose	O
39	.	O

1	The	O
2	subjects	O
3	were	O
4	diagnosed	O
5	on	O
6	the	O
7	basis	O
8	of	O
9	DSM	O
10	-	O
11	IV	O
12	pathological	O
13	gambling	O
14	criteria	O
15	and	O
16	completed	O
17	the	O
18	Turkish	O
19	Version	O
20	of	O
21	South	O
22	Oaks	O
23	Gambling	O
24	Screen	O
25	(	O
26	SOGS	O
27	).	O

1	Bipolarity	O
2	in	O
3	Jungian	O
4	type	O
5	theory	O
6	and	O
7	the	O
8	Myers	O
9	-	O
10	Briggs	O
11	Type	O
12	Indicator	O
13	.	O

1	Polyprotein	O
2	processing	O
3	in	O
4	Southampton	O
5	virus	O
6	:	O
7	identification	O
8	of	O
9	3C	B
10	-	I
11	like	I
12	protease	I
13	cleavage	O
14	sites	O
15	by	O
16	in	O
17	vitro	O
18	mutagenesis	O
19	.	O

1	Based	O
2	on	O
3	peptide	O
4	map	O
5	similarities	O
6	,	O
7	partial	O
8	amino	O
9	-	O
10	terminal	O
11	sequence	O
12	data	O
13	,	O
14	and	O
15	common	O
16	genetic	O
17	origin	O
18	,	O
19	it	O
20	is	O
21	suggested	O
22	that	O
23	p60	O
24	and	O
25	p62	B
26	have	O
27	identical	O
28	amino	O
29	acid	O
30	sequences	O
31	carboxy	O
32	-	O
33	terminal	O
34	to	O
35	the	O
36	p60	O
37	initiator	O
38	methionine	O
39	(	O
40	residue	O
41	21	O
42	of	O
43	p62	B
44	).	O

1	It	O
2	contains	O
3	25	O
4	exons	O
5	coding	O
6	for	O
7	a	O
8	4	O
9	.	O
10	7kb	O
11	transcript	O
12	including	O
13	large	O
14	5	O
15	'-	O
16	and	O
17	3	O
18	'-	O
19	(	O
20	1218bp	O
21	and	O
22	701bp	O
23	,	O
24	respectively	O
25	)	O
26	untranslated	O
27	regions	O
28	(	O
29	UTRs	O
30	).	O

1	Alanine	B
2	aminotransferase	I
3	(	I
4	ALT	I
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O

1	Clear	O
2	and	O
3	evidenced	O
4	-	O
5	based	O
6	information	O
7	should	O
8	be	O
9	provided	O
10	to	O
11	patients	O
12	as	O
13	to	O
14	the	O
15	means	O
16	of	O
17	prevention	O
18	with	O
19	special	O
20	attention	O
21	to	O
22	individual	O
23	risk	O
24	groups	O
25	such	O
26	as	O
27	IV	O
28	drug	O
29	abusers	O
30	.	O

1	Randomised	O
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	autologous	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	leukaemia	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	MRC	O
25	AML	B
26	10	O
27	trial	O
28	.	O

1	A	O
2	unique	O
3	leucine	O
4	-	O
5	proline	O
6	repeat	O
7	element	O
8	found	O
9	N	O
10	-	O
11	terminal	O
12	to	O
13	the	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	EmBP	O
20	-	O
21	1	O
22	does	O
23	not	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	DNA	O
31	-	O
32	binding	O
33	or	O
34	dimerization	O
35	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	determine	O
9	the	O
10	risk	O
11	factors	O
12	for	O
13	background	O
14	diabetic	O
15	retinopathy	O
16	(	O
17	BDR	O
18	)	O
19	and	O
20	PDR	O
21	by	O
22	following	O
23	394	O
24	Japanese	O
25	patients	O
26	with	O
27	early	O
28	-	O
29	onset	O
30	type	O
31	2	O
32	diabetes	O
33	diagnosed	O
34	before	O
35	30	O
36	years	O
37	of	O
38	age	O
39	(	O
40	mean	O
41	age	O
42	27	O
43	,	O
44	mean	O
45	blood	O
46	pressure	O
47	at	O
48	entry	O
49	116	O
50	/	O
51	73	O
52	mm	O
53	Hg	O
54	).	O

1	A	O
2	reduction	O
3	of	O
4	the	O
5	aspartate	B
6	aminotransferase	I
7	activity	O
8	was	O
9	observed	O
10	from	O
11	800	O
12	mg	O
13	/	O
14	kg	O
15	b	O
16	.	O
17	w	O
18	./	O
19	d	O
20	onwards	O
21	.	O

1	Collectively	O
2	,	O
3	these	O
4	data	O
5	indicate	O
6	that	O
7	HIP	O
8	is	O
9	a	O
10	membrane	O
11	-	O
12	associated	O
13	HP	B
14	-	I
15	binding	I
16	protein	I
17	expressed	O
18	on	O
19	the	O
20	surface	O
21	of	O
22	normal	O
23	human	O
24	uterine	O
25	epithelia	O
26	and	O
27	uterine	O
28	epithelial	O
29	cell	O
30	lines	O
31	.	O

1	In	O
2	contrast	O
3	,	O
4	in	O
5	LL	O
6	patients	O
7	during	O
8	ENL	O
9	the	O
10	ConA	O
11	-	O
12	induced	O
13	suppressor	O
14	response	O
15	was	O
16	markedly	O
17	reduced	O
18	.	O

1	Replacement	I
2	variant	I
3	histone	I
4	genes	I
5	contain	O
6	intervening	O
7	sequences	O
8	.	O

1	In	O
2	humans	O
3	,	O
4	three	O
5	tissue	B
6	-	I
7	specific	I
8	plastin	I
9	isoforms	I
10	have	O
11	been	O
12	identified	O
13	.	O

1	Within	O
2	the	O
3	span	O
4	of	O
5	attenuator	O
6	region	O
7	encoding	O
8	the	O
9	three	O
10	stem	O
11	-	O
12	loop	O
13	structures	O
14	of	O
15	mRNA	O
16	secondary	O
17	configuration	O
18	,	O
19	hot	O
20	spots	O
21	of	O
22	base	O
23	-	O
24	residue	O
25	divergence	O
26	were	O
27	localized	O
28	to	O
29	looped	O
30	-	O
31	out	O
32	regions	O
33	.	O

1	Large	O
2	-	O
3	scale	O
4	sequencing	O
5	of	O
6	two	O
7	regions	O
8	in	O
9	human	O
10	chromosome	O
11	7q22	O
12	:	O
13	analysis	O
14	of	O
15	650	O
16	kb	O
17	of	O
18	genomic	O
19	sequence	O
20	around	O
21	the	O
22	EPO	B
23	and	O
24	CUTL1	O
25	loci	O
26	reveals	O
27	17	O
28	genes	O
29	.	O

1	Beta	B
2	1	I
3	integrin	I
4	-	I
5	and	O
6	proteoglycan	O
7	-	O
8	mediated	O
9	stimulation	O
10	of	O
11	T	O
12	lymphoma	O
13	cell	O
14	adhesion	O
15	and	O
16	mitogen	B
17	-	I
18	activated	I
19	protein	I
20	kinase	I
21	signaling	O
22	by	O
23	thrombospondin	B
24	-	I
25	1	I
26	and	O
27	thrombospondin	B
28	-	I
29	1	I
30	peptides	I
31	.	I

1	The	O
2	first	O
3	one	O
4	is	O
5	a	O
6	TPA	O
7	-	O
8	responsive	O
9	element	O
10	that	O
11	controls	O
12	the	O
13	base	O
14	-	O
15	line	O
16	ST3	O
17	promoter	O
18	activity	O
19	but	O
20	is	O
21	not	O
22	required	O
23	for	O
24	its	O
25	activation	O
26	.	O

1	Immunoblotting	O
2	of	O
3	expressed	O
4	recombinant	O
5	proteins	O
6	with	O
7	the	O
8	monoclonal	O
9	08L	O
10	antibody	O
11	localized	O
12	the	O
13	08L	O
14	epitope	O
15	to	O
16	the	O
17	carboxyl	O
18	end	O
19	of	O
20	the	O
21	protein	O
22	.	O

1	Therefore	O
2	,	O
3	magnetic	O
4	resonance	O
5	imaging	O
6	was	O
7	used	O
8	to	O
9	determine	O
10	liver	O
11	volume	O
12	in	O
13	pediatric	O
14	and	O
15	adolescent	O
16	patients	O
17	,	O
18	in	O
19	whom	O
20	systemic	O
21	clearance	O
22	of	O
23	three	O
24	model	O
25	substrates	O
26	[	O
27	lorazepam	O
28	(	O
29	0	O
30	.	O
31	03	O
32	mg	O
33	/	O
34	kg	O
35	),	O
36	antipyrine	O
37	(	O
38	10	O
39	mg	O
40	/	O
41	kg	O
42	),	O
43	and	O
44	indocyanine	O
45	green	O
46	(	O
47	ICG	O
48	;	O
49	0	O
50	.	O
51	5	O
52	mg	O
53	/	O
54	kg	O
55	)]	O
56	was	O
57	also	O
58	determined	O
59	.	O

1	The	O
2	4	O
3	-	O
4	AP	B
5	(	I
6	4	I
7	-	I
8	20	O
9	mM	O
10	)	O
11	effect	O
12	resulted	O
13	in	O
14	a	O
15	decrease	O
16	of	O
17	the	O
18	sensory	O
19	activity	O
20	,	O
21	which	O
22	was	O
23	fully	O
24	restored	O
25	by	O
26	TEA	O
27	or	O
28	Ba2	B
29	+.	I

1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	B
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O

1	The	O
2	results	O
3	confirm	O
4	that	O
5	a	O
6	single	O
7	base	O
8	change	O
9	in	O
10	the	O
11	branchpoint	O
12	consensus	O
13	sequence	O
14	of	O
15	an	O
16	intron	O
17	can	O
18	cause	O
19	human	O
20	disease	O
21	although	O
22	this	O
23	sequence	O
24	is	O
25	poorly	O
26	conserved	O
27	in	O
28	mammals	O
29	.	O

1	The	O
2	systolic	O
3	peak	O
4	of	O
5	pulmonary	O
6	vein	O
7	was	O
8	higher	O
9	than	O
10	the	O
11	diastolic	O
12	peak	O
13	in	O
14	45	O
15	out	O
16	of	O
17	56	O
18	cases	O
19	.	O

1	The	O
2	human	B
3	T	I
4	cell	I
5	lymphotropic	I
6	retrovirus	I
7	type	I
8	I	I
9	(	I
10	HTLV	I
11	-	I
12	I	I
13	)	I
14	trans	I
15	-	I
16	activator	I
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	B
25	-	I
26	domain	I
27	/	I
28	leucine	I
29	-	I
30	zipper	I
31	(	I
32	bZip	I
33	)	I
34	protein	I
35	,	O
36	cAMP	B
37	response	I
38	element	I
39	binding	I
40	protein	I
41	(	I
42	CREB	I
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	O
48	Tax	B
49	-	I
50	responsive	I
51	element	I
52	consisting	O
53	of	O
54	three	O
55	imperfect	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	flanked	O
70	by	O
71	G	B
72	/	I
73	C	I
74	-	I
75	rich	I
76	sequences	I
77	.	I

1	In	O
2	the	O
3	COPD	O
4	patients	O
5	,	O
6	the	O
7	variability	O
8	of	O
9	Delta	O
10	-	O
11	inst	O
12	Rrs	O
13	(	O
14	30	O
15	%)	O
16	was	O
17	greater	O
18	than	O
19	that	O
20	of	O
21	FOT	O
22	Rrs	O
23	(	O
24	21	O
25	%).	O

1	The	O
2	carcinogen	O
3	bioassay	O
4	therefore	O
5	is	O
6	a	O
7	very	O
8	important	O
9	component	O
10	of	O
11	the	O
12	battery	O
13	of	O
14	toxicological	O
15	tests	O
16	used	O
17	in	O
18	hazard	O
19	evaluation	O
20	.	O

1	We	O
2	find	O
3	that	O
4	3T1	O
5	-	O
6	3T2	O
7	mixing	O
8	has	O
9	a	O
10	pronounced	O
11	effect	O
12	on	O
13	the	O
14	line	O
15	shape	O
16	and	O
17	radiative	O
18	decay	O
19	rate	O
20	of	O
21	emission	O
22	from	O
23	the	O
24	3T2	O
25	state	O
26	and	O
27	that	O
28	the	O
29	extent	O
30	of	O
31	mixing	O
32	depends	O
33	critically	O
34	on	O
35	the	O
36	magnitude	O
37	of	O
38	nontetrahedral	O
39	distortions	O
40	.	O

1	We	O
2	demonstrate	O
3	that	O
4	Ddc1p	O
5	interacts	O
6	physically	O
7	in	O
8	vivo	O
9	with	O
10	Mec3p	O
11	,	O
12	and	O
13	this	O
14	interaction	O
15	requires	O
16	Rad17p	O
17	.	O

1	The	O
2	membrane	O
3	-	O
4	distal	O
5	cytoplasmic	O
6	region	O
7	of	O
8	human	B
9	granulocyte	I
10	colony	I
11	-	I
12	stimulating	I
13	factor	I
14	receptor	I
15	is	O
16	required	O
17	for	O
18	STAT3	B
19	but	O
20	not	O
21	STAT1	B
22	homodimer	I
23	formation	O
24	.	O

1	Solution	O
2	structure	O
3	and	O
4	mechanism	O
5	of	O
6	the	O
7	MutT	O
8	pyrophosphohydrolase	O
9	.	O

1	The	O
2	mean	O
3	total	O
4	white	O
5	cell	O
6	count	O
7	increased	O
8	from	O
9	a	O
10	baseline	O
11	of	O
12	11	O
13	.	O
14	3	O
15	x	O
16	10	O
17	(	O
18	9	O
19	)/	O
20	L	O
21	(	O
22	SD	O
23	2	O
24	.	O
25	3	O
26	)	O
27	to	O
28	16	O
29	.	O
30	2	O
31	x	O
32	10	O
33	(	O
34	9	O
35	)/	O
36	L	O
37	(	O
38	SD	O
39	4	O
40	.	O
41	6	O
42	)	O
43	on	O
44	day	O
45	1	O
46	,	O
47	normalising	O
48	thereafter	O
49	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	Gel	O
2	shift	O
3	analysis	O
4	indicates	O
5	that	O
6	the	O
7	full	O
8	-	O
9	length	O
10	ERM	O
11	protein	O
12	is	O
13	able	O
14	to	O
15	bind	O
16	specifically	O
17	to	O
18	an	O
19	oligonucleotide	O
20	containing	O
21	the	O
22	consensus	O
23	nucleotide	O
24	core	O
25	sequence	O
26	GGAA	O
27	recognized	O
28	by	O
29	the	O
30	Ets	B
31	proteins	I
32	.	I

1	AGO1	O
2	is	O
3	similar	O
4	to	O
5	QDE	O
6	-	O
7	2	O
8	required	O
9	for	O
10	quelling	O
11	and	O
12	RDE	O
13	-	O
14	1	O
15	required	O
16	for	O
17	RNAi	O
18	.	O

1	However	O
2	,	O
3	a	O
4	>	O
5	10	O
6	-	O
7	fold	O
8	increase	O
9	in	O
10	ERK3	O
11	activity	O
12	in	O
13	each	O
14	PKC	B
15	beta	I
16	transfectant	O
17	was	O
18	shown	O
19	by	O
20	immunoprecipitation	O
21	with	O
22	anti	B
23	-	I
24	ERK3	I
25	monoclonal	I
26	antibody	I
27	followed	O
28	by	O
29	either	O
30	immune	B
31	complex	I
32	kinase	I
33	assay	O
34	or	O
35	by	O
36	in	O
37	gel	O
38	kinase	O
39	assay	O
40	.	O

1	Lipoprotein	B
2	lipase	I
3	(	I
4	LPL	I
5	),	O
6	a	O
7	key	O
8	enzyme	O
9	in	O
10	normal	O
11	lipoprotein	O
12	metabolism	O
13	,	O
14	has	O
15	a	O
16	complex	O
17	pattern	O
18	of	O
19	regulation	O
20	and	O
21	tissue	O
22	-	O
23	specific	O
24	expression	O
25	.	O

1	The	O
2	differential	O
3	investigation	O
4	of	O
5	lipoproteins	O
6	,	O
7	however	O
8	,	O
9	showed	O
10	that	O
11	the	O
12	high	O
13	-	O
14	density	O
15	lipoprotein	O
16	(	O
17	HDL	B
18	)	O
19	fractions	O
20	are	O
21	absolutely	O
22	or	O
23	relatively	O
24	decreased	O
25	with	O
26	respect	O
27	to	O
28	low	O
29	-	O
30	density	O
31	lipoproteins	O
32	(	O
33	LDL	B
34	)	O
35	in	O
36	cerebral	O
37	infarcts	O
38	and	O
39	in	O
40	transient	O
41	ischaemic	O
42	attacks	O
43	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	zinc	B
8	finger	I
9	protein	I
10	Gis1	O
11	acts	O
12	as	O
13	a	O
14	dosage	O
15	-	O
16	dependent	O
17	suppressor	O
18	of	O
19	the	O
20	rim15Delta	O
21	defect	O
22	in	O
23	nutrient	O
24	limitation	O
25	-	O
26	induced	O
27	transcriptional	O
28	derepression	O
29	of	O
30	SSA3	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	C	B
5	/	I
6	EBP	I
7	beta	I
8	and	I
9	C	I
10	/	I
11	EBP	I
12	gamma	I
13	readily	O
14	heterodimerize	O
15	with	O
16	each	O
17	other	O
18	as	O
19	well	O
20	as	O
21	with	O
22	C	B
23	/	I
24	EBP	I
25	alpha	I
26	.	I

1	Copper	O
2	treatments	O
3	were	O
4	assigned	O
5	to	O
6	simulate	O
7	the	O
8	different	O
9	levels	O
10	of	O
11	copper	O
12	intake	O
13	that	O
14	might	O
15	result	O
16	from	O
17	differences	O
18	in	O
19	daily	O
20	feed	O
21	intake	O
22	similar	O
23	to	O
24	the	O
25	practice	O
26	followed	O
27	with	O
28	commercial	O
29	industry	O
30	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	O
6	inhibits	O
7	tyrosine	B
8	phosphatases	I
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	B
16	.	I

1	The	O
2	Arabidopsis	O
3	FAD7	O
4	gene	O
5	encodes	O
6	a	O
7	chloroplast	B
8	omega	I
9	-	I
10	3	I
11	fatty	O
12	acid	O
13	desaturase	O
14	that	O
15	catalyzes	O
16	the	O
17	desaturation	O
18	of	O
19	lipid	O
20	-	O
21	linked	O
22	dienoic	O
23	fatty	O
24	acids	O
25	(	O
26	18	O
27	:	O
28	2	O
29	and	O
30	16	O
31	:	O
32	2	O
33	).	O

1	Transcription	O
2	factors	O
3	containing	O
4	a	O
5	basic	B
6	helix	I
7	-	I
8	loop	I
9	-	I
10	helix	I
11	(	I
12	bHLH	I
13	)	O
14	motif	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	tissue	O
20	-	O
21	specific	O
22	genes	O
23	in	O
24	a	O
25	number	O
26	of	O
27	mammalian	O
28	and	O
29	insect	O
30	systems	O
31	.	O

1	The	O
2	time	O
3	course	O
4	of	O
5	RNA1	O
6	replication	O
7	and	O
8	RNA3	O
9	synthesis	O
10	in	O
11	induced	O
12	yeast	O
13	paralleled	O
14	that	O
15	in	O
16	yeast	O
17	transfected	O
18	with	O
19	natural	O
20	FHV	O
21	virion	O
22	RNA	O
23	.	O

1	Radiolabeled	O
2	recombinant	O
3	TARC	O
4	specifically	O
5	bound	O
6	to	O
7	T	O
8	cell	O
9	lines	O
10	and	O
11	peripheral	O
12	T	O
13	cells	O
14	but	O
15	not	O
16	to	O
17	monocytes	O
18	or	O
19	granulocytes	O
20	.	O

1	Pulmonary	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	narrowing	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O

1	Effect	O
2	of	O
3	single	O
4	base	O
5	substitutions	O
6	at	O
7	glycine	O
8	-	O
9	870	O
10	codon	O
11	of	O
12	gramicidin	B
13	S	I
14	synthetase	I
15	2	I
16	gene	I
17	on	O
18	proline	O
19	activation	O
20	.	O

1	e	O
2	.	O

1	The	O
2	NF	B
3	-	I
4	kappaB	I
5	responsive	I
6	reporter	I
7	construct	I
8	,	O
9	(	O
10	PRDII	B
11	)(	I
12	4	I
13	)-	I
14	CAT	I
15	,	O
16	was	O
17	used	O
18	to	O
19	explore	O
20	transcription	O
21	resulting	O
22	from	O
23	NF	B
24	-	I
25	kappaB	I
26	activated	I
27	by	O
28	Tat	B
29	.	I

1	The	O
2	COL7A1	O
3	gene	O
4	,	O
5	which	O
6	encodes	O
7	type	B
8	VII	I
9	collagen	I
10	,	O
11	has	O
12	been	O
13	implicated	O
14	as	O
15	a	O
16	candidate	O
17	gene	O
18	for	O
19	dominantly	O
20	and	O
21	recessively	O
22	inherited	O
23	forms	O
24	of	O
25	dystrophic	O
26	epidermolysis	O
27	bullosa	O
28	.	O

1	The	O
2	most	O
3	common	O
4	characteristics	O
5	of	O
6	VRE	O
7	patients	O
8	were	O
9	recent	O
10	prior	O
11	vancomycin	O
12	use	O
13	,	O
14	recent	O
15	prior	O
16	susceptible	O
17	enterococcal	O
18	infection	O
19	,	O
20	coinfection	O
21	with	O
22	other	O
23	microbial	O
24	pathogens	O
25	,	O
26	and	O
27	concurrent	O
28	fungal	O
29	infection	O
30	.	O

1	After	O
2	giving	O
3	a	O
4	survey	O
5	on	O
6	the	O
7	situation	O
8	of	O
9	antibiotic	O
10	resistance	O
11	in	O
12	the	O
13	region	O
14	of	O
15	Northern	O
16	Bavaria	O
17	during	O
18	1973	O
19	/	O
20	74	O
21	and	O
22	comparing	O
23	the	O
24	activity	O
25	of	O
26	a	O
27	sulfamethoxazole	O
28	(	O
29	SMZ	O
30	)	O
31	trimethoprim	O
32	(	O
33	TMP	O
34	)	O
35	combination	O
36	to	O
37	other	O
38	commonly	O
39	used	O
40	antibiotics	O
41	and	O
42	chemotherapeutic	O
43	agents	O
44	,	O
45	the	O
46	results	O
47	of	O
48	tests	O
49	with	O
50	the	O
51	new	O
52	combination	O
53	of	O
54	N1	O
55	-(	O
56	4	O
57	,	O
58	5	O
59	-	O
60	dimethyl	B
61	-	I
62	2	I
63	-	I
64	oxazolyl	O
65	)-	O
66	sulfanilamide	O
67	)	O
68	(	O
69	sulfamoxole	O
70	)	O
71	and	O
72	2	O
73	,	O
74	4	O
75	-	O
76	diamino	O
77	-	O
78	5	O
79	-(	O
80	3	O
81	,	O
82	4	O
83	,	O
84	5	O
85	-	O
86	trimethoxy	O
87	-	O
88	benzyl	O
89	)-	O
90	pyrimidine	O
91	(	O
92	trimethoprim	O
93	)	O
94	at	O
95	a	O
96	ratio	O
97	of	O
98	5	O
99	:	O
100	1	O
101	(	O
102	CN	O
103	3123	O
104	;	O
105	Nevin	O
106	,	O
107	Supristol	O
108	)	O
109	are	O
110	compared	O
111	to	O
112	those	O
113	of	O
114	tests	O
115	with	O
116	TMP	O
117	/	O
118	SMZ	O
119	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	O
9	and	O
10	pelB	O
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	B
17	-	I
18	glucuronidase	I
19	gene	I
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	B
34	-	I
35	glucuronidase	I
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O

1	Mature	B
2	mRNA	I
3	for	O
4	cytosolic	O
5	phosphoenolpyruvate	B
6	carboxykinase	I
7	of	O
8	the	O
9	chicken	O
10	is	O
11	2	O
12	.	O
13	8	O
14	kilobases	O
15	in	O
16	length	O
17	,	O
18	similar	O
19	to	O
20	that	O
21	previously	O
22	noted	O
23	for	O
24	mRNA	O
25	coding	O
26	for	O
27	the	O
28	same	O
29	enzyme	O
30	in	O
31	the	O
32	rat	O
33	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	findings	O
6	show	O
7	that	O
8	16K	O
9	hPRL	O
10	inhibits	O
11	the	O
12	VEGF	B
13	-	I
14	induced	O
15	Ras	B
16	activation	O
17	;	O
18	this	O
19	antagonism	O
20	represents	O
21	a	O
22	novel	O
23	and	O
24	potentially	O
25	important	O
26	mechanism	O
27	for	O
28	the	O
29	control	O
30	of	O
31	angiogenesis	O
32	.	O

1	The	O
2	similar	O
3	phenotypes	O
4	of	O
5	bur6	O
6	and	O
7	bur3	O
8	(	O
9	mot1	O
10	)	O
11	mutations	O
12	suggest	O
13	that	O
14	Bur6p	O
15	and	O
16	Mot1p	O
17	have	O
18	related	O
19	,	O
20	but	O
21	not	O
22	identical	O
23	,	O
24	functions	O
25	in	O
26	modulating	O
27	the	O
28	activity	O
29	of	O
30	the	O
31	general	O
32	transcription	O
33	machinery	O
34	in	O
35	vivo	O
36	.	O

1	The	O
2	results	O
3	strengthen	O
4	the	O
5	conclusion	O
6	that	O
7	predominantly	O
8	dynamic	O
9	activity	O
10	increases	O
11	the	O
12	G4	O
13	content	O
14	of	O
15	mature	O
16	innervated	O
17	fast	O
18	muscles	O
19	.	O

1	In	O
2	14	O
3	cases	O
4	,	O
5	isolates	O
6	were	O
7	biotyped	O
8	yielding	O
9	eight	O
10	with	O
11	biotype	O
12	II	O
13	,	O
14	four	O
15	with	O
16	biotype	O
17	III	O
18	,	O
19	and	O
20	one	O
21	each	O
22	with	O
23	biotypes	O
24	IV	O
25	and	O
26	V	O
27	.	O

1	Ten	O
2	males	O
3	performed	O
4	both	O
5	test	O
6	conditions	O
7	and	O
8	oxygen	O
9	uptake	O
10	VO2	O
11	,	O
12	heart	O
13	rate	O
14	,	O
15	minute	O
16	ventilation	O
17	VE	O
18	,	O
19	perceived	O
20	exertion	O
21	and	O
22	spinal	O
23	shrinkage	O
24	were	O
25	recorded	O
26	.	O

1	This	O
2	protein	O
3	-	O
4	protein	O
5	interaction	O
6	does	O
7	not	O
8	require	O
9	the	O
10	simultaneous	O
11	binding	O
12	of	O
13	Oct	B
14	proteins	I
15	to	O
16	DNA	O
17	,	O
18	and	O
19	high	O
20	resolution	O
21	footprinting	O
22	of	O
23	the	O
24	Oct	B
25	-	I
26	DNA	O
27	interaction	O
28	reveals	O
29	that	O
30	binding	O
31	of	O
32	BOB	O
33	.	O
34	1	O
35	/	O
36	OBF	O
37	.	O
38	1	O
39	to	O
40	Oct1	O
41	or	O
42	Oct2	O
43	does	O
44	not	O
45	alter	O
46	the	O
47	interaction	O
48	with	O
49	DNA	O
50	.	O

1	Rigid	O
2	point	O
3	feature	O
4	registration	O
5	using	O
6	mutual	O
7	information	O
8	.	O

1	An	O
2	endometrial	O
3	luteal	O
4	phase	O
5	deficiency	O
6	was	O
7	detected	O
8	in	O
9	15	O
10	(	O
11	30	O
12	%)	O
13	of	O
14	aborting	O
15	patients	O
16	.	O

1	The	O
2	injection	O
3	of	O
4	XDRP1	O
5	protein	O
6	into	O
7	fertilized	O
8	Xenopus	O
9	eggs	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O

1	Mitogen	O
2	-	O
3	induced	O
4	lymphocyte	O
5	proliferation	O
6	was	O
7	diminished	O
8	.	O

1	Radioligand	O
2	binding	O
3	was	O
4	indistinguishable	O
5	for	O
6	both	O
7	transiently	O
8	expressed	O
9	constructs	O
10	.	O

1	There	O
2	is	O
3	general	O
4	agreement	O
5	that	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	is	O
11	efficiently	O
12	transmitted	O
13	parenterally	O
14	,	O
15	while	O
16	data	O
17	on	O
18	viral	O
19	transmission	O
20	from	O
21	mothers	O
22	to	O
23	babies	O
24	or	O
25	by	O
26	sexual	O
27	or	O
28	non	O
29	-	O
30	sexual	O
31	household	O
32	contact	O
33	are	O
34	conflicting	O
35	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O

1	(	O
2	1992	O
3	)	O
4	Genomics	O
5	12	O
6	,	O
7	58	O
8	-	O
9	62	O
10	).	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	eosinophils	O
35	.	O

1	Our	O
2	results	O
3	showed	O
4	that	O
5	compared	O
6	to	O
7	the	O
8	primary	O
9	photon	O
10	fluence	O
11	,	O
12	the	O
13	extra	O
14	-	O
15	focal	O
16	photon	O
17	fluence	O
18	from	O
19	the	O
20	primary	O
21	collimator	O
22	and	O
23	the	O
24	flattening	O
25	filter	O
26	was	O
27	11	O
28	%-	O
29	16	O
30	%	O
31	at	O
32	the	O
33	isocenter	O
34	,	O
35	among	O
36	which	O
37	70	O
38	%	O
39	was	O
40	contributed	O
41	by	O
42	the	O
43	flattening	O
44	filter	O
45	.	O

1	Induction	O
2	of	O
3	Jurkat	O
4	leukemic	O
5	T	O
6	cells	O
7	with	O
8	phorbol	O
9	12	O
10	-	O
11	myristate	O
12	13	O
13	-	O
14	acetate	O
15	and	O
16	ionomycin	O
17	did	O
18	not	O
19	affect	O
20	the	O
21	level	O
22	of	O
23	FKBP	B
24	mRNA	I
25	.	I

1	Brain	O
2	scan	O
3	with	O
4	99mTc	O
5	-	O
6	labelled	O
7	macroaggregated	B
8	albumin	I
9	(	O
10	MAA	O
11	brain	O
12	scan	O
13	)	O
14	and	O
15	computed	O
16	tomography	O
17	studies	O
18	(	O
19	CT	O
20	)	O
21	were	O
22	performed	O
23	on	O
24	78	O
25	patients	O
26	with	O
27	intracranial	O
28	diseases	O
29	.	O

1	The	O
2	former	O
3	procedure	O
4	is	O
5	economical	O
6	but	O
7	complicated	O
8	,	O
9	whereas	O
10	the	O
11	latter	O
12	is	O
13	simple	O
14	and	O
15	labour	O
16	-	O
17	saving	O
18	,	O
19	but	O
20	a	O
21	special	O
22	ultrafiltration	O
23	tube	O
24	is	O
25	required	O
26	.	O

1	Arnt3	O
2	mRNA	O
3	was	O
4	expressed	O
5	in	O
6	brain	O
7	,	O
8	skeletal	O
9	muscle	O
10	,	O
11	13	O
12	.	O
13	5	O
14	-	O
15	day	O
16	embryos	O
17	,	O
18	and	O
19	P19	O
20	cells	O
21	treated	O
22	with	O
23	retinoic	O
24	acid	O
25	.	O

1	Estrogen	O
2	replacement	O
3	therapy	O
4	and	O
5	risk	O
6	of	O
7	breast	O
8	cancer	O
9	:	O
10	results	O
11	of	O
12	two	O
13	meta	O
14	-	O
15	analyses	O
16	.	O

1	Symptoms	O
2	,	O
3	however	O
4	,	O
5	appear	O
6	to	O
7	correlate	O
8	poorly	O
9	with	O
10	oesophagitis	O
11	;	O
12	hence	O
13	,	O
14	severe	O
15	symptoms	O
16	do	O
17	not	O
18	indicate	O
19	there	O
20	is	O
21	greater	O
22	oesophageal	O
23	damage	O
24	.	O

1	At	O
2	the	O
3	C	O
4	-	O
5	terminus	O
6	of	O
7	the	O
8	protein	O
9	is	O
10	a	O
11	domain	O
12	that	O
13	contains	O
14	sequences	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	the	O
22	breakpoint	B
23	cluster	I
24	region	I
25	gene	I
26	product	I
27	,	O
28	n	O
29	-	O
30	chimerin	O
31	,	O
32	and	O
33	rho	O
34	GAP	B
35	,	O
36	all	O
37	of	O
38	which	O
39	have	O
40	been	O
41	shown	O
42	to	O
43	possess	O
44	intrinsic	O
45	GAP	B
46	activity	O
47	on	O
48	small	B
49	GTPases	I
50	.	I

1	E1A	B
2	autoactivation	O
3	mediated	O
4	by	O
5	these	O
6	sites	O
7	was	O
8	about	O
9	twofold	O
10	compared	O
11	with	O
12	a	O
13	ninefold	O
14	activation	O
15	described	O
16	for	O
17	the	O
18	complete	O
19	E1A	B
20	promoter	I
21	.	I

1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	Langer	O
8	-	O
9	Giedion	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	endpoints	O
36	.	O

1	Measurements	O
2	were	O
3	compared	O
4	with	O
5	two	O
6	computerised	O
7	treatment	O
8	planning	O
9	systems	O
10	--	O
11	Theraplan	O
12	VO5B	O
13	and	O
14	ADAC	O
15	Pinnacle3	O
16	V4	O
17	.	O
18	0b	O
19	.	O

1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O

1	The	O
2	participants	O
3	were	O
4	homosexual	O
5	men	O
6	in	O
7	hepatitis	O
8	B	O
9	vaccine	O
10	trials	O
11	in	O
12	Amsterdam	O
13	(	O
14	n	O
15	=	O
16	74	O
17	),	O
18	New	O
19	York	O
20	City	O
21	(	O
22	n	O
23	=	O
24	120	O
25	),	O
26	and	O
27	San	O
28	Francisco	O
29	(	O
30	n	O
31	=	O
32	168	O
33	).	O

1	MDBP	O
2	from	O
3	HeLa	O
4	and	O
5	Raji	O
6	cells	O
7	formed	O
8	DNA	O
9	-	O
10	protein	O
11	complexes	O
12	with	O
13	X	O
14	-	O
15	box	O
16	oligonucleotides	O
17	that	O
18	coelectrophoresed	O
19	with	O
20	those	O
21	containing	O
22	standard	O
23	MDBP	O
24	sites	O
25	.	O

1	The	O
2	RS447	O
3	human	O
4	megasatellite	O
5	tandem	O
6	repetitive	O
7	sequence	O
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	40	O
2	,	O
3	000	O
4	).	O

1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O

1	ESS	O
2	type	O
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O

1	Administration	O
2	of	O
3	the	O
4	dopamine	O
5	agonist	O
6	bromocriptine	O
7	(	O
8	2	O
9	.	O
10	5	O
11	mg	O
12	three	O
13	times	O
14	a	O
15	day	O
16	for	O
17	4	O
18	days	O
19	)	O
20	suppressed	O
21	(	O
22	P	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	)	O
29	mean	O
30	24	O
31	-	O
32	h	O
33	plasma	O
34	18	O
35	-	O
36	OHB	O
37	levels	O
38	from	O
39	21	O
40	.	O
41	9	O
42	+/-	O
43	2	O
44	.	O
45	0	O
46	to	O
47	14	O
48	.	O
49	8	O
50	+/-	O
51	1	O
52	.	O
53	4	O
54	ng	O
55	/	O
56	dl	O
57	.	O

1	Variable	O
2	FHR	O
3	decelerations	O
4	or	O
5	bradycardias	O
6	were	O
7	encountered	O
8	on	O
9	95	O
10	nonstress	O
11	tests	O
12	(	O
13	18	O
14	.	O
15	8	O
16	%)	O
17	in	O
18	80	O
19	(	O
20	33	O
21	.	O
22	5	O
23	%)	O
24	postdate	O
25	patients	O
26	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	third	O
7	SH3	B
8	domain	I
9	binds	O
10	to	O
11	Sos	B
12	,	O
13	a	O
14	guanine	B
15	nucleotide	I
16	exchange	I
17	factor	I
18	for	O
19	Ras	B
20	and	I
21	Rac	I
22	,	O
23	both	O
24	in	O
25	vitro	O
26	and	O
27	in	O
28	vivo	O
29	.	O

1	In	O
2	a	O
3	longitudinal	O
4	study	O
5	,	O
6	14	O
7	low	O
8	-	O
9	risk	O
10	fetuses	O
11	were	O
12	studied	O
13	at	O
14	2	O
15	-	O
16	week	O
17	intervals	O
18	from	O
19	32	O
20	weeks	O
21	of	O
22	gestation	O
23	onward	O
24	.	O

1	This	O
2	short	O
3	communication	O
4	compares	O
5	a	O
6	novel	O
7	fluorimetric	O
8	microplate	O
9	enzyme	O
10	immunoassay	O
11	(	O
12	FEIA	O
13	)	O
14	with	O
15	a	O
16	commercial	O
17	time	O
18	-	O
19	resolved	O
20	fluoroimmunoassay	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	thyrotropin	B
26	in	O
27	dried	O
28	blood	O
29	spots	O
30	.	O

1	A	O
2	7	O
3	-	O
4	day	O
5	treatment	O
6	of	O
7	amphotericin	O
8	B	O
9	(	O
10	5	O
11	mg	O
12	/	O
13	kg	O
14	/	O
15	day	O
16	i	O
17	.	O
18	p	O
19	.)	O
20	significantly	O
21	reduced	O
22	the	O
23	glomerular	O
24	filtration	O
25	rate	O
26	(	O
27	GFR	O
28	)	O
29	measured	O
30	as	O
31	inuline	O
32	clearance	O
33	and	O
34	creatinine	O
35	clearance	O
36	(	O
37	0	O
38	.	O
39	74	O
40	+/-	O
41	0	O
42	.	O
43	29	O
44	and	O
45	0	O
46	.	O
47	16	O
48	+/-	O
49	0	O
50	.	O
51	04	O
52	ml	O
53	/	O
54	min	O
55	,	O
56	respectively	O
57	)	O
58	in	O
59	comparison	O
60	to	O
61	vehicle	O
62	-	O
63	treated	O
64	rats	O
65	(	O
66	2	O
67	.	O
68	04	O
69	+/-	O
70	0	O
71	.	O
72	23	O
73	and	O
74	1	O
75	.	O
76	29	O
77	+/-	O
78	0	O
79	.	O
80	19	O
81	ml	O
82	/	O
83	min	O
84	,	O
85	respectively	O
86	).	O

1	The	O
2	ratio	O
3	of	O
4	radioactivity	O
5	in	O
6	tumour	O
7	compared	O
8	with	O
9	normal	O
10	tissue	O
11	(	O
12	T	O
13	:	O
14	N	O
15	ratio	O
16	)	O
17	was	O
18	determined	O
19	after	O
20	simultaneously	O
21	injecting	O
22	microspheres	O
23	into	O
24	the	O
25	portal	O
26	and	O
27	arterial	O
28	circulation	O
29	of	O
30	each	O
31	animal	O
32	.	O

1	In	O
2	contrast	O
3	,	O
4	when	O
5	the	O
6	isoform	O
7	containing	O
8	the	O
9	C	O
10	epsilon4	O
11	domain	O
12	joined	O
13	directly	O
14	to	O
15	the	O
16	M2	O
17	exon	O
18	(	O
19	IgE	B
20	grande	O
21	)	O
22	is	O
23	expressed	O
24	in	O
25	the	O
26	J558L	O
27	cell	O
28	line	O
29	,	O
30	it	O
31	is	O
32	degraded	O
33	intracellularly	O
34	,	O
35	suggesting	O
36	a	O
37	cell	O
38	line	O
39	-	O
40	dependent	O
41	regulation	O
42	of	O
43	secretion	O
44	.	O

1	Enhancement	O
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	aspecific	O
8	action	O
9	of	O
10	vaccine	O
11	additives	O
12	in	O
13	the	O
14	aerogenic	O
15	immunization	O
16	of	O
17	swine	O
18	against	O
19	swine	O
20	plague	B

1	However	O
2	,	O
3	five	O
4	new	O
5	mutation	O
6	sites	O
7	(	O
8	S61	O
9	,	O
10	SL1	B
11	,	O
12	S29	O
13	,	O
14	SL11	O
15	,	O
16	SL196	O
17	and	O
18	SL126	O
19	)	O
20	are	O
21	unique	O
22	to	O
23	the	O
24	nrdB	O
25	intron	O
26	and	O
27	disrupt	O
28	self	O
29	-	O
30	splicing	O
31	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	CBP90	O
8	had	O
9	no	O
10	significant	O
11	similarity	O
12	to	O
13	any	O
14	other	O
15	protein	O
16	,	O
17	but	O
18	it	O
19	had	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	domain	O
25	at	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	region	O
31	.	O

1	33	O
2	out	O
3	of	O
4	90	O
5	neurons	O
6	of	O
7	the	O
8	cat	O
9	medial	O
10	geniculate	O
11	body	O
12	revealed	O
13	the	O
14	selectivity	O
15	of	O
16	their	O
17	afterdischarges	O
18	to	O
19	movement	O
20	of	O
21	sound	O
22	when	O
23	velocity	O
24	of	O
25	the	O
26	movement	O
27	changed	O
28	from	O
29	30	O
30	to	O
31	180	O
32	deg	O
33	/	O
34	s	O
35	.	O

1	After	O
2	screening	O
3	the	O
4	Berkeley	O
5	Drosophila	O
6	Genome	O
7	Project	O
8	database	O
9	with	O
10	sequences	O
11	from	O
12	a	O
13	recently	O
14	characterized	O
15	Leu	O
16	-	O
17	rich	O
18	repeats	O
19	-	O
20	containing	O
21	G	B
22	protein	I
23	-	I
24	coupled	I
25	receptor	I
26	(	O
27	LGR	O
28	)	O
29	from	O
30	Drosophila	O
31	(	O
32	DLGR	O
33	-	O
34	1	O
35	),	O
36	we	O
37	identified	O
38	a	O
39	second	O
40	gene	O
41	for	O
42	a	O
43	different	O
44	LGR	O
45	(	O
46	DLGR	O
47	-	O
48	2	O
49	)	O
50	and	O
51	cloned	O
52	its	O
53	cDNA	O
54	.	O

1	Since	O
2	the	O
3	5	O
4	'-	O
5	flanking	O
6	region	O
7	of	O
8	this	O
9	gene	O
10	is	O
11	likely	O
12	involved	O
13	in	O
14	hormonal	O
15	regulation	O
16	of	O
17	its	O
18	expression	O
19	,	O
20	we	O
21	have	O
22	isolated	O
23	and	O
24	partially	O
25	characterized	O
26	an	O
27	avian	B
28	fatty	I
29	acid	I
30	synthase	I
31	gene	I
32	.	I

1	When	O
2	expressed	O
3	alone	O
4	in	O
5	test	O
6	cells	O
7	,	O
8	Atr	B
9	-	I
10	I	I
11	is	O
12	unable	O
13	to	O
14	bind	O
15	TGF	B
16	-	I
17	beta	I
18	,	O
19	activin	B
20	,	O
21	or	O
22	bone	O
23	morphogenetic	B
24	protein	I
25	2	I
26	.	I

1	We	O
2	have	O
3	determined	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	WNT	B
9	-	I
10	2B	I
11	gene	I
12	.	I

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	B
6	alpha	I
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	The	O
2	second	O
3	functional	O
4	pair	O
5	of	O
6	CreA	O
7	sites	O
8	is	O
9	located	O
10	between	O
11	the	O
12	two	O
13	transcription	O
14	initiation	O
15	sites	O
16	.	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	O
6	cDNA	O
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	Vibrio	I
2	cholerae	I
3	O139	O
4	in	O
5	Calcutta	O
6	.	O

1	The	O
2	infected	O
3	cell	O
4	protein	O
5	no	O
6	.	O
7	0	O
8	(	O
9	ICP0	O
10	)	O
11	of	O
12	herpes	B
13	simplex	I
14	virus	I
15	1	I
16	is	O
17	a	O
18	promiscuous	O
19	transactivator	O
20	shown	O
21	to	O
22	enhance	O
23	the	O
24	expression	O
25	of	O
26	genes	O
27	introducted	O
28	into	O
29	cells	O
30	by	O
31	infection	O
32	or	O
33	transfection	O
34	.	O

1	The	O
2	optimum	O
3	technique	O
4	for	O
5	the	O
6	pathological	O
7	examination	O
8	of	O
9	sentinel	O
10	lymph	O
11	nodes	O
12	(	O
13	SLNs	O
14	)	O
15	is	O
16	still	O
17	under	O
18	debate	O
19	.	O

1	Wherever	O
2	the	O
3	site	O
4	of	O
5	the	O
6	conditioning	O
7	stimulation	O
8	,	O
9	these	O
10	modifications	O
11	disappeared	O
12	after	O
13	ischaemia	O
14	of	O
15	the	O
16	leg	O
17	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	was	O
7	highly	O
8	conserved	O
9	across	O
10	the	O
11	wide	O
12	range	O
13	of	O
14	eukaryotes	O
15	(	O
16	vertebrates	O
17	,	O
18	invertebrates	O
19	,	O
20	fungi	O
21	,	O
22	plants	O
23	and	O
24	protozoa	O
25	)	O
26	in	O
27	which	O
28	this	O
29	gene	O
30	has	O
31	now	O
32	been	O
33	identified	O
34	.	O

1	In	O
2	epithelial	O
3	cells	O
4	,	O
5	the	O
6	PH	B
7	domain	I
8	of	O
9	Akt	B
10	/	I
11	PKB	I
12	localised	I
13	to	O
14	sites	O
15	of	O
16	cell	O
17	-	O
18	cell	O
19	and	O
20	cell	O
21	-	O
22	matrix	O
23	contact	O
24	,	O
25	distinct	O
26	from	O
27	focal	O
28	contacts	O
29	,	O
30	even	O
31	in	O
32	the	O
33	absence	O
34	of	O
35	serum	O
36	.	O

1	Antileukoproteinase	O
2	(	O
3	ALP	O
4	)	O
5	is	O
6	a	O
7	low	O
8	mol	O
9	wt	B
10	mucosal	I
11	secretory	I
12	protein	I
13	which	O
14	,	O
15	in	O
16	human	O
17	tissues	O
18	,	O
19	inhibits	O
20	the	O
21	activities	O
22	of	O
23	the	O
24	neutral	O
25	serine	O
26	lysosomal	B
27	proteinases	I
28	elastase	I
29	and	I
30	cathepsin	I
31	-	I
32	G	I
33	.	I

1	B	I
2	cell	I
3	-	I
4	specific	I
5	mb	I
6	-	I
7	1	I
8	and	O
9	B29	O
10	genes	O
11	encode	O
12	the	O
13	alpha	B
14	/	I
15	beta	I
16	components	O
17	of	O
18	the	O
19	BCR	B
20	-	I
21	associated	I
22	complex	I
23	in	O
24	mature	O
25	sIgM	O
26	+	O
27	B	O
28	cells	O
29	.	O

1	In	O
2	all	O
3	trials	O
4	,	O
5	antigen	O
6	challenge	O
7	followed	O
8	1	O
9	h	O
10	after	O
11	the	O
12	last	O
13	treatment	O
14	.	O

1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	B
18	tyrosine	I
19	phosphatase	I
20	1	I
21	gene	I
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O

1	Measurements	O
2	of	O
3	activity	O
4	with	O
5	the	O
6	radioprotective	B
7	chamber	I
8	VA	I
9	-	I
10	K	I
11	-	I
12	254	I
13	of	O
14	the	O
15	osimeter	B
16	VA	I
17	-	I
18	J18	I

1	All	O
2	subjects	O
3	were	O
4	submitted	O
5	to	O
6	ECG	O
7	and	O
8	arterial	O
9	blood	O
10	pressure	O
11	determination	O
12	and	O
13	were	O
14	assayed	O
15	for	O
16	TSH	B
17	,	O
18	thyroid	O
19	hormone	O
20	,	O
21	PRL	B
22	,	O
23	glucose	O
24	,	O
25	creatinine	O
26	,	O
27	nitrogen	O
28	,	O
29	glutamine	O
30	transaminase	O
31	,	O
32	cholesterol	O
33	and	O
34	triglycerides	O
35	plasma	O
36	levels	O
37	before	O
38	therapy	O
39	(	O
40	T0	O
41	),	O
42	after	O
43	30	O
44	treatment	O
45	days	O
46	(	O
47	T30	O
48	)	O
49	and	O
50	after	O
51	a	O
52	15	O
53	days	O
54	washout	O
55	(	O
56	T45	O
57	).	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	LvUSF2	O
8	is	O
9	nearly	O
10	identical	O
11	to	O
12	LvUSF1	O
13	except	O
14	at	O
15	the	O
16	amino	O
17	end	O
18	,	O
19	where	O
20	they	O
21	are	O
22	sharply	O
23	divergent	O
24	.	O

1	The	O
2	rhaB	O
3	transcription	O
4	start	O
5	site	O
6	was	O
7	mapped	O
8	to	O
9	-	O
10	24	O
11	relative	O
12	to	O
13	the	O
14	start	O
15	of	O
16	translation	O
17	.	O

1	One	O
2	hundred	O
3	replicate	O
4	data	O
5	sets	O
6	of	O
7	100	O
8	subjects	O
9	each	O
10	were	O
11	simulated	O
12	for	O
13	each	O
14	missing	O
15	data	O
16	scenario	O
17	.	O

1	The	O
2	large	O
3	subfamily	O
4	of	O
5	receptor	B
6	tyrosine	I
7	kinases	I
8	(	O
9	RTKs	O
10	)	O
11	for	O
12	which	O
13	EPH	O
14	is	O
15	the	O
16	prototype	O
17	have	O
18	likely	O
19	roles	O
20	in	O
21	intercellular	O
22	communication	O
23	during	O
24	normal	O
25	mammalian	O
26	development	O
27	,	O
28	but	O
29	the	O
30	biochemical	O
31	signalling	O
32	pathways	O
33	utilised	O
34	by	O
35	this	O
36	family	O
37	are	O
38	poorly	O
39	characterised	O
40	.	O

1	Two	O
2	protease	O
3	-	O
4	resistant	O
5	fragments	O
6	spanning	O
7	the	O
8	N	O
9	-	O
10	and	O
11	C	O
12	-	O
13	terminal	O
14	halves	O
15	of	O
16	the	O
17	nuclease	O
18	were	O
19	identified	O
20	using	O
21	different	O
22	proteases	O
23	which	O
24	cleave	O
25	the	O
26	protein	O
27	in	O
28	the	O
29	same	O
30	region	O
31	.	O

1	C	O
2	.	O
3	elegans	O
4	KLP	O
5	-	O
6	11	O
7	/	O
8	OSM	B
9	-	I
10	3	I
11	/	I
12	KAP	I
13	-	I
14	1	I
15	:	O
16	orthologs	O
17	of	O
18	the	O
19	sea	O
20	urchin	O
21	kinesin	B
22	-	I
23	II	I
24	,	O
25	and	O
26	mouse	O
27	KIF3A	O
28	/	O
29	KIFB	O
30	/	O
31	KAP3	O
32	kinesin	O
33	complexes	O
34	.	O

1	Conversely	O
2	,	O
3	E1A	B
4	binding	I
5	to	O
6	only	O
7	p300	B
8	/	I
9	CBP	I
10	results	O
11	in	O
12	an	O
13	increase	O
14	in	O
15	PARP	O
16	enzyme	O
17	activity	O
18	and	O
19	consequently	O
20	in	O
21	cell	O
22	death	O
23	susceptibility	O
24	to	O
25	irradiation	O
26	,	O
27	which	O
28	is	O
29	effectively	O
30	counteracted	O
31	by	O
32	the	O
33	PARP	O
34	chemical	O
35	inhibitor	O
36	3	O
37	-	O
38	aminobenzamide	O
39	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	Sp1	B
8	and	O
9	Sp3	B
10	as	O
11	major	O
12	factors	O
13	binding	O
14	to	O
15	the	O
16	Sp1	B
17	sites	I
18	of	O
19	the	O
20	p21	B
21	/	I
22	WAF1	I
23	/	I
24	Cip1	I
25	promoter	I
26	in	O
27	MG63	O
28	cells	O
29	through	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assays	O
34	and	O
35	showed	O
36	that	O
37	TSA	O
38	treatment	O
39	did	O
40	not	O
41	change	O
42	their	O
43	binding	O
44	activities	O
45	.	O

1	Thus	O
2	,	O
3	patients	O
4	with	O
5	metastatic	O
6	melanoma	O
7	are	O
8	not	O
9	tolerant	O
10	to	O
11	gp100	O
12	Ag	O
13	based	O
14	on	O
15	the	O
16	detection	O
17	of	O
18	CD8	B
19	+	I
20	T	O
21	cells	O
22	specific	O
23	for	O
24	multiple	O
25	HLA	B
26	-	I
27	A	I
28	*	I
29	0201	I
30	-	I
31	restricted	O
32	,	O
33	gp100	B
34	-	I
35	derived	I
36	epitopes	I
37	.	I

1	PURPOSE	O
2	:	O
3	A	O
4	two	O
5	-	O
6	generation	O
7	consanguineous	O
8	Pakistani	O
9	family	O
10	with	O
11	autosomal	O
12	recessive	O
13	Leber	O
14	congenital	O
15	amaurosis	O
16	(	O
17	LCA	O
18	,	O
19	MIM	O
20	204	O
21	,	O
22	000	O
23	)	O
24	and	O
25	keratoconus	O
26	was	O
27	identified	O
28	.	O

1	Production	O
2	costs	O
3	included	O
4	feed	O
5	,	O
6	non	O
7	-	O
8	feed	O
9	operating	O
10	,	O
11	fixed	O
12	,	O
13	and	O
14	replacement	O
15	stock	O
16	costs	O
17	.	O

1	The	O
2	nucleolin	B
3	gene	I
4	extends	O
5	over	O
6	9000	O
7	base	O
8	-	O
9	pairs	O
10	and	O
11	is	O
12	split	O
13	into	O
14	14	O
15	exons	O
16	that	O
17	encode	O
18	the	O
19	706	O
20	amino	O
21	acid	O
22	residues	O
23	of	O
24	the	O
25	protein	O
26	.	O

1	These	O
2	data	O
3	locate	O
4	the	O
5	aniridia	O
6	gene	O
7	(	O
8	AN2	O
9	)	O
10	and	O
11	a	O
12	recurrent	O
13	T	O
14	-	O
15	cell	O
16	leukemia	O
17	breakpoint	O
18	(	O
19	TCL2	O
20	)	O
21	in	O
22	the	O
23	marker	O
24	sequence	O
25	,	O
26	on	O
27	opposite	O
28	sides	O
29	of	O
30	MIC1	O
31	.	O

1	These	O
2	features	O
3	were	O
4	considered	O
5	consistent	O
6	with	O
7	a	O
8	diagnosis	O
9	of	O
10	Rothmund	O
11	-	O
12	Thomson	O
13	syndrome	O
14	.	O

1	Reaction	O
2	time	O
3	(	O
4	RT	O
5	)	O
6	and	O
7	P300	O
8	were	O
9	collected	O
10	simultaneously	O
11	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	100	O
6	-	O
7	bp	O
8	Col2a1	O
9	enhancer	O
10	revealed	O
11	several	O
12	sequence	O
13	motifs	O
14	similar	O
15	to	O
16	motifs	O
17	present	O
18	within	O
19	the	O
20	regulatory	O
21	region	O
22	of	O
23	the	O
24	link	B
25	protein	I
26	gene	I
27	,	O
28	another	O
29	cartilage	O
30	gene	O
31	.	O

1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	ischaemia	O
7	and	O
8	non	O
9	-	O
10	ischaemia	O
11	groups	O
12	on	O
13	the	O
14	basis	O
15	of	O
16	the	O
17	change	O
18	in	O
19	lactate	O
20	extraction	O
21	ratio	O
22	during	O
23	balloon	O
24	inflation	O
25	.	O

1	By	O
2	far	O
3	-	O
4	Western	O
5	analysis	O
6	and	O
7	coimmunoprecipitation	O
8	studies	O
9	,	O
10	we	O
11	demonstrate	O
12	that	O
13	ZNF74	O
14	interacts	O
15	,	O
16	via	O
17	its	O
18	zinc	O
19	finger	O
20	domain	O
21	,	O
22	with	O
23	the	O
24	hyperphosphorylated	O
25	largest	O
26	subunit	O
27	of	O
28	RNA	B
29	polymerase	I
30	II	I
31	(	I
32	pol	I
33	IIo	O
34	)	O
35	but	O
36	not	O
37	with	O
38	the	O
39	hypophosphorylated	O
40	form	O
41	.	O

1	A	O
2	second	O
3	domain	O
4	,	O
5	located	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	437	O
12	amino	O
13	acids	O
14	of	O
15	IE1	B
16	,	O
17	is	O
18	required	O
19	for	O
20	inhibitory	O
21	and	O
22	DNA	O
23	-	O
24	binding	O
25	activities	O
26	.	O

1	Studies	O
2	on	O
3	the	O
4	intracutaneous	O
5	infection	O
6	of	O
7	rabbits	O
8	by	O
9	Staphylococcus	O
10	aureus	O
11	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	-	O
6	negative	O
7	mutant	O
8	of	O
9	JNK1	O
10	also	O
11	suppressed	O
12	glucose	O
13	deprivation	O
14	-	O
15	induced	O
16	JNK1	O
17	activation	O
18	as	O
19	well	O
20	as	O
21	HSP70	B
22	gene	I
23	expression	O
24	.	O

1	Future	O
2	analysis	O
3	of	O
4	long	O
5	-	O
6	term	O
7	outcome	O
8	measures	O
9	of	O
10	performance	O
11	with	O
12	the	O
13	implant	O
14	will	O
15	confirm	O
16	or	O
17	dispute	O
18	the	O
19	benefit	O
20	of	O
21	ear	O
22	selection	O
23	using	O
24	the	O
25	Prom	O
26	-	O
27	EABR	O
28	.	O

1	A	O
2	recently	O
3	reported	O
4	new	O
5	member	O
6	of	O
7	the	O
8	Vav	B
9	family	I
10	proteins	I
11	,	O
12	Vav3	O
13	has	O
14	been	O
15	identified	O
16	as	O
17	a	O
18	Ros	B
19	receptor	I
20	protein	I
21	tyrosine	I
22	kinase	I
23	(	O
24	RPTK	O
25	)	O
26	interacting	O
27	protein	O
28	by	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	screening	O
34	.	O

1	The	O
2	statistical	O
3	analysis	O
4	consist	O
5	of	O
6	the	O
7	F	O
8	test	O
9	followed	O
10	by	O
11	Snedecor	O
12	'	O
13	s	O
14	contrast	O
15	test	O
16	.	O

1	Protein	O
2	electrophoresis	O
3	showed	O
4	decreased	O
5	albumin	B
6	levels	O
7	in	O
8	both	O
9	groups	O
10	,	O
11	with	O
12	lower	O
13	values	O
14	in	O
15	G2	O
16	.	O

1	But	O
2	,	O
3	as	O
4	Theriault	O
5	explains	O
6	,	O
7	improvements	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O

1	An	O
2	experiment	O
3	was	O
4	carried	O
5	on	O
6	133	O
7	grown	O
8	up	O
9	fowls	O
10	and	O
11	broilers	O
12	from	O
13	4	O
14	industrial	O
15	farms	O
16	,	O
17	vaccinated	O
18	with	O
19	spray	O
20	lento	O
21	and	O
22	mesogenic	O
23	vaccines	O
24	for	O
25	straining	O
26	the	O
27	immunity	O
28	against	O
29	pseodopest	O
30	through	O
31	RIHA	O
32	and	O
33	provoking	O
34	pseudoplague	O
35	with	O
36	a	O
37	pathogenic	O
38	virus	O
39	.	O

1	Whole	O
2	blood	O
3	serotonin	O
4	levels	O
5	were	O
6	investigated	O
7	in	O
8	a	O
9	control	O
10	group	O
11	(	O
12	n	O
13	=	O
14	35	O
15	)	O
16	and	O
17	in	O
18	a	O
19	group	O
20	of	O
21	chronic	O
22	renal	O
23	failure	O
24	patients	O
25	(	O
26	n	O
27	=	O
28	127	O
29	)	O
30	on	O
31	various	O
32	treatment	O
33	regimen	O
34	i	O
35	.	O
36	e	O
37	.	O
38	conservative	O
39	treatment	O
40	(	O
41	n	O
42	=	O
43	39	O
44	),	O
45	maintenance	O
46	haemodialysis	O
47	(	O
48	n	O
49	=	O
50	35	O
51	)	O
52	and	O
53	after	O
54	renal	O
55	transplantation	O
56	(	O
57	n	O
58	=	O
59	53	O
60	).	O

1	These	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	majority	O
8	of	O
9	tested	O
10	staphylococci	O
11	were	O
12	resistant	O
13	to	O
14	penicillin	O
15	G	O
16	,	O
17	erythromycin	O
18	,	O
19	and	O
20	produced	O
21	beta	B
22	-	I
23	lactamase	I
24	.	I

1	Each	O
2	group	O
3	received	O
4	15	O
5	ml	O
6	/	O
7	kg	O
8	of	O
9	either	O
10	6	O
11	%	O
12	pentafraction	O
13	,	O
14	6	O
15	%	O
16	pentastarch	O
17	,	O
18	or	O
19	plasma	O
20	followed	O
21	two	O
22	hours	O
23	later	O
24	by	O
25	1	O
26	.	O
27	5	O
28	micrograms	O
29	/	O
30	kg	O
31	/	O
32	0	O
33	.	O
34	5	O
35	hr	O
36	E	O
37	.	O

1	Sustained	O
2	ventricular	O
3	tachycardia	O
4	and	O
5	its	O
6	successful	O
7	prophylaxis	O
8	during	O
9	high	O
10	-	O
11	dose	O
12	bolus	O
13	interleukin	B
14	-	I
15	2	I
16	therapy	O
17	for	O
18	metastatic	O
19	renal	O
20	cell	O
21	carcinoma	O
22	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	analyze	O
9	the	O
10	temporal	O
11	characteristics	O
12	and	O
13	the	O
14	spatial	O
15	mapping	O
16	of	O
17	the	O
18	independent	O
19	components	O
20	identified	O
21	by	O
22	ICA	O
23	when	O
24	the	O
25	subject	O
26	performs	O
27	a	O
28	finger	O
29	-	O
30	tapping	O
31	task	O
32	.	O

1	Campomelic	O
2	dysplasia	O
3	translocation	O
4	breakpoints	O
5	are	O
6	scattered	O
7	over	O
8	1	O
9	Mb	O
10	proximal	O
11	to	O
12	SOX9	O
13	:	O
14	evidence	O
15	for	O
16	an	O
17	extended	O
18	control	O
19	region	O
20	.	O

1	The	O
2	algorithm	O
3	also	O
4	limited	O
5	TG	O
6	to	O
7	20	O
8	and	O
9	64	O
10	%,	O
11	apoB	O
12	to	O
13	6	O
14	and	O
15	20	O
16	%,	O
17	and	O
18	Lp	O
19	(	O
20	a	O
21	)	O
22	to	O
23	15	O
24	and	O
25	56	O
26	%,	O
27	of	O
28	low	O
29	-	O
30	and	O
31	high	O
32	-	O
33	risk	O
34	groups	O
35	,	O
36	respectively	O
37	.	O

1	MS	O
2	characteristics	O
3	of	O
4	coumarins	O
5	,	O
6	psoralens	O
7	and	O
8	polymethoxylated	O
9	flavones	O
10	with	O
11	different	O
12	substitution	O
13	patterns	O
14	were	O
15	determined	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	the	O
21	response	O
22	obtained	O
23	with	O
24	the	O
25	APcI	O
26	interface	O
27	.	O

1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	identified	O
6	encoding	O
7	a	O
8	second	O
9	GHS	B
10	-	I
11	R	I
12	-	I
13	related	I
14	gene	I
15	(	O
16	GPR39	O
17	).	O

1	Two	O
2	mammalian	O
3	enzymes	O
4	,	O
5	the	O
6	haem	O
7	-	O
8	controlled	O
9	repressor	O
10	(	O
11	HCR	O
12	)	O
13	and	O
14	the	O
15	double	O
16	-	O
17	stranded	O
18	RNA	O
19	-	O
20	activated	O
21	inhibitor	O
22	(	O
23	dsI	O
24	),	O
25	phosphorylate	O
26	Ser	O
27	-	O
28	51	O
29	of	O
30	the	O
31	alpha	O
32	subunit	O
33	,	O
34	thereby	O
35	inhibiting	O
36	the	O
37	exchange	O
38	of	O
39	bound	O
40	nucleotides	O
41	on	O
42	,	O
43	and	O
44	thus	O
45	the	O
46	recycling	O
47	of	O
48	,	O
49	eIF	B
50	-	I
51	2	I
52	.	I

1	Modulation	O
2	of	O
3	human	B
4	heat	I
5	shock	I
6	factor	I
7	trimerization	O
8	by	O
9	the	O
10	linker	O
11	domain	O
12	.	O

1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O

1	Management	O
2	of	O
3	hypertension	O
4	in	O
5	the	O
6	elderly	O
7	.	O

1	In	O
2	transient	O
3	cotransfections	O
4	E1A	B
5	could	O
6	induce	O
7	the	O
8	activity	O
9	of	O
10	the	O
11	p53	B
12	promoter	I
13	to	O
14	a	O
15	high	O
16	level	O
17	;	O
18	12S	B
19	E1A	I
20	was	O
21	threefold	O
22	as	O
23	efficient	O
24	as	O
25	13S	O
26	E1A	B
27	in	O
28	this	O
29	activity	O
30	,	O
31	and	O
32	YY1	B
33	bound	O
34	to	O
35	the	O
36	composite	O
37	element	O
38	was	O
39	shown	O
40	to	O
41	mediate	O
42	55	O
43	%	O
44	of	O
45	this	O
46	induction	O
47	.	O

1	In	O
2	group	O
3	I	O
4	,	O
5	Paw	O
6	,	O
7	delta	O
8	V	O
9	,	O
10	PaO2	O
11	,	O
12	Vinj	O
13	and	O
14	VT	O
15	significantly	O
16	decreased	O
17	whereas	O
18	operating	O
19	pressure	O
20	and	O
21	E	O
22	significantly	O
23	increased	O
24	when	O
25	the	O
26	internal	O
27	diameter	O
28	of	O
29	the	O
30	injector	O
31	cannula	O
32	was	O
33	reduced	O
34	.	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	O
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O

1	There	O
2	was	O
3	a	O
4	2	O
5	.	O
6	4	O
7	-	O
8	fold	O
9	difference	O
10	in	O
11	CAT	B
12	produced	O
13	from	O
14	these	O
15	transcripts	O
16	in	O
17	HeLa	O
18	cells	O
19	,	O
20	which	O
21	contain	O
22	a	O
23	greater	O
24	natural	O
25	abundance	O
26	of	O
27	PTB	O
28	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	MYC	B
6	-	I
7	related	I
8	DNA	I
9	binding	I
10	protein	I
11	was	O
12	isolated	O
13	by	O
14	DNA	O
15	-	O
16	ligand	O
17	binding	O
18	screening	O
19	,	O
20	using	O
21	the	O
22	67	O
23	-	O
24	bp	O
25	region	O
26	as	O
27	a	O
28	probe	O
29	,	O
30	and	O
31	designated	O
32	rd22BP1	O
33	.	O

1	Harel	O
2	,	O
3	E	O
4	.	O
5	M	O
6	.	O

1	Replacement	O
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	O
8	(	O
9	His128Asn	O
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O

1	We	O
2	use	O
3	the	O
4	term	O
5	corticosteroid	O
6	-	O
7	dependent	O
8	IA	O
9	to	O
10	refer	O
11	to	O
12	the	O
13	serious	O
14	problem	O
15	of	O
16	chronic	O
17	IA	O
18	requiring	O
19	maintenance	O
20	prednisone	O
21	therapy	O
22	.	O

1	In	O
2	the	O
3	whole	O
4	group	O
5	of	O
6	infected	O
7	children	O
8	,	O
9	an	O
10	age	O
11	-	O
12	specific	O
13	z	O
14	score	O
15	<	O
16	-	O
17	2	O
18	for	O
19	weight	O
20	and	O
21	for	O
22	FFM	O
23	was	O
24	significantly	O
25	associated	O
26	with	O
27	an	O
28	increased	O
29	risk	O
30	of	O
31	death	O
32	[	O
33	relative	O
34	risk	O
35	(	O
36	95	O
37	%	O
38	CI	O
39	)	O
40	=	O
41	11	O
42	.	O
43	4	O
44	(	O
45	3	O
46	.	O
47	1	O
48	,	O
49	41	O
50	.	O
51	0	O
52	)	O
53	and	O
54	5	O
55	.	O
56	1	O
57	(	O
58	1	O
59	.	O
60	5	O
61	,	O
62	18	O
63	.	O
64	2	O
65	),	O
66	respectively	O
67	];	O
68	when	O
69	only	O
70	children	O
71	with	O
72	more	O
73	severe	O
74	disease	O
75	were	O
76	considered	O
77	,	O
78	only	O
79	z	O
80	score	O
81	for	O
82	weight	O
83	was	O
84	significantly	O
85	associated	O
86	with	O
87	an	O
88	increased	O
89	risk	O
90	[	O
91	4	O
92	.	O
93	6	O
94	(	O
95	1	O
96	.	O
97	4	O
98	,	O
99	14	O
100	.	O
101	9	O
102	)].	B

1	The	O
2	Jem	O
3	peptide	O
4	sequence	O
5	shows	O
6	a	O
7	'	O
8	leucine	O
9	-	O
10	zipper	O
11	'	O
12	dimerisation	O
13	motif	O
14	with	O
15	limited	O
16	homology	O
17	to	O
18	Fos	B
19	/	I
20	Jun	I
21	and	O
22	ATF	B
23	/	I
24	CREB	I
25	proteins	I
26	and	O
27	several	O
28	putative	O
29	phosphorylation	O
30	sites	O
31	.	O

1	A	O
2	region	O
3	of	O
4	the	O
5	deduced	O
6	protein	O
7	shares	O
8	extensive	O
9	homology	O
10	with	O
11	a	O
12	catalytic	O
13	region	O
14	of	O
15	Raf	B
16	kinases	I
17	,	O
18	a	O
19	feature	O
20	shared	O
21	only	O
22	with	O
23	TFIIE	O
24	among	O
25	transcription	O
26	factors	O
27	.	O

1	The	O
2	data	O
3	provide	O
4	evidence	O
5	both	O
6	for	O
7	a	O
8	signal	O
9	transduction	O
10	pathway	O
11	independent	O
12	of	O
13	JNK	B
14	,	O
15	ERK	B
16	,	O
17	and	O
18	p38	B
19	MAP	I
20	kinase	I
21	to	O
22	be	O
23	involved	O
24	in	O
25	the	O
26	induction	O
27	of	O
28	rhoB	O
29	by	O
30	genotoxic	O
31	stress	O
32	,	O
33	and	O
34	furthermore	O
35	,	O
36	indicate	O
37	autoregulation	O
38	of	O
39	rhoB	O
40	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	and	O
6	craniofacial	O
7	dimensions	O
8	following	O
9	administration	O
10	of	O
11	the	O
12	antineoplastic	O
13	agent	O
14	vincristine	O
15	to	O
16	young	O
17	rats	O
18	.	O

1	The	O
2	size	O
3	of	O
4	the	O
5	group	O
6	allocated	O
7	to	O
8	the	O
9	good	O
10	compliance	O
11	category	O
12	by	O
13	the	O
14	use	O
15	of	O
16	the	O
17	digoxin	O
18	marker	O
19	was	O
20	equivalent	O
21	in	O
22	size	O
23	to	O
24	a	O
25	group	O
26	of	O
27	patients	O
28	who	O
29	had	O
30	returned	O
31	less	O
32	than	O
33	15	O
34	%	O
35	of	O
36	their	O
37	prescribed	O
38	dose	O
39	or	O
40	reported	O
41	a	O
42	deviation	O
43	of	O
44	less	O
45	than	O
46	6	O
47	%	O
48	from	O
49	their	O
50	prescription	O
51	.	O

1	We	O
2	have	O
3	found	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	GTPase	B
9	-	I
10	deficient	O
11	mutants	O
12	of	O
13	alpha	O
14	12	O
15	(	O
16	alpha	O
17	12Q229L	O
18	)	O
19	or	O
20	alpha	O
21	13	O
22	(	O
23	alpha	O
24	13Q226L	O
25	)	O
26	leads	O
27	to	O
28	robust	O
29	activation	O
30	of	O
31	the	O
32	Jun	B
33	kinase	I
34	/	I
35	stress	I
36	-	I
37	activated	I
38	protein	I
39	kinase	I
40	(	O
41	JNK	B
42	/	I
43	SAPK	I
44	)	O
45	pathway	O
46	.	O

1	Serotonin	B
2	receptors	I
3	in	O
4	suicide	O
5	victims	O
6	with	O
7	major	O
8	depression	O
9	.	O

1	A	O
2	series	O
3	of	O
4	amino	O
5	terminal	O
6	deletion	O
7	mutants	O
8	(	O
9	d10	O
10	,	O
11	d20	O
12	,	O
13	d27	O
14	,	O
15	d31	O
16	,	O
17	d40	O
18	,	O
19	d44	O
20	,	O
21	and	O
22	d73	O
23	)	O
24	were	O
25	compared	O
26	for	O
27	processing	O
28	,	O
29	cell	O
30	surface	O
31	expression	O
32	,	O
33	and	O
34	maintenance	O
35	of	O
36	their	O
37	biological	O
38	attributes	O
39	by	O
40	recombinant	O
41	expression	O
42	of	O
43	mutant	O
44	genes	O
45	using	O
46	a	O
47	plasmid	O
48	vector	O
49	(	O
50	pcDL	O
51	-	O
52	SR	B
53	alpha	I
54	-	I
55	296	I
56	)	O
57	in	O
58	CV	O
59	-	O
60	1	O
61	and	O
62	HeLa	O
63	cells	O
64	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	destrin	O
8	is	O
9	165	O
10	residues	O
11	long	O
12	and	O
13	is	O
14	very	O
15	similar	O
16	(	O
17	71	O
18	%	O
19	identical	O
20	)	O
21	to	O
22	that	O
23	of	O
24	cofilin	O
25	,	O
26	a	O
27	widely	O
28	distributed	O
29	,	O
30	pH	O
31	-	O
32	sensitive	O
33	actin	B
34	-	I
35	modulating	I
36	protein	I
37	.	I

1	Chronic	O
2	hypophosphatemia	O
3	is	O
4	the	O
5	most	O
6	common	O
7	type	O
8	of	O
9	"	O
10	resistant	O
11	"	O
12	rickets	O
13	.	O

1	Seven	O
2	patients	O
3	(	O
4	8	O
5	.	O
6	3	O
7	percent	O
8	)	O
9	had	O
10	latent	O
11	hypothyroidism	O
12	only	O
13	discovered	O
14	by	O
15	hormonal	O
16	determinations	O
17	.	O

1	Flavonoids	O
2	from	O
3	Brosimum	O
4	acutifolium	O
5	.	O

1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	An	O
2	extensive	O
3	inverted	O
4	repeat	O
5	is	O
6	present	O
7	3	O
8	'	O
9	of	O
10	rpeA	O
11	;	O
12	inverted	O
13	repeats	O
14	are	O
15	found	O
16	downstream	O
17	of	O
18	all	O
19	PE	O
20	operons	O
21	sequenced	O
22	to	O
23	date	O
24	,	O
25	although	O
26	the	O
27	sequence	O
28	is	O
29	not	O
30	conserved	O
31	.	O

1	The	O
2	malignity	O
3	of	O
4	nevoid	O
5	lentigo	O
6	.	O

1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	Whipple	O
8	-	O
9	specific	O
10	DNA	O
11	fragments	O
12	of	O
13	284	O
14	base	O
15	pairs	O
16	from	O
17	the	O
18	genome	O
19	of	O
20	the	O
21	Whipple	O
22	bacterium	O
23	(	O
24	Tropheryma	O
25	whippelii	O
26	)	O
27	were	O
28	demonstrated	O
29	.	O

1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O

1	For	O
2	HeLa	O
3	,	O
4	293	O
5	,	O
6	U937	O
7	,	O
8	and	O
9	A549	O
10	cells	O
11	,	O
12	participation	O
13	of	O
14	E2F	B
15	-	I
16	1	I
17	,	O
18	DP	B
19	-	I
20	1	I
21	,	O
22	cyclin	B
23	A	I
24	,	O
25	and	O
26	RB	O
27	was	O
28	involved	O
29	in	O
30	formation	O
31	of	O
32	some	O
33	complexes	O
34	only	O
35	,	O
36	assuming	O
37	participation	O
38	of	O
39	factors	O
40	different	O
41	from	O
42	E2F	B
43	-	I
44	1	I
45	or	O
46	DP	B
47	-	I
48	1	I
49	in	O
50	others	O
51	.	O

1	The	O
2	exodomain	O
3	alone	O
4	has	O
5	the	O
6	high	O
7	affinity	O
8	hormone	O
9	binding	O
10	site	O
11	but	O
12	is	O
13	not	O
14	capable	O
15	of	O
16	generating	O
17	hormonal	O
18	signal	O
19	.	O

1	Iodine	O
2	metabolism	O
3	in	O
4	chronic	O
5	thyroiditis	O
6	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	DNA	O
6	methylation	O
7	,	O
8	chromatin	O
9	structure	O
10	,	O
11	and	O
12	transactivation	O
13	at	O
14	an	O
15	Sp1	B
16	site	I
17	contribute	O
18	to	O
19	the	O
20	highly	O
21	restricted	O
22	expression	O
23	of	O
24	this	O
25	myelomonocytic	O
26	lineage	O
27	specific	O
28	gene	O
29	.	O

1	EMSA	O
2	with	O
3	crude	O
4	nuclear	O
5	extracts	O
6	demonstrated	O
7	that	O
8	stimulation	O
9	with	O
10	CD40L	O
11	results	O
12	in	O
13	the	O
14	induction	O
15	of	O
16	NF	B
17	-	I
18	kappaB	I
19	complexes	I
20	that	O
21	bind	O
22	to	O
23	each	O
24	of	O
25	the	O
26	three	O
27	NF	B
28	-	I
29	kappaB	I
30	sites	I
31	and	O
32	are	O
33	composed	O
34	mainly	O
35	of	O
36	p50	B
37	and	O
38	RelB	O
39	,	O
40	but	O
41	also	O
42	include	O
43	c	B
44	-	I
45	Rel	I
46	and	O
47	p65	B
48	.	I

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	Fc	B
7	epsilon	I
8	R1	I
9	is	O
10	a	O
11	33	O
12	-	O
13	kDa	O
14	tyrosine	O
15	phosphoprotein	O
16	,	O
17	but	O
18	the	O
19	p33	O
20	Grb2	B
21	-	I
22	binding	I
23	protein	I
24	described	O
25	in	O
26	the	O
27	present	O
28	report	O
29	is	O
30	not	O
31	the	O
32	Fc	B
33	epsilon	I
34	R1	I
35	beta	I
36	chain	I
37	and	O
38	its	O
39	identity	O
40	is	O
41	unknown	O
42	.	O

1	The	O
2	two	O
3	bases	O
4	immediately	O
5	flanking	O
6	the	O
7	5	O
8	'	O
9	end	O
10	of	O
11	the	O
12	element	O
13	proved	O
14	to	O
15	be	O
16	very	O
17	important	O
18	to	O
19	its	O
20	function	O
21	as	O
22	a	O
23	UAS	O
24	element	O
25	as	O
26	did	O
27	the	O
28	two	O
29	bases	O
30	immediately	O
31	3	O
32	'	O
33	of	O
34	the	O
35	bHLH	B
36	core	I
37	motif	I
38	.	I

1	In	O
2	the	O
3	past	O
4	,	O
5	immunology	O
6	in	O
7	Singapore	O
8	was	O
9	mainly	O
10	confined	O
11	to	O
12	serology	O
13	for	O
14	the	O
15	diagnosis	O
16	of	O
17	certain	O
18	infectious	O
19	diseases	O
20	.	O

1	Ultrastructural	O
2	study	O
3	of	O
4	polyarteritis	B

1	NF	B
2	kappa	I
3	B	I
4	was	O
5	activated	O
6	to	O
7	a	O
8	much	O
9	greater	O
10	extent	O
11	by	O
12	roscovitine	O
13	in	O
14	the	O
15	WT	O
16	cells	O
17	than	O
18	in	O
19	Y8	O
20	cells	O
21	.	O

1	Forty	O
2	4	O
3	-	O
4	month	O
5	old	O
6	SD	O
7	female	O
8	rats	O
9	were	O
10	randomly	O
11	divided	O
12	into	O
13	four	O
14	groups	O
15	,	O
16	namely	O
17	sham	O
18	operation	O
19	,	O
20	bilateral	O
21	ovariectomy	O
22	,	O
23	ovariectomy	O
24	plus	O
25	supplementary	O
26	ethinyl	O
27	estradiol	O
28	(	O
29	0	O
30	.	O
31	2	O
32	microgram	O
33	/	O
34	100	O
35	g	O
36	B	O
37	.	O

1	In	O
2	TNF	B
3	-	I
4	resistant	O
5	T24	O
6	bladder	O
7	carcinoma	O
8	cells	O
9	,	O
10	TNF	B
11	failed	O
12	to	O
13	alter	O
14	EGF	B
15	-	I
16	R	I
17	tyrosine	I
18	protein	I
19	kinase	I
20	activity	O
21	although	O
22	both	O
23	EGF	B
24	and	O
25	phorbol	O
26	ester	O
27	were	O
28	shown	O
29	to	O
30	modulate	O
31	the	O
32	enzymatic	O
33	activity	O
34	of	O
35	the	O
36	receptor	O
37	in	O
38	these	O
39	cells	O
40	.	O

1	272	O
2	,	O
3	1904	O
4	].	O

1	Treatment	O
2	was	O
3	well	O
4	-	O
5	tolerated	O
6	.	O

1	Hyperactivation	O
2	of	O
3	Cdc2	B
4	in	O
5	fission	O
6	yeast	O
7	causes	O
8	cells	O
9	to	O
10	undergo	O
11	a	O
12	lethal	O
13	premature	O
14	mitosis	O
15	called	O
16	mitotic	O
17	catastrophe	O
18	.	O

1	Aneurysmal	O
2	bone	O
3	cyst	O
4	of	O
5	the	O
6	jaws	O
7	:	O
8	analysis	O
9	of	O
10	11	O
11	cases	O
12	.	O

1	The	O
2	method	O
3	is	O
4	accurate	O
5	,	O
6	with	O
7	good	O
8	precision	O
9	and	O
10	adequate	O
11	sensitivity	O
12	.	O

1	All	O
2	patients	O
3	with	O
4	deterioriation	O
5	in	O
6	mental	O
7	status	O
8	showed	O
9	a	O
10	marked	O
11	increase	O
12	in	O
13	liver	O
14	enzymes	O
15	(	O
16	aspartate	O
17	and	O
18	alanine	O
19	aminotransaminases	O
20	)	O
21	and	O
22	severe	O
23	coagulopathy	O
24	.	O

1	The	O
2	p34	O
3	.	O
4	8	O
5	gene	O
6	has	O
7	a	O
8	strong	O
9	codon	O
10	usage	O
11	bias	O
12	which	O
13	is	O
14	strikingly	O
15	different	O
16	from	O
17	that	O
18	of	O
19	the	O
20	polyhedrin	B
21	gene	I
22	.	I

1	Effects	O
2	of	O
3	cisapride	O
4	on	O
5	upper	O
6	-	O
7	gastrointestinal	O
8	motility	O
9	and	O
10	digestive	B
11	hormones	I

1	Accordingly	O
2	,	O
3	no	O
4	Ha	B
5	-	I
6	ras	I
7	codon	O
8	12	O
9	mutations	O
10	are	O
11	found	O
12	in	O
13	the	O
14	EtNU	O
15	-	O
16	induced	O
17	mammary	O
18	tumors	O
19	.	O

1	Incidence	O
2	rate	O
3	ranging	O
4	between	O
5	122	O
6	/	O
7	100	O
8	,	O
9	000	O
10	/	O
11	year	O
12	and	O
13	190	O
14	/	O
15	100	O
16	,	O
17	000	O
18	/	O
19	year	O
20	were	O
21	found	O
22	(	O
23	minimum	O
24	,	O
25	estimated	O
26	and	O
27	raw	O
28	datasets	O
29	).	O

1	Anatomy	O
2	of	O
3	the	O
4	RNA	O
5	and	O
6	gene	O
7	products	O
8	of	O
9	MC29	O
10	and	O
11	MH2	O
12	,	O
13	two	O
14	defective	O
15	avian	O
16	tumor	O
17	viruses	O
18	causing	O
19	acute	O
20	leukemia	O
21	and	O
22	carcinoma	O
23	:	O
24	evidence	O
25	for	O
26	a	O
27	new	O
28	class	O
29	of	O
30	transforming	O
31	genes	O
32	.	O

1	After	O
2	determining	O
3	isoflurane	O
4	MAC	O
5	in	O
6	triplicate	O
7	,	O
8	birds	O
9	were	O
10	given	O
11	a	O
12	mu	O
13	-	O
14	opioid	O
15	agonist	O
16	(	O
17	morphine	O
18	,	O
19	n	O
20	=	O
21	9	O
22	)	O
23	or	O
24	a	O
25	kappa	B
26	-	I
27	opioid	I
28	agonist	O
29	(	O
30	U50488H	O
31	,	O
32	n	O
33	=	O
34	9	O
35	).	O

1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	O
40	subregion	O
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O

1	However	O
2	,	O
3	a	O
4	cosmid	O
5	clone	O
6	containing	O
7	the	O
8	entire	O
9	mouse	B
10	alpha	I
11	1	I
12	(	I
13	I	I
14	)	I
15	gene	I
16	,	O
17	including	O
18	3	O
19	.	O
20	7	O
21	kb	O
22	of	O
23	5	O
24	'-	O
25	and	O
26	4	O
27	kb	O
28	of	O
29	3	O
30	'-	O
31	flanking	O
32	DNA	O
33	,	O
34	was	O
35	expressed	O
36	at	O
37	reduced	O
38	levels	O
39	in	O
40	fibroblasts	O
41	overexpressing	O
42	oncogenic	B
43	ras	I
44	.	I

1	NH2	O
2	-	O
3	terminal	O
4	trimming	O
5	of	O
6	Xenopus	O
7	and	O
8	mammalian	O
9	FGF3s	O
10	may	O
11	therefore	O
12	be	O
13	a	O
14	prerequisite	O
15	of	O
16	optimal	O
17	biological	O
18	activity	O
19	.	O

1	The	O
2	following	O
3	technique	O
4	describes	O
5	a	O
6	modification	O
7	to	O
8	a	O
9	bar	O
10	superstructure	O
11	that	O
12	provided	O
13	the	O
14	advantages	O
15	of	O
16	convenience	O
17	,	O
18	security	O
19	,	O
20	and	O
21	consistent	O
22	positioning	O
23	even	O
24	though	O
25	one	O
26	implant	O
27	was	O
28	lost	O
29	and	O
30	the	O
31	angulation	O
32	of	O
33	implants	O
34	limited	O
35	accuracy	O
36	.	O

1	Envelope	O
2	-	O
3	function	O
4	matching	O
5	conditions	O
6	for	O
7	GaAs	O
8	/(	O
9	Al	O
10	,	O
11	Ga	O
12	)	O
13	As	O
14	heterojunctions	O
15	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	binding	O
9	of	O
10	the	O
11	GA	B
12	-	I
13	binding	I
14	protein	I
15	(	I
16	GABP	I
17	)	O
18	to	O
19	ets	B
20	sequence	O
21	motifs	O
22	within	O
23	each	O
24	repeated	O
25	unit	O
26	is	O
27	required	O
28	for	O
29	transcriptional	O
30	activation	O
31	of	O
32	the	O
33	COXIV	O
34	promoter	O
35	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	a	O
7	model	O
8	in	O
9	which	O
10	GATA	B
11	-	I
12	5	I
13	performs	I
14	a	O
15	unique	O
16	temporally	O
17	and	O
18	spatially	O
19	restricted	O
20	function	O
21	in	O
22	the	O
23	embryonic	O
24	heart	O
25	and	O
26	lung	O
27	.	O

1	Since	O
2	CENP	B
3	-	I
4	B	I
5	gene	I
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	O
13	-	O
14	B	O
15	boxes	O
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	Indoor	O
2	concentrations	O
3	were	O
4	only	O
5	weakly	O
6	correlated	O
7	with	O
8	outdoor	O
9	concentrations	O
10	,	O
11	however	O
12	,	O
13	and	O
14	personal	O
15	exposures	O
16	were	O
17	even	O
18	more	O
19	poorly	O
20	correlated	O
21	with	O
22	outdoor	O
23	concentrations	O
24	.	O

1	Following	O
2	extended	O
3	recovery	O
4	hippocampal	O
5	EEG	O
6	was	O
7	normal	O
8	despite	O
9	extensive	O
10	cellular	O
11	loss	O
12	in	O
13	areas	O
14	CA3	O
15	and	O
16	CA4	O
17	.	O

1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	O
10	molecule	O
11	.	O

1	A	O
2	single	O
3	rectal	O
4	dose	O
5	of	O
6	25	O
7	mg	O
8	/	O
9	kg	O
10	will	O
11	obtain	O
12	this	O
13	lower	O
14	concentration	O
15	within	O
16	1	O
17	h	O
18	of	O
19	administration	O
20	and	O
21	maintain	O
22	it	O
23	for	O
24	up	O
25	to	O
26	6	O
27	h	O
28	.	O

1	Here	O
2	,	O
3	we	O
4	alter	O
5	the	O
6	dimerization	O
7	specificity	O
8	of	O
9	Fos	B
10	by	O
11	precisely	O
12	replacing	O
13	its	O
14	leucine	O
15	zipper	O
16	with	O
17	that	O
18	from	O
19	GCN4	B
20	.	I

1	In	O
2	order	O
3	to	O
4	decipher	O
5	the	O
6	pathway	O
7	that	O
8	leads	O
9	to	O
10	Hox	B
11	gene	I
12	induction	O
13	,	O
14	we	O
15	have	O
16	investigated	O
17	whether	O
18	a	O
19	Hox	B
20	gene	I
21	regulator	I
22	,	O
23	the	O
24	leucine	B
25	zipper	I
26	transcription	I
27	factor	I
28	MafB	O
29	/	O
30	Kr	O
31	,	O
32	is	O
33	itself	O
34	transcriptionally	O
35	regulated	O
36	by	O
37	the	O
38	environmental	O
39	signals	O
40	.	O

1	Intravenous	O
2	amine	O
3	pressor	O
4	tests	O
5	in	O
6	healthy	O
7	volunteers	O
8	.	O

1	Moreover	O
2	,	O
3	Lck	O
4	was	O
5	reversibly	O
6	co	O
7	-	O
8	immunoprecipitated	O
9	with	O
10	p95Vav	O
11	,	O
12	and	O
13	the	O
14	stoichiometry	O
15	of	O
16	binding	O
17	increased	O
18	in	O
19	anti	B
20	-	I
21	CD3	I
22	-	I
23	treated	O
24	Jurkat	O
25	cells	O
26	.	O

1	In	O
2	a	O
3	control	O
4	group	O
5	both	O
6	common	O
7	carotid	O
8	arteries	O
9	(	O
10	CCA	O
11	)	O
12	were	O
13	ligated	O
14	.	O

1	Symposium	O
2	on	O
3	presenile	O
4	spongy	O
5	encephalopathies	O
6	.	O

1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	viral	I
28	protein	I
29	VP16	I
30	.	I

1	We	O
2	enrolled	O
3	253	O
4	HIV	O
5	-	O
6	antibody	O
7	positive	O
8	heroin	O
9	addicts	O
10	without	O
11	HIV	O
12	-	O
13	related	O
14	disease	O
15	(	O
16	n	O
17	=	O
18	81	O
19	)	O
20	or	O
21	with	O
22	persistent	O
23	generalized	O
24	lymphadenopathy	O
25	(	O
26	n	O
27	=	O
28	172	O
29	)	O
30	in	O
31	a	O
32	prospective	O
33	study	O
34	to	O
35	evaluate	O
36	clinical	O
37	progression	O
38	to	O
39	AIDS	O
40	related	O
41	complex	O
42	(	O
43	ARC	O
44	)	O
45	or	O
46	AIDS	O
47	and	O
48	to	O
49	identify	O
50	factors	O
51	of	O
52	possible	O
53	prognostic	O
54	relevance	O
55	.	O

1	Linking	O
2	continuous	O
3	community	O
4	-	O
5	based	O
6	morbidity	O
7	recording	O
8	of	O
9	influenza	O
10	-	O
11	like	O
12	illness	O
13	(	O
14	ILI	O
15	)	O
16	with	O
17	virological	O
18	sampling	O
19	has	O
20	consistently	O
21	proved	O
22	its	O
23	value	O
24	as	O
25	one	O
26	of	O
27	the	O
28	earliest	O
29	indicators	O
30	of	O
31	circulating	O
32	influenza	O
33	activity	O
34	.	O

1	The	O
2	87K	B
3	protein	I
4	,	O
5	together	O
6	with	O
7	proteins	O
8	of	O
9	105	O
10	,	O
11	000	O
12	and	O
13	75	O
14	,	O
15	000	O
16	daltons	O
17	,	O
18	are	O
19	translated	O
20	from	O
21	leftward	O
22	transcribed	O
23	(	O
24	1	O
25	-	O
26	strand	O
27	)	O
28	messenger	O
29	RNAs	O
30	that	O
31	are	O
32	complementary	O
33	to	O
34	the	O
35	viral	O
36	genome	O
37	between	O
38	positions	O
39	11	O
40	.	O
41	2	O
42	and	O
43	31	O
44	.	O
45	5	O
46	.	O

1	The	O
2	CCAAT	O
3	core	O
4	sequence	O
5	mutants	O
6	in	O
7	which	O
8	both	O
9	CIII	O
10	and	O
11	CI	O
12	/	O
13	CII	O
14	were	O
15	abolished	O
16	,	O
17	also	O
18	increased	O
19	the	O
20	promoter	O
21	activity	O
22	.	O

1	A	O
2	case	O
3	of	O
4	chronic	O
5	hepatitis	O
6	C	O
7	with	O
8	primary	O
9	hypothyroidism	O
10	manifested	O
11	during	O
12	interferon	B
13	treatment	O

1	Follow	O
2	-	O
3	up	O
4	controls	O
5	of	O
6	luteinizing	B
7	hormone	I
8	(	I
9	LH	I
10	),	O
11	follicle	B
12	stimulating	I
13	hormone	I
14	(	O
15	FSH	B
16	),	O
17	prolactin	B
18	(	O
19	HPRL	O
20	),	O
21	oestradiol	O
22	(	O
23	E2	O
24	),	O
25	progesterone	O
26	(	O
27	P	O
28	)	O
29	and	O
30	testosterone	O
31	(	O
32	T	O
33	)	O
34	in	O
35	the	O
36	catabolic	O
37	and	O
38	healing	O
39	phase	O
40	of	O
41	burn	O
42	disease	O
43	.	O

1	A	O
2	tyrosine	O
3	-	O
4	based	O
5	sorting	O
6	signal	O
7	in	O
8	the	O
9	beta2	B
10	integrin	I
11	cytoplasmic	I
12	domain	I
13	mediates	O
14	its	O
15	recycling	O
16	to	O
17	the	O
18	plasma	O
19	membrane	O
20	and	O
21	is	O
22	required	O
23	for	O
24	ligand	O
25	-	O
26	supported	O
27	migration	O
28	.	O

1	False	O
2	positive	O
3	PET	O
4	FDG	O
5	corresponded	O
6	to	O
7	lung	O
8	infection	O
9	,	O
10	degenerative	O
11	bone	O
12	disease	O
13	,	O
14	and	O
15	reconstruction	O
16	artifact	O
17	.	O

1	In	O
2	cases	O
3	of	O
4	1	O
5	degrees	O
6	HPT	O
7	,	O
8	the	O
9	plasma	O
10	1	O
11	,	O
12	25	O
13	-(	O
14	OH	O
15	)	O
16	2D	O
17	level	O
18	rose	O
19	significantly	O
20	in	O
21	all	O
22	cases	O
23	(	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	05	O
30	),	O
31	although	O
32	the	O
33	pattern	O
34	of	O
35	the	O
36	increase	O
37	was	O
38	not	O
39	uniform	O
40	.	O

1	Importantly	O
2	,	O
3	concomitant	O
4	expression	O
5	of	O
6	constitutive	O
7	activated	O
8	Raf	B
9	and	O
10	V12N38	O
11	Ras	B
12	results	O
13	in	O
14	almost	O
15	complete	O
16	loss	O
17	of	O
18	TTF	B
19	-	I
20	1	I
21	activity	O
22	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	is	O
6	characterized	O
7	by	O
8	a	O
9	putative	O
10	16	O
11	-	O
12	residue	O
13	amino	O
14	-	O
15	terminal	O
16	signal	O
17	peptide	O
18	that	O
19	is	O
20	cleaved	O
21	,	O
22	resulting	O
23	in	O
24	a	O
25	239	O
26	-	O
27	residue	O
28	polypeptide	O
29	.	O

1	Dosage	O
2	in	O
3	both	O
4	cases	O
5	was	O
6	0	O
7	.	O
8	2	O
9	g	O
10	/	O
11	m2	O
12	.	O

1	A	O
2	miracle	O
3	cure	O
4	and	O
5	its	O
6	solution	O

1	The	O
2	crystal	O
3	structure	O
4	of	O
5	the	O
6	VP16	B
7	core	I
8	has	O
9	been	O
10	determined	O
11	at	O
12	2	O
13	.	O
14	1	O
15	A	O
16	resolution	O
17	.	O

1	Association	O
2	with	O
3	HL	O
4	-	O
5	A	O
6	W	O
7	-	O
8	27	O
9	.	O

1	All	O
2	lambs	O
3	with	O
4	B	O
5	breeding	O
6	had	O
7	significantly	O
8	higher	O
9	Hb	B
10	levels	O
11	at	O
12	the	O
13	end	O
14	of	O
15	the	O
16	experiment	O
17	than	O
18	did	O
19	NB	O
20	lambs	O
21	.	O
22	b	O
23	and	O
24	S	O
25	x	O
26	B	O
27	lambs	O
28	had	O
29	higher	O
30	(	O
31	P	O
32	<	O
33	.	O
34	05	O
35	)	O
36	Hb	B
37	levels	O
38	than	O
39	the	O
40	D	O
41	x	O
42	B	O
43	lambs	O
44	,	O
45	and	O
46	B	O
47	lambs	O
48	had	O
49	the	O
50	highest	O
51	(	O
52	P	O
53	<	O
54	.	O
55	05	O
56	)	O
57	mean	O
58	corpuscular	O
59	hemoglobin	B
60	concentrations	O
61	.	O

1	Redistribution	O
2	of	O
3	mannosidase	B
4	I	I
5	was	O
6	also	O
7	observed	O
8	in	O
9	cells	O
10	incubated	O
11	at	O
12	15	O
13	degrees	O
14	C	O
15	.	O

1	The	O
2	prevalence	O
3	of	O
4	malnutrition	O
5	was	O
6	30	O
7	%	O
8	in	O
9	the	O
10	47	O
11	patients	O
12	without	O
13	CVD	O
14	and	O
15	was	O
16	significantly	O
17	higher	O
18	(	O
19	70	O
20	%,	O
21	P	O
22	<	O
23	0	O
24	.	O
25	001	O
26	)	O
27	in	O
28	the	O
29	70	O
30	patients	O
31	with	O
32	CVD	O
33	,	O
34	who	O
35	also	O
36	had	O
37	lower	O
38	tHcy	O
39	,	O
40	SAlb	O
41	,	O
42	plasma	O
43	IGF	B
44	-	I
45	1	I
46	,	O
47	serum	O
48	creatinine	O
49	(	O
50	SCr	O
51	),	O
52	and	O
53	blood	O
54	hemoglobin	B
55	.	I

1	Sequencing	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	0	O
7	.	O
8	54	O
9	-	O
10	and	O
11	0	O
12	.	O
13	4	O
14	-	O
15	kb	O
16	fragments	O
17	are	O
18	identical	O
19	except	O
20	for	O
21	150	O
22	nucleotides	O
23	missing	O
24	at	O
25	the	O
26	5	O
27	'	O
28	region	O
29	of	O
30	the	O
31	0	O
32	.	O
33	4	O
34	-	O
35	kb	O
36	fragment	O
37	.	O

1	Cell	I
2	factor	I
3	-	I
4	mediated	O
5	regulatory	O
6	interactions	O
7	are	O
8	involved	O
9	in	O
10	regulating	O
11	the	O
12	restricted	O
13	expression	O
14	of	O
15	the	O
16	HCMV	O
17	major	O
18	immediate	B
19	-	I
20	early	I
21	(	I
22	IE	I
23	)	I
24	gene	I
25	(	O
26	J	O
27	.	O

1	Mis3	O
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	B
9	ribosome	I
10	RNA	I
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O

1	Because	O
2	all	O
3	PDGFbetaR	O
4	fusions	O
5	described	O
6	thus	O
7	far	O
8	result	O
9	in	O
10	splicing	O
11	to	O
12	a	O
13	common	O
14	exon	O
15	of	O
16	this	O
17	gene	O
18	,	O
19	we	O
20	performed	O
21	5	O
22	'-	O
23	rapid	O
24	amplification	O
25	of	O
26	cDNA	O
27	ends	O
28	PCR	O
29	on	O
30	patient	O
31	RNA	O
32	.	O

1	The	O
2	first	O
3	identification	O
4	of	O
5	the	O
6	active	O
7	37LRP	O
8	/	O
9	p40	B
10	gene	I
11	presented	O
12	in	O
13	this	O
14	study	O
15	is	O
16	a	O
17	critical	O
18	step	O
19	toward	O
20	the	O
21	isolation	O
22	of	O
23	the	O
24	corresponding	O
25	human	B
26	gene	I
27	and	O
28	the	O
29	understanding	O
30	of	O
31	the	O
32	molecular	O
33	mechanisms	O
34	involved	O
35	in	O
36	the	O
37	up	O
38	-	O
39	regulation	O
40	of	O
41	its	O
42	expression	O
43	during	O
44	tumor	O
45	invasion	O
46	and	O
47	metastasis	O
48	.	O

1	To	O
2	investigate	O
3	the	O
4	potential	O
5	role	O
6	of	O
7	SP1	B
8	,	O
9	we	O
10	examined	O
11	nuclear	O
12	extracts	O
13	from	O
14	HCMV	O
15	-	O
16	infected	O
17	cells	O
18	.	O

1	Induced	I
2	gamma	I
3	-	I
4	ray	I
5	spectroscopy	I

1	We	O
2	report	O
3	here	O
4	the	O
5	discovery	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	I
11	related	I
12	gene	I
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	ACT4	O
22	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	clinical	O
6	profile	O
7	of	O
8	cavernous	O
9	malformations	O
10	with	O
11	and	O
12	without	O
13	associated	O
14	venous	O
15	malformations	O
16	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	a	O
7	mutant	O
8	form	O
9	of	O
10	XRN1	O
11	,	O
12	which	O
13	encodes	O
14	a	O
15	5	O
16	'-	O
17	3	O
18	'	O
19	exonuclease	O
20	,	O
21	was	O
22	identified	O
23	as	O
24	an	O
25	extragenic	O
26	suppressor	O
27	that	O
28	increases	O
29	the	O
30	half	O
31	-	O
32	life	O
33	of	O
34	rhis4	O
35	mRNA	O
36	,	O
37	leading	O
38	to	O
39	a	O
40	10	O
41	-	O
42	fold	O
43	increase	O
44	in	O
45	steady	O
46	-	O
47	state	O
48	mRNA	O
49	levels	O
50	compared	O
51	to	O
52	the	O
53	wild	B
54	-	I
55	type	I
56	HIS4	I
57	mRNA	I
58	level	O
59	.	O

1	Myocardial	O
2	SPET	O
3	imaging	O
4	with	O
5	99Tcm	O
6	-	O
7	tetrofosmin	O
8	in	O
9	clinical	O
10	practice	O
11	:	O
12	comparison	O
13	of	O
14	a	O
15	1	O
16	day	O
17	and	O
18	a	O
19	2	O
20	day	O
21	imaging	O
22	protocol	O
23	.	O

1	The	O
2	unfolded	O
3	protein	O
4	response	O
5	regulates	O
6	multiple	O
7	aspects	O
8	of	O
9	secretory	O
10	and	O
11	membrane	O
12	protein	O
13	biogenesis	O
14	and	O
15	endoplasmic	O
16	reticulum	O
17	quality	O
18	control	O
19	.	O

1	We	O
2	had	O
3	previously	O
4	analyzed	O
5	repair	O
6	rates	O
7	of	O
8	cyclobutane	O
9	pyrimidine	O
10	dimers	O
11	at	O
12	nucleotide	O
13	resolution	O
14	along	O
15	the	O
16	human	O
17	JUN	O
18	gene	O
19	in	O
20	normal	O
21	fibroblasts	O
22	and	O
23	found	O
24	very	O
25	efficient	O
26	repair	O
27	of	O
28	sequences	O
29	near	O
30	the	O
31	transcription	O
32	initiation	O
33	site	O
34	but	O
35	slow	O
36	repair	O
37	along	O
38	the	O
39	promoter	O
40	.	O

1	Baseline	O
2	measurements	O
3	of	O
4	forced	O
5	expiratory	O
6	volume	O
7	in	O
8	1	O
9	s	O
10	(	O
11	FEV1	O
12	),	O
13	specific	O
14	airway	O
15	conductance	O
16	(	O
17	SGaw	O
18	)	O
19	and	O
20	the	O
21	provocative	O
22	dose	O
23	of	O
24	carbachol	O
25	causing	O
26	a	O
27	35	O
28	%	O
29	reduction	O
30	in	O
31	SGaw	O
32	(	O
33	PD35	O
34	),	O
35	and	O
36	a	O
37	20	O
38	%	O
39	reduction	O
40	in	O
41	FEV1	O
42	(	O
43	PD20	O
44	)	O
45	were	O
46	established	O
47	on	O
48	entry	O
49	while	O
50	each	O
51	subject	O
52	was	O
53	still	O
54	smoking	O
55	.	O

1	Endocrine	O
2	cells	O
3	were	O
4	studied	O
5	by	O
6	means	O
7	of	O
8	Grimelius	O
9	'	O
10	silver	O
11	staining	O
12	and	O
13	immunostaining	O
14	for	O
15	chromogranin	O
16	,	O
17	a	O
18	general	O
19	marker	O
20	of	O
21	endocrine	O
22	cells	O
23	.	O

1	Our	O
2	experiments	O
3	suggest	O
4	that	O
5	the	O
6	SCL	B
7	gene	I
8	can	O
9	be	O
10	a	O
11	target	O
12	for	O
13	the	O
14	erythroid	B
15	transcription	I
16	factor	I
17	GATA	I
18	-	I
19	1	I
20	and	O
21	that	O
22	the	O
23	SCL	B
24	gene	I
25	product	I
26	serves	O
27	as	O
28	a	O
29	positive	O
30	regulator	O
31	of	O
32	erythroid	O
33	differentiation	O
34	.	O

1	Location	O
2	and	O
3	orientation	O
4	of	O
5	an	O
6	activating	O
7	region	O
8	in	O
9	the	O
10	Escherichia	B
11	coli	I
12	transcription	I
13	factor	I
14	,	O
15	FNR	O
16	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	Four	O
2	putative	O
3	positive	O
4	cDNA	O
5	clones	O
6	were	O
7	isolated	O
8	,	O
9	and	O
10	the	O
11	largest	O
12	insert	O
13	(	O
14	pASB	O
15	-	O
16	1	O
17	)	O
18	was	O
19	sequenced	O
20	in	O
21	both	O
22	orientations	O
23	.	O

1	The	O
2	functional	O
3	mature	O
4	domain	O
5	of	O
6	pediocin	O
7	AcH	O
8	(	O
9	Lys	O
10	+	O
11	1	O
12	to	O
13	Cys	O
14	+	O
15	44	O
16	)	O
17	is	O
18	targeted	O
19	into	O
20	the	O
21	E	O
22	.	O
23	coli	O
24	sec	O
25	machinery	O
26	and	O
27	secreted	O
28	to	O
29	the	O
30	periplasm	O
31	in	O
32	active	O
33	form	O
34	when	O
35	fused	O
36	in	O
37	frame	O
38	to	O
39	the	O
40	COOH	O
41	terminus	O
42	of	O
43	the	O
44	secretory	B
45	protein	I
46	maltose	I
47	-	I
48	binding	I
49	protein	I
50	(	I
51	MBP	I
52	).	O

1	A	O
2	genetic	O
3	screen	O
4	applied	O
5	to	O
6	mutants	O
7	in	O
8	the	O
9	branch	O
10	site	O
11	region	O
12	shows	O
13	that	O
14	all	O
15	positions	O
16	in	O
17	the	O
18	conserved	O
19	TACTAAC	O
20	sequence	O
21	are	O
22	important	O
23	for	O
24	intron	O
25	recognition	O
26	.	O

1	Biol	O
2	.	O

1	Interferon	B
2	beta	I
3	therapy	O
4	was	O
5	discontinued	O
6	for	O
7	4	O
8	weeks	O
9	.	O

1	We	O
2	provide	O
3	community	O
4	metabolic	O
5	data	O
6	that	O
7	indicate	O
8	that	O
9	large	O
10	changes	O
11	in	O
12	CO2	O
13	concentration	O
14	can	O
15	occur	O
16	in	O
17	coral	O
18	reef	O
19	waters	O
20	via	O
21	biogeochemical	O
22	processes	O
23	not	O
24	directly	O
25	associated	O
26	with	O
27	photosynthesis	O
28	,	O
29	respiration	O
30	,	O
31	calcification	O
32	,	O
33	and	O
34	CaCO3	O
35	dissolution	O
36	.	O

1	The	O
2	congenital	O
3	forms	O
4	(	O
5	7	O
6	cases	O
7	)	O
8	all	O
9	occurred	O
10	in	O
11	female	O
12	infants	O
13	and	O
14	involved	O
15	the	O
16	mucosa	O
17	overlying	O
18	either	O
19	the	O
20	anterior	O
21	ridge	O
22	of	O
23	the	O
24	maxilla	O
25	or	O
26	the	O
27	mandible	O
28	.	O

1	The	O
2	TATA	B
3	box	I
4	-	I
5	binding	I
6	protein	I
7	(	I
8	TBP	I
9	)	O
10	plays	O
11	an	O
12	essential	O
13	role	O
14	in	O
15	transcription	O
16	by	O
17	all	O
18	three	O
19	eukaryotic	B
20	nuclear	I
21	RNA	I
22	polymerases	I
23	,	O
24	polymerases	O
25	(	O
26	Pol	B
27	)	I
28	I	I
29	,	O
30	II	O
31	,	O
32	and	O
33	III	O
34	.	O

1	A	O
2	flow	O
3	rate	O
4	of	O
5	at	O
6	least	O
7	5	O
8	mL	O
9	/	O
10	h	O
11	is	O
12	required	O
13	through	O
14	the	O
15	receptor	O
16	(	O
17	volume	O
18	,	O
19	0	O
20	.	O
21	4	O
22	mL	O
23	)	O
24	for	O
25	accurate	O
26	results	O
27	.	O

1	The	O
2	96	O
3	-	O
4	bp	O
5	insert	O
6	contained	O
7	a	O
8	termination	O
9	signal	O
10	which	O
11	caused	O
12	the	O
13	premature	O
14	termination	O
15	of	O
16	the	O
17	protein	O
18	,	O
19	leading	O
20	to	O
21	the	O
22	generation	O
23	of	O
24	a	O
25	p53	B
26	product	I
27	9	O
28	amino	O
29	acids	O
30	shorter	O
31	than	O
32	usual	O
33	.	O

1	Developmental	O
2	toxicity	O
3	of	O
4	the	O
5	class	O
6	III	O
7	antiarrhythmic	O
8	agent	O
9	almokalant	O
10	in	O
11	mice	O
12	.	O

1	The	O
2	mechanism	O
3	by	O
4	which	O
5	E2	B
6	-	I
7	C	I
8	represses	I
9	E2	I
10	-	I
11	dependent	I
12	enhancer	I
13	activity	O
14	most	O
15	likely	O
16	involves	O
17	competition	O
18	with	O
19	E2	O
20	for	O
21	binding	O
22	to	O
23	a	O
24	common	O
25	transcriptional	O
26	regulatory	O
27	site	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O

1	Moreover	O
2	,	O
3	Western	O
4	blots	O
5	demonstrated	O
6	at	O
7	least	O
8	six	O
9	types	O
10	of	O
11	Ypt	O
12	in	O
13	both	O
14	Cr	O
15	and	O
16	Vc	O
17	,	O
18	suggesting	O
19	that	O
20	these	O
21	Ypt	O
22	are	O
23	used	O
24	for	O
25	household	O
26	functions	O
27	responsible	O
28	for	O
29	vesicle	O
30	transport	O
31	rather	O
32	than	O
33	for	O
34	cellular	O
35	differentiation	O
36	.	O

1	Functional	O
2	analysis	O
3	of	O
4	aryl	B
5	hydrocarbon	I
6	receptor	I
7	nuclear	I
8	translocator	O
9	interactions	O
10	with	O
11	aryl	B
12	hydrocarbon	I
13	receptor	I
14	in	O
15	the	O
16	yeast	O
17	two	O
18	-	O
19	hybrid	O
20	system	O
21	.	O

1	Following	O
2	the	O
3	results	O
4	of	O
5	toxicological	O
6	experiments	O
7	in	O
8	the	O
9	target	O
10	animals	O
11	"	O
12	Toxicological	O
13	Drinking	O
14	Water	O
15	Standards	O
16	for	O
17	Animals	O
18	"	O
19	can	O
20	be	O
21	established	O
22	.	O

1	No	O
2	significant	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	LVM	O
8	or	O
9	wall	O
10	thickness	O
11	and	O
12	body	O
13	surface	O
14	area	O
15	,	O
16	age	O
17	,	O
18	blood	O
19	pressure	O
20	,	O
21	heart	O
22	rate	O
23	,	O
24	cardiac	O
25	output	O
26	,	O
27	total	O
28	peripheral	O
29	resistance	O
30	and	O
31	left	O
32	ventricular	O
33	systolic	O
34	wall	O
35	stress	O
36	,	O
37	whereas	O
38	CD25	O
39	was	O
40	correlated	O
41	with	O
42	urinary	O
43	catecholamines	O
44	only	O
45	in	O
46	hypertensive	O
47	patients	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	606	O
54	,	O
55	p	O
56	less	O
57	than	O
58	0	O
59	.	O
60	001	O
61	).	O

1	Technetium	O
2	-	O
3	99m	O
4	methylene	O
5	diphosphonate	O
6	scintimammography	O
7	for	O
8	evaluation	O
9	of	O
10	palpable	O
11	breast	O
12	masses	O
13	.	O

1	Six	O
2	of	O
3	them	O
4	,	O
5	NUC1	O
6	,	O
7	PRP21	O
8	(	O
9	also	O
10	called	O
11	SPP91	O
12	),	O
13	CDC6	O
14	,	O
15	CRY2	O
16	,	O
17	the	O
18	gene	O
19	encoding	O
20	the	O
21	ribosomal	B
22	protein	I
23	S24	O
24	and	O
25	the	O
26	gene	O
27	coding	O
28	for	O
29	a	O
30	hypothetical	O
31	protein	O
32	of	O
33	599	O
34	amino	O
35	acids	O
36	,	O
37	have	O
38	been	O
39	sequenced	O
40	previously	O
41	.	O

1	The	O
2	small	O
3	monomeric	B
4	GTP	I
5	-	I
6	binding	I
7	proteins	I
8	of	O
9	the	O
10	RAB	O
11	subfamily	O
12	are	O
13	key	O
14	regulatory	O
15	elements	O
16	of	O
17	the	O
18	machinery	O
19	that	O
20	controls	O
21	membrane	O
22	traffic	O
23	in	O
24	eukaryotic	O
25	cells	O
26	.	O

1	Unusual	O
2	course	O
3	of	O
4	plasmocytosis	O
5	.	O

1	Structural	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	regulatory	O
8	region	O
9	reveals	O
10	that	O
11	the	O
12	c	B
13	-	I
14	met	I
15	promoter	I
16	lacks	O
17	TATA	O
18	or	O
19	CAAT	O
20	elements	O
21	but	O
22	has	O
23	an	O
24	extremely	O
25	high	O
26	G	B
27	-	I
28	C	I
29	content	O
30	and	O
31	multiple	O
32	Sp1	B
33	binding	I
34	sites	I
35	.	I

1	Blood	O
2	levels	O
3	of	O
4	melatonin	O
5	,	O
6	serotonin	O
7	,	O
8	cortisol	O
9	,	O
10	and	O
11	prolactin	B
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	O
21	uptake	O
22	.	O

1	All	O
2	33	O
3	subjects	O
4	were	O
5	given	O
6	psychometric	O
7	instruments	O
8	for	O
9	measuring	O
10	various	O
11	components	O
12	of	O
13	anger	O
14	and	O
15	anxiety	O
16	:	O
17	Spielberger	O
18	'	O
19	s	O
20	State	O
21	-	O
22	Trait	O
23	Personality	O
24	Inventory	O
25	,	O
26	the	O
27	Anger	O
28	Expression	O
29	Scale	O
30	,	O
31	and	O
32	the	O
33	State	O
34	Anger	O
35	Reaction	O
36	Scale	O
37	.	O

1	IL	B
2	-	I
3	1	I
4	and	O
5	TNF	B
6	increase	O
7	AND	O
8	-	O
9	34	O
10	transcript	O
11	levels	O
12	in	O
13	thymic	O
14	cortical	O
15	reticular	O
16	,	O
17	thymic	O
18	nurse	O
19	,	O
20	and	O
21	fibroblast	O
22	cell	O
23	lines	O
24	.	O

1	A	O
2	total	O
3	of	O
4	117	O
5	EVS	O
6	treatments	O
7	were	O
8	performed	O
9	on	O
10	34	O
11	patients	O
12	.	O

1	Resistance	O
2	ratios	O
3	for	O
4	the	O
5	other	O
6	field	O
7	strains	O
8	obtained	O
9	by	O
10	comparison	O
11	with	O
12	the	O
13	R5	O
14	strain	O
15	ranged	O
16	from	O
17	24	O
18	.	O
19	5	O
20	to	O
21	239	O
22	for	O
23	topical	O
24	application	O
25	and	O
26	from	O
27	1	O
28	.	O
29	2	O
30	to	O
31	9	O
32	.	O
33	8	O
34	for	O
35	the	O
36	glass	O
37	jar	O
38	method	O
39	.	O

1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	O
10	eccrine	O
11	sweat	O
12	duct	O
13	units	O
14	.	O

1	Transfection	O
2	experiments	O
3	demonstrated	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	(-	O
11	1894	O
12	to	O
13	+	O
14	37	O
15	)	O
16	of	O
17	the	O
18	mStaf	B
19	gene	I
20	drives	I
21	transcription	O
22	in	O
23	mouse	O
24	NMuMG	O
25	cells	O
26	and	O
27	that	O
28	a	O
29	construct	O
30	containing	O
31	a	O
32	fragment	O
33	from	O
34	-	O
35	387	O
36	to	O
37	+	O
38	37	O
39	showed	O
40	the	O
41	highest	O
42	transcriptional	O
43	activity	O
44	.	O

1	The	O
2	data	O
3	indicate	O
4	a	O
5	three	O
6	-	O
7	phase	O
8	reaction	O
9	after	O
10	B1	O
11	injection	O
12	:	O
13	Phase	O
14	1	O
15	--	O
16	shortly	O
17	after	O
18	injection	O
19	there	O
20	is	O
21	a	O
22	drop	O
23	of	O
24	all	O
25	parameters	O
26	lasting	O
27	for	O
28	30	O
29	sec	O
30	.	O

1	In	O
2	vivo	O
3	association	O
4	between	O
5	Shb	B
6	-	I
7	SH3	I
8	domain	I
9	proteins	I
10	v	I
11	-	I
12	Src	I
13	and	O
14	Eps8	O
15	was	O
16	detected	O
17	by	O
18	coimmunoprecipitation	O
19	.	O

1	The	O
2	PETCO2	O
3	measurement	O
4	during	O
5	precordial	O
6	compression	O
7	predicted	O
8	the	O
9	success	O
10	of	O
11	defibrillation	O
12	with	O
13	return	O
14	of	O
15	spontaneous	O
16	circulation	O
17	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	region	O
7	upstream	O
8	from	O
9	M	O
10	.	O
11	voltae	O
12	ORFtrpA	O
13	was	O
14	determined	O
15	and	O
16	revealed	O
17	the	O
18	presence	O
19	of	O
20	an	O
21	ORF	O
22	of	O
23	1227	O
24	nucleotides	O
25	(	O
26	ORFtrpB	O
27	)	O
28	encoding	O
29	a	O
30	409	O
31	amino	O
32	acid	O
33	polypeptide	O
34	of	O
35	mol	O
36	.	O
37	wt	O
38	.	O

1	No	O
2	evidence	O
3	for	O
4	the	O
5	presence	O
6	of	O
7	introns	O
8	within	O
9	the	O
10	acvA	O
11	gene	O
12	has	O
13	been	O
14	found	O
15	.	O

1	Diagnosis	O
2	of	O
3	FHCS	O
4	has	O
5	been	O
6	weighed	O
7	upon	O
8	laparoscopic	O
9	findings	O
10	.	O

1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	B
8	ascites	I

1	Determination	O
2	of	O
3	20	O
4	alpha	B
5	-	I
6	hydroxy	I
7	-	I
8	9	I
9	beta	I
10	,	O
11	10	O
12	alpha	B
13	-	I
14	pregna	I
15	-	I
16	4	I
17	,	I
18	6	I
19	-	I
20	dien	I
21	-	I
22	3	I
23	-	I
24	one	O
25	in	O
26	plasma	O
27	by	O
28	selected	O
29	ion	O
30	monitoring	O
31	.	O

1	We	O
2	have	O
3	used	O
4	a	O
5	site	O
6	-	O
7	directed	O
8	mutagenesis	O
9	approach	O
10	to	O
11	examine	O
12	how	O
13	the	O
14	Xaa	O
15	and	O
16	hydroxy	O
17	(	O
18	Ser	O
19	/	O
20	Thr	O
21	)	O
22	amino	O
23	acid	O
24	residues	O
25	in	O
26	sequons	O
27	influence	O
28	core	O
29	-	O
30	glycosylation	O
31	efficiency	O
32	.	O

1	The	O
2	Drosophila	B
3	melanogaster	I
4	Gart	I
5	gene	I
6	encodes	O
7	three	O
8	enzymatic	O
9	activities	O
10	in	O
11	the	O
12	pathway	O
13	for	O
14	purine	O
15	de	O
16	novo	O
17	synthesis	O
18	.	O

1	After	O
2	dopamine	O
3	infusion	O
4	in	O
5	women	O
6	with	O
7	polycystic	O
8	ovary	O
9	syndrome	O
10	and	O
11	in	O
12	matched	O
13	controls	O
14	,	O
15	steady	O
16	state	O
17	levels	O
18	of	O
19	plasma	O
20	dopamine	O
21	,	O
22	norepinephrine	O
23	,	O
24	and	O
25	the	O
26	ratio	O
27	of	O
28	dopamine	O
29	/	O
30	norepinephrine	O
31	were	O
32	similar	O
33	in	O
34	the	O
35	two	O
36	groups	O
37	.	O

1	The	O
2	platelet	O
3	adhesion	O
4	rate	O
5	on	O
6	these	O
7	layers	O
8	were	O
9	tested	O
10	concerning	O
11	the	O
12	valuation	O
13	of	O
14	the	O
15	haemocompatibility	O
16	of	O
17	the	O
18	basic	O
19	-	O
20	polymers	O
21	polyurethane	O
22	(	O
23	PUR	O
24	),	O
25	polyvinylchloride	O
26	(	O
27	PVC	O
28	),	O
29	and	O
30	polystyrene	O
31	(	O
32	PS	O
33	)	O
34	in	O
35	two	O
36	different	O
37	worked	O
38	test	O
39	chambers	O
40	.	O

1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	I
25	C	I
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	I
31	binding	I
32	site	I
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O

1	Reperfusion	O
2	with	O
3	normal	O
4	blood	O
5	in	O
6	the	O
7	beating	O
8	,	O
9	working	O
10	hearts	O
11	caused	O
12	extensive	O
13	structural	O
14	damage	O
15	,	O
16	reduced	O
17	reflow	O
18	,	O
19	and	O
20	failed	O
21	to	O
22	restore	O
23	contractility	O
24	in	O
25	any	O
26	instance	O
27	(-	O
28	27	O
29	%	O
30	systolic	O
31	shortening	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	Radiolabelled	O
2	palmitate	O
3	was	O
4	not	O
5	incorporated	O
6	into	O
7	the	O
8	mutated	O
9	protein	O
10	,	O
11	showing	O
12	that	O
13	lipid	O
14	modification	O
15	occurs	O
16	at	O
17	the	O
18	Cys	O
19	-	O
20	22	O
21	residue	O
22	.	O

1	The	O
2	present	O
3	paper	O
4	elucidates	O
5	the	O
6	existing	O
7	discrepancies	O
8	,	O
9	and	O
10	offers	O
11	a	O
12	consistent	O
13	terminology	O
14	incorporating	O
15	also	O
16	such	O
17	terms	O
18	as	O
19	"	O
20	additivity	O
21	",	O
22	"	O
23	potentiation	O
24	",	O
25	and	O
26	"	O
27	simple	O
28	similarity	O
29	".	B

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O

1	Deletion	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	essential	O
7	domain	O
8	of	O
9	this	O
10	promoter	O
11	,	O
12	termed	O
13	the	O
14	ORF5	O
15	/	O
16	deltaX	O
17	transcript	O
18	promoter	O
19	,	O
20	mapped	O
21	to	O
22	nucleotides	O
23	1525	O
24	-	O
25	1625	O
26	.	O

1	The	O
2	effect	O
3	of	O
4	Rho	B
5	on	O
6	AP	B
7	-	I
8	1	I
9	is	O
10	independent	O
11	of	O
12	the	O
13	mitogen	B
14	-	I
15	activated	I
16	protein	I
17	kinase	I
18	pathway	O
19	,	O
20	as	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	MEK	B
26	and	O
27	a	O
28	MEK	B
29	inhibitor	O
30	(	O
31	PD98059	O
32	)	O
33	did	O
34	not	O
35	affect	O
36	Rho	B
37	-	I
38	induced	O
39	AP	B
40	-	I
41	1	I
42	activity	O
43	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	the	O
6	acidimetric	O
7	test	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	the	O
13	chromogenic	O
14	cephalosporin	O
15	substrates	O
16	and	O
17	that	O
18	nitrocefin	O
19	and	O
20	S1	O
21	could	O
22	be	O
23	used	O
24	to	O
25	screen	O
26	for	O
27	beta	B
28	-	I
29	lactamase	I
30	production	O
31	in	O
32	these	O
33	tested	O
34	species	O
35	.	O

1	The	O
2	kinase	O
3	inhibitor	O
4	staurosporine	O
5	(	O
6	1	O
7	microM	O
8	)	O
9	blocks	O
10	LPA	O
11	-	O
12	induced	O
13	,	O
14	but	O
15	not	O
16	epidermal	B
17	growth	I
18	factor	I
19	-	I
20	induced	O
21	,	O
22	activation	O
23	of	O
24	p21ras	B
25	and	I
26	MAP	I
27	kinase	I
28	,	O
29	consistent	O
30	with	O
31	an	O
32	intermediate	B
33	protein	I
34	kinase	I
35	linking	O
36	the	O
37	LPA	B
38	receptor	I
39	to	O
40	p21ras	B
41	activation	O
42	.	O

1	Morphology	O
2	of	O
3	bacteriophages	O
4	of	O
5	Klebsiella	O
6	bacilli	O
7	.	O

1	A	O
2	series	O
3	of	O
4	5	O
5	'-	O
6	deletions	O
7	revealed	O
8	that	O
9	the	O
10	fragment	O
11	-	O
12	218	O
13	to	O
14	+	O
15	4	O
16	from	O
17	the	O
18	TSS	O
19	had	O
20	the	O
21	highest	O
22	promoter	O
23	activity	O
24	,	O
25	nearly	O
26	1000	O
27	-	O
28	fold	O
29	greater	O
30	than	O
31	the	O
32	promoterless	O
33	chloramphenicol	B
34	acetyltransferase	I
35	construct	I
36	.	I

1	Sequence	O
2	determination	O
3	of	O
4	isolated	O
5	peptides	O
6	suggested	O
7	that	O
8	Asn120	O
9	is	O
10	glycosylated	O
11	,	O
12	Asn65	O
13	and	O
14	Asn109	O
15	glycosylated	O
16	in	O
17	some	O
18	molecules	O
19	but	O
20	not	O
21	in	O
22	others	O
23	,	O
24	and	O
25	Asn72	O
26	not	O
27	glycosylated	O
28	.	O

1	A	O
2	.	O

1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O

1	Growth	O
2	curves	O
3	indicated	O
4	that	O
5	proliferation	O
6	of	O
7	clone	O
8	CA9	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	10	O
14	%	O
15	serum	O
16	was	O
17	reduced	O
18	by	O
19	60	O
20	%	O
21	compared	O
22	with	O
23	clone	O
24	ME10	O
25	.	O

1	The	O
2	first	O
3	algorithm	O
4	,	O
5	FOREPROJ	O
6	,	O
7	is	O
8	a	O
9	fast	O
10	-	O
11	forward	O
12	projection	O
13	algorithm	O
14	that	O
15	allows	O
16	calculation	O
17	of	O
18	the	O
19	3	O
20	-	O
21	D	O
22	attenuation	O
23	correction	O
24	factors	O
25	(	O
26	ACF	O
27	'	O
28	s	O
29	)	O
30	directly	O
31	from	O
32	a	O
33	two	O
34	-	O
35	dimensional	O
36	(	O
37	2	O
38	-	O
39	D	O
40	)	O
41	transmission	O
42	scan	O
43	,	O
44	without	O
45	first	O
46	reconstructing	O
47	the	O
48	attenuation	O
49	map	O
50	and	O
51	then	O
52	performing	O
53	a	O
54	3	O
55	-	O
56	D	O
57	forward	O
58	projection	O
59	.	O

1	Whereas	O
2	the	O
3	muscle	O
4	isoform	O
5	consists	O
6	of	O
7	997	O
8	amino	O
9	acids	O
10	and	O
11	terminates	O
12	with	O
13	the	O
14	sequence	O
15	Ala	O
16	-	O
17	Ile	O
18	-	O
19	Leu	O
20	-	O
21	Glu	O
22	,	O
23	the	O
24	second	O
25	isoform	O
26	is	O
27	1043	O
28	amino	O
29	acids	O
30	in	O
31	length	O
32	due	O
33	to	O
34	the	O
35	replacement	O
36	of	O
37	these	O
38	last	O
39	4	O
40	amino	O
41	acids	O
42	with	O
43	a	O
44	50	O
45	-	O
46	amino	O
47	acid	O
48	sequence	O
49	that	O
50	contains	O
51	a	O
52	potential	O
53	transmembrane	O
54	domain	O
55	followed	O
56	by	O
57	a	O
58	consensus	O
59	sequence	O
60	for	O
61	an	O
62	N	O
63	-	O
64	linked	O
65	glycosylation	O
66	site	O
67	.	O

1	The	O
2	latent	O
3	periods	O
4	from	O
5	the	O
6	antral	O
7	exclusion	O
8	to	O
9	the	O
10	occurrence	O
11	of	O
12	anastomotic	O
13	ulcers	O
14	after	O
15	a	O
16	subtotal	O
17	gastrectomy	O
18	with	O
19	Billroth	O
20	'	O
21	s	O
22	type	O
23	II	O
24	reconstruction	O
25	varied	O
26	from	O
27	a	O
28	few	O
29	days	O
30	to	O
31	19	O
32	years	O
33	,	O
34	with	O
35	an	O
36	average	O
37	of	O
38	2	O
39	.	O
40	8	O
41	years	O
42	.	O

1	SM	O
2	is	O
3	also	O
4	shown	O
5	to	O
6	be	O
7	associated	O
8	in	O
9	vivo	O
10	with	O
11	other	O
12	components	O
13	of	O
14	the	O
15	CRM	O
16	1	O
17	export	O
18	pathway	O
19	,	O
20	including	O
21	the	O
22	small	O
23	GTPase	B
24	Ran	I
25	and	O
26	the	O
27	nucleoporin	O
28	CAN	O
29	/	O
30	Nup214	O
31	.	O

1	Unilateral	O
2	naris	O
3	occlusion	O
4	and	O
5	the	O
6	rat	O
7	accessory	O
8	olfactory	O
9	bulb	O
10	.	O

1	Using	O
2	lectin	O
3	-	O
4	affinity	O
5	chromatography	O
6	,	O
7	discordance	O
8	between	O
9	the	O
10	pattern	O
11	of	O
12	O	O
13	-	O
14	glycosylation	O
15	of	O
16	SSBP	O
17	and	O
18	DSBP	O
19	was	O
20	demonstrated	O
21	.	O

1	In	O
2	Denmark	O
3	only	O
4	1	O
5	-	O
6	3	O
7	cases	O
8	of	O
9	transfusion	O
10	-	O
11	associated	O
12	hepatitis	O
13	NANB	O
14	(	O
15	TAH	O
16	-	O
17	NANB	O
18	)	O
19	are	O
20	registered	O
21	annually	O
22	or	O
23	about	O
24	1	O
25	case	O
26	per	O
27	100	O
28	,	O
29	000	O
30	units	O
31	transfused	O
32	.	O

1	Takahashi	O
2	,	O
3	H	O
4	.	O

1	Polymerization	O
2	of	O
3	neurofilament	O
4	L	O
5	protein	O
6	in	O
7	vitro	O
8	was	O
9	inhibited	O
10	by	O
11	phosphorylation	O
12	of	O
13	neurofilament	O
14	L	O
15	protein	O
16	by	O
17	PKN	B
18	.	I

1	Elimination	O
2	of	O
3	bagassosis	O
4	in	O
5	Louisiana	O
6	paper	O
7	manufacturing	O
8	plant	O
9	workers	O
10	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	and	O
5	genomic	O
6	sequences	O
7	shows	O
8	that	O
9	the	O
10	ZNF189	O
11	gene	O
12	spans	O
13	approximately	O
14	11	O
15	kb	O
16	and	O
17	is	O
18	organized	O
19	into	O
20	at	O
21	least	O
22	four	O
23	exons	O
24	,	O
25	the	O
26	large	O
27	3	O
28	'-	O
29	end	O
30	exon	O
31	coding	O
32	for	O
33	the	O
34	complete	O
35	zinc	O
36	finger	O
37	domain	O
38	and	O
39	the	O
40	3	O
41	'	O
42	untranslated	O
43	region	O
44	.	O

1	Refugees	O
2	living	O
3	in	O
4	Lund	O
5	and	O
6	repatriated	O
7	to	O
8	Chile	O
9	considered	O
10	their	O
11	health	O
12	as	O
13	bad	O
14	in	O
15	a	O
16	higher	O
17	proportion	O
18	than	O
19	their	O
20	Swedish	O
21	counterparts	O
22	,	O
23	with	O
24	an	O
25	odds	O
26	ratio	O
27	of	O
28	3	O
29	.	O
30	48	O
31	(	O
32	2	O
33	.	O
34	03	O
35	-	O
36	5	O
37	.	O
38	66	O
39	)	O
40	and	O
41	4	O
42	.	O
43	78	O
44	(	O
45	2	O
46	.	O
47	1	O
48	-	O
49	10	O
50	.	O
51	25	O
52	)	O
53	respectively	O
54	.	O

1	Applications	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	analysis	O
7	to	O
8	the	O
9	auditory	O
10	P300	O
11	.	O

1	In	O
2	HeLa	O
3	cells	O
4	,	O
5	the	O
6	JNKK2	B
7	-	I
8	JNK1	I
9	fusion	I
10	protein	I
11	showed	O
12	significant	O
13	JNK	B
14	activity	O
15	,	O
16	which	O
17	was	O
18	comparable	O
19	with	O
20	that	O
21	of	O
22	JNK1	B
23	activated	I
24	by	O
25	many	O
26	stimuli	O
27	and	O
28	activators	O
29	,	O
30	including	O
31	EGF	B
32	,	O
33	TNF	B
34	-	I
35	alpha	I
36	,	O
37	anisomycin	O
38	,	O
39	UV	O
40	irradiation	O
41	,	O
42	MEKK1	O
43	,	O
44	and	O
45	small	B
46	GTP	I
47	binding	I
48	proteins	I
49	Rac1	I
50	and	O
51	Cdc42Hs	B
52	.	I

1	The	O
2	low	O
3	number	O
4	of	O
5	false	O
6	positives	O
7	indicates	O
8	that	O
9	our	O
10	scheme	O
11	would	O
12	not	O
13	confuse	O
14	the	O
15	radiologist	O
16	by	O
17	suggesting	O
18	normal	O
19	regions	O
20	as	O
21	suspicious	O
22	.	O

1	The	O
2	human	O
3	cDNA	O
4	was	O
5	used	O
6	to	O
7	demonstrate	O
8	that	O
9	tumor	B
10	necrosis	I
11	factor	I
12	-	I
13	alpha	I
14	could	O
15	rapidly	O
16	stimulate	O
17	MARCKS	O
18	gene	O
19	transcription	O
20	in	O
21	the	O
22	human	O
23	promyelocytic	O
24	leukemia	O
25	cell	O
26	line	O
27	HL60	O
28	.	O

1	The	O
2	patient	O
3	had	O
4	developed	O
5	left	O
6	-	O
7	sided	O
8	low	O
9	-	O
10	frequency	O
11	tremor	O
12	and	O
13	hemidystonia	O
14	after	O
15	a	O
16	severe	O
17	head	O
18	trauma	O
19	sustained	O
20	at	O
21	15	O
22	years	O
23	of	O
24	age	O
25	.	O

1	Commutative	O
2	saccadic	O
3	generator	O
4	is	O
5	sufficient	O
6	to	O
7	control	O
8	a	O
9	3	O
10	-	O
11	D	O
12	ocular	O
13	plant	O
14	with	O
15	pulleys	O
16	.	O

1	Mammalian	O
2	sperm	O
3	motility	O
4	is	O
5	regulated	O
6	by	O
7	a	O
8	cascade	O
9	of	O
10	cAMP	B
11	-	I
12	dependent	I
13	protein	I
14	phosphorylation	O
15	events	O
16	mediated	O
17	by	O
18	protein	B
19	kinase	I
20	A	I
21	.	I

1	The	O
2	Menopause	O
3	-	O
4	Rating	O
5	-	O
6	Scale	O
7	(	O
8	MRS	O
9	I	O
10	)	O
11	was	O
12	used	O
13	in	O
14	clinical	O
15	practice	O
16	since	O
17	1992	O
18	.	O

1	Expression	O
2	of	O
3	activated	O
4	Cdc42	B
5	results	O
6	in	O
7	the	O
8	translocation	O
9	of	O
10	PKClambda	O
11	from	O
12	the	O
13	nucleus	O
14	into	O
15	the	O
16	cytosol	O
17	,	O
18	and	O
19	Cdc42	B
20	and	O
21	PKClambda	O
22	colocalize	O
23	at	O
24	the	O
25	plasma	O
26	membrane	O
27	and	O
28	in	O
29	the	O
30	cytoplasm	O
31	.	O

1	Gluzman	O
2	,	O
3	EMBO	O
4	J	O
5	.	O

1	A	O
2	385	O
3	bp	O
4	Glucocorticoid	O
5	Response	O
6	Unit	O
7	(	O
8	GRU	O
9	)	O
10	was	O
11	identified	O
12	whose	O
13	glucocorticoid	O
14	induction	O
15	was	O
16	enhanced	O
17	by	O
18	dibutyryl	O
19	-	O
20	cAMP	O
21	and	O
22	reduced	O
23	by	O
24	phorbol	O
25	esters	O
26	.	O

1	Natural	O
2	FL	O
3	protein	O
4	has	O
5	been	O
6	purified	O
7	from	O
8	a	O
9	stromal	O
10	cell	O
11	line	O
12	and	O
13	shown	O
14	to	O
15	be	O
16	a	O
17	65	O
18	kD	O
19	nondisulfide	B
20	-	I
21	linked	I
22	homodimeric	I
23	glycoprotein	I
24	comprised	I
25	of	O
26	30	O
27	kD	O
28	subunits	O
29	,	O
30	each	O
31	containing	O
32	12	O
33	kD	O
34	of	O
35	N	O
36	-	O
37	and	O
38	O	O
39	-	O
40	linked	O
41	sugars	O
42	.	O

1	TSA	O
2	treatment	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	detectably	B
9	alter	I
10	enhancer	I
11	factor	I
12	binding	I
13	or	O
14	the	O
15	positioning	O
16	of	O
17	nuc	O
18	-	O
19	1	O
20	on	O
21	the	O
22	majority	O
23	of	O
24	the	O
25	chromatin	O
26	templates	O
27	indicating	O
28	that	O
29	protein	O
30	acetylation	O
31	and	O
32	chromatin	O
33	remodeling	O
34	may	O
35	be	O
36	limiting	O
37	steps	O
38	that	O
39	occur	O
40	only	O
41	on	O
42	transcriptionally	O
43	competent	O
44	templates	O
45	,	O
46	or	O
47	that	O
48	remodeling	O
49	of	O
50	nuc	O
51	-	O
52	1	O
53	requires	O
54	additional	O
55	factors	O
56	.	O

1	It	O
2	was	O
3	shown	O
4	by	O
5	transient	O
6	expression	O
7	assay	O
8	that	O
9	HS	O
10	-	O
11	40	O
12	behaved	O
13	as	O
14	an	O
15	authentic	O
16	enhancer	O
17	for	O
18	high	O
19	-	O
20	level	O
21	zeta	B
22	2	I
23	globin	I
24	promoter	I
25	activity	O
26	in	O
27	K562	O
28	cells	O
29	,	O
30	an	O
31	erythroid	O
32	cell	O
33	line	O
34	of	O
35	embryonic	O
36	and	O
37	/	O
38	or	O
39	fetal	O
40	origin	O
41	.	O

1	Effects	O
2	of	O
3	a	O
4	perfluorochemical	O
5	blood	O
6	substitute	O
7	on	O
8	diazepam	O
9	binding	O
10	by	O
11	human	B
12	albumin	I
13	.	I

1	The	O
2	fission	O
3	yeast	O
4	dsk1	O
5	+	O
6	gene	O
7	,	O
8	a	O
9	multicopy	O
10	suppressor	O
11	for	O
12	cold	O
13	-	O
14	sensitive	O
15	dis1	O
16	mutants	O
17	,	O
18	encodes	O
19	a	O
20	novel	O
21	61	B
22	-	I
23	kd	I
24	protein	I
25	kinase	I
26	.	I

1	Molecular	O
2	cloning	O
3	and	O
4	characterisation	O
5	of	O
6	the	O
7	two	O
8	homologous	O
9	genes	O
10	coding	O
11	for	O
12	nitrate	B
13	reductase	I
14	in	O
15	tobacco	O
16	.	O

1	Pmt2	O
2	is	O
3	a	O
4	member	O
5	of	O
6	a	O
7	six	O
8	-	O
9	protein	O
10	family	O
11	in	O
12	yeast	O
13	that	O
14	catalyzes	O
15	the	O
16	first	O
17	step	O
18	in	O
19	O	O
20	mannosylation	O
21	of	O
22	target	O
23	proteins	O
24	.	O

1	The	O
2	most	O
3	striking	O
4	difference	O
5	in	O
6	the	O
7	birch	O
8	NAD	O
9	(	O
10	P	O
11	)	O
12	H	B
13	-	I
14	NR	I
15	sequence	O
16	in	O
17	comparison	O
18	to	O
19	NADH	B
20	-	I
21	NR	I
22	sequences	O
23	was	O
24	found	O
25	at	O
26	the	O
27	putative	O
28	pyridine	O
29	nucleotide	O
30	binding	O
31	site	O
32	.	O

1	Gap	O
2	b3	O
3	consists	O
4	of	O
5	two	O
6	polypeptide	O
7	chains	O
8	(	O
9	Mr	O
10	=	O
11	110	O
12	,	O
13	000	O
14	and	O
15	30	O
16	,	O
17	000	O
18	),	O
19	which	O
20	seem	O
21	to	O
22	be	O
23	proteolytic	O
24	cleavage	O
25	products	O
26	connected	O
27	by	O
28	disulfide	O
29	bonds	O
30	from	O
31	a	O
32	precursor	O
33	protein	O
34	.	O

1	Similarly	O
2	,	O
3	overexpression	O
4	of	O
5	increasing	O
6	concentration	O
7	of	O
8	COUP	B
9	-	I
10	TFI	I
11	,	O
12	but	O
13	not	O
14	COUP	B
15	-	I
16	TFI	I
17	delta35	O
18	,	O
19	can	O
20	squelch	O
21	the	O
22	silencing	O
23	activity	O
24	of	O
25	the	O
26	unliganded	O
27	TRbeta	O
28	.	O

1	Herein	O
2	,	O
3	we	O
4	show	O
5	that	O
6	Smad3	O
7	physically	O
8	interacts	O
9	with	O
10	the	O
11	HMG	B
12	box	I
13	domain	I
14	of	O
15	LEF1	O
16	and	O
17	that	O
18	TGFbeta	O
19	and	O
20	Wnt	B
21	pathways	O
22	synergize	O
23	to	O
24	activate	O
25	transcription	O
26	of	O
27	the	O
28	Xenopus	B
29	homeobox	I
30	gene	I
31	twin	I
32	(	O
33	Xtwn	O
34	).	O

1	Anti	B
2	-	I
3	hepatitis	O
4	A	O
5	virus	O
6	(	O
7	HAV	O
8	)	O
9	titer	O
10	after	O
11	vaccination	O
12	was	O
13	measured	O
14	in	O
15	83	O
16	HIV	O
17	-	O
18	positive	O
19	and	O
20	39	O
21	HIV	O
22	-	O
23	negative	O
24	men	O
25	.	O

1	The	O
2	gene	O
3	encoding	O
4	the	O
5	receptor	O
6	for	O
7	macrophage	B
8	colony	I
9	-	I
10	stimulating	I
11	factor	I
12	1	I
13	(	I
14	CSF	I
15	-	I
16	1	I
17	),	O
18	the	O
19	c	B
20	-	I
21	fms	I
22	protooncogene	I
23	,	O
24	is	O
25	selectively	O
26	expressed	O
27	in	O
28	immature	O
29	and	O
30	mature	O
31	mononuclear	O
32	phagocytes	O
33	and	O
34	trophoblasts	O
35	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	levels	O
7	of	O
8	oxygen	O
9	free	O
10	radicals	O
11	were	O
12	increased	O
13	in	O
14	hepatocytes	O
15	and	O
16	mitochondria	O
17	.	O

1	Since	O
2	we	O
3	have	O
4	observed	O
5	effects	O
6	of	O
7	growth	O
8	factors	O
9	and	O
10	cAMP	O
11	as	O
12	well	O
13	as	O
14	estradiol	O
15	(	O
16	E2	O
17	)	O
18	on	O
19	regulation	O
20	of	O
21	expression	O
22	of	O
23	some	O
24	genes	O
25	stimulated	O
26	by	O
27	the	O
28	estrogen	B
29	receptor	I
30	(	O
31	ER	O
32	),	O
33	we	O
34	have	O
35	undertaken	O
36	studies	O
37	to	O
38	examine	O
39	directly	O
40	whether	O
41	activators	O
42	of	O
43	protein	O
44	kinases	O
45	can	O
46	modulate	O
47	transcriptional	O
48	activity	O
49	of	O
50	the	O
51	ER	O
52	.	O

1	Recently	O
2	,	O
3	cell	O
4	-	O
5	surface	O
6	TRAIL	O
7	has	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	expressed	O
13	by	O
14	activated	O
15	human	O
16	and	O
17	mouse	O
18	T	O
19	lymphocytes	O
20	,	O
21	raising	O
22	the	O
23	possibility	O
24	that	O
25	TRAIL	O
26	might	O
27	be	O
28	involved	O
29	in	O
30	T	O
31	cell	O
32	-	O
33	mediated	O
34	cytotoxicity	O
35	and	O
36	/	O
37	or	O
38	immune	O
39	regulation	O
40	.	O

1	U24	O
2	has	O
3	two	O
4	separate	O
5	12	O
6	nt	O
7	long	O
8	complementarities	O
9	to	O
10	a	O
11	highly	O
12	conserved	O
13	tract	O
14	of	O
15	28S	B
16	rRNA	I
17	.	I

1	UAS1	O
2	is	O
3	the	O
4	binding	O
5	site	O
6	for	O
7	the	O
8	transcriptional	O
9	regulator	O
10	Adr1p	O
11	.	O

1	Consciousness	O
2	is	O
3	connected	O
4	with	O
5	attention	O
6	,	O
7	working	O
8	memory	O
9	and	O
10	perception	O
11	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	in	O
6	cultured	O
7	Jurkat	O
8	T	O
9	cells	O
10	,	O
11	Cbl	B
12	is	O
13	coprecipitated	O
14	with	O
15	antibody	O
16	against	O
17	the	O
18	adapter	O
19	protein	O
20	Grb2	B
21	.	I

1	Gemfibrozil	O
2	in	O
3	hyperlipidaemic	O
4	patients	O
5	with	O
6	peripheral	O
7	arterial	O
8	disease	O
9	:	O
10	some	O
11	undiscovered	O
12	actions	O
13	.	O

1	By	O
2	comparing	O
3	the	O
4	abundances	O
5	of	O
6	many	O
7	yeast	O
8	transcripts	O
9	in	O
10	isogenic	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	paf1	O
16	mutant	O
17	strains	O
18	,	O
19	we	O
20	have	O
21	identified	O
22	genes	O
23	whose	O
24	expression	O
25	is	O
26	affected	O
27	by	O
28	PAF1	O
29	.	O

1	Sequencing	O
2	analysis	O
3	has	O
4	shown	O
5	that	O
6	each	O
7	rap1t	O
8	allele	O
9	contains	O
10	a	O
11	nonsense	O
12	mutation	O
13	within	O
14	a	O
15	discrete	O
16	region	O
17	between	O
18	amino	O
19	acids	O
20	663	O
21	and	O
22	684	O
23	.	O

1	Regional	O
2	insertional	O
3	mutagenesis	O
4	of	O
5	specific	O
6	genes	O
7	on	O
8	the	O
9	CIC5F11	O
10	/	O
11	CIC2B9	O
12	locus	O
13	of	O
14	Arabidopsis	O
15	thaliana	O
16	chromosome	O
17	5	O
18	using	O
19	the	O
20	Ac	O
21	/	O
22	Ds	O
23	transposon	O
24	in	O
25	combination	O
26	with	O
27	the	O
28	cDNA	O
29	scanning	O
30	method	O
31	.	O

1	However	O
2	,	O
3	while	O
4	IL	B
5	-	I
6	1beta	I
7	and	O
8	TNF	B
9	-	I
10	alpha	I
11	both	O
12	induced	O
13	nuclear	O
14	binding	O
15	of	O
16	the	O
17	Rel	B
18	proteins	I
19	p50	I
20	and	O
21	p65	B
22	to	O
23	an	O
24	NF	B
25	-	I
26	kappaB	I
27	consensus	O
28	oligonucleotide	O
29	in	O
30	gel	O
31	shift	O
32	assays	O
33	and	O
34	caused	O
35	transient	O
36	degradation	O
37	of	O
38	inhibitor	O
39	of	O
40	NF	B
41	-	I
42	kappaB	I
43	-	I
44	alpha	I
45	(	I
46	IkappaB	I
47	-	I
48	alpha	I
49	)	O
50	in	O
51	the	O
52	cytoplasm	O
53	of	O
54	myofibroblasts	O
55	,	O
56	only	O
57	IL	B
58	-	I
59	1beta	I
60	upregulated	I
61	PDGF	I
62	-	I
63	Ralpha	O
64	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	several	O
6	E1	O
7	mutants	O
8	mapping	O
9	in	O
10	both	O
11	the	O
12	M	O
13	and	O
14	R	O
15	regions	O
16	and	O
17	a	O
18	single	O
19	mutant	O
20	of	O
21	the	O
22	upstream	O
23	regulatory	O
24	region	O
25	have	O
26	a	O
27	higher	O
28	transforming	O
29	activity	O
30	on	O
31	mouse	O
32	C127	O
33	cells	O
34	than	O
35	the	O
36	wild	O
37	-	O
38	type	O
39	genome	O
40	does	O
41	.	O

1	Value	O
2	of	O
3	urine	O
4	glucose	O
5	tests	O
6	in	O
7	the	O
8	management	O
9	of	O
10	type	O
11	II	O
12	diabetes	O
13	mellitus	O
14	.	O

1	Additionally	O
2	,	O
3	MIP	B
4	-	I
5	2A	I
6	antagonizes	O
7	cell	O
8	growth	O
9	regulatory	O
10	role	O
11	of	O
12	MBP	B
13	-	I
14	1	I
15	.	I

1	Our	O
2	findings	O
3	support	O
4	the	O
5	view	O
6	of	O
7	a	O
8	multifactorial	O
9	genesis	O
10	of	O
11	the	O
12	cardiac	O
13	involvement	O
14	in	O
15	uremic	O
16	patients	O
17	.	O

1	A	O
2	mutant	O
3	(	O
4	residues	O
5	1	O
6	-	O
7	332	O
8	)	O
9	showed	O
10	complete	O
11	Ca2	B
12	+/	I
13	CaM	I
14	-	I
15	dependent	I
16	activity	O
17	.	O

1	At	O
2	maximum	O
3	photosensitivity	O
4	the	O
5	inhibitory	O
6	amino	O
7	acids	O
8	gamma	B
9	-	I
10	aminobutyric	I
11	acid	O
12	and	O
13	taurine	O
14	were	O
15	lower	O
16	,	O
17	and	O
18	those	O
19	of	O
20	asparagine	O
21	(	O
22	metabolite	O
23	of	O
24	the	O
25	excitatory	O
26	amino	O
27	acid	O
28	aspartate	O
29	)	O
30	were	O
31	higher	O
32	,	O
33	than	O
34	when	O
35	the	O
36	animals	O
37	were	O
38	not	O
39	photosensitive	O
40	.	O

1	The	O
2	requirement	O
3	for	O
4	proteolytic	O
5	activity	O
6	of	O
7	both	O
8	FVIIa	O
9	and	O
10	FXa	O
11	suggests	O
12	that	O
13	protease	B
14	-	I
15	activated	I
16	receptors	I
17	may	O
18	be	O
19	involved	O
20	.	O

1	However	O
2	,	O
3	reoperation	O
4	for	O
5	bulky	O
6	cervical	O
7	disease	O
8	(	O
9	group	O
10	3	O
11	)	O
12	rarely	O
13	results	O
14	in	O
15	normal	O
16	calcitonin	B
17	levels	O
18	and	O
19	is	O
20	associated	O
21	with	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	permanent	O
27	hypoparathyroidism	O
28	.	O

1	SETTING	O
2	:	O
3	A	O
4	division	O
5	of	O
6	a	O
7	large	O
8	tea	O
9	plantation	O
10	in	O
11	Kandy	O
12	.	O

1	The	O
2	CPK	B
3	-	I
4	MB	I
5	isoenzyme	I
6	showed	O
7	no	O
8	percentage	O
9	increase	O
10	of	O
11	total	O
12	CPK	O
13	higher	O
14	than	O
15	5	O
16	%,	O
17	measured	O
18	at	O
19	6	O
20	,	O
21	12	O
22	,	O
23	and	O
24	24	O
25	h	O
26	after	O
27	the	O
28	shock	O
29	,	O
30	independent	O
31	of	O
32	the	O
33	number	O
34	of	O
35	attempts	O
36	of	O
37	cardioversion	O
38	.	O

1	Basal	O
2	plasma	B
3	renin	I
4	activity	O
5	(	O
6	PRA	O
7	)	O
8	was	O
9	slightly	O
10	raised	O
11	prior	O
12	to	O
13	training	O
14	(	O
15	P	O
16	<	O
17	0	O
18	.	O
19	07	O
20	)	O
21	compared	O
22	to	O
23	the	O
24	controls	O
25	and	O
26	post	O
27	-	O
28	training	O
29	.	O

1	Changes	O
2	in	O
3	ionic	O
4	content	O
5	of	O
6	the	O
7	mucous	O
8	suggest	O
9	that	O
10	cholinergic	O
11	mechanisms	O
12	affect	O
13	pressure	O
14	in	O
15	the	O
16	excretory	O
17	duct	O
18	of	O
19	the	O
20	gland	O
21	.	O

1	These	O
2	CTD	B
3	kinases	I
4	,	O
5	designated	O
6	CTDK1	O
7	and	O
8	CTDK2	O
9	,	O
10	are	O
11	fractionated	O
12	by	O
13	chromatography	O
14	on	O
15	Mono	O
16	Q	O
17	.	O

1	In	O
2	the	O
3	electrophoresis	O
4	mobility	O
5	shift	O
6	assay	O
7	using	O
8	nuclear	O
9	extracts	O
10	of	O
11	the	O
12	myogenic	O
13	cells	O
14	,	O
15	MyoD	B
16	and	O
17	myogenin	B
18	bound	O
19	to	O
20	the	O
21	right	O
22	E	O
23	-	O
24	box	O
25	in	O
26	the	O
27	enhancer	O
28	region	O
29	of	O
30	the	O
31	MCK	B
32	gene	I
33	even	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	BMP	B
39	-	I
40	2	I
41	.	I

1	The	O
2	effect	O
3	of	O
4	the	O
5	fatty	B
6	acid	I
7	cyclo	I
8	-	I
9	oxygenase	I
10	inhibitor	O
11	indomethacin	O
12	on	O
13	cerebral	O
14	blood	O
15	flow	O
16	(	O
17	CBF	O
18	)	O
19	and	O
20	the	O
21	metabolic	O
22	rate	O
23	for	O
24	oxygen	O
25	(	O
26	CMRO2	O
27	)	O
28	was	O
29	studied	O
30	in	O
31	paralyzed	O
32	and	O
33	artificially	O
34	ventilated	O
35	rats	O
36	.	O

1	Benefits	O
2	of	O
3	obtaining	O
4	board	O
5	certification	O
6	in	O
7	pharmacotherapy	O
8	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O

1	Patients	O
2	underwent	O
3	pretreatment	O
4	cystoscopy	O
5	and	O
6	detailed	O
7	tumor	O
8	mapping	O
9	,	O
10	and	O
11	were	O
12	treated	O
13	with	O
14	75	O
15	mg	O
16	.	O
17	/	O
18	m	O
19	.	O
20	2	O
21	cisplatin	O
22	on	O
23	day	O
24	1	O
25	and	O
26	1	O
27	gm	O
28	./	O
29	m	O
30	.	O
31	2	O
32	daily	O
33	,	O
34	5	O
35	-	O
36	fluorouracil	O
37	on	O
38	days	O
39	1	O
40	to	O
41	4	O
42	and	O
43	definitive	O
44	radiotherapy	O
45	.	O

1	The	O
2	films	O
3	were	O
4	analyzed	O
5	using	O
6	a	O
7	scanning	O
8	helium	O
9	-	O
10	neon	O
11	laser	O
12	densitometer	O
13	with	O
14	a	O
15	small	O
16	aperture	O
17	of	O
18	5	O
19	-	O
20	10	O
21	microns	O
22	.	O

1	Bronchial	O
2	mucosa	O
3	tattooing	O
4	in	O
5	persons	O
6	exposed	O
7	to	O
8	different	O
9	industrial	O
10	aerosols	O
11	did	O
12	not	O
13	depend	O
14	on	O
15	the	O
16	forms	O
17	of	O
18	PC	O
19	,	O
20	DB	O
21	and	O
22	the	O
23	diseases	O
24	'	O
25	stages	O
26	.	O

1	Thyreoliberin	O
2	VUFB	O
3	in	O
4	thyroid	O
5	gammagraphy	B

1	Carbonic	B
2	anhydrase	I
3	V	I
4	(	O
5	CA	O
6	V	O
7	)	O
8	is	O
9	expressed	O
10	in	O
11	mitochondrial	O
12	matrix	O
13	in	O
14	liver	O
15	and	O
16	several	O
17	other	O
18	tissues	O
19	.	O

1	Because	O
2	of	O
3	the	O
4	operon	O
5	structure	O
6	of	O
7	this	O
8	organism	O
9	,	O
10	traditional	O
11	methods	O
12	such	O
13	as	O
14	insertional	O
15	mutagenesis	O
16	run	O
17	the	O
18	risk	O
19	of	O
20	introducing	O
21	polar	O
22	effects	O
23	on	O
24	downstream	O
25	genes	O
26	or	O
27	creating	O
28	secondary	O
29	mutations	O
30	elsewhere	O
31	in	O
32	the	O
33	genome	O
34	.	O

1	The	O
2	patients	O
3	are	O
4	two	O
5	healthy	O
6	adult	O
7	males	O
8	.	O

1	Mutant	O
2	enzyme	O
3	forms	O
4	were	O
5	prepared	O
6	to	O
7	eliminate	O
8	the	O
9	initial	O
10	autoprocessing	O
11	site	O
12	and	O
13	thus	O
14	form	O
15	an	O
16	active	O
17	single	O
18	-	O
19	chain	O
20	protein	O
21	for	O
22	structure	O
23	-	O
24	function	O
25	studies	O
26	.	O

1	(	O
2	3	O
3	).	O

1	A	O
2	73	O
3	bp	O
4	fragment	O
5	(	O
6	X1	O
7	region	O
8	)	O
9	of	O
10	the	O
11	PRB	B
12	-	I
13	1b	I
14	promoter	I
15	,	O
16	located	O
17	between	O
18	positions	O
19	-	O
20	213	O
21	and	O
22	-	O
23	141	O
24	,	O
25	was	O
26	sufficient	O
27	to	O
28	confer	O
29	ethylene	O
30	responsiveness	O
31	to	O
32	the	O
33	reporter	O
34	gene	O
35	.	O

1	Charcoal	O
2	-	O
3	facilitated	O
4	dialysis	O
5	.	O

1	Surprisingly	O
2	,	O
3	nuclear	O
4	forms	O
5	of	O
6	IE110	O
7	were	O
8	found	O
9	to	O
10	move	O
11	a	O
12	cytoplasmic	O
13	form	O
14	of	O
15	IE175	O
16	into	O
17	nuclear	O
18	punctate	O
19	structures	O
20	,	O
21	and	O
22	a	O
23	cytoplasmic	O
24	form	O
25	of	O
26	IE110	O
27	was	O
28	able	O
29	to	O
30	retain	O
31	nuclear	O
32	forms	O
33	of	O
34	IE175	O
35	in	O
36	cytoplasmic	O
37	punctate	O
38	structures	O
39	.	O

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	B
15	ACTH	I
16	and	I
17	MSH	I
18	contents	I
19	.	I

1	The	O
2	cloning	O
3	of	O
4	PTR2	O
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	B
17	peptide	I
18	transport	I
19	gene	I
20	.	I

1	Granisetron	O
2	,	O
3	but	O
4	not	O
5	saline	O
6	,	O
7	abolished	O
8	vomiting	O
9	and	O
10	nausea	O
11	when	O
12	given	O
13	as	O
14	intervention	O
15	after	O
16	this	O
17	combined	O
18	emetic	O
19	regimen	O
20	.	O

1	Negatively	O
2	supercoiled	O
3	plasmid	O
4	pUC19	O
5	did	O
6	not	O
7	compete	O
8	,	O
9	whereas	O
10	an	O
11	otherwise	O
12	identical	O
13	plasmid	O
14	pUC19	O
15	(	O
16	CG	O
17	),	O
18	which	O
19	contained	O
20	a	O
21	(	O
22	dG	O
23	-	O
24	dC	O
25	)	O
26	7	O
27	segment	O
28	in	O
29	the	O
30	Z	O
31	-	O
32	form	O
33	was	O
34	an	O
35	excellent	O
36	competitor	O
37	.	O

1	ATP	B
2	gamma	I
3	S	I
4	inhibition	O
5	can	O
6	be	O
7	overcome	O
8	by	O
9	high	O
10	concentrations	O
11	of	O
12	ATP	O
13	,	O
14	dATP	O
15	,	O
16	araATP	O
17	,	O
18	or	O
19	ddATP	O
20	.	O

1	Three	O
2	pyridoxine	O
3	derivatives	O
4	have	O
5	been	O
6	isolated	O
7	from	O
8	the	O
9	fresh	O
10	stem	O
11	bark	O
12	of	O
13	Albizzia	O
14	julibrissin	O
15	DURAZZ	B
16	..	I

1	As	O
2	the	O
3	high	O
4	-	O
5	affinity	O
6	Mg2	O
7	+	O
8	binding	O
9	sites	O
10	are	O
11	filled	O
12	,	O
13	the	O
14	primer	O
15	terminus	O
16	migrates	O
17	from	O
18	the	O
19	exonuclease	O
20	site	O
21	to	O
22	a	O
23	highly	O
24	based	O
25	stacked	B
26	polymerase	I
27	active	O
28	site	O
29	.	O

1	Routine	O
2	clinical	O
3	analysis	O
4	revealed	O
5	lower	O
6	hematocrit	O
7	and	O
8	hemoglobin	B
9	,	O
10	and	O
11	elevated	O
12	BUN	O
13	and	O
14	alkaline	B
15	phosphatase	I
16	in	O
17	the	O
18	treated	O
19	group	O
20	.	O

1	The	O
2	expression	O
3	of	O
4	chloramphenicol	B
5	acetyltransferase	I
6	was	O
7	detected	O
8	within	O
9	1	O
10	h	O
11	after	O
12	infection	O
13	of	O
14	cells	O
15	with	O
16	recombinant	O
17	virus	O
18	,	O
19	reflecting	O
20	the	O
21	early	O
22	nature	O
23	of	O
24	the	O
25	promoters	O
26	used	O
27	.	O

1	The	O
2	presence	O
3	of	O
4	visna	O
5	-	O
6	maedi	O
7	in	O
8	Italy	O
9	is	O
10	reported	O
11	for	O
12	the	O
13	first	O
14	time	O
15	.	O

1	Slap	O
2	negatively	O
3	regulates	O
4	Src	B
5	mitogenic	O
6	function	O
7	but	O
8	does	O
9	not	O
10	revert	O
11	Src	B
12	-	I
13	induced	O
14	cell	O
15	morphology	O
16	changes	O
17	.	O

1	Demonstration	O
2	of	O
3	fine	O
4	structure	O
5	of	O
6	the	O
7	guinea	O
8	pig	O
9	organ	O
10	of	O
11	Corti	O
12	after	O
13	electron	O
14	microscopic	O
15	silver	O
16	staining	O

1	There	O
2	was	O
3	a	O
4	significant	O
5	but	O
6	similar	O
7	elevation	O
8	of	O
9	mean	O
10	O2	O
11	uptake	O
12	during	O
13	40	O
14	min	O
15	postexercise	O
16	by	O
17	13	O
18	.	O
19	6	O
20	%	O
21	in	O
22	both	O
23	the	O
24	fasted	O
25	(	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	)	O
33	and	O
34	fed	O
35	state	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O

1	Although	O
2	there	O
3	is	O
4	little	O
5	evidence	O
6	that	O
7	diet	O
8	composition	O
9	plays	O
10	a	O
11	clinically	O
12	important	O
13	role	O
14	in	O
15	the	O
16	absorption	O
17	or	O
18	expenditure	O
19	of	O
20	energy	O
21	,	O
22	it	O
23	does	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	food	O
31	intake	O
32	.	O

1	Specifically	O
2	,	O
3	the	O
4	deduced	O
5	FR	O
6	-	O
7	19	O
8	amino	O
9	acid	O
10	sequence	O
11	has	O
12	approximately89	O
13	,	O
14	77	O
15	,	O
16	and	O
17	68	O
18	%	O
19	overall	O
20	identity	O
21	to	O
22	chicken	B
23	TEF	I
24	-	I
25	1A	I
26	,	O
27	mouse	O
28	TEF	B
29	-	I
30	1	I
31	,	O
32	and	O
33	mouse	O
34	embryonic	O
35	TEA	B
36	domain	I
37	-	I
38	containing	I
39	factor	I
40	,	O
41	respectively	O
42	.	O

1	3	O
2	'-	O
3	Methyl	O
4	,	O
5	8	O
6	-	O
7	methyl	O
8	,	O
9	and	O
10	8	O
11	-	O
12	phenyl	O
13	derivatives	O
14	of	O
15	5	O
16	,	O
17	9	O
18	-	O
19	dimethyl	O
20	-	O
21	6	O
22	,	O
23	7	O
24	-	O
25	benzomorphans	O
26	.	O

1	This	O
2	R	O
3	-	O
4	domain	O
5	may	O
6	modulate	O
7	the	O
8	interaction	O
9	with	O
10	SRF	B
11	,	O
12	providing	O
13	a	O
14	mechanism	O
15	that	O
16	would	O
17	be	O
18	unique	O
19	to	O
20	FLI1	B
21	and	O
22	EWS	B
23	-	I
24	FLI1	I
25	,	O
26	thus	O
27	implicating	O
28	a	O
29	novel	O
30	function	O
31	for	O
32	these	O
33	ETS	B
34	transcription	I
35	factors	I
36	in	O
37	the	O
38	regulation	O
39	of	O
40	the	O
41	Egr1	B
42	gene	I
43	.	I

1	We	O
2	have	O
3	isolated	O
4	a	O
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	O
10	anemia	O
11	group	O
12	C	O
13	protein	O
14	(	O
15	FANCC	O
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O

1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	B
8	AM	I
9	gene	I
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	O
21	gene	O
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O

1	Among	O
2	these	O
3	360	B
4	ZFPs	I
5	,	O
6	a	O
7	novel	O
8	ZFP	B
9	cDNA	I
10	named	O
11	HFHZ	O
12	(	O
13	human	O
14	fetal	O
15	heart	O
16	ZFP	O
17	)	O
18	with	O
19	sequence	O
20	homology	O
21	to	O
22	a	O
23	Kruppel	B
24	-	I
25	associated	I
26	box	I
27	(	O
28	KRAB	B
29	)	O
30	was	O
31	identified	O
32	.	O

1	Protein	O
2	S	O
3	levels	O
4	were	O
5	virtually	O
6	undetectable	O
7	at	O
8	the	O
9	time	O
10	of	O
11	admission	O
12	and	O
13	failed	O
14	to	O
15	respond	O
16	to	O
17	infusions	O
18	of	O
19	fresh	O
20	frozen	O
21	plasma	O
22	,	O
23	despite	O
24	correction	O
25	of	O
26	other	O
27	procoagulant	O
28	and	O
29	anticoagulant	O
30	factors	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	a	O
7	novel	O
8	type	O
9	of	O
10	inhibitory	O
11	domain	O
12	in	O
13	the	O
14	N	O
15	-	O
16	terminal	O
17	60	O
18	amino	O
19	acids	O
20	of	O
21	IRF	B
22	-	I
23	1	I
24	which	O
25	strongly	O
26	inhibits	O
27	its	O
28	transcriptional	O
29	activity	O
30	.	O

1	Pancreaticoduodenal	O
2	lymph	O
3	node	O
4	enlargement	O
5	,	O
6	regardless	O
7	of	O
8	cause	O
9	,	O
10	has	O
11	been	O
12	a	O
13	source	O
14	of	O
15	imaging	O
16	confusion	O
17	because	O
18	of	O
19	its	O
20	propensity	O
21	to	O
22	mimic	O
23	pancreatic	O
24	malignancy	O
25	yet	O
26	not	O
27	cause	O
28	biliary	O
29	obstruction	O
30	.	O

1	The	O
2	scores	O
3	are	O
4	dependent	O
5	in	O
6	part	O
7	on	O
8	the	O
9	reliability	O
10	of	O
11	faculty	O
12	evaluations	O
13	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	CBF	O
9	/	O
10	NF	B
11	-	I
12	Y	I
13	to	O
14	the	O
15	inverted	O
16	CCAAT	O
17	box	O
18	is	O
19	responsible	O
20	for	O
21	transcriptional	O
22	activation	O
23	of	O
24	the	O
25	nTPH	B
26	gene	I
27	.	I

1	Cerebrospinal	O
2	fluid	O
3	transferrin	B
4	II	I
5	studies	O
6	in	O
7	ischemic	O
8	disorders	O
9	of	O
10	the	O
11	central	O
12	nervous	O
13	system	O
14	.	O

1	Furthermore	O
2	,	O
3	beta	B
4	2	I
5	-	I
6	adrenoceptor	I
7	sensitivity	O
8	appears	O
9	to	O
10	be	O
11	unaltered	O
12	in	O
13	BHT	O
14	.	O

1	These	O
2	factors	O
3	belong	O
4	to	O
5	a	O
6	set	O
7	of	O
8	genetically	O
9	distinct	O
10	molecules	O
11	,	O
12	including	O
13	AP	B
14	-	I
15	4	I
16	and	O
17	MLTF	O
18	,	O
19	that	O
20	bind	O
21	to	O
22	the	O
23	CACCTGTC	O
24	motif	O
25	or	O
26	related	O
27	sequences	O
28	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	IIIa	O
6	pre	O
7	-	O
8	mRNA	O
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	Ad	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	uninfected	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O

1	The	O
2	pCMBS	B
3	-	I
4	reactive	I
5	sulfhydryl	I
6	groups	O
7	were	O
8	located	O
9	exclusively	O
10	in	O
11	the	O
12	exofacial	O
13	half	O
14	of	O
15	the	O
16	plasma	O
17	membrane	O
18	and	O
19	,	O
20	when	O
21	presented	O
22	in	O
23	a	O
24	helical	O
25	model	O
26	,	O
27	lie	O
28	along	O
29	one	O
30	side	O
31	of	O
32	the	O
33	helices	O
34	.	O

1	Selected	O
2	topics	O
3	in	O
4	laboratory	O
5	animal	O
6	medicine	O
7	.	O

1	The	O
2	mEmBP	B
3	-	I
4	1	I
5	protein	I
6	can	O
7	activate	O
8	transcription	O
9	from	O
10	a	O
11	truncated	O
12	promoter	O
13	containing	O
14	a	O
15	pentamer	O
16	of	O
17	the	O
18	O2	O
19	site	O
20	in	O
21	yeast	O
22	cells	O
23	;	O
24	however	O
25	,	O
26	it	O
27	inhibited	O
28	regulated	O
29	transcription	O
30	of	O
31	a	O
32	22	O
33	kDa	O
34	zein	B
35	promoter	I
36	in	O
37	a	O
38	transient	O
39	expression	O
40	assay	O
41	using	O
42	cultured	O
43	maize	O
44	endosperm	O
45	cells	O
46	.	O

1	HYPOTHESIS	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	investigate	O
11	the	O
12	oxidative	O
13	susceptibility	O
14	of	O
15	apolipoprotein	B
16	B	I
17	-	I
18	containing	O
19	lipoproteins	O
20	and	O
21	antioxidant	O
22	status	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	coronary	O
28	syndromes	O
29	and	O
30	chronic	O
31	stable	O
32	angina	O
33	pectoris	O
34	.	O

1	The	O
2	detector	O
3	has	O
4	the	O
5	advantage	O
6	of	O
7	finding	O
8	both	O
9	ST	O
10	segment	O
11	deviations	O
12	and	O
13	entire	O
14	ST	O
15	-	O
16	T	O
17	complex	O
18	changes	O
19	thereby	O
20	providing	O
21	a	O
22	wider	O
23	characterization	O
24	of	O
25	the	O
26	potential	O
27	ischemic	O
28	events	O
29	.	O

1	Depth	O
2	-	O
3	controlled	O
4	grazing	O
5	-	O
6	incidence	O
7	diffraction	O
8	of	O
9	synchrotron	O
10	x	O
11	radiation	O
12	.	O

1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	authors	O
5	emphasize	O
6	that	O
7	the	O
8	initial	O
9	management	O
10	of	O
11	primary	O
12	STS	O
13	should	O
14	be	O
15	adequate	O
16	and	O
17	suggest	O
18	that	O
19	safty	O
20	margin	O
21	of	O
22	>	O
23	or	O
24	=	O
25	2	O
26	cm	O
27	should	O
28	be	O
29	adhered	O
30	to	O
31	.	O

1	The	O
2	clinical	O
3	picture	O
4	of	O
5	the	O
6	disease	O
7	was	O
8	significantly	O
9	different	O
10	from	O
11	anthropogenic	O
12	cutaneous	O
13	leishmaniasis	O
14	caused	O
15	by	O
16	L	O
17	.	O
18	tropica	O
19	but	O
20	similar	O
21	to	O
22	cutaneous	O
23	patterns	O
24	caused	O
25	by	O
26	L	O
27	.	O
28	infantum	O
29	which	O
30	was	O
31	a	O
32	prevalent	O
33	pattern	O
34	in	O
35	the	O
36	southern	O
37	France	O
38	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	an	O
5	amphibian	O
6	insulin	B
7	receptor	I
8	substrate	I
9	1	I
10	-	I
11	like	I
12	cDNA	I
13	and	O
14	involvement	O
15	of	O
16	phosphatidylinositol	B
17	3	I
18	-	I
19	kinase	I
20	in	O
21	insulin	B
22	-	I
23	induced	O
24	Xenopus	O
25	oocyte	O
26	maturation	O
27	.	O

1	The	O
2	HMG	B
3	domain	I
4	of	O
5	both	O
6	HMG20	O
7	proteins	O
8	is	O
9	most	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	yeast	O
15	NHP6A	O
16	(	O
17	38	O
18	%	O
19	to	O
20	42	O
21	%).	O

1	A	O
2	site	O
3	-	O
4	directed	O
5	R618K	O
6	mutation	O
7	in	O
8	the	O
9	Stat5	B
10	SH2	I
11	domain	I
12	abolished	O
13	the	O
14	phosphorylation	O
15	by	O
16	Jak2	O
17	,	O
18	while	O
19	deletion	O
20	of	O
21	the	O
22	C	O
23	terminus	O
24	led	O
25	to	O
26	Stat5	B
27	hyperphosphorylation	I
28	.	I

1	Effects	O
2	of	O
3	dioxins	O
4	on	O
5	thyroid	O
6	function	O
7	in	O
8	newborn	O
9	babies	O
10	.	O

1	These	O
2	results	O
3	support	O
4	a	O
5	model	O
6	in	O
7	which	O
8	p53	B
9	protein	I
10	contributes	O
11	to	O
12	the	O
13	maintenance	O
14	of	O
15	genomic	O
16	integrity	O
17	through	O
18	recombinational	O
19	repair	O
20	.	O

1	Temafloxacin	O
2	400	O
3	mg	O
4	b	O
5	.	O
6	i	O
7	.	O
8	d	O
9	.	O
10	administered	O
11	orally	O
12	for	O
13	28	O
14	days	O
15	represents	O
16	a	O
17	safe	O
18	and	O
19	effective	O
20	treatment	O
21	for	O
22	chronic	O
23	bacterial	O
24	prostatitis	O
25	.	O

1	VDR	B
2	/	O
3	RXR	B
4	bound	O
5	well	O
6	to	O
7	the	O
8	VDREs	O
9	and	O
10	to	O
11	DR4	O
12	and	O
13	DR5	O
14	using	O
15	the	O
16	electrophoretic	O
17	mobility	O
18	shift	O
19	assay	O
20	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bilinear	O
5	model	O
6	provided	O
7	a	O
8	significantly	O
9	better	O
10	fit	O
11	to	O
12	the	O
13	acuity	O
14	outcome	O
15	data	O
16	.	O

1	Both	O
2	filters	O
3	equally	O
4	contributed	O
5	to	O
6	elevation	O
7	of	O
8	iliac	O
9	venous	O
10	pressure	O
11	(	O
12	median	O
13	,	O
14	9	O
15	.	O
16	3	O
17	and	O
18	7	O
19	.	O
20	2	O
21	mm	O
22	Hg	O
23	[	O
24	n	O
25	=	O
26	9	O
27	]	O
28	with	O
29	the	O
30	spring	O
31	filter	O
32	and	O
33	RF02	O
34	filter	O
35	,	O
36	respectively	O
37	).	O

1	INTERVENTIONS	O
2	:	O
3	Subcutaneous	O
4	tissue	O
5	PO2	O
6	and	O
7	PCO2	O
8	tensions	O
9	were	O
10	measured	O
11	directly	O
12	in	O
13	patients	O
14	with	O
15	necrotising	O
16	fasciitis	O
17	and	O
18	in	O
19	healthy	O
20	volunteers	O
21	during	O
22	normobaric	O
23	and	O
24	hyperbaric	O
25	conditions	O
26	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	tissue	O
7	-	O
8	restricted	O
9	transcription	O
10	factors	O
11	including	O
12	PU	B
13	.	O
14	1	O
15	and	O
16	PU	B
17	.	O
18	1	O
19	interaction	O
20	partner	O
21	(	O
22	PIP	O
23	)	O
24	function	O
25	synergistically	O
26	with	O
27	c	B
28	-	I
29	Fos	I
30	plus	O
31	c	B
32	-	I
33	Jun	I
34	to	O
35	stimulate	O
36	the	O
37	kappaE3	O
38	'-	O
39	enhancer	O
40	in	O
41	3T3	O
42	cells	O
43	.	O

1	CONCLUSIONS	O
2	:	O
3	Significant	O
4	elevations	O
5	of	O
6	IL	B
7	-	I
8	1alpha	I
9	and	O
10	IL	B
11	-	I
12	1beta	I
13	occur	O
14	in	O
15	patients	O
16	with	O
17	bacterial	O
18	cystitis	O
19	and	O
20	microscopic	O
21	hematuria	O
22	.	O

1	Muscle	O
2	GSH	B
3	-	I
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	These	O
2	six	O
3	amino	O
4	acids	O
5	are	O
6	part	O
7	of	O
8	an	O
9	amphipathic	O
10	helix	O
11	that	O
12	is	O
13	highly	O
14	conserved	O
15	among	O
16	nuclear	B
17	hormone	I
18	receptors	I
19	and	O
20	contains	O
21	the	O
22	core	O
23	domain	O
24	of	O
25	the	O
26	ligand	O
27	-	O
28	dependent	O
29	transactivation	O
30	function	O
31	,	O
32	AF	B
33	-	I
34	2	I
35	.	I

1	Connector	O
2	enhancer	O
3	of	O
4	KSR	O
5	(	O
6	CNK	O
7	)	O
8	is	O
9	a	O
10	multidomain	O
11	protein	O
12	required	O
13	for	O
14	RAS	B
15	signaling	O
16	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	binding	O
6	affinity	O
7	for	O
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O

1	HEF1	B
2	,	O
3	p130	B
4	(	O
5	Cas	O
6	),	O
7	and	O
8	Efs	O
9	/	O
10	Sin	O
11	constitute	O
12	a	O
13	family	O
14	of	O
15	multidomain	O
16	docking	O
17	proteins	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	coordinating	O
24	the	O
25	regulation	O
26	of	O
27	cell	O
28	adhesion	O
29	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	isolate	O
6	genes	O
7	with	O
8	down	O
9	-	O
10	regulated	O
11	expression	O
12	at	O
13	the	O
14	mRNA	O
15	level	O
16	during	O
17	oncogenic	O
18	transformation	O
19	of	O
20	human	O
21	mammary	O
22	epithelial	O
23	cells	O
24	(	O
25	MECs	O
26	),	O
27	we	O
28	performed	O
29	subtractive	O
30	hybridization	O
31	between	O
32	normal	O
33	MEC	O
34	strain	O
35	76N	O
36	and	O
37	its	O
38	radiation	O
39	-	O
40	transformed	O
41	tumorigenic	O
42	derivative	O
43	76R	O
44	-	O
45	30	O
46	.	O

1	Stylohyoid	O
2	chain	O
3	ossification	O
4	:	O
5	choice	O
6	of	O
7	the	O
8	surgical	O
9	approach	O
10	.	O

1	Erythrocyte	O
2	AA	O
3	in	O
4	FO	O
5	+	O
6	EPO	B
7	-	I
8	supplemented	I
9	infants	O
10	remained	O
11	low	O
12	and	O
13	below	O
14	breast	O
15	-	O
16	and	O
17	placebo	O
18	formula	O
19	-	O
20	fed	O
21	levels	O
22	.	O

1	Myogenic	O
2	differentiation	O
3	can	O
4	be	O
5	inhibited	O
6	by	O
7	the	O
8	adenovirus	B
9	E1a	I
10	protein	I
11	in	O
12	the	O
13	rat	O
14	L6	O
15	muscle	O
16	cell	O
17	line	O
18	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	compare	O
5	pregnancy	O
6	complications	O
7	in	O
8	women	O
9	having	O
10	genetic	O
11	amniocentesis	O
12	at	O
13	11	O
14	-	O
15	14	O
16	weeks	O
17	versus	O
18	those	O
19	undergoing	O
20	amniocentesis	O
21	at	O
22	16	O
23	-	O
24	19	O
25	weeks	O
26	'	O
27	gestation	O
28	.	O

1	Objective	O
2	responses	O
3	also	O
4	occurred	O
5	in	O
6	studies	O
7	that	O
8	explored	O
9	sequential	O
10	use	O
11	of	O
12	exemestane	O
13	after	O
14	failure	O
15	of	O
16	aminoglutethimide	O
17	(	O
18	26	O
19	%	O
20	with	O
21	exemestane	O
22	200	O
23	mg	O
24	/	O
25	day	O
26	)	O
27	or	O
28	other	O
29	nonsteroidal	O
30	aromatase	B
31	inhibitors	O
32	(	O
33	6	O
34	.	O
35	6	O
36	%	O
37	with	O
38	exemestane	O
39	25	O
40	mg	O
41	/	O
42	day	O
43	).	O

1	We	O
2	produced	O
3	transgenic	O
4	plants	O
5	expressing	O
6	the	O
7	antisense	O
8	Arabidopsis	O
9	HD	O
10	(	O
11	AtHD1	O
12	)	O
13	gene	O
14	.	O

1	In	O
2	H4IIE	O
3	rat	O
4	hepatoma	O
5	cells	O
6	,	O
7	glucocorticoids	O
8	,	O
9	retinoic	O
10	acid	O
11	and	O
12	cyclic	O
13	AMP	O
14	(	O
15	cAMP	O
16	)	O
17	increase	O
18	PEPCK	B
19	gene	I
20	transcription	O
21	whereas	O
22	insulin	B
23	and	O
24	phorbol	O
25	esters	O
26	have	O
27	the	O
28	opposite	O
29	effect	O
30	.	O

1	A	O
2	rapid	O
3	staining	O
4	technique	O
5	for	O
6	Leishmania	O
7	parasites	O
8	in	O
9	splenic	O
10	aspirate	O
11	smears	O
12	.	O

1	Framingham	O
2	Type	O
3	A	O
4	behavior	O
5	was	O
6	positively	O
7	associated	O
8	with	O
9	diastolic	O
10	blood	O
11	pressure	O
12	(	O
13	r	O
14	=	O
15	0	O
16	.	O
17	17	O
18	,	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	05	O
25	)	O
26	among	O
27	the	O
28	women	O
29	.	O

1	Initial	O
2	screening	O
3	of	O
4	a	O
5	rat	O
6	liver	O
7	cDNA	O
8	library	O
9	with	O
10	an	O
11	oligonucleotide	O
12	probe	O
13	derived	O
14	from	O
15	the	O
16	rat	O
17	SCP2	O
18	protein	O
19	sequence	O
20	revealed	O
21	an	O
22	825	O
23	-	O
24	base	O
25	pair	O
26	cDNA	O
27	clone	O
28	coding	O
29	for	O
30	the	O
31	complete	O
32	SCP2	O
33	protein	O
34	sequence	O
35	.	O

1	Iodine	O
2	-	O
3	123	O
4	was	O
5	satisfactorily	O
6	imaged	O
7	only	O
8	with	O
9	the	O
10	MEC	O
11	and	O
12	pinhole	O
13	collimators	O
14	,	O
15	which	O
16	in	O
17	turn	O
18	yielded	O
19	MTF	O
20	values	O
21	comparable	O
22	to	O
23	those	O
24	measured	O
25	for	O
26	99mTc	O
27	.	O

1	Positive	O
2	CRP	B
3	test	O
4	were	O
5	seen	O
6	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	proteasome	O
6	inhibition	O
7	leads	O
8	to	O
9	upregulation	O
10	of	O
11	specific	O
12	members	O
13	of	O
14	transcription	O
15	factor	O
16	families	O
17	controlling	O
18	cellular	O
19	stress	O
20	response	O
21	and	O
22	proliferation	O
23	.	O

1	The	O
2	uncomplicated	O
3	cases	O
4	of	O
5	typhoid	O
6	fever	O
7	were	O
8	found	O
9	to	O
10	have	O
11	an	O
12	intact	O
13	CMIR	O
14	as	O
15	compared	O
16	to	O
17	the	O
18	complicated	O
19	cases	O
20	.	O

1	Furthermore	O
2	,	O
3	a	O
4	p21X	O
5	protein	O
6	lacking	O
7	the	O
8	N	O
9	-	O
10	terminus	O
11	of	O
12	Rex1	O
13	was	O
14	expressed	O
15	at	O
16	high	O
17	levels	O
18	;	O
19	our	O
20	data	O
21	indicate	O
22	that	O
23	p21X	O
24	is	O
25	translated	O
26	from	O
27	the	O
28	1	O
29	.	O
30	6	O
31	-	O
32	kb	O
33	mRNA	O
34	which	O
35	is	O
36	derived	O
37	primarily	O
38	from	O
39	deleted	O
40	proviruses	O
41	.	O

1	Of	O
2	the	O
3	cases	O
4	with	O
5	PLD	O
6	,	O
7	50	O
8	%	O
9	had	O
10	associated	O
11	renal	O
12	cysts	O
13	and	O
14	10	O
15	%	O
16	of	O
17	the	O
18	cases	O
19	with	O
20	APCD	O
21	had	O
22	associated	O
23	liver	O
24	cysts	O
25	.	O

1	In	O
2	addition	O
3	,	O
4	using	O
5	biochemical	O
6	activity	O
7	assays	O
8	for	O
9	Rho	B
10	-	I
11	like	I
12	GTPases	I
13	,	O
14	we	O
15	show	O
16	that	O
17	the	O
18	expression	O
19	of	O
20	beta1A	O
21	,	O
22	beta1D	O
23	,	O
24	or	O
25	IL2R	B
26	-	I
27	beta1A	O
28	in	O
29	GE11	O
30	or	O
31	GD25	O
32	cells	O
33	triggers	O
34	activation	O
35	of	O
36	both	O
37	RhoA	B
38	and	O
39	Rac1	B
40	,	O
41	but	O
42	not	O
43	of	O
44	Cdc42	B
45	.	I

1	Glutathione	B
2	peroxidase	I
3	in	O
4	human	O
5	red	O
6	cells	O
7	in	O
8	health	O
9	and	O
10	disease	O
11	.	O

1	The	O
2	relationships	O
3	among	O
4	blood	O
5	concentrations	O
6	of	O
7	thyroid	O
8	hormones	O
9	and	O
10	selenium	O
11	,	O
12	zinc	O
13	,	O
14	retinol	O
15	,	O
16	and	O
17	alpha	O
18	-	O
19	tocopherol	O
20	were	O
21	studied	O
22	in	O
23	44	O
24	healthy	O
25	Northern	O
26	Italian	O
27	oldest	O
28	-	O
29	old	O
30	subjects	O
31	(	O
32	age	O
33	range	O
34	,	O
35	90	O
36	-	O
37	107	O
38	yr	O
39	),	O
40	selected	O
41	by	O
42	the	O
43	criteria	O
44	of	O
45	the	O
46	SENIEUR	O
47	protocol	O
48	.	O

1	The	O
2	financial	O
3	impact	O
4	of	O
5	childhood	O
6	asthma	O
7	has	O
8	not	O
9	been	O
10	assessed	O
11	since	O
12	Vance	O
13	and	O
14	Taylor	O
15	reported	O
16	their	O
17	data	O
18	in	O
19	Annals	O
20	of	O
21	Allergy	O
22	13	O
23	years	O
24	ago	O
25	.	O

1	These	O
2	clones	O
3	overlapped	O
4	and	O
5	contained	O
6	the	O
7	structural	O
8	gene	O
9	encoding	O
10	the	O
11	complete	O
12	C5	B
13	alpha	I
14	-	I
15	chain	I
16	and	O
17	90	O
18	%	O
19	of	O
20	the	O
21	beta	B
22	-	I
23	chain	I
24	.	I

1	Detection	O
2	of	O
3	poisoning	O
4	by	O
5	Impila	O
6	(	O
7	Callilepis	O
8	laureola	O
9	)	O
10	in	O
11	a	O
12	mother	O
13	and	O
14	child	O
15	.	O

1	Supershift	O
2	assays	O
3	,	O
4	using	O
5	Jun	B
6	and	I
7	Fos	I
8	family	I
9	member	I
10	-	I
11	specific	I
12	antibodies	I
13	,	O
14	showed	O
15	that	O
16	protein	O
17	complexes	O
18	formed	O
19	by	O
20	AtT	O
21	-	O
22	20	O
23	cell	O
24	nuclear	O
25	extracts	O
26	bound	O
27	to	O
28	the	O
29	c	B
30	-	I
31	jun	I
32	AP	I
33	-	I
34	1	I
35	site	I
36	were	O
37	comprised	O
38	of	O
39	Jun	B
40	family	I
41	members	O
42	,	O
43	JunD	B
44	,	O
45	JunB	O
46	,	O
47	and	O
48	cJun	O
49	.	O

1	Isomers	O
2	were	O
3	differentiated	O
4	based	O
5	on	O
6	the	O
7	MS	O
8	-	O
9	MS	O
10	data	O
11	of	O
12	the	O
13	trofluoroacetyl	O
14	-	O
15	biphenylol	O
16	derivatives	O
17	.	O

1	The	O
2	routine	O
3	administration	O
4	of	O
5	fat	O
6	-	O
7	soluble	O
8	vitamins	O
9	appears	O
10	unnecessary	O
11	but	O
12	it	O
13	is	O
14	prudent	O
15	to	O
16	measure	O
17	prothrombin	B
18	time	O
19	and	O
20	serum	O
21	vitamins	O
22	A	O
23	and	O
24	E	O
25	at	O
26	intervals	O
27	.	O

1	In	O
2	a	O
3	country	O
4	where	O
5	general	O
6	HIV	O
7	prevalence	O
8	is	O
9	low	O
10	,	O
11	the	O
12	strategy	O
13	is	O
14	cost	O
15	-	O
16	effective	O
17	for	O
18	location	O
19	and	O
20	counselling	O
21	of	O
22	unknowingly	O
23	seropositive	O
24	individuals	O
25	.	O

1	To	O
2	study	O
3	the	O
4	retinal	O
5	surface	O
6	in	O
7	the	O
8	human	O
9	eye	O
10	in	O
11	normal	O
12	and	O
13	diseased	O
14	states	O
15	we	O
16	used	O
17	laser	O
18	scanning	O
19	tomography	O
20	.	O

1	Regulation	O
2	of	O
3	avian	B
4	fibroblast	I
5	growth	I
6	factor	I
7	receptor	I
8	1	I
9	(	I
10	FGFR	I
11	-	I
12	1	I
13	)	I
14	gene	I
15	expression	O
16	during	O
17	skeletal	O
18	muscle	O
19	differentiation	O
20	.	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	bulbospinal	O
7	micturition	O
8	reflex	O
9	evoked	O
10	by	O
11	bladder	O
12	filling	O
13	and	O
14	L	O
15	-	O
16	dopa	O
17	involves	O
18	a	O
19	descending	O
20	pathway	O
21	where	O
22	transmission	O
23	is	O
24	partly	O
25	mediated	O
26	by	O
27	spinal	O
28	alpha	B
29	1	I
30	-	I
31	adrenoceptors	I
32	.	I

1	METHODS	O
2	:	O
3	The	O
4	former	O
5	group	O
6	included	O
7	patients	O
8	who	O
9	had	O
10	been	O
11	treated	O
12	with	O
13	at	O
14	least	O
15	four	O
16	PGE1	B
17	alpha	I
18	-	I
19	ciclodestrina	O
20	,	O
21	short	O
22	-	O
23	term	O
24	treatment	O
25	cycles	O
26	per	O
27	year	O
28	while	O
29	the	O
30	latter	O
31	was	O
32	a	O
33	historical	O
34	reference	O
35	group	O
36	managed	O
37	without	O
38	prostaglandins	O
39	.	O

1	Pharmacologic	O
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	functionally	O
6	characterized	O
7	the	O
8	mouse	O
9	gene	O
10	for	O
11	the	O
12	C2	B
13	subunit	I
14	of	O
15	the	O
16	20S	B
17	proteasome	I
18	.	I

1	Characterization	O
2	of	O
3	polymorphic	O
4	TNRs	O
5	in	O
6	novel	O
7	and	O
8	even	O
9	known	O
10	genes	O
11	expressed	O
12	in	O
13	human	O
14	spinal	O
15	cord	O
16	is	O
17	likely	O
18	to	O
19	help	O
20	in	O
21	the	O
22	identification	O
23	of	O
24	new	O
25	candidates	O
26	for	O
27	genes	O
28	involved	O
29	in	O
30	neurodegenerative	O
31	disorders	O
32	.	O

1	Regulation	O
2	of	O
3	the	O
4	Raf	B
5	kinase	I
6	in	O
7	T	O
8	cells	O
9	differs	O
10	from	O
11	findings	O
12	with	O
13	a	O
14	variety	O
15	of	O
16	cell	O
17	lines	O
18	that	O
19	the	O
20	catalytic	O
21	domain	O
22	of	O
23	Raf	B
24	(	I
25	Raf	I
26	(	O
27	delta26	O
28	-	O
29	303	O
30	))	O
31	shows	O
32	no	O
33	activity	O
34	.	O

1	Next	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	O
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	I

1	Furthermore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	43	O
8	-	O
9	bp	O
10	region	O
11	of	O
12	the	O
13	24p3	O
14	promoter	O
15	required	O
16	for	O
17	the	O
18	Dex	O
19	responsiveness	O
20	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	O
10	a	O
11	21	O
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	This	O
2	suggests	O
3	that	O
4	the	O
5	DcuS	O
6	-	O
7	DcuR	O
8	system	O
9	responds	O
10	to	O
11	external	O
12	substrates	O
13	.	O

1	The	O
2	findings	O
3	demonstrate	O
4	that	O
5	AMPH	O
6	administration	O
7	induces	O
8	a	O
9	significant	O
10	increase	O
11	in	O
12	the	O
13	height	O
14	of	O
15	a	O
16	major	O
17	electroactive	O
18	peak	O
19	in	O
20	the	O
21	caudate	O
22	nucleus	O
23	of	O
24	pigtail	O
25	monkeys	O
26	,	O
27	and	O
28	further	O
29	that	O
30	such	O
31	amphetamine	O
32	-	O
33	induced	O
34	increases	O
35	can	O
36	be	O
37	manipulated	O
38	by	O
39	altering	O
40	the	O
41	affective	O
42	and	O
43	/	O
44	or	O
45	emotional	O
46	state	O
47	of	O
48	the	O
49	animal	O
50	.	O

1	The	O
2	results	O
3	of	O
4	induced	O
5	coexpression	O
6	were	O
7	also	O
8	supported	O
9	by	O
10	rapid	O
11	generation	O
12	of	O
13	FeLV	O
14	recombinants	O
15	when	O
16	FeLV	O
17	-	O
18	C	O
19	was	O
20	used	O
21	to	O
22	infect	O
23	the	O
24	feline	O
25	3201B	O
26	cell	O
27	line	O
28	that	O
29	constitutively	O
30	expresses	O
31	high	O
32	levels	O
33	of	O
34	endogenous	O
35	FeLV	B
36	-	I
37	specific	I
38	mRNAs	I
39	.	I

1	A	O
2	narrow	O
3	zone	O
4	of	O
5	myelin	O
6	-	O
7	axonal	O
8	dissociation	O
9	was	O
10	also	O
11	observed	O
12	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	pgp2	O
7	/	O
8	mdr1b	O
9	gene	O
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	pgp2GC	O
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	mdr	O
25	genes	O
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	I
32	.	I

1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O

1	The	O
2	U14	B
3	genes	I
4	of	O
5	mouse	O
6	as	O
7	well	O
8	as	O
9	rat	O
10	,	O
11	hamster	O
12	,	O
13	human	O
14	,	O
15	Xenopus	O
16	and	O
17	trout	O
18	are	O
19	encoded	O
20	within	O
21	introns	O
22	of	O
23	the	O
24	constitutively	O
25	expressed	O
26	70	B
27	-	I
28	kDa	I
29	-	I
30	cognate	I
31	-	I
32	heat	I
33	-	I
34	shock	I
35	protein	I
36	gene	I
37	(	O
38	hsc70	O
39	).	O

1	Mutation	O
2	of	O
3	the	O
4	presumptive	O
5	phosphorylated	O
6	tyrosine	O
7	and	O
8	threonine	O
9	residues	O
10	of	O
11	Mpk1p	O
12	individually	O
13	to	O
14	phenylalanine	O
15	and	O
16	alanine	O
17	,	O
18	respectively	O
19	,	O
20	severely	O
21	impaired	O
22	Mpk1p	O
23	function	O
24	.	O

1	After	O
2	that	O
3	report	O
4	,	O
5	carboxypeptidase	O
6	D	O
7	(	O
8	CPD	O
9	)	O
10	was	O
11	subsequently	O
12	purified	O
13	from	O
14	bovine	O
15	pituitary	O
16	and	O
17	characterized	O
18	as	O
19	a	O
20	novel	O
21	carboxypeptidase	O
22	E	O
23	(	O
24	CPE	B
25	)-	I
26	like	I
27	enzyme	I
28	,	O
29	with	O
30	many	O
31	characteristics	O
32	in	O
33	common	O
34	with	O
35	duck	O
36	gp180	O
37	(	O
38	Song	O
39	,	O
40	L	O
41	.,	O
42	Fricker	O
43	,	O
44	L	O
45	.	O
46	D	O
47	.,	O
48	1995	O
49	.	O

1	T1	O
2	-	O
3	weighted	O
4	MRI	O
5	on	O
6	the	O
7	49th	O
8	postoperative	O
9	day	O
10	demonstrated	O
11	bilateral	O
12	and	O
13	symmetrical	O
14	hyperintense	O
15	lesions	O
16	in	O
17	the	O
18	globus	O
19	pallidus	O
20	.	O

1	Varieties	O
2	of	O
3	envious	O
4	experience	O
5	.	O

1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	Aviators	O
2	from	O
3	the	O
4	Light	O
5	Attack	O
6	Wing	O
7	,	O
8	Pacific	O
9	were	O
10	surveyed	O
11	and	O
12	the	O
13	results	O
14	were	O
15	categorized	O
16	by	O
17	aircraft	O
18	type	O
19	.	O

1	Here	O
2	we	O
3	have	O
4	examined	O
5	the	O
6	ability	O
7	of	O
8	the	O
9	cellular	B
10	protein	I
11	YB	I
12	-	I
13	1	I
14	to	O
15	modulate	O
16	transcription	O
17	of	O
18	the	O
19	HIV	B
20	-	I
21	1	I
22	promoter	I
23	in	O
24	a	O
25	human	O
26	astrocytic	O
27	cell	O
28	line	O
29	(	O
30	U	O
31	-	O
32	87MG	O
33	),	O
34	a	O
35	neuronal	O
36	cell	O
37	line	O
38	(	O
39	SK	O
40	-	O
41	N	O
42	-	O
43	MC	O
44	)	O
45	and	O
46	lymphoid	O
47	cells	O
48	(	O
49	Jurkat	O
50	)	O
51	by	O
52	transfection	O
53	assay	O
54	.	O

1	Overexpression	O
2	of	O
3	mcl	O
4	-	O
5	1	O
6	is	O
7	sufficient	O
8	to	O
9	protect	O
10	against	O
11	apoptosis	O
12	,	O
13	while	O
14	transfection	O
15	of	O
16	a	O
17	mcl	O
18	-	O
19	1	O
20	antisense	O
21	plasmid	O
22	causes	O
23	cell	O
24	death	O
25	.	O

1	The	O
2	treatment	O
3	group	O
4	also	O
5	showed	O
6	in	O
7	vivo	O
8	T	O
9	-	O
10	cell	O
11	activation	O
12	with	O
13	an	O
14	initial	O
15	lymphopenia	O
16	followed	O
17	by	O
18	a	O
19	rebound	O
20	lymphocytosis	O
21	and	O
22	upregulation	O
23	of	O
24	the	O
25	subset	O
26	markers	O
27	CD25	O
28	(	O
29	interleukin	B
30	2	I
31	receptor	I
32	)	O
33	and	O
34	CD45RO	O
35	(	O
36	T	O
37	-	O
38	memory	O
39	cells	O
40	).	O

1	Tih1	O
2	maps	O
3	to	O
4	distal	O
5	mouse	O
6	Chr	O
7	1	O
8	and	O
9	human	O
10	Chr	O
11	1q31	O
12	,	O
13	chromosomal	O
14	regions	O
15	that	O
16	have	O
17	not	O
18	shown	O
19	evidence	O
20	for	O
21	imprinting	O
22	and	O
23	,	O
24	in	O
25	contrast	O
26	to	O
27	Ipl	O
28	,	O
29	Tih1	O
30	is	O
31	expressed	O
32	equally	O
33	from	O
34	both	O
35	parental	O
36	alleles	O
37	.	O

1	The	O
2	MMA	O
3	,	O
4	DMA	O
5	,	O
6	and	O
7	TMA	O
8	methyltransferases	O
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	O
26	and	O
27	TMA	O
28	methyltransferases	O
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	The	O
2	number	O
3	of	O
4	bacteria	O
5	in	O
6	the	O
7	lung	O
8	,	O
9	peripheral	O
10	white	O
11	blood	O
12	cell	O
13	and	O
14	BAL	O
15	fluid	O
16	cell	O
17	also	O
18	decreased	O
19	by	O
20	the	O
21	administration	O
22	of	O
23	FN	B
24	.	I

1	In	O
2	the	O
3	budding	O
4	yeast	O
5	,	O
6	Saccharomyces	O
7	cerevisiae	O
8	,	O
9	replicators	O
10	can	O
11	function	O
12	outside	O
13	the	O
14	chromosome	O
15	as	O
16	autonomously	O
17	replicating	O
18	sequence	O
19	(	O
20	ARS	O
21	)	O
22	elements	O
23	;	O
24	however	O
25	,	O
26	within	O
27	chromosome	O
28	III	O
29	,	O
30	certain	O
31	ARSs	O
32	near	O
33	the	O
34	transcriptionally	O
35	silent	B
36	HML	I
37	locus	I
38	show	O
39	no	O
40	replication	O
41	origin	O
42	activity	O
43	.	O

1	The	O
2	full	O
3	length	O
4	cDNA	O
5	sequence	O
6	of	O
7	a	O
8	Type	O
9	I	O
10	transforming	B
11	growth	I
12	factor	I
13	-	I
14	beta	I
15	(	O
16	TGF	B
17	-	I
18	beta	I
19	)	I
20	receptor	I
21	has	O
22	been	O
23	isolated	O
24	from	O
25	the	O
26	filarial	O
27	parasitic	O
28	nematode	O
29	Brugia	O
30	pahangi	O
31	.	O

1	The	O
2	N	O
3	-	O
4	terminus	O
5	of	O
6	another	O
7	open	O
8	reading	O
9	frame	O
10	was	O
11	found	O
12	3	O
13	'	O
14	from	O
15	nifA	O
16	and	O
17	tentatively	O
18	identified	O
19	as	O
20	nifB	O
21	by	O
22	amino	O
23	acid	O
24	sequence	O
25	comparison	O
26	.	O

1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	nonsustained	O
9	.	O

1	Antihistamines	O
2	in	O
3	asthma	O
4	.	O

1	Each	O
2	parent	O
3	interacted	O
4	with	O
5	their	O
6	4	O
7	-	O
8	or	O
9	5	O
10	-	O
11	year	O
12	-	O
13	old	O
14	son	O
15	or	O
16	daughter	O
17	in	O
18	each	O
19	of	O
20	two	O
21	conversations	O
22	--	O
23	unstructured	O
24	(	O
25	social	O
26	conversation	O
27	)	O
28	and	O
29	structured	O
30	(	O
31	task	O
32	activity	O
33	).	O

1	Human	B
2	granulocyte	I
3	-	I
4	macrophage	I
5	colony	I
6	-	I
7	stimulating	I
8	factor	I
9	(	I
10	hGM	I
11	-	I
12	CSF	I
13	)	O
14	activates	O
15	a	O
16	set	O
17	of	O
18	genes	O
19	such	O
20	as	O
21	c	B
22	-	I
23	fos	I
24	,	I
25	jun	I
26	,	I
27	myc	I
28	,	O
29	and	O
30	early	B
31	growth	I
32	response	I
33	gene	I
34	1	I
35	(	I
36	egr	I
37	-	I
38	1	I
39	).	O

1	Thus	O
2	,	O
3	the	O
4	characterization	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	should	O
10	help	O
11	to	O
12	define	O
13	regulatory	O
14	elements	O
15	that	O
16	control	O
17	neuron	O
18	-	O
19	specific	O
20	and	O
21	developmental	O
22	expression	O
23	of	O
24	the	O
25	MAP1B	B
26	gene	I
27	.	I

1	Central	O
2	venous	O
3	catheter	O
4	used	O
5	for	O
6	recording	O
7	intracardiac	O
8	electrocardiogram	O
9	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	O
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	I

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	diazepam	O
8	-	O
9	binding	O
10	inhibitor	O
11	in	O
12	Drosophila	O
13	melanogaster	O
14	:	O
15	cloning	O
16	,	O
17	structure	O
18	,	O
19	and	O
20	localization	O
21	of	O
22	the	O
23	gene	O
24	.	O

1	Tolterodine	O
2	users	O
3	were	O
4	7	O
5	.	O
6	5	O
7	times	O
8	more	O
9	likely	O
10	to	O
11	have	O
12	received	O
13	another	O
14	spasmolytic	O
15	drug	O
16	(	O
17	RR	O
18	7	O
19	.	O
20	5	O
21	,	O
22	95	O
23	%	O
24	CI	O
25	4	O
26	.	O
27	8	O
28	to	O
29	11	O
30	.	O
31	9	O
32	).	O

1	Restriction	O
2	enzyme	O
3	and	O
4	heteroduplex	O
5	analyses	O
6	confirmed	O
7	that	O
8	sequences	O
9	unique	O
10	to	O
11	FeSV	O
12	(	O
13	src	B
14	sequences	O
15	)	O
16	are	O
17	located	O
18	at	O
19	the	O
20	center	O
21	of	O
22	the	O
23	FeSV	O
24	genome	O
25	and	O
26	are	O
27	approximately	O
28	1	O
29	.	O
30	5	O
31	kilobase	O
32	pairs	O
33	in	O
34	length	O
35	.	O

1	Retroviral	O
2	transduction	O
3	of	O
4	T	O
5	/	O
6	T	O
7	(	O
8	L	O
9	)	O
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	O
29	/	O
30	T	O
31	(	O
32	F	O
33	)	O
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O

1	During	O
2	the	O
3	aftermath	O
4	of	O
5	excitation	O
6	of	O
7	the	O
8	skin	O
9	sympathetic	O
10	nerve	O
11	by	O
12	mental	O
13	arithmetics	O
14	,	O
15	3	O
16	/	O
17	12	O
18	A	O
19	delta	O
20	units	O
21	were	O
22	turned	O
23	to	O
24	the	O
25	active	O
26	state	O
27	with	O
28	decreased	O
29	mechanical	O
30	threshold	O
31	.	O

1	Study	O
2	of	O
3	antinuclear	O
4	autoantibodies	O
5	by	O
6	immunofluorescence	O
7	technic	O
8	in	O
9	collagen	B
10	diseases	I

1	Optimal	O
2	monitoring	O
3	of	O
4	ODA	O
5	remains	O
6	undefined	O
7	.	O

1	Measurement	O
2	of	O
3	the	O
4	time	O
5	constant	O
6	of	O
7	VO2	O
8	and	O
9	oxygen	O
10	pulse	O
11	during	O
12	constant	O
13	work	O
14	rate	O
15	exercise	O
16	are	O
17	useful	O
18	for	O
19	the	O
20	objective	O
21	evaluation	O
22	of	O
23	the	O
24	training	O
25	effect	O
26	of	O
27	patients	O
28	with	O
29	COPD	O
30	.	O

1	The	O
2	peptide	O
3	sequences	O
4	reveal	O
5	that	O
6	the	O
7	factor	O
8	consists	O
9	of	O
10	GABP	B
11	alpha	I
12	and	O
13	GABP	B
14	beta	I
15	1	I
16	with	O
17	Ets	B
18	and	O
19	Notch	B
20	motifs	O
21	,	O
22	respectively	O
23	.	O

1	A	O
2	total	O
3	of	O
4	1459	O
5	men	O
6	aged	O
7	48	O
8	to	O
9	84	O
10	years	O
11	,	O
12	who	O
13	were	O
14	diagnosed	O
15	for	O
16	the	O
17	first	O
18	time	O
19	by	O
20	physicians	O
21	as	O
22	having	O
23	BPH	O
24	in	O
25	1994	O
26	and	O
27	who	O
28	had	O
29	not	O
30	received	O
31	treatment	O
32	,	O
33	participated	O
34	in	O
35	the	O
36	study	O
37	.	O

1	Recently	O
2	,	O
3	a	O
4	mutation	O
5	in	O
6	the	O
7	amino	O
8	-	O
9	terminus	O
10	of	O
11	IB1	O
12	was	O
13	associated	O
14	with	O
15	diabetes	O
16	.	O

1	They	O
2	were	O
3	almost	O
4	regularly	O
5	excited	O
6	by	O
7	pressure	O
8	to	O
9	the	O
10	ipsilateral	O
11	cornea	O
12	or	O
13	to	O
14	both	O
15	corneas	O
16	at	O
17	a	O
18	strength	O
19	well	O
20	above	O
21	the	O
22	human	O
23	corneal	O
24	pain	O
25	threshold	O
26	.	O

1	The	O
2	lymph	O
3	nodes	O
4	from	O
5	two	O
6	of	O
7	the	O
8	patients	O
9	with	O
10	rheumatoid	O
11	arthritis	O
12	contained	O
13	numerous	O
14	sarcoid	O
15	like	O
16	granulomata	O
17	,	O
18	further	O
19	indicating	O
20	a	O
21	possible	O
22	association	O
23	between	O
24	sarcoidosis	O
25	and	O
26	rheumatoid	O
27	arthritis	O
28	.	O

1	The	O
2	gene	O
3	sequence	O
4	also	O
5	identified	O
6	a	O
7	340	O
8	-	O
9	nucleotide	O
10	RNA	O
11	in	O
12	total	O
13	yeast	O
14	RNA	O
15	and	O
16	in	O
17	purified	O
18	RNase	B
19	MRP	I
20	enzyme	I
21	preparations	O
22	.	O

1	These	O
2	viruses	O
3	depend	O
4	on	O
5	the	O
6	host	O
7	cell	O
8	machinery	O
9	for	O
10	their	O
11	existence	O
12	,	O
13	and	O
14	interference	O
15	with	O
16	these	O
17	processes	O
18	typically	O
19	interferes	O
20	with	O
21	other	O
22	important	O
23	host	O
24	physiology	O
25	.	O

1	Cotransfection	O
2	of	O
3	the	O
4	coactivator	O
5	CREB	B
6	-	I
7	binding	I
8	protein	I
9	relieved	O
10	the	O
11	transcriptional	O
12	repression	O
13	of	O
14	PPARalphawt	O
15	by	O
16	PPARalphatr	O
17	,	O
18	suggesting	O
19	that	O
20	the	O
21	dominant	O
22	negative	O
23	effect	O
24	of	O
25	PPARalphatr	O
26	might	O
27	occur	O
28	through	O
29	competition	O
30	for	O
31	essential	O
32	coactivators	O
33	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	gene	I
6	is	O
7	overexpressed	O
8	in	O
9	a	O
10	variety	O
11	of	O
12	tumor	O
13	types	O
14	and	O
15	appears	O
16	to	O
17	play	O
18	an	O
19	important	O
20	role	O
21	in	O
22	the	O
23	abnormal	O
24	growth	O
25	of	O
26	a	O
27	number	O
28	of	O
29	cell	O
30	types	O
31	.	O

1	Subunit	O
2	composition	O
3	and	O
4	domain	O
5	structure	O
6	of	O
7	the	O
8	Spo0A	O
9	sporulation	O
10	transcription	O
11	factor	O
12	of	O
13	Bacillus	B
14	subtilis	I
15	.	I

1	Conversely	O
2	,	O
3	when	O
4	VDR	B
5	is	O
6	overexpressed	O
7	,	O
8	vitamin	O
9	D3	O
10	attenuates	O
11	9	O
12	-	O
13	cis	O
14	RA	O
15	induction	O
16	from	O
17	an	O
18	RXR	B
19	-	I
20	responsive	I
21	element	I
22	.	I

1	In	O
2	addition	O
3	,	O
4	carp	O
5	JAK1	O
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	B
12	JAK1	<s>
13	in	O
14	both	O
15	the	O
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	O
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	O
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O

1	Recently	O
2	,	O
3	the	O
4	3	O
5	.	O
6	6	O
7	-	O
8	kb	O
9	full	B
10	-	I
11	length	I
12	alpha	I
13	-	I
14	GalNAc	O
15	cDNA	O
16	sequence	O
17	was	O
18	isolated	O
19	and	O
20	found	O
21	to	O
22	have	O
23	remarkable	O
24	nucleotide	O
25	and	O
26	predicted	O
27	amino	O
28	acid	O
29	homology	O
30	(	O
31	55	O
32	.	O
33	8	O
34	and	O
35	46	O
36	.	O
37	9	O
38	%,	O
39	respectively	O
40	)	O
41	with	O
42	the	O
43	human	B
44	alpha	I
45	-	I
46	galactosidase	I
47	A	I
48	(	I
49	alpha	I
50	-	I
51	Gal	I
52	A	I
53	)	I
54	cDNA	I
55	.	I

1	Addition	O
2	of	O
3	synthetic	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	peptides	O
8	derived	O
9	from	O
10	betac	O
11	cytoplasmic	O
12	tyrosines	O
13	prior	O
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	stimulation	O
19	inhibited	O
20	the	O
21	in	O
22	vitro	O
23	activation	O
24	of	O
25	STAT5	B
26	.	I

1	The	O
2	transforming	O
3	protein	O
4	of	O
5	Rous	O
6	sarcoma	O
7	virus	O
8	,	O
9	pp60v	B
10	-	I
11	src	I
12	,	O
13	and	O
14	its	O
15	normal	O
16	cellular	O
17	homolog	O
18	,	O
19	pp60c	B
20	-	I
21	src	I
22	,	O
23	differ	O
24	not	O
25	only	O
26	in	O
27	oncogenic	O
28	potential	O
29	but	O
30	also	O
31	in	O
32	their	O
33	subcellular	O
34	localization	O
35	and	O
36	cytoskeletal	O
37	binding	O
38	ability	O
39	.	O
40	pp60v	B
41	-	I
42	src	I
43	has	O
44	been	O
45	shown	O
46	to	O
47	stably	O
48	associate	O
49	with	O
50	a	O
51	detergent	O
52	-	O
53	insoluble	O
54	cytoskeletal	O
55	matrix	O
56	,	O
57	whereas	O
58	pp60c	B
59	-	I
60	src	I
61	does	O
62	not	O
63	.	O

1	Thus	O
2	,	O
3	the	O
4	bovine	O
5	PEDF	O
6	cDNA	O
7	isolated	O
8	here	O
9	codes	O
10	for	O
11	a	O
12	functional	O
13	soluble	O
14	secreted	O
15	PEDF	B
16	glycoprotein	I
17	.	I

1	The	O
2	indoor	O
3	radon	O
4	concentration	O
5	in	O
6	the	O
7	summer	O
8	(	O
9	1990	O
10	)	O
11	period	O
12	ranged	O
13	between	O
14	8	O
15	and	O
16	81	O
17	Bq	O
18	m	O
19	-	O
20	3	O
21	,	O
22	while	O
23	in	O
24	the	O
25	winter	O
26	(	O
27	1989	O
28	-	O
29	1990	O
30	)	O
31	it	O
32	ranged	O
33	between	O
34	20	O
35	and	O
36	143	O
37	Bq	O
38	m	O
39	-	O
40	3	O
41	for	O
42	the	O
43	first	O
44	year	O
45	of	O
46	measurements	O
47	or	O
48	between	O
49	8	O
50	and	O
51	92	O
52	Bq	O
53	m	O
54	-	O
55	3	O
56	in	O
57	the	O
58	summer	O
59	(	O
60	1991	O
61	)	O
62	period	O
63	and	O
64	between	O
65	12	O
66	and	O
67	119	O
68	Bq	O
69	m	O
70	-	O
71	3	O
72	in	O
73	the	O
74	winter	O
75	(	O
76	1990	O
77	-	O
78	1991	O
79	)	O
80	for	O
81	the	O
82	second	O
83	year	O
84	of	O
85	measurements	O
86	.	O

1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O

1	A	O
2	randomized	O
3	,	O
4	prospective	O
5	study	O
6	was	O
7	conducted	O
8	to	O
9	compare	O
10	ovarian	O
11	stimulation	O
12	with	O
13	human	B
14	menopausal	I
15	gonadotropin	I
16	(	O
17	hMG	O
18	)	O
19	and	O
20	human	B
21	follicle	I
22	-	I
23	stimulating	I
24	hormone	I
25	(	O
26	hFSH	O
27	)	O
28	in	O
29	an	O
30	in	O
31	vitro	O
32	fertilization	O
33	and	O
34	embryo	O
35	transfer	O
36	(	O
37	IVF	O
38	-	O
39	ET	O
40	)	O
41	program	O
42	.	O

1	An	O
2	open	O
3	reading	O
4	frame	O
5	encoding	O
6	a	O
7	protein	O
8	which	O
9	shows	O
10	significant	O
11	similarity	O
12	to	O
13	invertases	O
14	and	O
15	resolvases	O
16	was	O
17	located	O
18	immediately	O
19	upstream	O
20	of	O
21	the	O
22	Pac25I	B
23	R	I
24	-	I
25	M	I
26	operon	I
27	.	I

1	In	O
2	the	O
3	8	O
4	patients	O
5	the	O
6	difference	O
7	betweent	O
8	he	O
9	mean	O
10	diastolic	O
11	values	O
12	of	O
13	delta	O
14	PU	B
15	and	O
16	delta	O
17	PM	O
18	was	O
19	-	O
20	0	O
21	.	O
22	54	O
23	+/-	O
24	1	O
25	.	O
26	0	O
27	(	O
28	SD	O
29	)	O
30	mmHg	O
31	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Only	O
2	after	O
3	a	O
4	pretreatment	O
5	aimed	O
6	at	O
7	increasing	O
8	its	O
9	oxide	O
10	surface	O
11	layer	O
12	was	O
13	titanium	O
14	powder	O
15	found	O
16	to	O
17	accelerate	O
18	the	O
19	precipitation	O
20	from	O
21	solutions	O
22	containing	O
23	2	O
24	mmol	O
25	/	O
26	L	O
27	CaCl2	O
28	,	O
29	2	O
30	mmol	O
31	/	O
32	L	O
33	KH2PO4	O
34	,	O
35	50	O
36	mmol	O
37	/	O
38	L	O
39	Hepes	O
40	,	O
41	pH	O
42	7	O
43	.	O
44	2	O
45	,	O
46	and	O
47	to	O
48	induce	O
49	precipitation	O
50	from	O
51	metastable	O
52	solutions	O
53	containing	O
54	1	O
55	.	O
56	2	O
57	mmol	O
58	/	O
59	L	O
60	CaCl2	O
61	,	O
62	1	O
63	.	O
64	2	O
65	mmol	O
66	/	O
67	L	O
68	KH2PO4	O
69	,	O
70	50	O
71	mmol	O
72	/	O
73	L	O
74	Hepes	O
75	,	O
76	pH	O
77	7	O
78	.	O
79	2	O
80	,	O
81	at	O
82	37	O
83	degrees	O
84	C	O
85	.	O

1	Alena	O
2	is	O
3	a	O
4	nurse	O
5	in	O
6	Prague	O
7	--	O
8	she	O
9	dreams	O
10	of	O
11	higher	O
12	wages	O
13	and	O
14	a	O
15	trip	O
16	across	O
17	the	O
18	ocean	B

1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O

1	Diagnosis	O
2	of	O
3	prostatic	O
4	carcinoma	O
5	:	O
6	the	O
7	yield	O
8	of	O
9	serum	O
10	prostate	O
11	specific	O
12	antigen	O
13	,	O
14	digital	O
15	rectal	O
16	examination	O
17	and	O
18	transrectal	O
19	ultrasonography	O
20	.	O

1	Neither	O
2	CES1	O
3	nor	O
4	CES4	O
5	is	O
6	essential	O
7	for	O
8	cell	O
9	growth	O
10	,	O
11	and	O
12	a	O
13	double	O
14	deletion	O
15	mutant	O
16	is	O
17	viable	O
18	.	O

1	Story	O
2	of	O
3	a	O
4	hospital	O
5	that	O
6	filmed	O
7	its	O
8	employee	O
9	orientation	O
10	program	O
11	.	O

1	Branch	O
2	occlusion	O
3	of	O
4	Heubner	O
5	'	O
6	s	O
7	artery	O
8	,	O
9	or	O
10	perforators	O
11	from	O
12	the	O
13	proximal	O
14	anterior	O
15	or	O
16	middle	O
17	cerebral	O
18	arteries	O
19	were	O
20	the	O
21	posited	O
22	mechanism	O
23	of	O
24	infarction	O
25	.	O

1	These	O
2	genes	O
3	are	O
4	expressed	O
5	within	O
6	a	O
7	few	O
8	hours	O
9	of	O
10	the	O
11	initiation	O
12	of	O
13	development	O
14	;	O
15	their	O
16	mRNAs	O
17	accumulate	O
18	to	O
19	a	O
20	peak	O
21	at	O
22	12	O
23	hr	O
24	and	O
25	persist	O
26	until	O
27	culmination	O
28	.	O

1	Sequence	O
2	requirements	O
3	for	O
4	premature	O
5	transcription	O
6	arrest	O
7	within	O
8	the	O
9	first	O
10	intron	O
11	of	O
12	the	O
13	mouse	O
14	c	B
15	-	I
16	fos	I
17	gene	I
18	.	I

1	Purification	O
2	of	O
3	MvaT	O
4	enriched	O
5	for	O
6	two	O
7	polypeptides	O
8	of	O
9	approximate	O
10	molecular	O
11	mass	O
12	15	O
13	kDa	O
14	and	O
15	16	O
16	kDa	O
17	,	O
18	designated	O
19	P15	O
20	and	O
21	P16	O
22	.	O

1	Current	O
2	status	O
3	of	O
4	chemotherapy	O
5	for	O
6	Hodgkin	O
7	'	O
8	s	O
9	disease	O

1	CONCLUSION	O
2	:	O
3	In	O
4	Cdks	O
5	functioning	O
6	throughout	O
7	the	O
8	cell	O
9	cycle	O
10	,	O
11	tyrosine	O
12	phosphorylation	O
13	is	O
14	inhibitory	O
15	to	O
16	the	O
17	activation	O
18	of	O
19	kinase	O
20	,	O
21	whereas	O
22	the	O
23	phosphorylation	O
24	of	O
25	threonine	O
26	in	O
27	the	O
28	T	O
29	-	O
30	loop	O
31	is	O
32	essential	O
33	for	O
34	activation	O
35	.	O

1	Lung	O
2	and	O
3	multi	O
4	-	O
5	system	O
6	damage	O
7	were	O
8	early	O
9	indicators	O
10	of	O
11	poor	O
12	outcome	O
13	in	O
14	severe	O
15	non	O
16	-	O
17	fatal	O
18	disease	O
19	.	O

1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O

1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	B
17	loci	I
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O

1	That	O
2	sequence	O
3	strongly	O
4	promoted	O
5	the	O
6	transcription	O
7	of	O
8	the	O
9	promotorless	O
10	chloramphenicol	B
11	acetyltranferase	O
12	(	O
13	CAT	B
14	)	I
15	gene	I
16	in	O
17	cells	O
18	of	O
19	pancreatic	O
20	origin	O
21	(	O
22	AR	O
23	-	O
24	42J	O
25	)	O
26	but	O
27	not	O
28	in	O
29	cells	O
30	of	O
31	non	O
32	-	O
33	pancreatic	O
34	origin	O
35	(	O
36	Rat	O
37	2	O
38	and	O
39	IEC	O
40	6	O
41	).	O

1	At	O
2	1	O
3	,	O
4	5	O
5	,	O
6	and	O
7	9	O
8	months	O
9	after	O
10	initial	O
11	isolation	O
12	of	O
13	C	O
14	.	O
15	kutscheri	O
16	from	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	hamsters	O
22	were	O
23	euthanatized	O
24	,	O
25	and	O
26	attempts	O
27	were	O
28	made	O
29	to	O
30	culture	O
31	C	O
32	.	O
33	kutscheri	O
34	from	O
35	13	O
36	additional	O
37	sites	O
38	.	O

1	CONCLUSION	O
2	:	O
3	This	O
4	study	O
5	documents	O
6	that	O
7	regression	O
8	of	O
9	choroidal	O
10	neovascularization	O
11	that	O
12	occurred	O
13	with	O
14	alpha	B
15	interferon	I
16	treatment	O
17	was	O
18	minimal	O
19	.	O

1	Eighty	O
2	patients	O
3	presenting	O
4	to	O
5	HGGM	O
6	with	O
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	lymphomas	O
13	between	O
14	1962	O
15	and	O
16	1986	O
17	,	O
18	were	O
19	reviewed	O
20	.	O

1	Magnetic	O
2	resonance	O
3	spectroscopy	O
4	(	O
5	MRS	O
6	)	O
7	and	O
8	imaging	O
9	(	O
10	MRI	O
11	)	O
12	are	O
13	now	O
14	well	O
15	established	O
16	techniques	O
17	for	O
18	the	O
19	study	O
20	of	O
21	cellular	O
22	metabolism	O
23	and	O
24	gross	O
25	structure	O
26	of	O
27	muscle	O
28	.	O

